{"title": "PDF", "author": "PDF", "url": "https://opendata.uni-halle.de/bitstream/1981185920/14116/1/Habilschrift_Quandt_Juli_2019.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Aus der Medizinischen Fakult\u00e4t der Martin-Luther-Universit\u00e4t  Halle-Wittenberg Institut f\u00fcr Anatomie und Zellbiologie Direktorin: Frau Prof. Dr. med. Heike Kielstein   T-Zellen im Kontext von Autoimmunit\u00e4t und malignen Neoplasien    H A B I L I T A T I O N S S C H R I F T  zur Erlangung des akademischen Grades Dr. rer. nat., rer. medic. habil. f\u00fcr das Fachgebiet Experimentelle Biomedizin     kumulative Schrift vorgelegt  der Medizinischen Fakult\u00e4t         der Martin-Luther-Universit\u00e4t Halle-Wittenberg            von  Dr. rer. nat. Dagmar Quandt         geboren am 29.7.1975 in Stollberg  Gutachter: Prof. Dr. rer. nat. Jochen H\u00fchn           Prof. Dr. med. Thomas Kamradt Lehrprobe am: 02.04.2019 Datum der Verteidigung: 18.06.2019\tReferat  T-Zellen als Teil der adaptiven Immunit\u00e4t sind von fundamentaler Bedeutung f\u00fcr die Immunabwehr gegen Pathogene und den Kampf gegen Tumore. Im Falle des Auftretens von Autoimmunit\u00e4t k\u00f6nnen beispielhaft f\u00fcr die rheumatoide Arthritis (RA) T-Zellen autoreaktiv agieren. Sie greifen k\u00f6rpereigene Strukturen an und sind ma\u00dfgeblich an der Pathogenese der Erkrankung beteiligt. Bei Vorliegen einer Krebserkrankung wird das Immunsystem, u.a. krebsspezifische T-Zellen, vom Tumor kontrolliert und damit eine ad\u00e4quate Bek\u00e4mpfung verhindert. In den hier dargestellten Forschungsarbeiten wurde die Steuerung von T-Zell-Antworten zur Aufrechterhaltung ihrer Hom\u00f6ostase, zum Kampf gegen das maligne Melanom bzw. Nierenzellkarzinom und zur reaktiv \u00fcbersteigerten Aktivit\u00e4t bei RA untersucht. Es galt dabei, sowohl krankheitsspezifische als auch \u00fcbergeordnete Grundprinzipien der T-Zell-Immunologie zu entschl\u00fcsseln. Hierf\u00fcr wurden T-Zellen aus dem Blut von Patienten/Patientinnen, gesunden Probanden/Probandinnen und aus Lymphorganen von M\u00e4usen mit experimenteller Arthritis verwendet. Des Weiteren wurden biologische Zielstrukturen der Patienten/Patientinnen wie Haut und Synovialgewebe analysiert und die gewonnenen experimentellen Ergebnisse mit den klinischen Daten der Patienten/Patientinnen korreliert. Analysen an Zelllinien verschiedener Gewebetypen vervollst\u00e4ndigten die Untersuchungen. Wesentliche Erkenntnisse des ersten Schwerpunktes \u201eT-zellul\u00e4re Beteiligung bei der RA\u201c ergaben sich aus der Beschreibung und Charakterisierung multifunktioneller doppelt positiver (CD4+CD8+) T-Zellen. Au\u00dferdem konnten LIR-1 und das murine Ortholog PIR-B als wichtige T-Zell-Regulatoren bei der RA identifiziert werden. Eine Infektion mit dem Cytomegalievirus f\u00fchrte bei RA-Patienten/-Patientinnen einhergehend mit hochreaktiven T-Zellen zu einem schwereren Krankheitsverlauf. Im zweiten Schwerpunkt \u201eT-zellul\u00e4re Beteiligung bei malignen Neoplasien\u201c wurde eine prominente Rolle von B7-H4 f\u00fcr das \u00dcberleben von Melanompatienten/-patientinnen und die zytokingesteuerte Regulation von B7-H1 im Nierenzellkarzinom identifiziert. Der Kostimulator B7-H3 auf Keratinozyten ist an der T-Zell-Hom\u00f6ostase in der Haut beteiligt. Die Erkenntnisse der durchgef\u00fchrten Forschungsarbeiten komplettieren das Verst\u00e4ndnis der Beteiligung verschiedener T-Zell-Subpopulationen und Regulationsmechanismen von T-Zell-Antworten im Kontext von Autoimmunit\u00e4t und malignen Neoplasien. Neue Zielstrukturen f\u00fcr therapeutische Ans\u00e4tze und f\u00fcr fortf\u00fchrende Forschungsarbeiten konnten mit der vorliegenden Habilitationsschrift aufgezeigt werden.  Bibliographische Beschreibung  Dr. rer. nat. Dagmar Quandt T-Zellen im Kontext von Autoimmunit\u00e4t und malignen Neoplasien Universit\u00e4t Halle-Wittenberg, Habilitation 141 Seiten, 175 Literaturangaben, 6 Abbildungen, 7 eigene Originalarbeiten, 2018 \t\n\tI\t\t\t\t\t\tInhaltsverzeichnis I. Einleitung.............................................................................................................................1 1.1. T-Zellen als aktive Gestalter der Immunabwehr................................................................1 1.1.1. CD4+ T-Helferzellen........................................................................................................5  1.1.2. CD8+ Zytotoxische T-Zellen............................................................................................6 1.1.3. CD4+CD8+ doppelt positive (DP) T-Zellen.....................................................................7  1.2. Die Steuerung von T-Zell-Antworten.................................................................................9 1.3. T-Zell-Immunit\u00e4t im Melanom und Nierenzellkarzinom...................................................13 1.4. Rheumatoide Arthritis \u2013 eine T-Zell gesteuerte Autoimmunerkrankung..........................14 1.5. Cytomegalovirusinfektionen (CMV) \u2013 T-zellul\u00e4re Ver\u00e4nderungen...................................15 1.6. Fragestellung...................................................................................................................17 II. Ergebnisse aus Originalarbeiten.....................................................................................19 2.1. T-Zell Subpopulationen mit fundamentaler Bedeutung f\u00fcr den Krankheits-         verlauf der rheumatoiden Arthritis (RA)..........................................................................21 2.1.1. CMV Virus-spezifische T-Zellen und die RA.................................................................21 2.1.2. CD4+CD8+ doppelt positive T-Zellen und die Pathogenese der RA..............................23 2.1.3. Kontrollmechanismen reaktiver T-Zellen in der Arthritis...............................................25 2.2. Die Rolle von Kostimulatoren und Koinhibitoren f\u00fcr die T-Zell-Hom\u00f6ostase und          die antitumorale T-zellul\u00e4re Immunabwehr.....................................................................28 2.2.1. T-Zell-Steuerung durch B7-H3 auf Hautzellen..............................................................28 2.2.2. T-Zell-Kontrolle durch Koinhibitorexpression auf Tumorzellen.....................................29 III  Diskussion/Ausblick........................................................................................................32 3.1. T-Zell-Subpopulationen mit fundamentaler Bedeutung f\u00fcr den Krankheitsverlauf der        rheumatoiden Arthritis (RA).............................................................................................32 3.1.1. LIR-1 positive CMV Virus-spezifische T-Zellen im Kontext der RA..............................32 3.1.2. Polyfunktionale CD4+CD8+ doppelt positive T-Zellen in der Pathogenese der RA.......35  3.1.3. Kontrollmechanismen reaktiver T-Zellen in der RA......................................................37 3.2. Die Bedeutung von Kostimulatoren und Koinhibitoren f\u00fcr die T-Zell-Hom\u00f6ostase und         die antitumorale T-zellul\u00e4re Immunabwehr......................................................................40  3.2.1. T-Zell-Aktivierung durch B7-H3 auf Hautzellen............................................................40 3.2.2. T-Zell-Kontrolle durch Koinhibitorexpression auf Tumorzellen.....................................41 IV Zusammenfassung...........................................................................................................45 V Literaturverzeichnis..........................................................................................................47 VI Thesen...............................................................................................................................60 VII Originalarbeiten...............................................................................................................63 VII Appendix........................................................................................................................137 \t\n\tII\t\t\t\t\t\tAbk\u00fcrzungsverzeichnis (Abst\u00e4nde hinter die Abk\u00fcrzungen) ACPA   Anti-citrullinierte Peptid/Protein Antik\u00f6rper AMPK   Adenosinmonophosphat Kinase APZ   Antigen-pr\u00e4sentierende Zellen ATL   Akutes T-Zell-Lymphom ATP   Adenosintriphosphat B7-H-xy  B7 Familienmitglieder Ko-stimulatoren, -inhibitoren BTLA   B und T-Lymphozyten Attenuator CMV   Cytomegalievirus CTLA-4  Zytotoxisches T-Lymphozyten assoziiertes Antigen 4 CX3CR1  Chemokinrezeptor 1, Fraktalkin-Rezeptor DP T-Zellen  CD4+/CD8+ doppelt positive T-Zellen DNA   Desoxyribonukleins\u00e4uren Fas/FasL  Todesrezeptorpaar, TNF Familie HD   Gesunde Probanden HLA   Humanes Leukozyten Antigen / humaner Haupthistokompatibilit\u00e4tskomplex HIV   Humanes Immundefizienz Virus IFN   Interferon IkB   Inhibitor von NFkB IL-xy   Interleukin ITIM   Immunrezeptor Tyrosinbasierendes Inhibitorisches Motiv LFA-1   Lymphozyten Funktionsassoziiertes Antigen 1 LIR1   Leukozyten Immunoglobulin \u00e4hnlicher Rezeptor 1, auch CD85j, ILT2 MAPK   Mitogen aktivierte Proteinkinase MCP-1  Monozyten chemotaktisches Protein-1 MHC   Major Histocompatibility Complex MS   Multiple Sklerose  NFkB   Transkriptionsfaktor Nukleusfaktor kappa B leichte Kette Verst\u00e4rker NF-90   RNA bindendes Protein Nukleusfaktor 90 PD-1 (R)  Programmierter Zelltod-Rezeptor PD-L1   Programmierter Zelltod-Ligand \t\n\tIII\t\t\t\t\t\tPI3k   Phosphoinositid-3-Kinase PIR-B   Gepaarter Immunoglobulin \u00e4hnlicher Rezeptor B PKC  Proteinkinase C PMA   Phorbolmyristin Azetat  RA   Rheumatoide Arthritis RBP   RNA bindendes Protein  RNA   Ribonukleins\u00e4ure  Runx3   Runt verwandter Transkriptionsfaktor 3 SASP   Senszenz-assoziierter sekretorischer Ph\u00e4notyp SKG  Mausmodell mit Spontanmutation SLE   Systemischer Lupus Erythematodes SPF   Spezifisch pathogenfrei  STAT6  Signal \u00dcbermittler und Aktivator der Transkription 6  TAA   Tumor-assoziierte Antigene TAM   Tumor-assoziierte Makrophage  TEMRA  Terminal differenzierte Effektor-Ged\u00e4chtniszellen TFh    T-Follikulare Helferzellen TGF-\u03b2   Transformierender Wachstumsfaktor beta Th   T-Helferzellen Th1, 2, 9 , 17, 22  Numerisch differenzierte Subtypen der T-Helferzellen ThPOK  Transkriptionsfaktor, T-Helfer induzierend, Zinkfinger beinhaltend TIGIT   T-Zellen-Immunrezeptor mit Immunglobulin und ITIM Motiven TLS   Terti\u00e4re lymphoide Strukturen TNF   Tumor-Nekrose Faktor Treg   Regulatorische T-Zellen  TRAIL/ TRAILR  Tumor-Nekrose Faktor verwandte Apoptose induzierendes Rezeptorpaar TZR   T-Zell-Rezeptor \u03b1\u03b2-, \u03b3\u03b4 TZR Alpha-beta bzw. gamma-delta T-Zell-Rezeptor wt  Wildtyp \t\n\t1\t\t\t\t\t\t1. Einleitung  1.1. T-Zellen als aktive Gestalter der Immunabwehr T-Zellen, auch T-Lymphozyten genannt, bilden zusammen mit den B-Zellen die zellul\u00e4re Ebene des adaptiven Immunsystems. T-Zellen werden in 2 gro\u00dfe Hauptgruppen, die CD4+ und CD8+ T-Zellen, eingeteilt. Des Weiteren werden Mikromilieu-assoziierte, funktionelle, lokal begrenzte und differenzierungsverankerte Subtypen beschrieben. Diese T-Zell-Subtypen unterscheiden sich ph\u00e4notypisch durch Zelloberfl\u00e4chenmolek\u00fcle bzw. Differenzierungsmarker und durch ihre vielgestaltigen Funktionen. T-Zell-Subtypen repr\u00e4sentieren keine starren, sondern plastische Ph\u00e4notypen, d.h., sie k\u00f6nnen zu einem bestimmten Zeitpunkt an einem Entz\u00fcndungsort dem einen oder anderen Subtyp angeh\u00f6ren, wobei diese Zugeh\u00f6rigkeit in einem anderen immunologischen Kontext ver\u00e4ndert werden kann. Dies setzt eine gewisse Langlebigkeit dieses Zelltyps voraus; und in der Tat sind T-Zellen der Gesamtlebenszeit verschiedener Organismen angepasst, wobei sie bis zu Jahrzehnten \u00fcberleben und in dem erforderlichen Immungeschehen entsprechend aktiv werden k\u00f6nnen. Die T-Zell-Entwicklung wird ab dem Stadium der Lymphozytenprogenitoren, die das Knochenmark verlassen haben, \u00fcber verschiedene Stufen in unterschiedlich strukturierten Bereichen des Thymusgewebes vollzogen. Die unterschiedlichen  T-Zell-Entwicklungsstufen sind durch eine differentielle Expression der Korezeptoren CD4 und CD8 auf der Zelloberfl\u00e4che gekennzeichnet. Um T-Zellen zu entwickeln, die als naive CD4 bzw. CD8 einzel positive T-Zellen den Thymus verlassen, sind vor allem 2 Transkriptionsfaktoren verantwortlich. Dies sind die Transkriptionsfaktoren ThPOK f\u00fcr CD4+ T-Zellen und Runx3 f\u00fcr CD8+ T-Zellen. ThPOK bindet das CD8a Verst\u00e4rkerelement (engl. Enhancer) und unterdr\u00fcckt die Transkription von CD8 und anderen zytotoxischen Effektorgenen. Parallel bindet es an das geneigene D\u00e4mpfer- (engl. Silencer) Element und steuert dadurch die kontinuierliche Eigentranskription, was letztlich zu einer CD4 T-Zellentwicklung f\u00fchrt (Egawa and Littman 2008, Wang et al. 2008, Mucida et al. 2013). Die Funktion von Runx3 f\u00fcr die CD8 T-Zellentwicklung ist \u00e4hnlich.   Naive T-Zellen werden in die Peripherie entlassen und k\u00f6nnen dort nach einer Aktivierung in die verschiedenen Differenzierungsstadien (Effektor-Ged\u00e4chtniszellen, zentrale Ged\u00e4chtniszellen und terminal differenzierte Effektorzellen) \u00fcbergehen. \t\n\t2\t\t\t\t\t\t(Abb.1). Die F\u00e4higkeit der T-Zellen, infolge einer Aktivierung in verschiedene Differenzierungsstufen zu wechseln, diese zu erhalten bzw. kontextspezifisch anzupassen, begr\u00fcndet die enorme Leistung des adaptiven Immunsystems, den vielf\u00e4ltigen Aufgaben ad\u00e4quat zu begegnen. \n Im gealterten Organismus ist der Thymus als prim\u00e4res lymphatisches Organ zur\u00fcckgebildet. Naive T-Zellen in der Peripherie \u00fcbernehmen eine Art Stammzellfunktion und erhalten das T-Zell-Kompartiment durch hom\u00f6ostatische Proliferation, periphere Selektion und Aktivierung verschiedener Differenzierungsprogramme (Yanes et al. 2017). T-Zellen werden spezifisch \u00fcber im HLA-Kontext pr\u00e4sentierte Peptide (auch Antigene oder Peptidantigene), die nach Spaltung aus Proteinen entstehen, \u00fcber ihren T-Zell-Rezeptorkomplex (TZR) aktiviert. Eine T-Zelle tr\u00e4gt jeweils nur einen bestimmten T-Zell-Rezeptor, der durch Kreuzreaktivit\u00e4ten allerdings spezifisch f\u00fcr mehrere Peptide sein kann (Birnbaum et al. 2014). Der gr\u00f6\u00dfte Teil der T-Zellen des Blutes tr\u00e4gt TZR mit \u03b1\u03b2-Ketten, nur 1-5 % der T-Zellen des Blutes exprimieren TZR mit \u03b3\u03b4 Ketten. T-Zellen des \u03b3\u03b4 Ketten-Typs zeichnen sich durch ihre F\u00e4higkeit aus, Nicht-Peptidantigene, wie z.B. Phosphoantigene des Isoprenoid-Metabolismus HLA-Antigen-Komplex-unabh\u00e4ngig zu erkennen. T-Zellen mit \u03b3\u03b4 TZR sind vorrangig in muk\u00f6sen Geweben, z.B. der Darmmukosa oder im Epithel der Lunge lokalisiert.  Die Peptidpr\u00e4sentation f\u00fcr die Aktivierung von T-Zellen des \u03b1\u03b2-Ketten-Typs wird von professionellen Antigen-pr\u00e4sentierenden Zellen (APZ) (Abb. 2, dendritische Zellen, \n\t\nAbb.1 Darstellung der T-Zell-Differenzierungsmarker. Differenzierungsstufen CD4 und CD8 positiver T-Zellen werden durchflusszytometrisch entsprechend der Expression nachfolgend aufgef\u00fchrter Oberfl\u00e4chenmarker unterschieden: naiv (naive): CD45RA+CCR7+CD27++CD28++, zentrale Ged\u00e4chtniszellen (CM) CD45RA-CD45RO+CCR7+CD27+++CD28+++, Effektor-Ged\u00e4chtniszellen (EM) CD45RA- CD45RO+CCR7-CD27+/-CD28+/-PD1+, terminal differenzierte Effektor-Ged\u00e4chtniszellen (TEMRA) CD45RA+CCR7-CD27-CD28-PD1+CD57+KLRG1+,  modifiziert nach (Larbi and Fulop 2014) \t\t\n\t3\t\t\t\t\t\tMonozyten/Makrophagen, B-Zellen) oder aber von nicht-professionellen Antigen-pr\u00e4sentierenden Zellen (konstitutiv HLA Klasse I tragende K\u00f6rperzellen verschiedener Organe, K\u00f6rperzellen, die durch Zytokine HLA Klasse II exprimieren oder \u03b3\u03b4 T-Zellen, \u00fcber deren HLA Klasse I Expression) \u00fcbernommen. Peptidantigene werden f\u00fcr die Pr\u00e4sentation auf der Zelloberfl\u00e4che auf Molek\u00fcle des Haupthistokompatibilit\u00e4tskomplex (HLA) geladen, nachdem eine komplexe intrazellul\u00e4re Antigen-Prozessierung mit Passage des Ubiquitin-Proteasoms und des lysosomalen Systems erfolgt ist (Wieczorek et al. 2017).  Im Allgemeinen werden CD4 positive T-Zellen (T-Helferzellen) durch einen Antigen-HLA-Komplex der HLA-Klasse II Molek\u00fcle, die bevorzugt extrazellul\u00e4re/exogene Peptide pr\u00e4sentieren, aktiviert. CD8 positive, sogenannte zytotoxische, T-Zellen hingegen werden durch einen Antigen-HLA-Komplex unter Beteiligung der HLA-Klasse I Molek\u00fcle, die bevorzugt zytosolische/endogene Peptide pr\u00e4sentieren, aktiviert.  Die Funktion der Korezeptoren CD4 und CD8 liegt in der Stabilisierung des Peptid-HLA-TZR Komplexes auf der Zelloberfl\u00e4che und in der Assoziation verschiedener intrazellul\u00e4rer Signalmolek\u00fcle, die zur Aktivierung von T-Zellen f\u00fchren (Doyle and Strominger 1987, Barber et al. 1989, Salter et al. 1990). Eine komplexe Kaskade verschiedener Signalmolek\u00fcle f\u00fchrt letztlich zur klonalen Expansion und zu verschiedenen T-zellul\u00e4ren Effektorfunktionen, wie Zytokinsekretion, B-Zellaktivierung oder die Apoptoseinduktion in Zielzellen. T-Zellen finden sich im K\u00f6rper nicht nur im Blut, in prim\u00e4ren (Knochenmark, Thymus) und sekund\u00e4ren Lymphorganen (Milz, Lymphknoten, Tonsillen, Peyerschen Plaques, Appendix), sondern in der Haut, dem Intestinaltrakt und der Lunge. Die Verteilung der unterschiedlichen T-Zell-Differenzierungsstadien ist in den Geweben stark unterschiedlich (Sathaliyawala et al. 2013).   \t\n\t4\t\t\t\t\t\t \nAbb.2 Schema der T-Zell-Aktivierung. Die Ketten des T-Zell-Rezeptorheterodimers und dessen Ko-Rezeptoren CD4 bzw. CD8 sind assoziiert mit Tyrosinkinasen. Zahlreiche Signalmolek\u00fcle (u.a. Src Kinasen und ZAP70) sind an der Weiterleitung des durch die Bindung des TZRs an Peptid-HLA Komplexe initiierten Aktivierungssignals, beteiligt.  Sie f\u00fchren letztlich zu multiplen zellul\u00e4ren Ver\u00e4nderungen, die f\u00fcr die T-Zell-Effektorfunktionen notwendig sind. Peptide/MHC-Complex = Peptide/HLA-Komplex (Whitacre et al. 2012).\t\n\t\n\t5\t\t\t\t\t\t   1.1.1.CD4+ T-Helferzellen  CD4 positive T-Helferzellen (Th) haben vielgestaltige Aufgaben im adaptiven Immunsystem, die durch eine Aufgabenteilung spezialisierter Th-Untergruppen m\u00f6glich wird. Th-Zellen sezernieren eine Vielzahl verschiedener Zytokine. Z.B. leisten sie den B-Zellen Hilfe (durch Th2-Zytokine) bei der Antik\u00f6rperproduktion, aktivieren u.a. Makrophagen (durch Th1-Zytokine) vor allem im Zuge der Erkennung, Prozessierung und Pr\u00e4sentation von exogenen Antigenen bakteriellen Ursprungs. Th17-Zellen bilden eine Spezialeinheit, die vorrangig f\u00fcr die Bek\u00e4mpfung von Pilzen, aber auch Bakterien in der Haut und auf muk\u00f6sen Oberfl\u00e4chen verantwortlich sind (Wacleche et al. 2017). T-Follikulare Helferzellen (TFh) wurden anhand ihres Transkriptionsprofils und ihrer F\u00e4higkeit die B-Zellen zu unterst\u00fctzen, bei fehlendem Vorkommen der Th2 T-Zellen, als eigene T-Helfer-Zellpopulation mit Lokalisation im Follikel und Blut  identifiziert (Ma and Phan 2017). CD4+ Treg Zellen sind zus\u00e4tzlich zu anderen Funktionen f\u00fcr die Aufrechterhaltung der peripheren und zentralen Toleranz als Mechanismus zur Verhinderung der Autoimmunit\u00e4t zust\u00e4ndig (Kraj and Ignatowicz 2017). Weitere CD4 Th-Subzelltypen, die sich durch die Produktion von IL-9 (Th9) bzw. IL-22 (Th22) auszeichnen, wurden in j\u00fcngerer Vergangenheit identifiziert (Geginat et al. 2014). Nach neueren Erkenntnissen ist davon auszugehen, dass eine Differenzierung naiver CD4+ T-Zellen zu Th1, Th2, Th17, TFh und Treg-Zellen in bestimmten Zwischenstufen einer Reprogrammierbarkeit unterliegt, die durch das vorhandene Zytokinmilieu (ma\u00dfgeblich IL-2, IL-4, IL-6, IL-12, IL-21, IFN\u03b3 und TGF-\u03b2) gesteuert wird (DuPage and Bluestone 2016). Die Zytokin-mediierte Plastizit\u00e4t der T-Helferzellpopulationen sorgt f\u00fcr die notwendige Flexibilit\u00e4t der adaptiven T-Zell- Immunit\u00e4t. Im Falle von Immunpathologien wurden Th1/Th17-T-Zellen vor allem bei Autoimmunerkrankungen wie Multipler Sklerose (MS), Diabetes mellitus Typ 1 oder auch rheumatoider Arthritis (RA) als Effektor-T-Zellen identifiziert (Crane and Forrester 2005). Th2 Zytokine produzierende T-Zellen kennzeichnen die Autoimmunkrankheit Systemischer Lupus Erythematodes (SLE) und weitere Immunpathologien wie Allergien, Asthma und reaktive Arthritis (Quandt 2006). TFh \t\n\t6\t\t\t\t\t\tT-Zellen zeigen Funktionsst\u00f6rungen bei diversen Autoimmunkrankheiten, wie z.B. der RA, SLE und der MS (Ma and Deenick 2014).  1.1.2. CD8+ Zytotoxische T-Zellen Ihrem Namen entsprechend besteht die Hauptaufgabe von CD8+ T-Zellen darin, Zielzellen zu t\u00f6ten. Dieser Vorgang wird nach Aktivierung durch den entsprechenden TZR-HLA-Antigenkomplex und unter Einschaltung verschiedener molekularer Signalwege (\u00fcber Perforin/Granzym bzw. TRAIL-R/TRAIL oder Fas/FasL) gezielt und gerichtet eingeleitet (Martinez-Lostao et al. 2015). Zu t\u00f6tende Zellen sind meist viral infiziert oder hinsichtlich ihrer Expression von Tumorantigenen ver\u00e4ndert. Dar\u00fcber hinaus k\u00f6nnen CD8+ T-Zellen suppressorische Aktivit\u00e4ten entwickeln, wobei sie dendritische Zellen in einen tolerogenen Zustand versetzen. Durch diesen Prozess werden CD4+ T-Zell-Antworten blockiert (Xu et al. 2016). Die Entscheidung, ob eine naive CD8 T-Zelle zu einer kurzlebigen Effektorzelle oder zu einer langlebigen Ged\u00e4chtniszelle differenziert, wird durch viele Faktoren, wie die St\u00e4rke des TZR Signals, beteiligte kostimulatorische Molek\u00fcle, Transkriptions-faktoren und das sogenannte immunologische Mikromilieu bedingt (Chang et al. 2014). Aus einer naiven T-Zelle mit einer TZR-Spezifit\u00e4t somit sowohl Effektor-T-Zellen als auch Ged\u00e4chtnis-T-Zellen (Gerlach et al. 2010). Verschiedene Modelle beschreiben die Wege dieser Differenzierung, wobei im wesentlichen 2 dieser Modelle im Fokus stehen. Dies ist zum einen das Modell der Abspaltung von Ged\u00e4chtniszellen aus naiven T-Zellen direkt nach der T-Zell-Aktivierung und zum anderen das Modell der Generierung von Ged\u00e4chtniszellen aus vorherigen Effektorzellen. Changs Ergebnisse einer asymmetrischen ersten Zellteilung unterst\u00fctzen das erste Modell (Chang et al. 2007). Neuste Forschungsarbeiten an humanen Gelbfieber-spezifischen T-Zellen hingegen belegen, dass Ged\u00e4chtniszellen aus stark proliferierenden Effektorzellen differenzieren, die Effektormolek\u00fcle abschalten und Transkriptionsprofile naiver Zellen neu erwerben (Akondy et al. 2017). Ebenfalls von h\u00f6chster Wichtigkeit sind in diesem Kontext Erkenntnisse zu CD8 T-Zellen mit einem Stammzell-\u00e4hnlichen Potential, die als distinkte T-Zell-Population neben konventionellen Ged\u00e4chtniszellen nach einer Infektion zur\u00fcckbleiben. Diesen T-Zellen wird \u00e4hnlich wie von Chang 2007 postuliert nach Aktivierung eine sehr fr\u00fche Abspaltung von den Effektor-T-Zellen attestiert (Restifo 2014).  \t\n\t7\t\t\t\t\t\tJ\u00fcngste Forschungsarbeiten zeigen eine beachtenswerte Abh\u00e4ngigkeit der CD8 T-Zell-Differenzierung von der Aktivit\u00e4t des Proteasoms. Das Proteasom ist ein Multiproteinkomplex, der f\u00fcr den geordneten Abbau von Proteinen in der Zelle und damit fundamental f\u00fcr das Zell\u00fcberleben verantwortlich ist (Finley 2009). Effektor CD8+ T-Zellen weisen eine geringe Proteasomaktivit\u00e4t auf, wohingegen Ged\u00e4chtnis CD8+ T-Zellen im pr\u00e4klinischen Mausmodell eine hohe Proteasomaktivit\u00e4t  besitzen (Widjaja et al. 2017). Manipulatoren der Proteasomaktivit\u00e4t, denen derzeit ein hohes therapeutisches Potential zugesprochen wird (Cromm and Crews 2017), k\u00f6nnten daher ma\u00dfgeblich in die T-Zell-Differenzierung eingreifen. Die Identifikation von CD4+ T-Zellen, die nicht wie zuvor beschrieben Helferfunktionen \u00fcbernehmen, sondern zytotoxisch wirken, und CD8+ T-Zellen, die nicht t\u00f6ten, aber B-Zellhilfe leisten, zeigt eine h\u00f6here Komplexit\u00e4t T-Zell-vermittelter Immunantworten auf (Wagner et al. 1998, Brown 2010). Diese T-Zellen k\u00f6nnen somit auf ein vorhandenes Antigenspektrum sowohl im Kontext einer HLA Klasse I- (CD8+) als auch einer HLA Klasse II (CD4+) vermittelten Antigenpr\u00e4sentation mit der auf die Situation angepassten Effektorreaktion immunologisch t\u00e4tig werden.   1.1.3. CD4+CD8+ doppelt positive (DP) T-Zellen CD4+CD8+ DP T-Zellen geh\u00f6ren als intermedi\u00e4re Entwicklungsstufe der T-Zell-Reifung zum typischen Bild einer durchflusszytometrischen T-Zell-Analyse im Thymus (Issuree et al. 2017). Periphere DP (CD4+CD8+) T-Zellen sind mit einer H\u00e4ufigkeit von 0,5-1% der T-Zellen im Blut von gesunden Probanden zu finden (Parel and Chizzolini 2004). Bereits vor \u00fcber 25 Jahren wurden sie erstmalig beschrieben (Paliard et al. 1988). Die Zahl, die Antigenspezifit\u00e4t, das Effektorpotential und die Lokalisation dieser DP T-Zellen unterscheiden sich vom gesunden Normalbild im Falle von Autoimmunit\u00e4t, Virusinfektionen und Tumorerkrankungen, wodurch eine pathologische Rolle dieser Zellen impliziert wird (Nascimbeni et al. 2004, Parel et al. 2007, Desfrancois et al. 2010).  \t\n\t8\t\t\t\t\t\tObwohl noch nicht abschlie\u00dfend verstanden, wird davon ausgegangen, dass diese T-Zellen nicht dem Stadium unreifer CD4+CD8+-Thymozyten entspringen, sondern bereits aus einfach-positiven CD4+ bzw. CD8+ T-Zellen in der Peripherie entstehen (Abb.3).  Diese Hypothese wird durch das Fehlen von Markern unreifer, sich noch entwickelnder T-Zellen (Nascimbeni et al. 2004), und durch eine \u00e4hnlich hohe TZR-Dichte auf CD4+CD8+-T-Zellen wie auf CD4+ bzw. CD8+ einzel positiven peripheren T-Zellen (Paliard et al. 1988) unterst\u00fctzt. Hinweise f\u00fcr das Entstehen DP (s.o.) T-Zellen in der Peripherie bietet ebenfalls eine Arbeit \u00fcber Patienten/Patientinnen, die unter einem akuten T-Zell-Lymphom leiden. In ihnen exprimieren die entarteten peripheren CD4+ T-Zellen im Verlauf der Erkrankung zus\u00e4tzlich das CD8 Molek\u00fcl, ohne unmittelbar zuvor dem Thymus entsprungen zu sein (Yamada et al. 1984).  Auf Transkriptionsfaktorebene konnte gezeigt werden, dass die f\u00fcr den Thymus zun\u00e4chst als exklusiv beschriebene Ko-Expression von ThPOK oder Runx3 auch f\u00fcr periphere T-Zellen zutreffen kann. Eine gleichzeitige Expression beider Marker ist folglich m\u00f6glich, womit eine weitere Erkl\u00e4rung f\u00fcr das Zustandekommen peripherer CD4+CD8+ T-Zellen geliefert wurde (Reis et al. 2013).  DP T-Zellen (Colombatti et al. 1998, Ghia et al. 2007) steigen \u00e4hnlich anderen T-Zell-Populationen zahlenm\u00e4\u00dfig mit dem Alter an.  \nAbb.3  Darstellung der DP (CD4+CD8+) T-Zellen Doppelt positive T-Zellen w\u00e4hrend der T-Zell-Entwicklung im Thymus (immature Thymozyten) und als gereifte (mature) T- Zellen, die aus einzel CD4+ bzw. CD8+ T-Zellen hervorgehen (Parel and Chizzolini 2004) \t\t\n\t9\t\t\t\t\t\tEs werden 3 Subgruppen CD4+CD8+ DP T-Zellen, die sich durch eine unterschiedliche Korezeptorst\u00e4rke auszeichnen (CD4++CD8+, CD4++CD8++ und CD4+CD8++), differenziert (Parel and Chizzolini 2004).  Im Gegensatz zu anderen altersassoziierten T-Zell-Populationen werden DP T-Zellen als multifunktionell charakterisiert. Es konnte beispielsweise gezeigt werden, dass intratumorale DP T-Zellen in Melanompatienten/-patientinnen eine hohe Produktion an pro-inflammatorischem TNF\u03b1 und anti-inflammatorischen IL-4, IL-5 und IL-13 aufweisen und DP T-Zellen autologe Melanomzellen t\u00f6ten k\u00f6nnen (Desfrancois et al. 2010). In HIV Patienten/Patientinnen weisen DP T-Zellen eine Multifunktionalit\u00e4t auf, die unabh\u00e4ngig von Immunantworten anderer T-Zell-Populationen ist (Frahm et al. 2012). Sehr interessant in diesem Zusammenhang ist au\u00dferdem eine Arbeit aus dem Jahr 2007 an Patienten/Patientinnen mit systemischer Sklerose, in der gezeigt wurde, dass DP T-Zellen sowohl IFN\u03b3 als auch IL-4 produzieren und zytotoxische parallel zu B-Zellhelferaktivit\u00e4t aufweisen (Parel et al. 2007). Die Tatsache, dass DP T-Zellen durch die Expression von CD4 und CD8 Molek\u00fclen mit Antigenen, die auf HLA-I und HLA-II exprimiert werden, interagieren k\u00f6nnen, erm\u00f6glicht ihnen ein weitaus breiteres Wirkspektrum als einzel CD4+ bzw. CD8+ positiven T-Zellen.  1.2. Die Steuerung von T-Zell-Antworten T-Zell-Antworten m\u00fcssen f\u00fcr eine optimale protektive Immunit\u00e4t bei paralleler Verhinderung von Autoimmunit\u00e4t sorgf\u00e4ltig gesteuert werden. Diese Steuerung wird ma\u00dfgeblich durch Liganden und Rezeptoren der Kostimulatoren, z.B. der B7-Familie bewerkstelligt, welche kostimulatorische bzw koinhibitorische Funktionen warnehmen (Schildberg et al. 2016). Gemeinhin versteht man unter kostimulatorischer Wirkweise die Unterst\u00fctzung der T-Zell-Antworten, wobei koinhibitorische Signale die T-Zell-Antwort trotz spezifischer Antigenerkennung \u00fcber den TZR-Peptid-HLA Komplex unterdr\u00fccken (Abb.3). T-Zell-Aktivierung ist daher abh\u00e4ngig von der Antigenspezifit\u00e4t und der korrekten Pr\u00e4sentation des Antigens \u00fcber den TZR-Peptid-HLA Komplex (Signal 1), aber auch von weiteren Signalgebern, wie den Molek\u00fclen der Kostimulatoren, die \u00fcber Rezeptor-Ligand-Interaktionen (Signal 2) agieren (Abb.4). Die Liganden der Mitglieder der B7-Familie (B7-H1=PD-L1, B7-H2, B7-DC, B7-H3, B7-H4, B7-H6, B7-H7) werden zumeist von Antigen-pr\u00e4sentierenden Zellen exprimiert. Aber auch aktivierte T-Zellen (Khanna et al. 2016) bzw. K\u00f6rperzellen (z.B. \t\n\t10\t\t\t\t\t\tEpithelzellen) (Cao et al. 2011) und Stroma-Zellen des Knochenmarks (Xu et al. 2011) k\u00f6nnen diese Molek\u00fcle exprimieren und zeigen damit eine weitere Ebene der Regulation von T-Zell-Antworten auf. Zytokine werden als Signal 3 der T-Zell-Aktivierung betrachtet. Ohne eine koordinierte Zytokinsekretion werden T-Zellen auch bei optimalen Signal 1 und 2 Impulsen nicht ad\u00e4quat aktiviert (Curtsinger et al. 1999). Bemerkenswerterweise kann ein \u00fcberschie\u00dfendes Vorkommen an Zytokinen vor der \u201eAbfrage\u201c von Signal 1 und 2 die Antigen-spezifische Aktivierung von CD4+ T-Zellen verhindern (Sckisel et al. 2015). Die Ligandenexpression kostimuatorischer/koninhibtorischer Molek\u00fcle, beispielhaft f\u00fcr PD-L1, ist vielschichtig, geschieht \u00fcber Zytokine, vor allem \u00fcber Typ II Interferone wie das IFN\u03b3 (Blank et al. 2005) und \u00fcber transkriptionelle und posttranskriptionelle Steuerung (Chen et al. 2016).   Adh\u00e4sionsmolek\u00fcle wie LFA-1 sind zus\u00e4tzlich wichtig f\u00fcr eine koordinierte T-Zell-Antwort und damit wichtige Steuerelemente der T-Zell-Aktivierung (Grakoui et al. 1999). Adh\u00e4sionsmolek\u00fcle unterst\u00fctzen die Bildung der immunologischen Synapse. Die Formierung einer immunologischen Synapse, einer strukturellen Einheit an der Kontaktzone zwischen T-Zelle und APZ (Mukherjee et al. 2017), in der sich alle Molek\u00fcle der T-Zell-Aktivierung eng versammeln, wurde erstmals vor mehr als 20 Jahren beschrieben (Paul and Seder 1994). \t\n\t11\t\t\t\t\t\tEin zukunftsweisender Forschungszweig, der T-Zell-Antworten steuert, ist die M\u00f6glichkeit der T-Zell-Aktivierung \u00fcber Antigen-HLA-Komplexe, die in von dendritischen Zellen abgeschn\u00fcrten Exosomen eingebettet sind (Robbins and Morelli 2014). Exosomen bilden 30-120 nm gro\u00dfe extrazellul\u00e4re Vesikel, die von diversen Zellen abgeschn\u00fcrt werden. Sie entfalten lokale und systemische Wirkung, indem sie Proteine, Peptide, HLA, RNA, DNA und Metabolite tragen bzw. einschlie\u00dfen, die in verschiedene Regionen des K\u00f6rpers transportiert werden (Thery et al. 2009). Exosomen mit Antigen-HLA-Komplexen k\u00f6nnen T-Zellen entweder direkt (ohne weitere Zellhilfe, Kostimulation auf Exosomen vorhanden) oder indirekt (Hilfe von dendritischen Zellen, die als sogenannte \u201eZuschauer\u201c engl. Bystander, Kostimulation liefern) aktivieren (Robbins and Morelli 2014).  \nDie Steuerung von T-Zell-Antworten findet \u00fcber die geschilderten Prozesse hinaus auf mehreren weiteren Regulationsebenen statt, beispielsweise \u00fcber \nAbb.4 Signal 1 und Signal 2 der T-Zell-Aktivierung Die Aktivierung von T-Zellen erfolgt \u00fcber a) Signal 1 = Peptide-MHC-TZR und Signal 2 = Kostimulation b) Ligand-Rezeptorbeziehungen von B7 Familienmitgliedern (Seliger and Quandt 2012)\t\n\t\n\t12\t\t\t\t\t\tposttranslationale Modifikationen bestimmter Effektorgene (Perforin, Granzym, IFN\u03b3, IL-2) durch RNA-bindende Proteine (RBP), non-coding RNAs und cis-regulatorische Elemente (Salerno and Wolkers 2015). Interessanterweise konnte gezeigt werden, dass es nach Kreuzvernetzung von CD28 bzw. LFA-1 durch NF-90, ein RBP, zur mRNA Stabilisierung von IFN\u03b3 und IL-2 kommt (Shim et al. 2002, Wang et al. 2006).  T-Zell-Abschaltung, respektive Stopp von IFN\u03b3 Produktion, wird ebenfalls posttranslational durch Bindung eines mRNA abbauenden Molek\u00fcls Tristetrapolin (TTP) gesteuert (Ogilvie et al. 2009).  Neueste Forschungsarbeiten dokumentieren die Anpassung des T-Zell-Metabolismus \u00fcber AMPK, ein Regulator intrazellul\u00e4rer ATP Level, als Steuerelement von T-Zell-Antworten (Ma et al. 2017).  Dar\u00fcber hinaus haben Entwicklungen unserer modernen Gesellschaft, wie ein verst\u00e4rktes Auftreten von Adipositas (Green and Beck 2017) und das l\u00e4ngere \u00dcberleben (Yanes et al. 2017), einen profunden Einfluss auf  das T-zellimmunologische Aktionspotenzial durch Ver\u00e4nderungen in der Hom\u00f6ostase und Plastizit\u00e4t.    \t\n\t13\t\t\t\t\t\t1.3. T-Zell-Immunit\u00e4t im Melanom und Nierenzellkarzinom   Melanome und Nierenzellkarzinome sind solide, immunogene Tumore, die komplexe Interaktionen mit dem Immunsystem eingehen.  T-Zellen erkennen tumorassoziierte Antigene (TAA) auf Antigen-HLA Komplexen, die sich aus Proteinen verschiedener biologischer Klassen rekrutieren. Es werden Differenzierungsantigene, gewebsspezifische Antigene, mutierte Antigene die im Zusammenhang mit der Onkogenese bzw. urs\u00e4chlich f\u00fcr das Tumorwachstum verantwortlich sind, unterschieden (Pitcovski et al. 2017). Im Tumormikromilieu finden sich bei immunogenen Tumoren zahlreiche Vertreter des Immunsystems, unter ihnen CD4+ und CD8+ T-Zellen. Entscheidend f\u00fcr den Verlauf der Erkrankung und die Therapierbarkeit der Tumore sind dabei nicht allein die Anzahl der Immunzellen, sondern das Verh\u00e4ltnis verschiedener Populationen zueinander und die genaue Lokalisation im Tumorgewebe (Bindea et al. 2013). T-Zellen werden h\u00e4ufig in lokalen angrenzenden Lymphknoten aktiviert und wandern dann ins Tumorgewebe ein. Es kann aber ebenfalls im Tumor direkt zu einer Antigen-spezifischen Prim\u00e4raktivierung oder einer \u201eZuschauer\u201c gleichbedeutend mit einer Antigen-unspezifischen T-Zell-Aktivierung kommen. Die Tumore k\u00f6nnen Zellen der angeborenen und erworbenen Immunit\u00e4t f\u00fcr ihre Entwicklung nutzen. T-Zellen und andere Immunzellen, die sich gegen den Tumor richten, k\u00f6nnen in ihrer Funktion blockiert werden, wodurch Tumore sich der Bek\u00e4mpfung durch das Immunsystem entziehen (Chen and Mellman 2017). Tumorzellen, u.a. Melanome und Nierenzellkarzinome, exprimieren Kostimulatoren/Koinhibitoren, beispielsweise der B7-Familie, wodurch sie direkt T-Zell-Antworten steuern k\u00f6nnen (Seliger and Quandt 2012). Die Expression von PD-L1 wird durch verschiedene Signalwege, wie den PI3k und MAPK Weg, \u00fcber Zytokine und epigenetisch beispielsweise \u00fcber microRNAs kontrolliert (Atefi et al. 2014, Chen et al. 2016). Chemotherapeutika und Radiotherapien k\u00f6nnen wissenswerterweise ebenfalls die Expression und damit Funktion von kostimulatorischen Molek\u00fclen, wie f\u00fcr PD-L1 gezeigt, modulieren (Deng et al. 2014, Funaki et al. 2017). Ein Zusammenhang zwischen dem seneszenten Immunsystem und dem vermindert erfolgreichen Kampf des Immunsystems gegen Krebs wurde und wird zunehmend entschl\u00fcsselt (Hurez et al. 2017). \t\n\t14\t\t\t\t\t\tModerne Krebstherapie adressiert das Immunsystem, im Besonderen die T-Zellen. Molek\u00fcle der Kostimulation stehen dabei im Mittelpunkt, es wird versucht koinhibitorische Molek\u00fcle wie CTLA-4 und PD-1 mittels spezifischer Antik\u00f6rper (Ipilimumab, Nivolumab oder Pembroluzimab) zu blockieren, um eine Inhibition/Abschaltung spezifischer T-Zell-Antworten gegen den Tumor aufzuheben (Mazza et al. 2017, O'Reilly and Larkin 2017). Diese neuen Immuntherapien f\u00fchren zu guten Erfolgen bei der Krebsbek\u00e4mpfung einiger Patienten/Patientinnen, f\u00fchren jedoch bei anderen Patienten/Patientinnen zu Autoimmunph\u00e4nomenen wie beispielsweise zur rheumatoiden Arthritis (Cappelli et al. 2017). Dies ist vermutlich der T-Zell-Antigen-unspezifischen Aufhebung wichtiger T-Zell-Kontrollelemente geschuldet.  1.4. Rheumatoide Arthritis \u2013 eine T-Zell-gesteuerte Autoimmunerkrankung Die rheumatoide Arthritis ist eine systemische Autoimmunerkrankung, bei der durch entz\u00fcndliche Prozesse im Gelenk das Knorpel- und Knochengewebe gesch\u00e4digt wird (McInnes and Schett 2011). Die entz\u00fcndlichen Prozesse im Gelenk f\u00fchren letztlich h\u00e4ufig zum Knorpelabbau und zur Knochendestruktion. Die zellul\u00e4re Beteiligung erstreckt sich \u00fcber das angeborene und erworbene Immunsystem. Des Weiteren  sind gelenksresidente Zellen wie Synoviozyten und Knorpelzellen im synovialen Gewebe an der Pathogenese beteiligt (Angelotti et al. 2017). In einem substanziellen Teil der RA-Patienten/-Patientinnen findet man Autoantik\u00f6rper gegen posttranslational modifizierte Proteine (Nakken et al. 2017). Dazu z\u00e4hlen citrullinierte Proteine, die durch die Aktivit\u00e4t einer Peptidylarginin Deaminase, die Citrullin gegen Arginin tauscht, entstehen.  Die Bedeutung der T-Zellen f\u00fcr die RA wurde bereits vor \u00fcber 30 Jahren entdeckt, als genetische Assoziationsstudien eine Pr\u00e4valenz HLA-DR1 (auch bekannt als shared epitope) und -DR4 tragender Personen f\u00fcr die Entwicklung einer Arthritis aufdeckten (Stastny 1978, Gregersen et al. 1987). In j\u00fcngeren Tagen wird oft von multifaktoriellen Voraussetzungen f\u00fcr die Entwicklung einer RA gesprochen, die HLA-DR Molek\u00fcle geh\u00f6ren nach wie vor dazu (Messemaker et al. 2015). Im Falle von Autoimmunerkrankungen richten sich aus noch ungekl\u00e4rter Ursache CD4+ aber auch CD8+ T-Zellen gegen k\u00f6rpereigene Strukturen (Autoantigene), und l\u00f6sen somit eine Kaskade an Ereignissen aus, die zur organspezifischen Zerst\u00f6rung \t\n\t15\t\t\t\t\t\tf\u00fchrt. Neben den sehr intensiv studierten CD4 positiven T-Zellen, die Autoantigene erkennen, konnten in verschiedenen Autoimmunkrankheiten (RA, Diabetes mellitus, Multiple Sklerose) CD8 positive Zellen identifiziert werden, die aktiv in den pathologischen Prozess eingreifen (Wagner et al. 1998, Friese and Fugger 2009, Mallone et al. 2011). F\u00fcr die Pathogenit\u00e4t CD4 positiver T-Helferzellen bei der RA ist das Verh\u00e4ltnis von Th1, Th17 und Treg Zellen wichtig. Moderne immunologische Therapieverfahren bei der RA schlie\u00dfen anti-TNF\u03b1 Antik\u00f6rper (z.B. Adalimumab) und Antik\u00f6rper gegen den IL-6R (z.B. Tocilizumab) ein (Smolen et al. 2017). Tocilizumab verhindert IL-6 Rezeptorbindung, wodurch die Aktion des pleitropen Zytokins, welches u.a. Th17 Differenzierung bef\u00f6rdert und Treg-Zellen unterdr\u00fcckt, inhibiert wird (Schinnerling et al. 2017).   1.5. Cytomegalovirusinfektionen (CMV) \u2013 T-zellul\u00e4re Ver\u00e4nderungen Das Cytomegalievirus (CMV) geh\u00f6rt zur Familie der Herpesviridae und bleibt dem Menschen nach dem Erstkontakt als latente Infektion ein Leben lang erhalten. Die Latenzorte f\u00fcr den Virus sind zahlreich, es kann in Endothelzellen, renalen Epithelzellen, im Gewebe der Lunge und in Immunzellen myeloiden Ursprungs in einem ruhenden Zustand \u00fcberleben (Gerna et al. 2004).  CMV Infektionen hinterlassen deutliche Spuren in T-zellul\u00e4ren aber auch in Nat\u00fcrlichen Killerzell-Kompartimenten des adaptiven/angeborenen Immunsystems in gesunden Probanden (Appay et al. 2008, Heath et al. 2016). Es kommt zu einem differenzierten T-zellul\u00e4ren Ph\u00e4notyp mit erh\u00f6htem Verlust des Kostimulators CD28 auf CD4 und CD8 positiven T-Zellen, zur verst\u00e4rkten Expression des Seneszenzmarkers CD57 und des inhibitorischen Rezeptors LIR-1, sowie in einem Teil der T-Zellen zu einem erh\u00f6hten zytotoxischen Potential  (Northfield et al. 2005, Pourgheysari et al. 2007, Appay et al. 2008). Chronische Virusinfektionen wie CMV, aber auch maligne Neoplasien f\u00fchren zum verst\u00e4rkten Auftreten von dysfunktionellen, ersch\u00f6pften CD8+ T-Zellen. Diese T-Zellen sind durch ein komplexes Oberfl\u00e4chenmarkerprofil welches weitestgehend dem TEMRA Differenzierungsstadium (Abb.1) entspricht, den Verlust der Proliferationsf\u00e4higkeit und durch funktionelle Inaktivit\u00e4t gekennzeichnet.   Ersch\u00f6pfte T-Zellen zeigen einige Gemeinsamkeiten mit seneszenten T-Zellen. Der wichtigste Unterschied liegt im Verlust von Haupt-Effektorfunktionen, wie die \t\n\t16\t\t\t\t\t\tF\u00e4higkeit, Zytokine zu sezernieren und Zielzellen zu t\u00f6ten (Akbar and Henson 2011). Seneszente T-Zellen zeigen bisweilen erh\u00f6hte Effektorfunktionen, die im Seneszenz-Assoziierten Sekretorischen Ph\u00e4notyp (SASP) akkumulieren (Callender et al. 2017). Das CMV-spezifische terminal differenzierte T-Zell-Kompartiment beherbergt seneszente und funktionell ersch\u00f6pfte T-Zellen, deren Ratio einen bedeutenden Einfluss auf die immunologische Gesamtsituation in CMV tragenden Probanden nimmt. Da die Gesamtheit der T-Zellen beschr\u00e4nkt auf den vorhandenen Raum und die Ressourcen ist, sind erh\u00f6hte Zahlen an ersch\u00f6pften T-Zellen f\u00fcr ein intaktes Immunsystem problematisch und werden nicht einfach ersetzt.     \t\n\t17\t\t\t\t\t\t1.5. Fragestellung  Innerhalb dieser Habilitation wurden folgende Fragestellungen bez\u00fcglich der Rolle von T-Zell-Subpopulationen, T-Zell-Differenzierung und T-Zell-Steuerung bei der rheumatoiden Arthritis, malignen Erkrankungen und der T-Zell-Hom\u00f6ostase untersucht. T-Zellen spielen f\u00fcr die Pathogenese der rheumatoiden Arthritis und malignen Neoplasien eine herausragende Rolle. T-Zellen sind urs\u00e4chlich an der Entstehung dieser Erkrankungen beteiligt, bestimmen die Schwere, sind von hoher diagnostischer Relevanz und bilden einen therapeutischen Ansatzpunkt. Das bessere Verst\u00e4ndnis T-zellul\u00e4rer Wirkweisen, krankheitsspezifischer und \u00fcbergreifender Mechanismen ist daher von hohem medizinischen Interesse.  a) CMV und T-Zell-Populationen Umfangreiche T-zellul\u00e4re Untersuchungen an peripherem Blut in Zusammenschau mit dem CMV Status und den klinischen Daten von Patienten/Patientinnen mit rheumatoider Arthritis dienten der Beantwortung der Frage nach dem Zusammenhang zwischen einer CMV Infektion und dem Aufkommen bestimmter T-Zell-Populationen und der Schwere einer rheumatoiden Arthritis.   b) DP (CD4+CD8+) T-Zellen Zur Identifikation der Bedeutung von CD4+CD8+ T-Zellen in der rheumatoiden Arthritis wurde peripheres Blut von: i) RA-Patienten/-Patientinnen, ii) SLE Patienten/Patientinnen und iii) gesunden Probanden untersucht. Eine supplement\u00e4re Analyse vom Immunzellinfiltrat erfolgte im Synovialgewebe von RA-Patienten/-Patientinnen. Funktionelle Charakterisierungen, TZR Repertoirebestimmungen als auch Untersuchungen zur CMV Spezifit\u00e4t sollten Aufschluss \u00fcber die Pathogenit\u00e4t dieser T-Zell-Subpopulation bei der RA geben.  c) Kontrolle reaktiver T-Zellen in der Arthritis in vivo Zur Beantwortung der Frage nach der T-Zell-Abschaltung bei der Arthritis wurde ein Mausmodell mit einer Spontanmutation im TZR verwendet. Diese Tiere entwickeln eine der rheumatoiden Arthritis \u00e4hnliche Erkrankung mit steigendem Alter.  \t\n\t18\t\t\t\t\t\tVergleichende Analysen in vitro wurden an T-Zellen von Mutanten und Wildtyp- Tieren vorgenommen. In vivo wurde die spontan auftretende Arthritis klinisch und immunzellul\u00e4r untersucht.  d) B7-H3 und die T-Zell-Hom\u00f6ostase in der Haut In dieser Studie wurde die Bedeutung von Kostimulatormolek\u00fclen der Keratinozyten gesunder Haut f\u00fcr die Interaktion mit T-Zellen untersucht. Neben in situ Untersuchungen der Haut wurden prim\u00e4re und immortalisierte Keratinozyten f\u00fcr die Experimente genutzt. T-Zell-Keratinozyten Ko-Kultursysteme zur Identifizierung der Funktion von B7-H3 komplettierten die Analysen.   e) T-Zell-inhibitorische B7 Molek\u00fcle im Melanom und Nierenzellkarzinom Die Rolle des B7-H4 Molek\u00fcls f\u00fcr die Erkrankung des malignen Melanoms wurde mittels in vitro Zellsystemen (genetisch manipulierte Melanomzelllinien, TAA-spezifische T-Zell-Linien und prim\u00e4re T-Zellen) und an Patienten-/Patientinnenmaterialien (Histologie und klinische Daten) untersucht.    f) Untersuchungen an Nierenzellkarzinomzelllinien wurden durchgef\u00fchrt, um die Zytokin-vermittelte Regulation von B7-H Molek\u00fclen auf Tumorzellen, als Modell eines Tumormikromilieus, zu identifizieren. An der Regulation beteiligte Signalmolek\u00fcle wurden durch entsprechende Verfahren ermittelt. T-Zell-Tumor-Kokultursysteme dienten der Beantwortung der Frage nach der funktionellen Konsequenz von zytokingesteuertem B7-H1 auf Tumorzellen.    \t\n\t19\t\t\t\t\t\t2. Ergebnisse/Originalarbeiten Den hier dargestellten Ergebnissen liegen folgende eigene Originalarbeiten zu Grunde, welche sich im Anhang befinden und die ausgewiesenen Abbildungen beinhalten.  2.1. T-Zell-Subpopulationen mit fundamentaler Bedeutung f\u00fcr den        Krankheitsverlauf der rheumatoiden Arthritis  2.1.1. CMV-spezifische T-Zellen und die rheumatoide Arthritis  Pierer M, Rothe K, Quandt D, Schulz A, Rossol M, Scholz R, Baerwald C, Wagner U. Association of anticytomegalovirus seropositivity with more severe joint destruction and more frequent joint surgery. Arthritis Rheum. 2012 Jun;64(6):1740-9.         IF: 7,5  Rothe K. Quandt D., Kristin Schubert1, Maria Klingner1, Simon Jasinski-Bergner2,Roger Scholz1, MD, Barbara Seliger2, Pierer M. and Wagner U: Latent CMV  infection in RA increases cytolytic LIR-1+ CD8+ T cells, Arthritis Rheumatol. 2016 Feb;68(2):337-46.doi: 10.1002/art.39331                       IF: 7,8        2.1.2. CD4+CD8+ doppelt positive T-Zellen, die aktiv Einfluss in die Pathogenese       der Arthritis nehmen  Quandt D., Rothe K, Scholz R, Baerwald C and Wagner U.  Peripheral CD4CD8 doube positive T cells with a distinct helper cytokine profile are increased in rheumatoid arthritis, PLoS One. 2014 Mar 25;9(3):e93293                     IF: 3,2  2.1.3. Kontrollmechanismen reaktiver T-Zellen in der Arthritis  Rothe K., Raulien N., Pierer M., Quandt D. and Wagner U. Autoimmune arthritis induces paired immunoglobulin-like receptor B expression on CD4+ T cells from SKG mice, Eur J Immunol. 2017 Sep;47(9):1457-1467. doi: 10.1002/eji.201646747. Epub 2017 Jul 27., geteilte Letztautorenschaft                       IF: 4,2    \t\n\t20\t\t\t\t\t\t2.2. Die Bedeutung von Kostimulatoren und Koinhibitoren der B7-Familie f\u00fcr        die T-Zell-Hom\u00f6ostase und die antitumorale T-zellul\u00e4re Immunabwehr  2.2.1.  T-Zell-Steuerung durch B7-H3 auf Hautzellen  Quandt D., Fiedler E, M\u00fcller, A, Marsch W Ch and Seliger B.: High constitutive B7-H3 expression on human keratinocytes supports T cell immunity, J Dermatol Sci. 2017 Jul;87(1):82-85. doi: 10.1016/j.jdermsci.2017.02.287. Epub 2017 Apr 11.         IF: 3,7  2.2.2. T-Zell-Kontrolle durch Koinhibitorexpression auf Tumorzellen  Quandt D., Jasinski, S., M\u00fcller U., Schubert, B. and Seliger  B. Synergistic effect of IL-4 and TNF\u03b1 on the induction of B7-H1 in RCC cell lines that inhibits allogeneic T cell proliferation, J Transl Med. 2014 May 30;12(1):151           IF: 3,9  Quandt D., Fiedler E, Boettcher D, Marsch W Ch and Seliger  B: B7-H4 expression inhuman melanoma: its association with patients\u2019 survival and anti tumor immune response Clin Cancer Res. 2011 May 15;17(10):3100-11. Epub 2011 Mar 4     IF: 7,7   \t\n\t21\t\t\t\t\t\t2.1. T-Zell-Subpopulationen mit fundamentaler Bedeutung f\u00fcr den        Krankheitsverlauf der rheumatoiden Arthritis  2.1.1. CMV-spezifische CD4+ und CD8+ T-Zellen und die rheumatoide Arthritis CMV Infektionen werden oft fr\u00fchzeitig im Leben erfahren, bleiben latent ein Leben lang erhalten, verlaufen i.d.R. klinisch asymptomatisch, indes hinterlassen sie deutliche Spuren im T-zellul\u00e4ren Kompartiment des Immunsystems (Harari et al. 2004). Inwieweit diese T-zellul\u00e4ren Ver\u00e4nderungen in peripheren CD4+ und CD8+ T-Zellen einen Einfluss auf die Schwere einer rheumatoiden Arthritis haben und welche Molek\u00fcle im Besonderen auf T-Zellen differentiell exprimiert werden und funktionelle Konsequenzen nach sich ziehen, wurde in den beiden hier dargestellten Originalarbeiten untersucht.  In einem ersten Arbeitspunkt wurden CMV positive und CMV negative RA-Patienten/-Patientinnen hinsichtlich ihres CD4+ T-Zell-Kompartiments ph\u00e4notypisch n\u00e4her charakterisiert. Es wurde eine signifikante Erh\u00f6hung CD4+CD28- T-Zellen in CMV+ RA-Patienten/-Patientinnen bei vergleichender Betrachtung zu RA-Patienten/-Patientinnen die CMV negativ sind, gefunden (Abb.1) (Pierer et al. 2012). Eine in vitro durchgef\u00fchrte durchflusszytometrische CMV Peptid-spezifische Proliferationsmessung der T-Zellen zeigte keine verst\u00e4rkte Proliferation der CD4+ T-Zellen aus RA-Patienten/-Patientinnen gegen\u00fcber Kontrollen gesunder Probanden (Abb.1) (Pierer et al. 2012). Der bei einer Proliferation typischerweise verst\u00e4rkt exprimierte Oberfl\u00e4chenmarker CD71 (Transferrinrezeptor) wurde in den CMV stimulierten Proben aus CMV positiven Probanden hochreguliert. Die Expressionsst\u00e4rke von CD71 unterschied sich nicht in CMV positiven RA-Patienten/-Patientinnen gegen\u00fcber CMV positiven gesunden Kontrollen (Abb.1, (Pierer et al. 2012). Hingegen konnte eine h\u00f6here Zahl CMV-spezifischer CD3+CD4+ IFN\u03b3 Produzenten in RA gegen\u00fcber gesunden Kontrollen (HD) nach in vitro Restimulation sowohl mit dem CMV-spezifischen dominanten pp65 Peptid als auch dem CMV Lysat detektiert werden (Abb.2) (Pierer et al. 2012). Der Einsatz des CMV Lysats f\u00fcr die in vitro Restimulation der Zellen erm\u00f6glicht die Analyse multipler T-Zellen, die spezifisch gegen verschiedene immundominante Epitope des CMV Proteins sind. Durch die notwendige Antigenprozessierung durch Antigen-pr\u00e4sentierende Zellen bei einer in vitro Restimulation mittels Protein ist diese Stimulation der in vivo Situation \u00e4hnlicher und bildet die real existierende Bandbreite verschiedener reaktiver T-Zellen besser ab. \t\n\t22\t\t\t\t\t\tChemokine sind als Subgruppe der Zytokine wichtige Mediatoren zellul\u00e4rer Kommunikation. Sie sorgen u.a. f\u00fcr die gerichtete Verteilung von Immunzellen im K\u00f6rper und im Falle einer Entz\u00fcndung f\u00fcr die Rekrutierung der Immunzellen an den Entz\u00fcndungsherd. Chemokin-Spiegel im Serum geben R\u00fcckschluss auf einen systemischen Entz\u00fcndungszustand im K\u00f6rper. MCP-1 (CCL2) ist vor allem als Chemoattraktor f\u00fcr Monozyten, aber auch f\u00fcr Osteoklasten (Sucur et al. 2017) bekannt. Die Analyse zeigte eine signifikante Erh\u00f6hung des Chemokins MCP-1 in CMV positiven gegen\u00fcber CMV negativen RA-Patienten/-Patientinnen (Seite 1744), ((Pierer et al. 2012).  Klinisch konnte festgestellt werden, dass sich RA-Patienten/-Patientinnen mit einer CMV Infektion signifikant \u00f6fter einer Synovektomie, bzw. bei additiver Betrachtung von Gelenkersatz und Osteotomie, \u00f6fter einer Operation (in der Originalpublikation als \u201etotal joint procedures\u201c) im Gelenkbereich unterziehen m\u00fcssen (Pierer et al. 2012).  Fortf\u00fchrende Untersuchungen zur Rolle CMV-spezifischer CD8+ T-Zellen bei RA- Patienten/-Patientinnen deckten mittels indirekter TZR Markierung (Dextramer) einen h\u00f6heren Prozentsatz CMVpp65 positiver CD8+T-Zellen auf (Abb.1) (Rothe et al. 2016). Andere CMV bekannte T-Zell-Spezifit\u00e4ten konnten aufgrund technischer Limitationen nicht n\u00e4her untersucht werden. Latente CMV Infektionen wurden mit einer erh\u00f6hten Expression von LIR-1 (Immunoglobulin-like transcript 2, CD85j) auf CD8+ T-Zellen assoziiert (Anfossi et al. 2004). LIR-1 wird auf verschiedenen Immunzellen exprimiert und f\u00fchrt i.d.R. mittels eines intrazellul\u00e4ren inhibitorischen Motivs zur Inhibition von Zellen. Die Ergebnisse unserer hier dargestellten Studie zeigen eine verst\u00e4rkte Frequenz und erh\u00f6hte Molek\u00fclexpressionsst\u00e4rke LIR-1 positiver CD8+ T-Zellen bei CMV positiven RA- Patienten/-Patientinnen im Vergleich zu CMV positiven gesunden Kontrollen. Dieser Befund ist auf das CD8+ T-Zell-Kompartiment begrenzt. CD4+ T-Zellen zeigen im Vergleich zu CD8+ T-Zellen eine 10-fach geringere LIR-1 Expression, die sich in RA-Patienten/-Patientinnen gegen\u00fcber gesunden Kontrollen unver\u00e4ndert darstellt (Abb.1, (Rothe et al. 2016). Eine vertiefende ph\u00e4notypische Charakterisierung von LIR-1+CD8+ T-Zellen ergab eine Zugeh\u00f6rigkeit zum terminal differenzierten Effektor-Zelltyp mit Verlust von CD27, CD28 und CCR7, verst\u00e4rkter CD56 Expression und Re-Expression von CD45RA. \t\n\t23\t\t\t\t\t\tPD-1 wurde interessanterweise nicht verst\u00e4rkt exprimiert (Abb.4), (Rothe et al. 2016). Expressionsanalysen wichtiger Chemokinrezeptoren ergaben eine verst\u00e4rkte CX3CR1 Expression auf LIR-1+CD8+ T-Zellen von RA-Patienten/-Patientinnen gegen\u00fcber gesunden Kontrollen (Abb.4), (Rothe et al. 2016). Terminal differenzierte proliferativ eingeschr\u00e4nkte T-Zellen nehmen mit dem Alter zu (Akbar et al. 2016). LIR-1+CD8+ T-Zellen von RA-Patienten/-Patientinnen korrelieren positiv mit dem Alter (Abb.3), (Rothe et al. 2016). Der gr\u00f6\u00dfte Unterschied in der H\u00e4ufigkeit LIR-1+CD8+ T-Zellen von RA-Patienten/-Patientinnen gegen\u00fcber gesunden Kontrollen ist in der Altersgruppe der unter 50-j\u00e4hrigen Patienten/-Patientinnen feststellbar (Abb.3), (Rothe et al. 2016). Die CMV-spezifische proliferative Kompetenz dieser T-Zellen bleibt unbeeintr\u00e4chtigt (Abb.5), (Rothe et al. 2016). Untersuchungen zum sekretorischen Ph\u00e4notyp LIR-1+CD8+ T-Zellen ergab funktionell kompetente Zellen, die CMV-spezifisch IFN\u03b3 produzieren und zytolytische Kompetenz aufweisen. Die F\u00e4higkeit zum CMV-spezifischen T\u00f6ten zeigt sich bei CD8+ T-Zellen von RA-Patienten/-Patientinnen signifikant erh\u00f6ht gegen\u00fcber gesunden Kontrollen (Abb.5), (Rothe et al. 2016). HLA-G wurde als Ligand von LIR-1 beschrieben. Eine in vitro vorgenommene Inkubation von HLA-G bei paralleler Aktivierung der LIR-1+CD8+ T-Zellen f\u00fchrt zur verminderten IFN\u03b3 Produktion und geringerer T\u00f6tungskompetenz (Abb.6), (Rothe et al. 2016). Die besondere Rolle der LIR-1+CD8+ T-Zellen in RA-Patienten/-Patientinnen tritt besonders durch die positive Korrelation mit der Krankheitsschwere, ermittelt \u00fcber den DAS28 (disease activity score), der verschiedene klinische Parameter ber\u00fccksichtigt, hervor (Abb.3), (Rothe et al. 2016). Die Ergebnisse der beiden hier vorgestellten Untersuchungen zum T-zellul\u00e4ren CD4+ und CD8+ Kompartiment des Immunsystems in CMV positiven RA-Patienten/-Patientinnen deckten richtungsweisende, zuvor unbekannte krankheitsspezifische Unterschiede sowohl zu CMV negativen RA-Patienten/-Patientinnen als auch zu gesunden CMV positiven Kontrollen auf.  2.1.2. CD4+CD8+ doppelt positive T-Zellen und die Pathogenese der RA \t\n\t24\t\t\t\t\t\t CD4+CD8+ doppelt positive T-Zellen finden sich im peripheren Blut gesunder Probanden und machen ca. 1% der T-Zellen aus (Parel and Chizzolini 2004). Die Besonderheit liegt in der Expression beider Korezeptoren CD4 und CD8, wobei es sich nicht um T-Zellen der CD4+CD8+ doppelt positiven Entwicklungsstufe im Thymus handelt. Eine erh\u00f6hte Zahl DP T-Zellen mit antiviraler Spezifit\u00e4t und hohem Effektorpotential fand sich nach Virusinfektionen wie HIV und Hepatitis (Nascimbeni et al. 2004, Frahm et al. 2012). Bez\u00fcglich einer Beteiligung von DP T-Zellen an Autoimmunerkrankungen zeigt sich eine Arbeit an Patienten/Patientinnen mit systemischer Sklerodermie bedeutungsvoll, bei der diese Zellen erh\u00f6ht in Hautl\u00e4sionen gefunden wurden (Parel et al. 2007).  Eine m\u00f6gliche Rolle der DP T-Zellen f\u00fcr die adulte autoimmune rheumatoide Arthritis war bisher nicht untersucht und hinsichtlich des zuvor dargestellten (2.1.1.) starken Einflusses einer CMV Virusinfektion auf die RA von besonderem Interesse. Die Untersuchung zur H\u00e4ufigkeit der DP T-Zellen im peripheren Blut von Patienten/Patientinnen mit rheumatoider Arthritis deckte eine signifikant h\u00f6here Zahl dieser Zellen in RA-Patienten/-Patientinnen, die Autoantik\u00f6rper gegen citrullinierte Peptide tragen (ACPA), im Vergleich zu gesunden Kontrollen gleichen Alters auf (Abb.1), (Quandt et al. 2014). RA-Patienten/-Patientinnen, die keine Autoantik\u00f6rper gegen citrullinierte Peptide aufweisen, und Patienten/Patientinnen mit SLE wurden vergleichend betrachtet und zeigten keine Erh\u00f6hung peripherer CD4+CD8+ doppelt positiver T-Zellen (Abb.1), (Quandt et al. 2014). Die Anzahl DP positiver T-Zellen in RA-Patienten/-Patientinnen zeigt sich im Gegensatz zu gesunden Kontrollen unabh\u00e4ngig vom Alter.  Ph\u00e4notypische Untersuchungen peripherer DP T-Zellen in der RA zeigte, dass diese zu \u00fcber 80% den Ged\u00e4chtniszellen zugeh\u00f6rig sind (Abb.2), (Quandt et al. 2014). Marker f\u00fcr Differenzierung (CD38) und Aktvierung (HLA-DR) unterschieden sich in ihrer Expressionsst\u00e4rke signifikant von CD4 einzel positiven T-Zellen (Abb.2), (Quandt et al. 2014). Eine h\u00f6here Expression von TCRVa24-Ja18:Vb11 als Marker f\u00fcr iNKT T-Zellen konnte in DP T-Zellen der RA-Patienten/-Patientinnen nicht gefunden werden. Untersuchungen von 24 verschiedenen TZR BV Ketten mittels Durchflusszytometrie deckten keine signifikanten Unterschiede in DP T-Zellen gegen\u00fcber CD4 bzw. CD8 einzel positiven T-Zellen in RA-Patienten/-Patientinnen auf (Abb.3), (Quandt et al. 2014). \t\n\t25\t\t\t\t\t\tZum Verst\u00e4ndnis der funktionellen Charakteristika CD4+CD8+ doppelt positiver T-Zellen in RA-Patienten/-Patientinnen untersuchten wir deren Vorkommen im Synovialgewebe des Gelenks und analysierten das Zytokinprofil dieser Zellen nach einer polyklonalen in vitro Restimulation. In Abb. 4 und 5 der Originalpublikation sind die Ergebnisse f\u00fcr die mittels durchflusszytometrischer Analysen gewonnenen Zytokinprofile dargestellt. DP T-Zellen in der RA produzieren mehr IL-4 und IFN\u03b3 im Vergleich zu DP T-Zellen aus gesunden Probanden (Quandt et al. 2014). Die Frequenz IL- 21 und IL-17 positiver T-Zellen unterschied sich nicht zwischen DP T-Zellen aus RA-Patienten/-Patientinnen und gesunden Kontrollen. Beim Vergleich der IL-17 Produktion von DP T-Zellen und CD4 einzel positiven T-Zellen aus RA-Patienten/-Patientinnen zeigten sich signifikant erniedrigte Frequenzen IL-17 produzierender DP T-Zellen (Abb.4), (Quandt et al. 2014). Das pathophysiologische Zielorgan der RA sind die Gelenke. Das Synovialgewebe bildet einen Teil der Gelenkkapsel. Sowohl CD4+CD8+ doppelt positive T-Zellen als auch B-Zellen wurden nach einem Gewebeverdau im Synovialgewebe der RA-Patienten/-Patientinnen durchflusszytometrisch detektiert (Abb.5), (Quandt et al. 2014). Ein weiterer wichtiger Untersuchungsschwerpunkt lag in der Betrachtung des Zusammenhangs zwischen einer CMV Infektion und DP T-Zellen in RA-Patienten/-Patientinnen. Es zeigten sich signifikant erh\u00f6hte Frequenzen DP T-Zellen in der Peripherie CMV positiver RA-Patienten/-Patientinnen im Vergleich zu CMV negativen RA-Patienten/-Patientinnen (Abb.6), (Quandt et al. 2014). T-Zellen, die den Kostimulator CD28 verloren haben und zu den terminal differenzierten T-Zellen mit polyfunktionellem Potenzial geh\u00f6ren, treten h\u00e4ufiger in CMV positiven RA-Patienten/-Patientinnen auf (Pierer et al. 2012). Die Frequenz DP T-Zellen korreliert positiv mit der Frequenz an CD4+CD28- Zellen in RA-Patienten/-Patientinnen (Abb.6), (Quandt et al. 2014). Besonders wichtig ist der Befund, dass DP T-Zellen von RA-Patienten/-Patientinnen eine CMV-spezifisch erh\u00f6hte Produktion an inflammatorischem Effektorzytokin IFN\u03b3 im Vergleich zu gesunden Kontrollen aufwiesen (Abb.6), (Quandt et al. 2014). Zusammenfassend stellen die Ergebnisse dieser Studie die Pathogenit\u00e4t peripherer CD4+CD8+ doppelt positiver T-Zellen, insbesondere bei Vorhandensein von Autoantik\u00f6rpern (ACPA+) und CMV positiver rheumatoider Arthritis dar.   \t\n\t26\t\t\t\t\t\t2.1.3. Kontrollmechanismen reaktiver T-Zellen in der Arthritis  Mausmodelle unterst\u00fctzen wesentlich den Erkenntnisgewinn zur Entstehung, zum Progress, der Zellbeteiligung und den Therapieoptionen verschiedenster humaner Krankheiten. Zahlreiche Mausmodelle f\u00fcr die Arthritis, beispielsweise die Kollagen-induzierte Arthritis (CIA), die TZR transgene K/BxN Maus, das TNF\u03b1-Transgen Modell und die Arthritis im SKG Mausmodell trugen und tragen zum vorhandenen Erkenntnisstand der pathogenen Prozesse der humanen rheumatoiden Arthritis bei (Bessis et al. 2017).  Die SKG Arthritis in Balb/c Tieren geht auf eine Spontanmutation in der SH2C Domaine der zeta- Ketten assoziierten Proteinkinase 70 (ZAP-70) des T-Zell-Rezeptorkomplexes zur\u00fcck. Diese genetische f\u00fchrt zu einer ver\u00e4nderten T-Zell-Aktivierung (Sakaguchi et al. 2003). Es kommt zur positiven Selektion autoreaktiver T-Zell-Klone im Thymus. Diese T-Zellen sind im Zusammenspiel mit dem Mikrobiom (Yoshitomi et al. 2005) hauptverantwortlich f\u00fcr die Entwicklung einer spontanen Arthritis mit entz\u00fcndlichen Gelenkschwellungen.   PIR-B ist das dem humanen LIR-1 orthologe Molek\u00fcl im Mausmodell. Die bisherige Literatur weist PIR-B vor allem in B-Zellen, dendritischen Zellen, Mastzellen und pr\u00e4thymischen Progenitoren, nicht in reifen T-Zellen von Wildtyp-Tieren aus (Kubagawa et al. 1999, Imada et al. 2009).   Die Ergebnisse der hier durchgef\u00fchrten durchflusszytometrischen Untersuchung zeigen erstmals eine konstitutive und altersabh\u00e4ngige Expression von PIR-B in CD4+ und CD8+ T-Zellen in sekund\u00e4r lymphatischen Organen in SKG Tieren (Abb.1 und Daten nicht gezeigt), (Rothe et al. 2017). M\u00e4use anderer, oft f\u00fcr die experimentelle Induktion einer Arthritis genutzten St\u00e4mme (DBA/J und BL/6) als auch Balb/c Tiere zeigten altersunabh\u00e4ngig keine bzw. eine geringe (Balb/c, auf Milz beschr\u00e4nkt) Expression von PIR-B  (Daten nicht gezeigt und (Abb.1), (Rothe et al. 2017). Das Transkript f\u00fcr PIR-B konnte mittels konventioneller RT-PCR nachgewiesen werden. Ein extrem wichtiger Befund der einen Molek\u00fcltransfer von stark PIR-B exprimierenden Zellen unwahrscheinlich macht (Supp-Abb.1), (Rothe et al. 2017). Beachtlich, die Expressionsst\u00e4rke von PIR-B auf CD4+ T-Zellen korreliert mit dem Mikrobiom. Tiere in konventioneller Haltung wiesen eine st\u00e4rkere Expression von PIR-B auf im Vergleich zu Tieren unter spezifisch pathogenfreien (SPF) Haltungsbedingungen.  \t\n\t27\t\t\t\t\t\tDie ph\u00e4notypische Charakterisierung der PIR-B+ T-Zellen zeigte eine erh\u00f6hte Expression des Aktivierungsmarkers CD69 und des Koinhibitors PD-1 (Abb.1), (Rothe et al. 2017). Zur Beantwortung der Frage nach funktionellen Unterschieden von PIR-B+ T-Zellen wurden Zytokine mittels durchflusszytometrischen Zytokinsekretionsassays bzw. intrazellul\u00e4ren Zytokinnachweises bestimmt. PIR-B+ T-Zellen aus SKG Tieren zeigten signifikant h\u00f6here IFN\u03b3 und IL-17 Produktion im Vergleich zu PIR-B negativen T-Zellen nach in vitro Restimulation mit PMA/Ionomycin (Abb.4), (Rothe et al. 2017). IL-17 z\u00e4hlt zu den Zytokinen mit dem gr\u00f6\u00dften Einfluss auf das inflammatorische Milieu und infolge dessen auf das destruktive Geschehen bei der Arthritis. PIR-B positive T-Zellen sezernieren bemerkenswerterweise bis zu 5x mehr IFN\u03b3 im Vergleich zu IL-17. PMA/Ionomycin wurde als Stimulus gew\u00e4hlt, da bekannt war, dass T-Zellen aus SKG Tieren eine geringere Aktivierbarkeit durch TZR Kreuzvernetzung aufweisen (Hirota et al. 2007). Dieser Unterschied in der Aktivierbarkeit von T-Zellen aus SKG Tieren durch TZR Kreuzvernetzung mittels Antik\u00f6rpern gegen CD3 bzw. durch PMA/Ionomycin (direkter Trigger von PKC und Ca2+-Freisetzung) konnte mittels der hier erhobenen Daten best\u00e4tigt werden (Abb.2 und 3), (Rothe et al. 2017). In vitro Aktivierung von T-Zellen aus SKG und Balb/c Tieren f\u00fchrt  zur Induktion von PIR-B, wobei SKG T-Zellen stets eine st\u00e4rkere Expression zeigten (Abb.2 und 3), (Rothe et al. 2017). Die Aktivierung kann dabei sowohl \u00fcber ein TZR Signal als auch \u00fcber einen Trigger der PKC mit Calcium-Mobilisierung erfolgen. Die in vitro induzierten PIR-B exprimierenden Zellen aus Balb/c Tieren sezernieren IFN\u03b3, nicht aber IL-17. PIR-B induziert daher nicht die IL-17 Produktion, sondern IL-17 Produzenten aus arthritischen SKG Tieren exprimieren verst\u00e4rkt PIR-B. Eine hohe Expression von PIR-B zusammen mit einem inflammatorischen Zytokinprofil in 11-Monate alten SKG Tieren geht einher mit einer klinisch messbaren Arthritis. Die Arthritis ist zum diesem Zeitpunkt bereits manifestiert, erste klinische Anzeichen wurden im Alter von 4-6 Monaten dokumentiert. SKG Tiere mit einer geringeren PIR-B Expression (<35%) haben im Vergleich zu Tieren mit einer PIR-B Expression gr\u00f6\u00dfer als 35% einen h\u00f6heren Arthritis-Score, welcher durch die St\u00e4rke und Anzahl geschwollener  Pfoten bestimmt wird (Abb.6), (Rothe et al. 2017). Diese Korrelation einer hohen Zahl an PIR-B positiven CD4 T-Zellen mit einer milderen Arthritis konnte zus\u00e4tzlich durch einen histologischen Arthritis-Score als Ma\u00df der Zellinfiltration und Knorpeldestruktion best\u00e4tigt werden (Abb.6), (Rothe et al. 2017). \t\n\t28\t\t\t\t\t\tPIR-B positive T-Zellen in der Arthritis sind zusammenfassend betrachtet nicht die treibende Kraft eines destruktiven Krankheitsverlaufes, sondern PIR-B fungiert eher als attenuierendes Signal. Die Hypothese einer Aktivierungsbegrenzung \u00fcber PIR-B wird durch eine dominierende IFN\u03b3 Produktion und durch erh\u00f6hte PD-1 (koinhibitorischer Rezeptor) Expressionsspiegel unterst\u00fctzt.     \t\n\t29\t\t\t\t\t\t2.2. Die Rolle von Kostimulatoren und Koinhibitoren f\u00fcr die T-Zell-        Hom\u00f6ostase und die antitumorale T-zellul\u00e4re Immunabwehr  2.2.1. T-Zell-Steuerung durch B7-H3 auf Hautzellen  Die Haut beherbergt im Vergleich zum peripheren Blut die doppelte Zahl an T-Zellen (Clark 2010). Diese geh\u00f6ren meist den Ged\u00e4chtnis-T-Zellen an und sind sowohl vom CD4 T-Helferzelltypus als auch vom CD8 T-Zell-Typ, wobei insbesondere kaum zytolytische Potenz von diesen T-Zellen ausgeht (Schaerli et al. 2004, Judith A. Seidel 2016). Keratinozyten der Haut interagieren mit CD4+ und CD8+ T-Zellen, wobei durch eine fehlende konstitutive Expression von HLA Klasse II Molek\u00fclen die Interaktion mit CD4 T-Zellen erst im entz\u00fcndlichen Prozess m\u00f6glich wird (Griffiths et al. 1990). B7-H3 geh\u00f6rt zur B7-H Molek\u00fcl-Familie der Kostimulatoren/Koinhibitoren, f\u00fcr das 2 unterschiedliche Rezeptoren auf T-Zellen vermutet werden, welche durch kontroverse Forschungsergebnisse noch nicht abschlie\u00dfend anerkannt sind (Hashiguchi et al. 2008, Leitner et al. 2009). Die Untersuchungen dieser hier vorgestellten Studie deckten eine konstitutiv hohe Expression von B7-H3 in situ in gesunden Keratinozyten der Basalzellschicht der Epidermis auf (Abb.1), (Quandt et al. 2017). Diese B7-H3 Expression war auf 80% der Biopsien oberfl\u00e4chlich und intrazellul\u00e4r detektierbar. Die St\u00e4rke der Molek\u00fclexpression war von einer angrenzenden malignen oder benignen Hautpartie  unabh\u00e4ngig (Supplement (Quandt et al. 2017). Anschlie\u00dfende in vitro Experimente an prim\u00e4ren und immortalisierten Keratinozyten  best\u00e4tigten eine hohe konstitutive Expression von B7-H3 auf Transkript- und Proteinebene (Abb.1), (Quandt et al. 2017). INF\u03b3 Behandlung von Keratinozyten ver\u00e4ndert die B7-H3 Expression nicht, wobei andere Molek\u00fcle der B7 Familie,  der Adh\u00e4sion- und Antigenpr\u00e4sentation, wie B7-H1, ICAM-1 und HLA-Klasse-II signifikant hochreguliert wurden (Abb.1), (Quandt et al. 2017). Zur Bestimmung der Rolle von B7-H3 auf Keratinozyten f\u00fcr die T-Zell-Immunologie, wurde B7-H3 experimentell mittels spezifischer shRNA herunterreguliert (Abb.2, (Quandt et al. 2017), wobei B7-H1 und HLA-Klasse-I Molek\u00fcle unver\u00e4ndert exprimiert blieben. Ko-Kulturen von T-Zellen gesunder Spender mit den B7-H3 manipulierten Keratinozyten wurden durchgef\u00fchrt. Das Prinzip einer alloreaktiven T-Zell-Antwort kam zur Anwendung, bei der die T-Zellen aus Spendern mit einem zu \t\n\t30\t\t\t\t\t\tden Keratinozyten (HLA-A31,-B40,-B51) divergenten HLA-A,-B Typ ausgestattet waren. T-Zell-Proliferation, T-Zell-Aktivierung und T-zellul\u00e4re IFN\u03b3 Produktion zeigten sich nach Ko-Kultur mit herunterreguliertem B7-H3 auf Keratinozyten verringert (Abb.2, (Quandt et al. 2017). Die Ergebnisse der B7-H3 Studie deckten ein v\u00f6llig neues Expressionsprofil des Molek\u00fcls auf humanen Keratinozyten auf, welches nicht durch eine maligne Neoplasie gesteuert wird. Funktionell konnte eine kostimulatorische Funktion f\u00fcr T-Zellen identifiziert werden, welche sich in vivo als Teil der hom\u00f6ostatischen Erhaltung der T-Zellen in der Haut darstellen k\u00f6nnte.  2.2.2. T-Zell-Kontrolle durch Koinhibitorexpression auf Tumorzellen  Molek\u00fcle der Familie der Kostimulatoren stellen einen komplexen Regulationsmechanismus zur Steuerung von T-Zell-Immunantworten dar (Seliger and Quandt 2012). Zu Beginn dieser Untersuchungen war bekannt, dass Tumorzellen Molek\u00fcle verschiedener Kostimulatorfamilien, so auch der B7-Familie, exprimieren k\u00f6nnen (Schildberg et al. 2016). B7-H1 (PD-L1) B7-H4 wurden als Inhibitor der T-Zell-Antworten in verschiedenen Tumorentit\u00e4ten beschrieben und konnte mit klinischen Parametern der Patienten/Patientinnen assoziiert werden (Krambeck et al. 2006, Thompson et al. 2006, Hino et al. 2010). Die Bedeutung von B7-H4 f\u00fcr das maligne Melanom war bis dahin noch unverstanden. Die Regulation der Expression von B-H1 und B7-H4 auf Tumorzellen ist f\u00fcr das Verst\u00e4ndnis ihrer Rolle in der Tumorpathogenese und ihrer therapeutischen Manipulierbarkeit essentiell. Inflammatorische Zytokine der Familie der Interferone steuern die Expressionsst\u00e4rke von B7-H1 (Blank et al. 2005, Kondo et al. 2010). Die Rolle von anti-inflammatorischen Interleukinen und inflammatorischen Zytokinen der TNF Familie f\u00fcr die Expression und funktionelle Konsequenz von B7-H1,-H2, -H3, und B7-H4 auf Nierenzellkarzinomzellen war ebenfalls noch ungekl\u00e4rt und stellte daher einen wichtigen Arbeitspunkt dar. Es konnte in den durchgef\u00fchrten Untersuchungen B7-H4 in situ in Melanomzellen von Patienten/Patientinnen mit malignem Melanom gefunden werden (Abb. 1), (Quandt et al. 2011). Die Expressionsst\u00e4rke von B7-H4 lag im Prim\u00e4rtumor und den \t\n\t31\t\t\t\t\t\tMetastasen signifikant \u00fcber der des angrenzenden gesunden Hautgewebes. Die Expression zeigte sich des Weiteren in der Patienten-/Patientinnenkohorte unterschiedlich, womit eine Gruppierung in B7-H4 niedrig- und hochexprimierend indiziert war (Abb. 1), (Quandt et al. 2011). Das Immunzellinfiltrat der malignen Melanome bestand vor allem aus CD8+ T-Zellen und CD68+ Makrophagen, wobei letztere signifikant erh\u00f6ht in B7-H4 hochexprimierenden Patienten/Patientinnen gefunden wurden (Tab. 1), (Quandt et al. 2011)). Von besonderer Bedeutung ist der Befund, dass eine niedrigere B7-H4 Expression mit einem l\u00e4ngeren \u00dcberleben assoziiert war (Abb. 2), (Quandt et al. 2011). Umfangreiche Untersuchungen an Zelllinien zeigten trotz positiver Transkripte f\u00fcr B7-H4 keine konstitutive Proteinexpression auf Melanomzelllinien, wohingegen Brustkrebstumorzelllinien f\u00fcr B7-H4 positiv durchflusszytometrisch markiert wurden (Abb.3), (Quandt et al. 2011). Experimentelle \u00dcberexpression von B7-H4 und anschlie\u00dfende T-Zell-Tumor Kokulturassays zeigten keine Ver\u00e4nderung f\u00fcr die T-zellul\u00e4re T\u00f6tungskompetenz, aber gleichwertig relevant konnte eine Inhibition der T-zellul\u00e4ren Zytokinproduktion von IFN\u03b3, IL-2 und TNF\u03b1 festgestellt werden. Dies galt f\u00fcr Melan-A monospezifische als auch f\u00fcr multispezifische T-Zellen gesunder Spender, welche durch wiederholte Restimulationen mit Tumorzellen generiert wurden (Abb.5), (Quandt et al. 2011). B7-H3 wurde in Melanomen in situ und in den Melanomzelllinien in vitro konstitutiv exprimiert, wobei sich aber keine Assoziation zu klinischen Daten finden lie\u00df und melanomspezifische T-Zellen keine unterschiedlichen Effektorfunktionen nach experimenteller Blockade der B7-H3 Expression auf den Tumorzellen zeigten (Abb.4), (Quandt et al. 2011). Die Behandlung von verschiedenen Nierenzellkarzinomzelllinien mit IL-4, TNF\u03b1 oder der Kombination beider Zytokine f\u00fchrte zu einer unterschiedlichen Regulation von B7-H1-B7-H4 Molek\u00fclen. B7-H1 wird durch singul\u00e4re Gabe von IL-4 und TNF\u03b1 zeitabh\u00e4ngig auf mRNA und Proteinebene reguliert, wobei die Kombination beider Zytokine zu einer synergistischen Hochregulation f\u00fchrt (Abb.2 und 3), (Quandt et al. 2014). B7-H2 wird durch TNF\u03b1 hochreguliert, wobei die Addition von IL-4 keinen zus\u00e4tzlichen Effekt brachte. B7-H3 und B7-H4 blieben in ihrer Expression von den Zytokinen als Einzelgabe oder in Kombination weitestgehend unbeeinflusst. Nierenzellkarzinomzelllinien f\u00fchren kein Transkript f\u00fcr IL-4, wohingegen TNF\u03b1 als Transkript vorliegt, aber als Protein nur in wenigen Zelllinien in sehr geringen Dosen von 40pg/ml sezerniert wird (Abb.1), (Quandt et al. 2014).  \t\n\t32\t\t\t\t\t\tDie Zytokin-induzierte Hochregulation von B7-H1 f\u00fchrt in allogenen PD-1 tragenden T-Zell-Tumor-Kokulturen zu einer T-Zell-Proliferationsblockade, wobei die Sekretion von IFN\u03b3 unbeeinflusst blieb (Abb.5), (Quandt et al. 2014). Als beteiligte Signalmolek\u00fcle wurden NFkB, IkB und STAT6 ermittelt, deren Phosphorylierungsmuster sich ver\u00e4ndert zeigten, wobei NFKB am Serin 529 deutlich st\u00e4rker durch die Kombination beider Zytokine phosphoryliert wird als durch TNF\u03b1 allein und IL-4 keinen Einfluss auf die Phosphorylierung von NFkB nimmt (Abb.4), (Quandt et al. 2014). Die Kombination beider Zytokine war mit einer deutlich gesteigerten Promotoraktivit\u00e4t von B7-H1 verbunden. Die Microarray-Daten einer frei verf\u00fcgbaren Datenbank zeigten eine positive Korrelation von B7-H1 mit NFkB und STAT6 in Nierentumorgeweben (Abb. 4), (Quandt et al. 2014) und r2 database, (http://r2.amc.nl ).  Zusammenfassend komplettieren und erweitern diese beiden Arbeiten die Kenntnisse \u00fcber inhibitorische Molek\u00fcle der B7 Familie auf Tumoren. B7-H4 k\u00f6nnte f\u00fcr die Therapie des malignen Melanoms eine neue Zielstruktur bilden. Die Erkenntnisse zu B7-H1 sind im besonderen aktuell von hoher Relevanz, da die PD-L1 Antik\u00f6rpertherapie als neue Immun-Checkpoint-Therapie f\u00fcr das maligne Melanom, das Nierenzellkarzinom und andere Tumorentit\u00e4ten auf dem Vormarsch ist.   \t\n\t33\t\t\t\t\t\t3. Diskussion/Ausblick 3.1. T-Zell-Subpopulationen mit fundamentaler Bedeutung f\u00fcr den        Krankheitsverlauf der rheumatoiden Arthritis  3.1.1. CMV Virus-spezifische CD4+ und CD8+ T-Zellen, LIR-1 und die rheumatoide          Arthritis  CMV Infektionen hinterlassen deutliche Spuren in T-zellul\u00e4ren aber auch in Nat\u00fcrlichen Killerzellen (Heath et al. 2016) Kompartimenten des adaptiven/angeborenen Immunsystems in gesunden Probanden. Es kommt zu einem differenzierten T-zellul\u00e4ren Ph\u00e4notyp mit erh\u00f6htem Verlust des Kostimulators CD28 auf CD4 und CD8 positiven T-Zellen, zur verst\u00e4rkten Expression des Seneszenzmarkers CD57 und des inhibitorischen Rezeptors LIR-1, sowie zu einem erh\u00f6hten zytotoxischen Potential  (Northfield et al. 2005, Pourgheysari et al. 2007, Appay et al. 2008). Diese CMV-spezifischen T-zellul\u00e4ren Ver\u00e4nderungen konnten in unserer Studie in der gesunden Kontrollkohorte best\u00e4tigt werden. Die Daten der beiden hier vorgestellten Originalarbeiten zeigen, dass diese T-zellul\u00e4ren Ver\u00e4nderungen durch eine rheumatische Erkrankung ausgebaut werden. Es konnten erh\u00f6hte Zahlen von CD4+CD28- T-Zellen mit gesteigerter Kapazit\u00e4t IFN\u03b3 zu produzieren und erh\u00f6hte Zahlen von LIR-1+CD8+ T-Zellen mit einem verst\u00e4rkten zytotoxischen Ph\u00e4notyp, die mit der Krankheitsschwere korrelieren, identifiziert werden. Diese T-zellul\u00e4ren Ver\u00e4nderungen gehen mit einer gesteigerten Inzidenz an operativen Eingriffen bei CMV positiven RA-Patienten/-Patientinnen einher (Abb.5, Diskussion).  Es wird vermutet, dass eine persistente CMV-Infektion zur klonalen Expansion von funktionell ersch\u00f6pften (exhausted) T-Zellen f\u00fchrt. Suboptimal agierende CMV-spezifische T-Zellen h\u00e4tten zur Folge, dass mehr T-Zellen f\u00fcr die Kontrolle der CMV-Infektion ben\u00f6tigt w\u00fcrden (Akbar and Fletcher 2005).  Beachtlich, dysfunktionelle (exhausted) T-Zellen werden infolge systemischer chronischer Viruserkrankungen wie beispielsweise CMV als auch in Tumor infiltrierenden T-Zell-Populationen verschiedener Tumorentit\u00e4ten gefunden. Das Vorhandensein inhibitorischer Molek\u00fcle wie LIR-1, PD-1, TIGIT, BTLA oder auch CTLA-4, die mit dem dysfunktionellen Ph\u00e4notyp bei Virus- und Tumorerkrankungen assoziiert werden (Wherry and Kurachi 2015), kann nicht allein Aufschluss \u00fcber die Zugeh\u00f6rigkeit der T-Zell-Populationen geben, da sie ebenfalls im Laufe einer gesunden T-Zell-Aktivierung differentiell exprimiert werden. Dysfunktionelle T-Zellen \t\n\t34\t\t\t\t\t\tzeigen zus\u00e4tzlich zu der Kombination inhibitorischer Oberfl\u00e4chenmolek\u00fcle eine verminderte Proliferation auf. Dar\u00fcber hinaus weisen sie typische von anderen T-Zell-Populationen distinkte Transkriptomprofile und epigenetische Signaturen auf (Wang et al. 2017), die Zielstrukturen therapeutischer Interventionen bilden. LIR-1+ CD8+ T-Zellen unserer Studie zeigen eine CMV-spezifisch gesteigerte Proliferation gegen\u00fcber LIR-1- CD8+ T-Zellen, was gegen eine dysfunktionelle Subpopulation spricht. Eine k\u00fcrzlich erschienene Arbeit best\u00e4tigt die Zugeh\u00f6rigkeit der LIR-1+ CD8+ T-Zellen zur Population mit seneszentem Ph\u00e4notyp. Untypisch f\u00fcr seneszente T-Zellen sind sie aber mit einem hohen CMV-spezifischen proliferativem und zytolytischem Effektorpotential in gesunden Probanden ausgestattet (Gustafson et al. 2017). Der Befund der erh\u00f6hten Expression des Fraktalkin-Rezeptors CX3CR1 auf LIR-1+ CD8+ T-Zellen in RA impliziert eine erh\u00f6hte Mobilit\u00e4t dieser T-Zell-Population. Fraktalkinspiegel im Serum als auch im Synovium sind bei RA-Patienten/-Patientinnen erh\u00f6ht, wodurch CX3CR1 tragende Monozyten, Osteklasten und T-Zellen angelockt, aktiviert und ihr \u00dcberleben gesteuert wird (Nanki et al. 2017). LIR-1+ CD8+ T-Zellen konnten in unseren Untersuchungen ebenfalls in der Synovialfl\u00fcssigkeit und der Synovialmembran detektiert werden (Daten nicht gezeigt) und sind m\u00f6glicherweise \u00fcber eine Fraktalkin-spezifische Migration eingewandert. LIR-1 bindet verschiedene klassische (HLA-A und HLA-B) und nicht-klassische HLA Klasse I Molek\u00fcle wie HLA-G, wobei letzteres mit deutlich st\u00e4rkerer Bindungsaffinit\u00e4t (Shiroishi et al. 2003). HLA-G ist weitl\u00e4ufig als Molek\u00fcl der embryonalen Immuntoleranz und als Tumor-Escape-Mechanismus bekannt (Seliger 2016). In Patienten/Patientinnen mit rheumatischen Erkrankungen wurden zum einen verminderte l\u00f6sliche Serum-Spiegel f\u00fcr HLA-G gemessen (Verbruggen et al. 2006), zum anderen wurde in einer aktuelleren Studie eine verminderte Bindungsaffinit\u00e4t von l\u00f6slichem HLA-G f\u00fcr LIR-1 (Veit et al. 2015) dokumentiert. Beide Studien \u00fcber die geringere Bioverf\u00fcgbarkeit von l\u00f6slichem HLA-G lassen sich gut mit unserem Ergebnis einer reaktiveren unkontrollierten Effektorpotenz der LIR-1+CD8+ T-Zellen in RA-Patienten/-Patientinnen korrelieren. Die erh\u00f6hte LIR-1 Expression der CD8+ T-Zellen bei RA k\u00f6nnte somit ein Mechanismus der versuchten Immunkontrolle dieser T-Zell-Population sein. Diese Hypothese st\u00fctzt sich auf die hier vorliegenden Ergebnisse, dass die zytotoxische Aktivit\u00e4t der LIR-1+ T-Zellen durch eine in vitro Gabe von \t\n\t35\t\t\t\t\t\tl\u00f6slichem HLA-G hemmbar ist, somit LIR-1 funktionell auf den CD8+ T-Zellen der RA-Patienten/-Patientinnen vorliegt. Gustafson et al. beschreibt bei gesunden Spendern eine gesteigerte CMV-spezifische Proliferation von LIR-1+ T-Zellen bei unver\u00e4nderter Zytokinproduktion in einem in vitro Zellsystem, bei dem LIR-1 durch Antik\u00f6rper blockiert ist und somit seine inhibitorische Wirkung vermittelt durch HLA Klasse I nicht wahrnehmen kann (Gustafson et al. 2017). Die Diskrepanz bez\u00fcglich der CMV-spezifischen Zytokinproduktion zu unseren Daten k\u00f6nnte an den unterschiedlichen in vitro Systemen zur Identifizierung der funktionellen Kompetenz LIR-1+ T-Zellen liegen und/oder dem Spenderkollektiv gesunder Probanden (Gustafson et al.) gegen\u00fcber RA-Patienten/-Patientinnen (Rothe, Quandt et al.) geschuldet sein. Gemeinsam weisen die Ergebnisse aus der in dieser Schrift dargelegten Studie und der von Gustafson et al. auf eine Immun-Checkpoint Funktion von LIR-1 hin, welche bei entsprechender Bindungspartnerverf\u00fcgbarkeit die Gr\u00f6\u00dfe des CMV-spezifischen Effektorpools kontrolliert und die zytolytische Effektorpotenz CMV-spezifischer Zellen bei RA-Patienten/-Patientinnen eingrenzen kann. In CMV negativen RA-Patienten/-Patientinnen scheint die chronische inflammatorische Situation ebenfalls zur Verst\u00e4rkung des LIR-1 Molek\u00fcls auf CD8+ T-Zellen beizutragen, obwohl die Ergebnisse hier nur Tendenzen zeigten (Rothe et al. 2016). Diese Befunde unterst\u00fctzen eine m\u00f6gliche, eher generelle Aufgabe des LIR-1 Molek\u00fcls in der T-Zell-Biologie bei entz\u00fcndlichen chronischen Prozessen, zu denen letztlich auch die Situation einer Tumorerkrankung z\u00e4hlt.  \n \nAbb.5 T-zellul\u00e4re Ver\u00e4nderungen durch CMV und rheumatoide Arthritis, CMV: Cytomegalovirus, DAS: disease activity score, RA: rheumatoide Arthritis\t\t\n\t36\t\t\t\t\t\tEine nat\u00fcrliche CMV Infektion f\u00fchrt zur Aktivierung klassischer HLA-Klasse I- restringierter CD8 T-Zell-Antworten. Bemerkenswerte neue Forschungsans\u00e4tze in der Impfstoffentwicklung zeigen den Einsatz von CMV basierten, genetisch ver\u00e4nderten Vektoren, welche klassische und nicht-klassische (HLA-II restringiert und HLA-E restringierte) CD8 T-Zell-Antworten in Primaten hervorrufen (Fruh and Picker 2017). Eine Impfung gegen CMV, bzw. gegen andere bisher nicht-kontrollierbare Viren, k\u00f6nnte erfolgreich sein, wenn die nat\u00fcrlich auftretende insuffiziente CD8 T-Zellantwort um eine vielgestaltige CD8 T-Zell-Antwort mit hoher Zahl an potenten Effektor-Ged\u00e4chtnis-Zellen erweitert w\u00fcrde, die keine systemischen T-zellul\u00e4ren Ver\u00e4nderungen, wie oben ausgef\u00fchrt, hinterlassen.  3.1.2. Polyfunktionale CD4+CD8+ doppelt positive T-Zellen in der Pathogenese der          RA  Die Ergebnisse dieser Studie zeigen zum ersten Mal erh\u00f6hte polyfunktionale CD4+CD8+ doppelt positive T-Zellen in der Peripherie von adulten ACPA+ RA-Patienten/-Patientinnen. In einer fr\u00fcheren Untersuchung an 4 Patienten mit juveniler rheumatoider Arthritis konnten CD4+CD8+ doppelt positive T-Zellen aus dem Synovialgewebe isoliert werden, Untersuchungen in der Peripherie und zur Funktion wurden nicht durchgef\u00fchrt (De Maria et al. 1987). CD4+CD8+ doppelt positive T-Zellen lassen sich hinsichtlich der Intensit\u00e4t der Ko-Rezeptorexpression in 3 weitere Subgruppierungen (CD4++CD8+, CD4++CD8++, CD4+CD8++) unterteilen (Parel and Chizzolini 2004, Overgaard et al. 2015). Die hier erhobenen Daten zeigen die am h\u00e4ufigsten vertretene Fraktion in der Subgruppe der CD4++CD8+ positiven T-Zellen. Diese Tatsache, zusammen mit publizierten Daten, die eine Blockade des CD4 typischen Transkriptionsfaktorprogramms, das f\u00fcr eine de novo CD8 Expression sorgt (Mucida et al. 2013, Reis et al. 2013), l\u00e4sst die Vermutung zu, dass diese Zellen aus peripheren CD4 einzel positiven T-Zellen entstanden sind. Der Fakt, dass DP T-Zellen in der RA erh\u00f6hte Mengen an IL-4 sezernieren, k\u00f6nnte f\u00fcr die Aufrechterhaltung der CD8 Expression von DP T-Zellen mitverantwortlich sein, denn IL-4 wurde in einer fr\u00fcheren Arbeit als Triebkraft f\u00fcr eine CD8 Expression identifiziert (Paliard et al. 1988).  Die Ergebnisse dieser Studie zeigen eine erh\u00f6hte Zahl DP T-Zellen in Patienten/Patientinnen mit Antik\u00f6rpern gegen citrullinierte Peptide. T-Zell-Antworten gegen citrullinierte Peptide aus Proteinen des Zytoskeletts, der Blutgerinnung und \t\n\t37\t\t\t\t\t\tder Hautverhornung wurden bei RA gefunden (Snir et al. 2011, Gertel et al. 2017). Eigene Ergebnisse an CD4 einzel positiven T-Zellen von RA-Patienten/-Patientinnen zeigen erh\u00f6hte Zytokinproduzenten beim Kontakt mit citrulliniertem Vimentin gegen\u00fcber nicht-citrulliniertem Vimentin (Daten nicht gezeigt). Fortf\u00fchrende Untersuchungen zur Spezifit\u00e4t von DP T-Zellen f\u00fcr citrullinierte Peptide aus Proteinen wie Vimentin, Fibrinogen und Fillagrin, den Hauptautoantigenen der RA (Masson-Bessiere et al. 2001, Vossenaar et al. 2004) k\u00f6nnten sich sinnvoll an die hier gewonnen Erkenntnisse anschlie\u00dfen. Die T-Zell-Antwort bei der RA weist vor allem im Verlauf einen klaren Th1 Bias mit vorrangiger Produktion von IFN\u03b3 und IL-17 auf (Leipe et al. 2010). Interessanterweise h\u00e4ngt das Zytokinprofil im Synovium vom Zeitpunkt der Untersuchung ab. So liegt in RA-Patienten/-Patientinnen in einem fr\u00fchen Stadium eher ein Th2 Ph\u00e4notyp mit erh\u00f6htem Level an IL-4 und IL-13 und kaum IFN\u03b3 in der Synovialfl\u00fcssigkeit vor (Raza et al. 2005). Das Vorhandensein von IL-4 Produzenten bei der RA wird auch von Sieper et al., 1999 nach polyklonaler Restimulation der Zellen in vitro best\u00e4tigt (Yin et al. 1999). Eine weitere Arbeit zeigt, dass synoviales IL-4 von CD8 T-Zellen produziert wird (Cho et al. 2012). Diese CD8 T-Zellen k\u00f6nnten gleichzeitig CD4 positiv sein, was in der Studie von Cho et al. nicht betrachtet wurde. Dar\u00fcber hinaus  kann IL-4 entscheidend in die pathogene Antik\u00f6rperproduktion bei der RA, zumindest in einem der humanen RA sehr \u00e4hnlichem Mausmodell, eingreifen (Ohmura et al. 2005).  Die Ergebnisse unserer Untersuchungen weisen des Weiteren auf eine Multifunktionalit\u00e4t der DP T-Zellen bei der RA hin. Neben den IL-4 Produzenten sezernieren diese T-Zellen ebenfalls CMV-spezifisch mehr IFN\u03b3 als die Vergleichspopulation aus gesunden Spendern. Eine latente CMV Infektion f\u00fchrt, wie zuvor ausgef\u00fchrt (3.1.1.), zum schwereren Verlauf einer rheumatoiden Erkrankung. Dies k\u00f6nnte in der h\u00f6heren Zahl reaktiver T-Zellen, die CD4 und CD8 einzel positiv, aber auch CD4+CD8+ doppelt positiv sind, begr\u00fcndet sein. DP positive T-Zellen konnten bei gesunden Spendern bereits mit einer CMV Infektion korreliert werden. Diese T-Zellen zeigten eine CMV-spezifische verst\u00e4rkte Zytokinproduktion, Proliferation und Zytotoxizit\u00e4t (Suni et al. 2001). K\u00fcrzlich wurden diese Befunde f\u00fcr DP T-Zellen aus gesunden Spendern mit einer vorliegenden CMV Reaktivit\u00e4t erweitert. T-bet und Eomes, zwei wichtige Transkriptionsfaktoren, die zahlreiche T-Zell-Effektorfunktionen steuern, sind in CMV+ gegen\u00fcber CMV- DP T-Zellen und \t\n\t38\t\t\t\t\t\tgegen\u00fcber CD4 bzw. CD8 einzel positiven Zellen erh\u00f6ht exprimiert (Hassouneh et al. 2017). In Zusammenschau mit zahlreichen anderen Studien der letzten 25 Jahre, best\u00e4tigt unsere Studie die Existenz peripherer CD4+CD8+ doppelt positiver T-Zellen mit krankheitsspezifischem Effektorpotenzial (Overgaard et al. 2015). Dennoch ist es wissenswert, dass die genaue Anzahl dieser Zellen vermutlich geringer ist als vielfach publiziert, da es methodisch bedingt obgleich wie in unserer Studie angewandter state of the art durchgef\u00fchrter durchflusszytometrischer Analytik, zur Detektion einer geringen Anzahl (\u2264 0,3%) von CD4+CD8+ Zellaggregaten kommt (Overgaard et al. 2017). Mehr und mehr in den Fokus der Untersuchungen r\u00fcckt die Rolle des Metabolismus f\u00fcr T-Zell-Funktionen bei der rheumatoiden Arthritis. Arthritogene T-Zellen wechseln f\u00fcr ihren Energiehaushalt von der Glykolyse zum Pentosephosphatweg. Dies ist begleitet von einem reduzierten Redox-Signaling, was sich in Hyperproliferation, einem ver\u00e4nderten Zellzyklus und Zeichen einer vorzeitigen Alterung niederschl\u00e4gt (Weyand et al. 2017). Inwieweit CD4+CD8+ doppelt positive T-Zellen diesen ver\u00e4nderten Metabolismus aufzeigen ist noch unverstanden und wird Gegenstand fortf\u00fchrender Untersuchungen sein. Von vermutlich fundamentaler Bedeutung f\u00fcr das Verst\u00e4ndnis der Entstehung und den Verlauf der rheumatoiden Arthritis ist die in den letzten Jahren verst\u00e4rkt erforschte Rolle des Mikrobioms. Als Mikrobiom wird die Gesamtheit der vorhandenen Mikroorganismen eines Organismus bezeichnet. Sowohl das Darm- als auch das Mundmilieu-assoziierte Mikrobiom nehmen Einfluss auf den Verlauf der RA (Lee and Kim 2017). Das mit einer Periodontitis assoziierte Bakterium Porphyromonas gingivalis kann f\u00fcr eine verst\u00e4rkte TH17 Polarisierung sorgen und dar\u00fcber hinaus die Citrullinierung von Proteinen erm\u00f6glichen (Rosenstein et al. 2004, Moutsopoulos et al. 2012). Beide Vorg\u00e4nge sind essentiell wichtig f\u00fcr den Progress bzw. die Entstehung von RA. DP T-Zellen sind aktive Gestalter der Pathogenese bei RA und bilden sowohl neue Zielstrukturen in der Diagnostik als auch f\u00fcr neue therapeutische Ans\u00e4tze.  3.1.3. Kontrollmechanismen reaktiver T-Zellen in der Arthritis  \t\n\t39\t\t\t\t\t\tDie durchgef\u00fchrte Studie zeigt eine zuvor unbekannte Expression von PIR-B in murinen T-Zellen. Diese Expression wird durch eine St\u00f6rung im TZR Signalweg in der Peripherie und durch das komplexe inflammatorische Geschehen einer Arthritiserkrankung gef\u00f6rdert.  T-Zell-Antworten m\u00fcssen nach einer gew\u00fcnschten immunologischen Reaktion wieder abgeschaltet werden k\u00f6nnen. Dies geschieht u.a. durch die verst\u00e4rkte Expression inhibitorischer Molek\u00fcle wie beispielsweise CTLA-4 oder PD-1 in Effektor T-Zellen. Bei Vorliegen von Autoimmunit\u00e4t k\u00f6nnen diese Mechanismen gest\u00f6rt sein. M\u00f6glicherweise sind alternative Mechanismen vorhanden, die es zu finden gilt. Die Abschaltung/Begrenzung von initial unerw\u00fcnschten autoreaktiven T-Zell-Antworten stellt eine besondere Herausforderung f\u00fcr das Immunsystem dar. PIR-B wird in murinen CD4 und CD8 T-Zellen im Verlauf einer Arthritiserkrankung hochreguliert und ist am st\u00e4rksten bei Tieren mit einem verminderten Arthritisscore exprimiert (Rothe et al. 2017). Diese Tatsache l\u00e4sst die Annahme zu, dass PIR-B die Immunantwort der T-Zellen herunterreguliert, also als ein Abschalter fungiert. Spannend ist, dass PIR-B+ CD4 T-Zellen mehr IFN\u03b3 als PIR-B negative Zellen sezernieren und die ex vivo Analyse der IL-17 Produzenten blieb negativ. Erst eine vitro Restimulation zeigte die Kapazit\u00e4t der Zellen zur IL-17 Produktion in 40 Wochen alten arthritischen SKG Tieren (Rothe et al. 2017) im Kontrast zu j\u00fcngeren SKG Tieren in fr\u00fcheren Untersuchungen von Hirota et al. (Hirota et al. 2007). IFN\u03b3 hat einen sehr breiten Aktionsradius, es gilt als inflammatorischer Mediator, aber ebenfalls als Suppressor, durch die F\u00e4higkeit, die Th17 Differenzierung in SKG M\u00e4usen zu blockieren (Hirota et al. 2007). Infolge einer experimentell herbeigef\u00fchrten \u00dcberexpression von PIR-B in peripheren T-Zellen aus Balb/c Tieren kommt es zu einer verminderten Th-1 Immunantwort (Imada et al. 2009). Dies unterst\u00fctzt die von uns identifizierte inhibitorische Funktion des Molek\u00fcls in T-Zellen. PIR-B entfaltet ebenfalls inhibitorische Kompetenz in anderen Immunzellen (Ujike et al. 2002, Karo-Atar et al. 2013). Dies ist zus\u00e4tzlich gut vereinbar mit seinem intrazellul\u00e4r inhibitorisch-wirkenden Signalweiterleiter, ITIM (intracellular inhibitory motif) (Kubagawa et al. 1997).  PD-1 wurde verst\u00e4rkt in T-Zellen aus dem Synovium gefunden, wodurch ein kontrolliertes Abschalten der T-Zell-Reaktionen erm\u00f6glicht scheint. In der Tat bleiben die synovialen T-Zellen aber insbesondere bei der reaktiven Arthritis in hohem Ma\u00dfe aktiv, die Abschaltung der T-Zell-Antwort durch PD-1 am Ort des inflammatorischen \t\n\t40\t\t\t\t\t\tGeschehens ist also beeintr\u00e4chtigt (Raptopoulou et al. 2010). Dies zeigt auf, dass regulatorische Mechanismen vielschichtig gesteuert sind und durch das lokale Mikromilieu kontrolliert werden.  PIR-B knockout M\u00e4use zeigen keine offensichtlichen Ver\u00e4nderungen im T-Zell-Kompartiment des Immunsystems und zeigen auch keinen autoimmunen Ph\u00e4notyp (Imada et al. 2009). Dies deckt sich mit unseren Daten insofern, dass PIR-B nicht f\u00fcr die T-Zell-Entwicklung wichtig ist, des Weiteren PIR-B nicht der Initiator einer multiparameterbedingten Autoimmunit\u00e4t, sondern erst infolge einer solchen induziert wird und als Regulator fungieren kann.  K\u00fcrzlich konnte durch Einf\u00fchren der SKG Mutation in C57/BL6 und \u2013BL10 Tieren eine gleiche Symptomatik mit einer gest\u00f6rten T-Zell-Selektion im Thymus, einer ver\u00e4nderten T-Zell-Aktivierung und mit Formen der Arthritis nach Mannangabe, induziert werden (Guerard et al. 2016). Diese Tiere erm\u00f6glichen ein breiteres Spektrum der Erforschung der genauen Kostimulator- und Koinhibitor-Signalkaskaden in T-Zellen verschiedener Subtypen durch Einkreuzungen von transgenen bzw. knockout M\u00e4usen, die weitestgehend f\u00fcr den C57/BL6 Background vorliegen. Dar\u00fcber hinaus w\u00e4ren diese Tiere hinsichtlich der Untersuchung zur PIR-B Expression ein relevantes Modellsystem, dass unsere Daten im erweiterten Kontext validieren k\u00f6nnten. Effektor T-Zellen k\u00f6nnen im Vergleich zu naiven T-Zellen TZR Signale zus\u00e4tzlich zur TZR-CD3zeta-ZAP70 Kaskade \u00fcber einen alternativen Signalweg, den TZR-FcR\u03b3-Syk Weg, weitergeben (Krishnan et al. 2003). Inwieweit dieser alternative TZR Signalweg f\u00fcr die Expression von PIR-B in der Peripherie eine Rolle spielt ist unbekannt und w\u00e4re ein weiterer lohnender experimenteller Ansatzpunkt. Zap70 Defizienz durch Mutationen im Menschen f\u00fchrt zu einem dem Scid Syndrom \u00e4hnlichen Ph\u00e4nomen, dabei sind CD4+ T-Zellen meist nur gering ver\u00e4ndert, CD8+ T-Zellen stark reduziert oder fehlen in der Peripherie g\u00e4nzlich (Shirkani et al. 2017). Zus\u00e4tzlich zu diesem T-Zell-Entwicklungsstopp hat das Fehlen/ die eingeschr\u00e4nkte Funktion von ZAP70 Auswirkungen auf die Stimulierbarkeit der peripheren CD4+ T-Zellen (Kaur et al. 2014). Dies geht klinisch einher mit schwer kontrollierbaren bakteriellen, viralen und fungalen Infektionen. Zus\u00e4tzlich findet sich bei Menschen mit einem ZAP-70 Defekt ein vermindertes peripheres T-Zell-Repertoire (Roifman et al. 2010), \u00e4hnlich wie bei Patienten/Patientinnen mit einer rheumatoiden Arthritis (Wagner et al. 1998) und anderen T-zellassoziierten Autoimmunkrankheiten.  \t\n\t41\t\t\t\t\t\tDer Befund einer h\u00f6heren Expression von PIR-B in T-Zellen in Abh\u00e4ngigkeit vom Mikrobiom bietet wegweisende neu Ansatzpunkte. Unver\u00f6ffentlichte Daten demonstrieren eine verst\u00e4rkte Expression von PIR-B nach einer CMV Infektion von SKG Tieren im Vergleich zu altersidentischen und bez\u00fcglich der Arthritis klinisch vergleichbaren, nicht infizierten Tieren.  PIR-B scheint daher sowohl infolge einer T-zellul\u00e4ren Immunantwort gegen Pathogene, als auch infolge einer Auseinandersetzung des Immunsystem mit Autoimmunit\u00e4t exprimiert zu werden. Dies sollte in anderen experimentellen Mausmodellen, beispielsweise der experimentellen autoimmunen Enzephalomyelitis und durch Infektion von CMV bzw. anderer Pathogene in Wildtyp-Mausst\u00e4mmen, evaluiert werden.   3.2. Die Bedeutung von Kostimulatoren und Koinhibitoren f\u00fcr die T-Zell-        Hom\u00f6ostase und die antitumorale T-zellul\u00e4re Immunabwehr  3.2.1. T-Zell-Aktivierung durch B7-H3 auf Hautzellen Die Haut z\u00e4hlt zu den wichtigsten Organen der prim\u00e4ren Abwehrlinie gegen Erreger aus der Umwelt. Sie arbeitet synergistisch mit anderen Abwehrlinien, beispielsweise den T-Zellen der adaptiven Immunit\u00e4t zusammen. Die in dieser Forschungsarbeit gewonnenen Ergebnisse der B7-H3 Expression auf Keratinozyten der Epidermis, die die h\u00f6mostatische T-Zellproliferation steuern, tragen somit wesentlich zum Verst\u00e4ndnis der Zusammenarbeit dieser Systeme bei.  In Erwachsenen wird die Aufrechterhaltung des T-Zell-Pools durch verschiedenste Organsysteme erf\u00fcllt, nur ca. 2,2% aller Lymphozyten zirkulieren im Blut. Die \u00fcberwiegende Zahl befindet sich in Lymphknoten, gefolgt von anderen prim\u00e4ren und sekund\u00e4ren Lymphorganen, wobei ebenfalls nur ca. 2% in anderen Organsystemen verweilen (Ganusov and De Boer 2007). Interessanterweise beherbergt die Haut eines Menschen ca. 2x mehr T-Zellen als sich in der Zirkulation befinden, was die T-zellbiologischen Vorg\u00e4nge in der Haut um so relevanter macht (Clark 2010). Die Ergebnisse der B7-H3 Studie zeigen eine gleichartig hohe Expression von B7-H3 auf Transkript- und Proteinebene in den Keratinozyten der oberen Hautschicht. Das unterscheidet dieses gesunde Gewebe von anderen Geweben, bei denen vielfach eine posttranskriptionale Kontrolle die Proteinexpression von B7-H3 trotz hoher Transkriptmengen unterbindet (Chapoval et al. 2001). \t\n\t42\t\t\t\t\t\tIm Gegensatz zu B7-H1 und B7-H4 ist die Affilierung von B7-H3 als Kostimulator bzw. Koinhibitor nicht festgelegt, sondern vielmehr zellkontext- und rezeptorabh\u00e4ngig (Chapoval et al. 2001, Suh et al. 2003).  In der hier dokumentierten Studie konnte B7-H3 als Kostimulator der T-Zell-Antwort identifiziert werden. Weitere eigene unver\u00f6ffentlichte Daten im Nierenzellkarzinom zeigen einen signifikant geringeren Prim\u00e4rtumorumfang in situ bei hoher tumoraler B7-H3 Expression, einhergehend mit einem erh\u00f6hten CD8 T-Zell-Infiltrat und erniedrigtem CD4 T-Zell-Infiltrat. Dies spricht ebenfalls f\u00fcr einen kostimulierenden Effekt einer CD8 T-Zell-Antwort durch B7-H3 auf Nierenkarzinomzelllinien. Andere Arbeiten zur Bedeutung von B7-H3 bei Tumoren reihen sich ein in die Divergenz der Funktion des Molek\u00fcls. Es wurde eine tumorunterst\u00fctzende Rolle f\u00fcr zervikale und Lungen-Tumore (Mao et al. 2015, Li et al. 2017) und eine tumorinhibierende Wirkung im Pankreaskarzinom (Loos et al. 2009) gefunden. Wichtig zu betrachten ist der Fakt, dass es oft zu einer koordinierten parallelen oder zeitlich begrenzten, sich ver\u00e4ndernden Expression multipler Liganden und Rezeptoren der B7 Familie, wie auch der Kostimulatoren/Koinhibitoren anderer Familien, z.B der TNF/TNF-Rezeptor Familie, auf den beteiligten Zellen kommen kann. Insofern sind Ergebnisse aus einer isolierten experimentellen Fokussierung auf eines der Ligand/Rezeptorpaare immer kritisch zu betrachten und decken nicht die ganze Bandbreite zellbiologischer Prozesse in vivo ab.  Ein weiterer Forschungsansatz von hoher Relevanz w\u00e4re die Untersuchung der funktionellen Konsequenz eines \u00fcber B7-H3 vermittelten Signals f\u00fcr die Keratinozyten. Dies geht auf Forschungsarbeiten zur\u00fcck die zeigen konnten, dass B7-H3 selbst als Rezeptor fungieren kann und in anderen Geweben die Zelldifferenzierung der B7-H3 tragenden Zelle steuert (Xu et al. 2011).  3.2.2. T-Zell-Kontrolle durch Koinhibitorexpression auf Tumorzellen Das Tumormikromilieu wird neben den Tumorzellen durch verschiedenste Zelltypen wie Immunzellen, Fibroblasten, Adipozyten, Perizyten, Endothelzellen und Stammzellen, dar\u00fcber hinaus aus nicht-zellul\u00e4ren Bestandteilen der extrazellul\u00e4ren Matrix gebildet. Metabolische Produkte und zellul\u00e4re Botenstoffe aller vorhandenen Zelltypen bestimmen das Geschehen (Reina-Campos et al. 2017). Zytokine und Chemokine sind essentielle zellul\u00e4re Botenstoffe der Immunzellen, aber auch der \t\n\t43\t\t\t\t\t\tGewebszellen verschiedener Organe und der Gef\u00e4\u00dfzellen, die das Tumorgewebe solider Tumoren vaskularisieren. Die durchgef\u00fchrte Studie zur Regulation der B7-H Molek\u00fcle durch Zytokine spiegelt in Teilen experimentell diese komplexe Situation verschiedener Botenstoffe wieder. Die konstitutive Analyse der B7-H Expression in Nierenkarzinomzelllinien best\u00e4tigte publizierte Expressionsmuster von B7-H1 (Thompson et al. 2006), B7-H3 (Crispen et al. 2008) und B7-H4 (Krambeck et al. 2006). B7-H2 (ICOS-L) Expression und Regulation hingegen wurde durch unsere Forschungsarbeit erstmals beschrieben. Fortf\u00fchrende Untersuchungen zur Rolle von B7-H2 f\u00fcr das Nierenzellkarzinom k\u00f6nnten sich sinnvoll anschlie\u00dfen, denn CD4+ T-Zellen, die Haupttr\u00e4ger des ICOS Rezeptors, wurden bereits sehr fr\u00fch als wichtige Kontributoren der anti-tumoralen Immunantwort identifiziert (Pardoll and Topalian 1998).  Die Ergebnisse unserer Studie des synergistischen Effektes anti-inflammatorischer und pro-inflammatorischer Zytokine auf die B7-H1 Expression sind wichtig f\u00fcr das Verst\u00e4ndnis der patienten-/patientinnenspezifischen Expressionsdaten von B7-H1 auf Tumorzellen, die sich durch das unterschiedliche Mikromilieu bestimmen k\u00f6nnen. Begr\u00fcndet durch die hohe Variabilit\u00e4t des Immunsystems und der Tumore der Patienten/Patientinnen wird moderne Krebstherapie zunehmend zur individualisierten Medizin (Quandt et al. 2017). Die untersuchten Zytokine werden im Wesentlichen durch das Immunzellinfiltrat im Tumor sezerniert. Zus\u00e4tzlich zu den T-Zellen und myeloiden Zellen sind auch B-Zellen vor Ort. B-Zellen k\u00f6nnen \u00fcber verschiedene Mechanismen, u.a. durch Zytokinsezernierung von z.B. IL-10 oder IL-4 (Harris et al. 2000), aktiv das Geschehen im Tumormikromilieu beeinflussen (Cai et al. 2016, Chiaruttini et al. 2017). B-Zellen sind im Tumormikromilieu hochorganisiert, sie befinden sich in terti\u00e4ren lymphoiden Strukturen (TLS) (Dieu-Nosjean et al. 2016), die \u00c4hnlichkeiten mit der Organisation in Lymphknoten, den sekund\u00e4ren lymphatischen Geweben, aufweisen.  Neben der Regulation durch Zytokine gibt es andere Signalwege, die eine aberrante B7-H1 Expression in Tumoren bewirken. Hier sind Mutationen in der 3\u2019UTR des Gens (Kataoka et al. 2016), und Ver\u00e4nderungen in STAT3 und AKT Signalwegen zu nennen (Parsa et al. 2007, Marzec et al. 2008). PD-1 und B7-H1 (PD-L1) sind mittlerweile Zielstrukturen moderner Immuntherapien im Nierenzellkarzinom (Atkins et al. 2017, Mazza et al. 2017). Trotz dieser erfreulichen Entwicklung neuer Therapieoptionen gibt es Patienten/Patientinnen, die von diesen Therapieans\u00e4tzen \t\n\t44\t\t\t\t\t\tnicht profitieren. Der zun\u00e4chst naheliegendste Grund f\u00fcr ein Nicht-Ansprechen auf die anti-PD-L1 Therapie, eine unterschiedliche Expression von B7-H1 (PD-L1) auf den Tumorzellen, hat sich nur teilweise best\u00e4tigt. Wichtig f\u00fcr ein Therapieansprechen scheint eine PD-L1 Expression auf verschiedenen Immunzellen im Tumormikromilieu zu sein (Herbst et al. 2014, Quandt et al. 2017). In pr\u00e4klinischen Modellen konnte ein Ansprechen der anti-PD-L1 und anti-PD-1 Therapie trotz fehlender tumoraler B7-H1 (PD-L1) Expression aufgezeigt werden (Kleinovink et al. 2017).  Mit Nachdruck wird in der sogenannten \u201eliquid biopsy\u201c, dem Blut, nach Markern/Markerprofilen, die ein Ansprechens bzw. Nicht-Ansprechen auf diese Immuntherapien vorhersagen gesucht. Es wird ein bestimmtes Immunprofil bzw. ein zu Beginn der Therapie bestehender kostimulatorischer/koinhibitorischer Rezeptorstatus auf den Immunzellen vermutet.   \n Die Resultate unserer Studie zu B7-H4 im Melanom zeigen die Bedeutung des Molek\u00fcls f\u00fcr die Pathogenese dieser Tumorerkrankung auf. B7-H4 auf Melanomzellen dient m\u00f6glicherweise, \u00e4hnlich wie B7-H1, als Tumorescape-Strategie, \nAbb.6 B7-H4 als neue Zielstruktur im malignen Melanom B7-H4 tragende Tumorzellen inhibieren die Zytokinsekretion und damit eine essentielle Effektorfunktion tumorspezifischer CD8+ T-Zellen. \t\n\t45\t\t\t\t\t\tdenn die antitumorale Immunantwort wird \u00fcber dieses Ligand-Rezeptorpaar unterdr\u00fcckt (Abb. 6).  Die Ergebnisse der Untersuchungen zu B7-H4 im Melanom wurden vielfach zitiert und f\u00fcgen sich in die Reihe verschiedener Tumorentit\u00e4ten, f\u00fcr die B7-H4 als prognostisch relevante Zielstruktur identifiziert wurde, ein (Podojil and Miller 2017).   Interessanterweise wird B7-H4 nicht nur auf den Tumorzellen, sondern ebenfalls auf Immunzellen des Tumormikromilieus, z.B. den Tumor-assoziierten Makrophagen (TAM), \u00fcberexprimiert, wodurch es zu einer Inhibition der CD8+ T-Zellen kommt (Kryczek et al. 2006). Wir fanden in unserer Studie signifikant erh\u00f6hte Zahlen an TAMs in den Patienten/Patientinnen mit k\u00fcrzerem \u00dcberleben. Das Immunzellinfiltrat im hier untersuchten Patienten/-Patientinnenmaterial bestand vor allem aus Makrophagen und CD8+ T-Zellen und zeigte ebenfalls eine B7-H4 \u00dcberexpression, was trotz fehlender Kof\u00e4rbung zur Identifizierung des Immunzelltyps den Schluss nahe legt, dass auch im Melanom inhibitorisch wirkende Makrophagen an der Pathogenese beteiligt sind. Der Rezeptor f\u00fcr B7-H4 auf T-Zellen ist immer noch nicht identifiziert (Podojil and Miller 2017). Diese Identifikation des Rezeptors ist ein wichtiger experimenteller Forschungsansatz, denn so k\u00f6nnte \u00e4hnlich wie f\u00fcr PD-1 (Rezeptor von B7-H1, (Guo et al. 2017)) der Rezeptor f\u00fcr B7-H4 selbst direkt Angriffspunkt f\u00fcr neue therapeutische Ans\u00e4tze sein.  \t\n\t46\t\t\t\t\t\tZusammenfassung  Autoimmunkrankheiten wie die rheumatoide Arthritis und maligne Neoplasien verursachen erhebliche Kosten und Arbeitsausfall f\u00fcr die Gesellschaft und pers\u00f6nliches Leid f\u00fcr den betroffenen Patienten/Patientinnen.  Das Durchleben von Infektionen, das Auftreten von Autoimmunkrankheiten und die Bildung maligner Neoplasien sind scheinbar getrennte Ereignisse. Die Ergebnisse dieser Arbeit und weltweit durchgef\u00fchrter Analysen decken eine enge immunologische Verzahnung dieser Ereignisse auf, die deutlich machen, dass sich ein \u201eerinnerndes\u201c Immunsystem diesen Aufgaben in Abh\u00e4ngigkeit einer individuell verschiedenen Patienten-/Patientinnenhistorie widmet und urs\u00e4chlich zum Auftreten dieser Erkrankungen beitr\u00e4gt.  Chronische Infektionen wie CMV ver\u00e4ndern den zellul\u00e4ren Immunstatus ma\u00dfgeblich und sollten daher klinisch Ber\u00fccksichtigung finden. Es wird zunehmend davon ausgegangen, dass der Verlauf und die Therapieoptionen dieser Erkrankungen vom immunologischen Profil der Patienten/Patientinnen abh\u00e4ngen. Trotz deutlicher Fortschritte in der Behandlung, wie beispielsweise durch den Einsatz der TNF\u03b1 Therapie bei der rheumatoiden Arthritis und den Einsatz der neuen Immuntherapien zur Behandlung von malignen Neoplasien, bleiben viele Patienten/Patientinnen therapeutisch unterversorgt. Daher ist ein tieferes Verst\u00e4ndnis der immunologischen Vorg\u00e4nge, die urs\u00e4chlich krankheitsrelevant bzw. im Verlauf der Erkrankung zur Bek\u00e4mpfung selbiger beitragen k\u00f6nnen, notwendig, um weitere Therapieoptionen implementieren zu k\u00f6nnen. T-Zellen als Vertreter der adaptiven Immunit\u00e4t spiegeln pathologische Vorg\u00e4nge wieder und geben dabei R\u00fcckschlussm\u00f6glichkeiten f\u00fcr den Progress und bilden selbst therapeutische Zielstrukturen zur Behandlung.  Das Verst\u00e4ndnis allgemeing\u00fcltiger sowohl als auch krankheitsspezifischer T-zellbiologischer Wirkweisen er\u00f6ffnet neue Denkstrukturen und Forschungsans\u00e4tze.  \t\n\t47\t\t\t\t\t\tDie in den hier vorgestellten kliniknahen grundlagenwissenschaftlichen Forschungsarbeiten dokumentierten Ergebnisse zur Rolle von CD4+CD28-, CD8+LIR-1+, CD4+/PIR-B+ und CD4+CD8+ doppelt positiven T-Zellen im Kontext mit rheumatischen Erkrankungen mit vorgeschalteter persistierender CMV Infektion tragen zur weiteren Wissensvertiefung der T-zellimmunologischen Vorg\u00e4nge bei. Die durchgef\u00fchrten tumorimmunologischen Untersuchungen mit Fokus auf die Familie kostimulatorischer Molek\u00fcle der B7-Familie im translationalen Forschungsgebiet solider Tumore f\u00fchrten zur Aufdeckung bisher unbekannter T-zellul\u00e4rer Mechanismen, deren Kenntnis in zuk\u00fcnftige Therapieentwicklungen und die Erweiterung des Einsatzes bestehender Therapieoptionen einflie\u00dfen sollten. \t\n\t48\t\t\t\t\t\tLiteraturverzeichnis  Akbar, A. N. and J. M. Fletcher (2005). \"Memory T cell homeostasis and senescence during aging.\" Curr Opin Immunol 17(5): 480-485. Akbar, A. N. and S. M. Henson (2011). \"Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?\" Nat Rev Immunol 11(4): 289-295. Akbar, A. N., S. M. Henson and A. Lanna (2016). \"Senescence of T Lymphocytes: Implications for Enhancing Human Immunity.\" Trends Immunol 37(12): 866-876. Akondy, R. S., M. Fitch, S. Edupuganti, S. Yang, H. T. Kissick, K. W. Li, B. A. Youngblood, H. A. Abdelsamed, D. J. McGuire, K. W. Cohen, G. Alexe, S. Nagar, M. M. McCausland, S. Gupta, P. Tata, W. N. Haining, M. J. McElrath, D. Zhang, B. Hu, W. J. Greenleaf, J. J. Goronzy, M. J. Mulligan, M. Hellerstein and R. Ahmed (2017). \"Origin and differentiation of human memory CD8 T cells after vaccination.\" Nature 552(7685): 362-367. Anfossi, N., J. M. Doisne, M. A. Peyrat, S. Ugolini, O. Bonnaud, D. Bossy, V. Pitard, P. Merville, J. F. Moreau, J. F. Delfraissy, J. Dechanet-Merville, M. Bonneville, A. Venet and E. Vivier (2004). \"Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells.\" J Immunol 173(12): 7223-7229. Angelotti, F., A. Parma, G. Cafaro, R. Capecchi, A. Alunno and I. Puxeddu (2017). \"One year in review 2017: pathogenesis of rheumatoid arthritis.\" Clin Exp Rheumatol 35(3): 368-378. Appay, V., R. A. van Lier, F. Sallusto and M. Roederer (2008). \"Phenotype and function of human T lymphocyte subsets: consensus and issues.\" Cytometry A 73(11): 975-983. Atefi, M., E. Avramis, A. Lassen, D. J. Wong, L. Robert, D. Foulad, M. Cerniglia, B. Titz, T. Chodon, T. G. Graeber, B. Comin-Anduix and A. Ribas (2014). \"Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.\" Clin Cancer Res 20(13): 3446-3457. Atkins, M. B., J. I. Clark and D. I. Quinn (2017). \"Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.\" Ann Oncol. Barber, E. K., J. D. Dasgupta, S. F. Schlossman, J. M. Trevillyan and C. E. Rudd (1989). \"The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex.\" Proc Natl Acad Sci U S A 86(9): 3277-3281. Bessis, N., P. Decker, E. Assier, L. Semerano and M. C. Boissier (2017). \"Arthritis models: usefulness and interpretation.\" Semin Immunopathol 39(4): 469-486. Bindea, G., B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner, A. C. Obenauf, H. Angell, T. Fredriksen, L. Lafontaine, A. Berger, P. Bruneval, W. H. Fridman, C. Becker, F. Pages, M. R. Speicher, Z. Trajanoski and J. Galon (2013). \"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.\" Immunity 39(4): 782-795. Birnbaum, M. E., J. L. Mendoza, D. K. Sethi, S. Dong, J. Glanville, J. Dobbins, E. Ozkan, M. M. Davis, K. W. Wucherpfennig and K. C. Garcia (2014). \"Deconstructing the peptide-MHC specificity of T cell recognition.\" Cell 157(5): 1073-1087. Blank, C., T. F. Gajewski and A. Mackensen (2005). \"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.\" Cancer Immunol Immunother 54(4): 307-314. \t\n\t49\t\t\t\t\t\tBrown, D. M. (2010). \"Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy.\" Cell Immunol 262(2): 89-95. Cai, C., J. Zhang, M. Li, Z. J. Wu, K. H. Song, T. W. Zhan, L. H. Wang and Y. H. Sun (2016). \"Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma.\" Tumour Biol 37(6): 8209-8218. Callender, L. A., E. C. Carroll, R. W. J. Beal, E. S. Chambers, S. Nourshargh, A. N. Akbar and S. M. Henson (2017). \"Human CD8(+) EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK.\" Aging Cell. Cao, Y., L. Zhang, Y. Kamimura, P. Ritprajak, M. Hashiguchi, S. Hirose and M. Azuma (2011). \"B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin.\" Cancer Res 71(4): 1235-1243. Cappelli, L. C., A. K. Gutierrez, C. O. Bingham, 3rd and A. A. Shah (2017). \"Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.\" Arthritis Care Res (Hoboken) 69(11): 1751-1763. Chang, J. T., V. R. Palanivel, I. Kinjyo, F. Schambach, A. M. Intlekofer, A. Banerjee, S. A. Longworth, K. E. Vinup, P. Mrass, J. Oliaro, N. Killeen, J. S. Orange, S. M. Russell, W. Weninger and S. L. Reiner (2007). \"Asymmetric T lymphocyte division in the initiation of adaptive immune responses.\" Science 315(5819): 1687-1691. Chang, J. T., E. J. Wherry and A. W. Goldrath (2014). \"Molecular regulation of effector and memory T cell differentiation.\" Nat Immunol 15(12): 1104-1115. Chapoval, A. I., J. Ni, J. S. Lau, R. A. Wilcox, D. B. Flies, D. Liu, H. Dong, G. L. Sica, G. Zhu, K. Tamada and L. Chen (2001). \"B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.\" Nat Immunol 2(3): 269-274. Chen, D. S. and I. Mellman (2017). \"Elements of cancer immunity and the cancer-immune set point.\" Nature 541(7637): 321-330. Chen, J., C. C. Jiang, L. Jin and X. D. Zhang (2016). \"Regulation of PD-L1: a novel role of pro-survival signalling in cancer.\" Ann Oncol 27(3): 409-416. Cheng, M. and S. Hu (2017). \"Lung-resident gammadelta T cells and their roles in lung diseases.\" Immunology 151(4): 375-384. Chiaruttini, G., S. Mele, J. Opzoomer, S. Crescioli, K. M. Ilieva, K. E. Lacy and S. N. Karagiannis (2017). \"B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment.\" Oncoimmunology 6(4): e1294296. Cho, B. A., J. H. Sim, J. A. Park, H. W. Kim, W. H. Yoo, S. H. Lee, D. S. Lee, J. S. Kang, Y. I. Hwang, W. J. Lee, I. Kang, E. B. Lee and H. R. Kim (2012). \"Characterization of Effector Memory CD8(+) T Cells in the Synovial Fluid of Rheumatoid Arthritis.\" J Clin Immunol. Clark, R. A. (2010). \"Skin-resident T cells: the ups and downs of on site immunity.\" J Invest Dermatol 130(2): 362-370. Colombatti, A., R. Doliana, M. Schiappacassi, C. Argentini, E. Tonutti, C. Feruglio and P. Sala (1998). \"Age-related persistent clonal expansions of CD28(-) cells: phenotypic and molecular TCR analysis reveals both CD4(+) and CD4(+)CD8(+) cells with identical CDR3 sequences.\" Clin Immunol Immunopathol 89(1): 61-70. \t\n\t50\t\t\t\t\t\tCrane, I. J. and J. V. Forrester (2005). \"Th1 and Th2 lymphocytes in autoimmune disease.\" Crit Rev Immunol 25(2): 75-102. Crispen, P. L., Y. Sheinin, T. J. Roth, C. M. Lohse, S. M. Kuntz, X. Frigola, R. H. Thompson, S. A. Boorjian, H. Dong, B. C. Leibovich, M. L. Blute and E. D. Kwon (2008). \"Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.\" Clin Cancer Res 14(16): 5150-5157. Cromm, P. M. and C. M. Crews (2017). \"The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target.\" ACS Cent Sci 3(8): 830-838. Curtsinger, J. M., C. S. Schmidt, A. Mondino, D. C. Lins, R. M. Kedl, M. K. Jenkins and M. F. Mescher (1999). \"Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells.\" J Immunol 162(6): 3256-3262. De Maria, A., M. Malnati, A. Moretta, D. Pende, C. Bottino, G. Casorati, F. Cottafava, G. Melioli, M. C. Mingari, N. Migone and et al. (1987). \"CD3+4-8-WT31-(T cell receptor gamma+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis.\" Eur J Immunol 17(12): 1815-1819. Deng, L., H. Liang, B. Burnette, M. Beckett, T. Darga, R. R. Weichselbaum and Y. X. Fu (2014). \"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.\" J Clin Invest 124(2): 687-695. Desfrancois, J., A. Moreau-Aubry, V. Vignard, Y. Godet, A. Khammari, B. Dreno, F. Jotereau and N. Gervois (2010). \"Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas.\" PLoS One 5(1): e8437. Dieu-Nosjean, M. C., N. A. Giraldo, H. Kaplon, C. Germain, W. H. Fridman and C. Sautes-Fridman (2016). \"Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.\" Immunol Rev 271(1): 260-275. Doyle, C. and J. L. Strominger (1987). \"Interaction between CD4 and class II MHC molecules mediates cell adhesion.\" Nature 330(6145): 256-259. DuPage, M. and J. A. Bluestone (2016). \"Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.\" Nat Rev Immunol 16(3): 149-163. Egawa, T. and D. R. Littman (2008). \"ThPOK acts late in specification of the helper T cell lineage and suppresses Runx-mediated commitment to the cytotoxic T cell lineage.\" Nat Immunol 9(10): 1131-1139. Finley, D. (2009). \"Recognition and processing of ubiquitin-protein conjugates by the proteasome.\" Annu Rev Biochem 78: 477-513. Frahm, M. A., R. A. Picking, J. D. Kuruc, K. S. McGee, C. L. Gay, J. J. Eron, C. B. Hicks, G. D. Tomaras and G. Ferrari (2012). \"CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection.\" J Immunol 188(9): 4289-4296. Friese, M. A. and L. Fugger (2009). \"Pathogenic CD8(+) T cells in multiple sclerosis.\" Ann Neurol 66(2): 132-141. Fruh, K. and L. Picker (2017). \"CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination.\" Curr Opin Immunol 47: 52-56. \t\n\t51\t\t\t\t\t\tFunaki, S., Y. Shintani, T. Kawamura, R. Kanzaki, M. Minami and M. Okumura (2017). \"Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-beta induced epithelial mesenchymal transition in non-small cell lung cancer.\" Oncol Rep 38(4): 2277-2284. Ganusov, V. V. and R. J. De Boer (2007). \"Do most lymphocytes in humans really reside in the gut?\" Trends Immunol 28(12): 514-518. Geginat, J., M. Paroni, S. Maglie, J. S. Alfen, I. Kastirr, P. Gruarin, M. De Simone, M. Pagani and S. Abrignani (2014). \"Plasticity of human CD4 T cell subsets.\" Front Immunol 5: 630. Gerlach, C., J. W. van Heijst, E. Swart, D. Sie, N. Armstrong, R. M. Kerkhoven, D. Zehn, M. J. Bevan, K. Schepers and T. N. Schumacher (2010). \"One naive T cell, multiple fates in CD8+ T cell differentiation.\" J Exp Med 207(6): 1235-1246. Gerna, G., F. Baldanti and M. G. Revello (2004). \"Pathogenesis of human cytomegalovirus infection and cellular targets.\" Hum Immunol 65(5): 381-386. Gertel, S., G. Karmon, S. Vainer, O. Shovman, M. Cornillet, G. Serre, Y. Shoenfeld and H. Amital (2017). \"Immunomodulation of RA Patients&#x2019; PBMC with a Multiepitope Peptide Derived from Citrullinated Autoantigens.\" Mediators of Inflammation 2017: 9. Ghia, P., G. Prato, S. Stella, C. Scielzo, M. Geuna and F. Caligaris-Cappio (2007). \"Age-dependent accumulation of monoclonal CD4+CD8+ double positive T lymphocytes in the peripheral blood of the elderly.\" Br J Haematol 139(5): 780-790. Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen and M. L. Dustin (1999). \"The immunological synapse: a molecular machine controlling T cell activation.\" Science 285(5425): 221-227. Green, W. D. and M. A. Beck (2017). \"Obesity altered T cell metabolism and the response to infection.\" Curr Opin Immunol 46: 1-7. Gregersen, P. K., J. Silver and R. J. Winchester (1987). \"The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.\" Arthritis Rheum 30(11): 1205-1213. Griffiths, C. E., J. Esmann, G. J. Fisher, J. J. Voorhees and B. J. Nickoloff (1990). \"Differential modulation of keratinocyte intercellular adhesion molecule-I expression by gamma interferon and phorbol ester: evidence for involvement of protein kinase C signal transduction.\" Br J Dermatol 122(3): 333-342. Guerard, S., M. Boieri, M. Hultqvist, R. Holmdahl and K. Wing (2016). \"The SKG Mutation in ZAP-70 also Confers Arthritis Susceptibility in C57 Black Mouse Strains.\" Scand J Immunol 84(1): 3-11. Guo, L., H. Zhang and B. Chen (2017). \"Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.\" J Cancer 8(3): 410-416. Gustafson, C. E., Q. Qi, J. Hutter-Saunders, S. Gupta, R. Jadhav, E. Newell, H. Maecker, C. M. Weyand and J. J. Goronzy (2017). \"Immune Checkpoint Function of CD85j in CD8 T Cell Differentiation and Aging.\" Front Immunol 8: 692. Harari, A., S. C. Zimmerli and G. Pantaleo (2004). \"Cytomegalovirus (CMV)-specific cellular immune responses.\" Hum Immunol 65(5): 500-506. \t\n\t52\t\t\t\t\t\tHarris, D. P., L. Haynes, P. C. Sayles, D. K. Duso, S. M. Eaton, N. M. Lepak, L. L. Johnson, S. L. Swain and F. E. Lund (2000). \"Reciprocal regulation of polarized cytokine production by effector B and T cells.\" Nat Immunol 1(6): 475-482. Hashiguchi, M., H. Kobori, P. Ritprajak, Y. Kamimura, H. Kozono and M. Azuma (2008). \"Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.\" Proc Natl Acad Sci U S A 105(30): 10495-10500. Hassouneh, F., N. Lopez-Sejas, C. Campos, B. Sanchez-Correa, R. Tarazona, A. Pera and R. Solana (2017). \"Effect of Cytomegalovirus (CMV) and Ageing on T-Bet and Eomes Expression on T-Cell Subsets.\" Int J Mol Sci 18(7). Heath, J., N. Newhook, E. Comeau, M. Gallant, N. Fudge and M. Grant (2016). \"NKG2C(+)CD57(+) Natural Killer Cell Expansion Parallels Cytomegalovirus-Specific CD8(+) T Cell Evolution towards Senescence.\" J Immunol Res 2016: 7470124. Herbst, R. S., J. C. Soria, M. Kowanetz, G. D. Fine, O. Hamid, M. S. Gordon, J. A. Sosman, D. F. McDermott, J. D. Powderly, S. N. Gettinger, H. E. Kohrt, L. Horn, D. P. Lawrence, S. Rost, M. Leabman, Y. Xiao, A. Mokatrin, H. Koeppen, P. S. Hegde, I. Mellman, D. S. Chen and F. S. Hodi (2014). \"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.\" Nature 515(7528): 563-567. Hino, R., K. Kabashima, Y. Kato, H. Yagi, M. Nakamura, T. Honjo, T. Okazaki and Y. Tokura (2010). \"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.\" Cancer 116(7): 1757-1766. Hirota, K., M. Hashimoto, H. Yoshitomi, S. Tanaka, T. Nomura, T. Yamaguchi, Y. Iwakura, N. Sakaguchi and S. Sakaguchi (2007). \"T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.\" J Exp Med 204(1): 41-47. Hurez, V., A. Padron, R. S. Svatek and T. J. Curiel (2017). \"Considerations for successful cancer immunotherapy in aged hosts.\" Exp Gerontol. Imada, M., K. Masuda, R. Satoh, Y. Ito, Y. Goto, T. Matsuoka, S. Endo, A. Nakamura, H. Kawamoto and T. Takai (2009). \"Ectopically expressed PIR-B on T cells constitutively binds to MHC class I and attenuates T helper type 1 responses.\" Int Immunol 21(10): 1151-1161. Issuree, P. D., C. P. Ng and D. R. Littman (2017). \"Heritable Gene Regulation in the CD4:CD8 T Cell Lineage Choice.\" Front Immunol 8: 291. Judith A. Seidel, S. H. H., Natalie Riddell, Milica Vukmanovic-Stejic, Malcolm H. Rustin, Frank Nestle, Katie Lacy, Arne N. Akbar (2016). \"Skin resident CD8+ T cells display low cytotoxic potential in healthy skin and fail to fully mature in primary melanoma lesions.\" Journal of Dermatological Science 84(1): e156-e157. Karo-Atar, D., I. Moshkovits, O. Eickelberg, M. Konigshoff and A. Munitz (2013). \"Paired immunoglobulin-like receptor-B inhibits pulmonary fibrosis by suppressing profibrogenic properties of alveolar macrophages.\" Am J Respir Cell Mol Biol 48(4): 456-464. Kataoka, K., Y. Shiraishi, Y. Takeda, S. Sakata, M. Matsumoto, S. Nagano, T. Maeda, Y. Nagata, A. Kitanaka, S. Mizuno, H. Tanaka, K. Chiba, S. Ito, Y. Watatani, N. Kakiuchi, H. Suzuki, T. Yoshizato, K. Yoshida, M. Sanada, H. Itonaga, Y. Imaizumi, Y. Totoki, W. Munakata, H. Nakamura, N. Hama, K. Shide, Y. Kubuki, T. Hidaka, T. Kameda, K. Masuda, N. Minato, K. Kashiwase, K. Izutsu, A. Takaori-Kondo, Y. Miyazaki, S. Takahashi, T. Shibata, H. Kawamoto, Y. Akatsuka, K. Shimoda, K. Takeuchi, T. Seya, S. Miyano and S. Ogawa \t\n\t53\t\t\t\t\t\t(2016). \"Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.\" Nature 534(7607): 402-406. Kaur, M., M. Singh and O. Silakari (2014). \"Insight into the therapeutic aspects of 'Zeta-Chain Associated Protein Kinase 70 kDa' inhibitors: a review.\" Cell Signal 26(11): 2481-2492. Khanna, S., A. Thomas, D. Abate-Daga, J. Zhang, B. Morrow, S. M. Steinberg, A. Orlandi, P. Ferroni, J. Schlom, F. Guadagni and R. Hassan (2016). \"Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.\" J Thorac Oncol 11(11): 1993-2005. Kleinovink, J. W., K. A. Marijt, M. J. A. Schoonderwoerd, T. van Hall, F. Ossendorp and M. F. Fransen (2017). \"PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.\" Oncoimmunology 6(4): e1294299. Kondo, A., T. Yamashita, H. Tamura, W. Zhao, T. Tsuji, M. Shimizu, E. Shinya, H. Takahashi, K. Tamada, L. Chen, K. Dan and K. Ogata (2010). \"Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.\" Blood 116(7): 1124-1131. Kraj, P. and L. Ignatowicz (2017). \"The mechanisms shaping the repertoire of CD4(+) Foxp3(+) regulatory T cells.\" Immunology. Krambeck, A. E., R. H. Thompson, H. Dong, C. M. Lohse, E. S. Park, S. M. Kuntz, B. C. Leibovich, M. L. Blute, J. C. Cheville and E. D. Kwon (2006). \"B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.\" Proc Natl Acad Sci U S A 103(27): 10391-10396. Krishnan, S., V. G. Warke, M. P. Nambiar, G. C. Tsokos and D. L. Farber (2003). \"The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells.\" J Immunol 170(8): 4189-4195. Kryczek, I., L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, A. Lackner, X. Alvarez, A. Ochoa, L. Chen and W. Zou (2006). \"B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.\" J Exp Med 203(4): 871-881. Kubagawa, H., P. D. Burrows and M. D. Cooper (1997). \"A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells.\" Proc Natl Acad Sci U S A 94(10): 5261-5266. Kubagawa, H., C. C. Chen, L. H. Ho, T. S. Shimada, L. Gartland, C. Mashburn, T. Uehara, J. V. Ravetch and M. D. Cooper (1999). \"Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B.\" J Exp Med 189(2): 309-318. Larbi, A. and T. Fulop (2014). \"From \"truly naive\" to \"exhausted senescent\" T cells: when markers predict functionality.\" Cytometry A 85(1): 25-35. Lee, N. and W. U. Kim (2017). \"Microbiota in T-cell homeostasis and inflammatory diseases.\" Exp Mol Med 49(5): e340. Leipe, J., M. Grunke, C. Dechant, C. Reindl, U. Kerzendorf, H. Schulze-Koops and A. Skapenko (2010). \"Role of Th17 cells in human autoimmune arthritis.\" Arthritis Rheum 62(10): 2876-2885. \t\n\t54\t\t\t\t\t\tLeitner, J., C. Klauser, W. F. Pickl, J. Stockl, O. Majdic, A. F. Bardet, D. P. Kreil, C. Dong, T. Yamazaki, G. Zlabinger, K. Pfistershammer and P. Steinberger (2009). \"B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction.\" Eur J Immunol 39(7): 1754-1764. Li, Y., X. Yang, Y. Wu, K. Zhao, Z. Ye, J. Zhu, X. Xu, X. Zhao and C. Xing (2017). \"B7-H3 promotes gastric cancer cell migration and invasion.\" Oncotarget. Loos, M., D. M. Hedderich, M. Ottenhausen, N. A. Giese, M. Laschinger, I. Esposito, J. Kleeff and H. Friess (2009). \"Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer.\" BMC Cancer 9: 463. Ma, C. S. and E. K. Deenick (2014). \"Human T follicular helper (Tfh) cells and disease.\" Immunol Cell Biol 92(1): 64-71. Ma, C. S. and T. G. Phan (2017). \"Here, there and everywhere: T follicular helper cells on the move.\" Immunology 152(3): 382-387. Ma, E. H., M. C. Poffenberger, A. H. Wong and R. G. Jones (2017). \"The role of AMPK in T cell metabolism and function.\" Curr Opin Immunol 46: 45-52. Mallone, R., V. Brezar and C. Boitard (2011). \"T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives.\" Clin Dev Immunol 2011: 513210. Mao, Y., W. Li, K. Chen, Y. Xie, Q. Liu, M. Yao, W. Duan, X. Zhou, R. Liang and M. Tao (2015). \"B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.\" Oncotarget 6(5): 3452-3461. Martinez-Lostao, L., A. Anel and J. Pardo (2015). \"How Do Cytotoxic Lymphocytes Kill Cancer Cells?\" Clin Cancer Res 21(22): 5047-5056. Marzec, M., Q. Zhang, A. Goradia, P. N. Raghunath, X. Liu, M. Paessler, H. Y. Wang, M. Wysocka, M. Cheng, B. A. Ruggeri and M. A. Wasik (2008). \"Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).\" Proc Natl Acad Sci U S A 105(52): 20852-20857. Masson-Bessiere, C., M. Sebbag, E. Girbal-Neuhauser, L. Nogueira, C. Vincent, T. Senshu and G. Serre (2001). \"The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin.\" J Immunol 166(6): 4177-4184. Mazza, C., B. Escudier and L. Albiges (2017). \"Nivolumab in renal cell carcinoma: latest evidence and clinical potential.\" Ther Adv Med Oncol 9(3): 171-181. McInnes, I. B. and G. Schett (2011). \"The pathogenesis of rheumatoid arthritis.\" N Engl J Med 365(23): 2205-2219. Messemaker, T. C., T. W. Huizinga and F. Kurreeman (2015). \"Immunogenetics of rheumatoid arthritis: Understanding functional implications.\" J Autoimmun 64: 74-81. Moutsopoulos, N. M., H. M. Kling, N. Angelov, W. Jin, R. J. Palmer, S. Nares, M. Osorio and S. M. Wahl (2012). \"Porphyromonas gingivalis promotes Th17 inducing pathways in chronic periodontitis.\" J Autoimmun 39(4): 294-303. Mucida, D., M. M. Husain, S. Muroi, F. van Wijk, R. Shinnakasu, Y. Naoe, B. S. Reis, Y. Huang, F. Lambolez, M. Docherty, A. Attinger, J. W. Shui, G. Kim, C. J. Lena, S. Sakaguchi, C. Miyamoto, P. Wang, K. Atarashi, Y. Park, T. Nakayama, K. Honda, W. Ellmeier, M. \t\n\t55\t\t\t\t\t\tKronenberg, I. Taniuchi and H. Cheroutre (2013). \"Transcriptional reprogramming of mature CD4(+) helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes.\" Nat Immunol 14(3): 281-289. Mukherjee, M., E. M. Mace, A. F. Carisey, N. Ahmed and J. S. Orange (2017). \"Quantitative Imaging Approaches to Study the CAR Immunological Synapse.\" Mol Ther 25(8): 1757-1768. Nakken, B., G. Papp, V. Bosnes, M. Zeher, G. Nagy and P. Szodoray (2017). \"Biomarkers for rheumatoid arthritis: From molecular processes to diagnostic applications-current concepts and future perspectives.\" Immunol Lett. Nanki, T., T. Imai and S. Kawai (2017). \"Fractalkine/CX3CL1 in rheumatoid arthritis.\" Mod Rheumatol 27(3): 392-397. Nascimbeni, M., E. C. Shin, L. Chiriboga, D. E. Kleiner and B. Rehermann (2004). \"Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions.\" Blood 104(2): 478-486. Northfield, J., M. Lucas, H. Jones, N. T. Young and P. Klenerman (2005). \"Does memory improve with age? CD85j (ILT-2/LIR-1) expression on CD8 T cells correlates with 'memory inflation' in human cytomegalovirus infection.\" Immunol Cell Biol 83(2): 182-188. O'Reilly, A. and J. Larkin (2017). \"Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.\" Expert Rev Anticancer Ther 17(7): 647-655. Ogilvie, R. L., J. R. Sternjohn, B. Rattenbacher, I. A. Vlasova, D. A. Williams, H. H. Hau, P. J. Blackshear and P. R. Bohjanen (2009). \"Tristetraprolin mediates interferon-gamma mRNA decay.\" J Biol Chem 284(17): 11216-11223. Ohmura, K., L. T. Nguyen, R. M. Locksley, D. Mathis and C. Benoist (2005). \"Interleukin-4 can be a key positive regulator of inflammatory arthritis.\" Arthritis Rheum 52(6): 1866-1875. Overgaard, N. H., J. L. Cruz, J. A. Bridge, H. J. Nel, I. H. Frazer, N. L. La Gruta, A. Blumenthal, R. J. Steptoe and J. W. Wells (2017). \"CD4+CD8beta+ double-positive T cells in skin-draining lymph nodes respond to inflammatory signals from the skin.\" J Leukoc Biol. Overgaard, N. H., J. W. Jung, R. J. Steptoe and J. W. Wells (2015). \"CD4+/CD8+ double-positive T cells: more than just a developmental stage?\" J Leukoc Biol 97(1): 31-38. Paliard, X., R. W. Malefijt, J. E. de Vries and H. Spits (1988). \"Interleukin-4 mediates CD8 induction on human CD4+ T-cell clones.\" Nature 335(6191): 642-644. Pardoll, D. M. and S. L. Topalian (1998). \"The role of CD4+ T cell responses in antitumor immunity.\" Curr Opin Immunol 10(5): 588-594. Parel, Y., M. Aurrand-Lions, A. Scheja, J. M. Dayer, E. Roosnek and C. Chizzolini (2007). \"Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis.\" Arthritis Rheum 56(10): 3459-3467. Parel, Y. and C. Chizzolini (2004). \"CD4+ CD8+ double positive (DP) T cells in health and disease.\" Autoimmun Rev 3(3): 215-220. Parsa, A. T., J. S. Waldron, A. Panner, C. A. Crane, I. F. Parney, J. J. Barry, K. E. Cachola, J. C. Murray, T. Tihan, M. C. Jensen, P. S. Mischel, D. Stokoe and R. O. Pieper (2007). \"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.\" Nat Med 13(1): 84-88. \t\n\t56\t\t\t\t\t\tPaul, W. E. and R. A. Seder (1994). \"Lymphocyte responses and cytokines.\" Cell 76(2): 241-251. Pierer, M., K. Rothe, D. Quandt, A. Schulz, M. Rossol, R. Scholz, C. Baerwald and U. Wagner (2012). \"Association of anticytomegalovirus seropositivity with more severe joint destruction and more frequent joint surgery in rheumatoid arthritis.\" Arthritis Rheum 64(6): 1740-1749. Pitcovski, J., E. Shahar, E. Aizenshtein and R. Gorodetsky (2017). \"Melanoma antigens and related immunological markers.\" Crit Rev Oncol Hematol 115: 36-49. Podojil, J. R. and S. D. Miller (2017). \"Potential targeting of B7-H4 for the treatment of cancer.\" Immunol Rev 276(1): 40-51. Pourgheysari, B., N. Khan, D. Best, R. Bruton, L. Nayak and P. A. Moss (2007). \"The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire.\" J Virol 81(14): 7759-7765. Quandt, D. (2006). \"In vivo und in vitro Immunregulation von T-und B-Lymphozyten:  Die besondere Rolle von CTLA-4.\" Dissertation. Quandt, D., E. Fiedler, D. Boettcher, W. Marsch and B. Seliger (2011). \"B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response.\" Clin Cancer Res 17(10): 3100-3111. Quandt, D., E. Fiedler, A. Muller, W. C. Marsch and B. Seliger (2017). \"High constitutive B7-H3 expression on human keratinocytes supports T cell immunity.\" J Dermatol Sci. Quandt, D., S. Jasinski-Bergner, U. Muller, B. Schulze and B. Seliger (2014). \"Synergistic effects of IL-4 and TNFalpha on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation.\" J Transl Med 12: 151. Quandt, D., K. Rothe, R. Scholz, C. W. Baerwald and U. Wagner (2014). \"Peripheral CD4CD8 double positive T cells with a distinct helper cytokine profile are increased in rheumatoid arthritis.\" PLoS One 9(3): e93293. Quandt, D., H. D. Zucht, A. Amann, A. Wulf-Goldenberg, C. Borrebaeck, M. Cannarile, D. Lambrechts, H. Oberacher, J. Garrett, T. Nayak, M. Kazinski, C. Massie, H. Schwarzenbach, M. Maio, R. Prins, B. Wendik, R. Hockett, D. Enderle, M. Noerholm, H. Hendriks, H. Zwierzina and B. Seliger (2017). \"Implementing liquid biopsies into clinical decision making for cancer immunotherapy.\" Oncotarget. Raptopoulou, A. P., G. Bertsias, D. Makrygiannakis, P. Verginis, I. Kritikos, M. Tzardi, L. Klareskog, A. I. Catrina, P. Sidiropoulos and D. T. Boumpas (2010). \"The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.\" Arthritis Rheum 62(7): 1870-1880. Raza, K., F. Falciani, S. J. Curnow, E. J. Ross, C. Y. Lee, A. N. Akbar, J. M. Lord, C. Gordon, C. D. Buckley and M. Salmon (2005). \"Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin.\" Arthritis Res Ther 7(4): R784-795. Reina-Campos, M., J. Moscat and M. Diaz-Meco (2017). \"Metabolism shapes the tumor microenvironment.\" Curr Opin Cell Biol 48: 47-53. \t\n\t57\t\t\t\t\t\tReis, B. S., A. Rogoz, F. A. Costa-Pinto, I. Taniuchi and D. Mucida (2013). \"Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4(+) T cell immunity.\" Nat Immunol 14(3): 271-280. Restifo, N. P. (2014). \"Big bang theory of stem-like T cells confirmed.\" Blood 124(4): 476-477. Robbins, P. D. and A. E. Morelli (2014). \"Regulation of immune responses by extracellular vesicles.\" Nat Rev Immunol 14(3): 195-208. Roifman, C. M., H. Dadi, R. Somech, A. Nahum and N. Sharfe (2010). \"Characterization of zeta-associated protein, 70 kd (ZAP70)-deficient human lymphocytes.\" J Allergy Clin Immunol 126(6): 1226-1233 e1221. Rosenstein, E. D., R. A. Greenwald, L. J. Kushner and G. Weissmann (2004). \"Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis.\" Inflammation 28(6): 311-318. Rothe, K., D. Quandt, K. Schubert, M. Rossol, M. Klingner, S. Jasinski-Bergner, R. Scholz, B. Seliger, M. Pierer, C. Baerwald and U. Wagner (2016). \"Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIR-1+CD8+ T Cells.\" Arthritis Rheumatol 68(2): 337-346. Rothe, K., N. Raulien, G. Kohler, M. Pierer, D. Quandt and U. Wagner (2017). \"Autoimmune arthritis induces paired immunoglobulin-like receptor B expression on CD4+ T cells from SKG mice.\" Eur J Immunol. Sakaguchi, N., T. Takahashi, H. Hata, T. Nomura, T. Tagami, S. Yamazaki, T. Sakihama, T. Matsutani, I. Negishi, S. Nakatsuru and S. Sakaguchi (2003). \"Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice.\" Nature 426(6965): 454-460. Salerno, F. and M. C. Wolkers (2015). \"T-cells require post-transcriptional regulation for accurate immune responses.\" Biochem Soc Trans 43(6): 1201-1207. Salter, R. D., R. J. Benjamin, P. K. Wesley, S. E. Buxton, T. P. Garrett, C. Clayberger, A. M. Krensky, A. M. Norment, D. R. Littman and P. Parham (1990). \"A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2.\" Nature 345(6270): 41-46. Sathaliyawala, T., M. Kubota, N. Yudanin, D. Turner, P. Camp, J. J. Thome, K. L. Bickham, H. Lerner, M. Goldstein, M. Sykes, T. Kato and D. L. Farber (2013). \"Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets.\" Immunity 38(1): 187-197. Schaerli, P., L. Ebert, K. Willimann, A. Blaser, R. S. Roos, P. Loetscher and B. Moser (2004). \"A skin-selective homing mechanism for human immune surveillance T cells.\" J Exp Med 199(9): 1265-1275. Schildberg, F. A., S. R. Klein, G. J. Freeman and A. H. Sharpe (2016). \"Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.\" Immunity 44(5): 955-972. Schinnerling, K., J. C. Aguillon, D. Catalan and L. Soto (2017). \"The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.\" Clin Exp Immunol 189(1): 12-20. Sckisel, G. D., M. N. Bouchlaka, A. M. Monjazeb, M. Crittenden, B. D. Curti, D. E. Wilkins, K. A. Alderson, C. M. Sungur, E. Ames, A. Mirsoian, A. Reddy, W. Alexander, A. Soulika, B. R. \t\n\t58\t\t\t\t\t\tBlazar, D. L. Longo, R. H. Wiltrout and W. J. Murphy (2015). \"Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity.\" Immunity 43(2): 240-250. Seliger, B. (2016). \"Role of microRNAs on HLA-G expression in human tumors.\" Hum Immunol 77(9): 760-763. Seliger, B. and D. Quandt (2012). \"The expression, function, and clinical relevance of B7 family members in cancer.\" Cancer Immunol Immunother 61(8): 1327-1341. Shim, J., H. Lim, R. Y. J and M. Karin (2002). \"Nuclear export of NF90 is required for interleukin-2 mRNA stabilization.\" Mol Cell 10(6): 1331-1344. Shirkani, A., M. Shahrooei, G. Azizi, H. Rokni-Zadeh, H. Abolhassani, S. Farrokhi, G. Frans, X. Bossuyt and A. Aghamohammadi (2017). \"Novel Mutation of ZAP-70-related Combined Immunodeficiency: First Case from the National Iranian Registry and Review of the Literature.\" Immunol Invest 46(1): 70-79. Shiroishi, M., K. Tsumoto, K. Amano, Y. Shirakihara, M. Colonna, V. M. Braud, D. S. Allan, A. Makadzange, S. Rowland-Jones, B. Willcox, E. Y. Jones, P. A. van der Merwe, I. Kumagai and K. Maenaka (2003). \"Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G.\" Proc Natl Acad Sci U S A 100(15): 8856-8861. Smolen, J. S., R. Landewe, J. Bijlsma, G. Burmester, K. Chatzidionysiou, M. Dougados, J. Nam, S. Ramiro, M. Voshaar, R. van Vollenhoven, D. Aletaha, M. Aringer, M. Boers, C. D. Buckley, F. Buttgereit, V. Bykerk, M. Cardiel, B. Combe, M. Cutolo, Y. van Eijk-Hustings, P. Emery, A. Finckh, C. Gabay, J. Gomez-Reino, L. Gossec, J. E. Gottenberg, J. M. W. Hazes, T. Huizinga, M. Jani, D. Karateev, M. Kouloumas, T. Kvien, Z. Li, X. Mariette, I. McInnes, E. Mysler, P. Nash, K. Pavelka, G. Poor, C. Richez, P. van Riel, A. Rubbert-Roth, K. Saag, J. da Silva, T. Stamm, T. Takeuchi, R. Westhovens, M. de Wit and D. van der Heijde (2017). \"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.\" Ann Rheum Dis 76(6): 960-977. Snir, O., M. Rieck, J. A. Gebe, B. B. Yue, C. A. Rawlings, G. Nepom, V. Malmstrom and J. H. Buckner (2011). \"Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients.\" Arthritis Rheum 63(10): 2873-2883. Stastny, P. (1978). \"Association of the B-cell alloantigen DRw4 with rheumatoid arthritis.\" N Engl J Med 298(16): 869-871. Sucur, A., Z. Jajic, M. Artukovic, M. I. Matijasevic, B. Anic, D. Flegar, A. Markotic, T. Kelava, S. Ivcevic, N. Kovacic, V. Katavic and D. Grcevic (2017). \"Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.\" Arthritis Res Ther 19(1): 142. Suh, W. K., B. U. Gajewska, H. Okada, M. A. Gronski, E. M. Bertram, W. Dawicki, G. S. Duncan, J. Bukczynski, S. Plyte, A. Elia, A. Wakeham, A. Itie, S. Chung, J. Da Costa, S. Arya, T. Horan, P. Campbell, K. Gaida, P. S. Ohashi, T. H. Watts, S. K. Yoshinaga, M. R. Bray, M. Jordana and T. W. Mak (2003). \"The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses.\" Nat Immunol 4(9): 899-906. Suni, M. A., S. A. Ghanekar, D. W. Houck, H. T. Maecker, S. B. Wormsley, L. J. Picker, R. B. Moss and V. C. Maino (2001). \"CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens.\" Eur J Immunol 31(8): 2512-2520. \t\n\t59\t\t\t\t\t\tThery, C., M. Ostrowski and E. Segura (2009). \"Membrane vesicles as conveyors of immune responses.\" Nat Rev Immunol 9(8): 581-593. Thompson, R. H., S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse, W. S. Webster, S. Sengupta, I. Frank, A. S. Parker, H. Zincke, M. L. Blute, T. J. Sebo, J. C. Cheville and E. D. Kwon (2006). \"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.\" Cancer Res 66(7): 3381-3385. Ujike, A., K. Takeda, A. Nakamura, S. Ebihara, K. Akiyama and T. Takai (2002). \"Impaired dendritic cell maturation and increased T(H)2 responses in PIR-B(-/-) mice.\" Nat Immunol 3(6): 542-548. Veit, T. D., J. A. Chies, M. Switala, B. Wagner, P. A. Horn, M. Busatto, C. V. Brenol, J. C. Tavares Brenol, R. Machado Xavier and V. Rebmann (2015). \"The paradox of high availability and low recognition of soluble HLA-G by LILRB1 receptor in rheumatoid arthritis patients.\" PLoS One 10(4): e0123838. Verbruggen, L. A., V. Rebmann, C. Demanet, S. De Cock and H. Grosse-Wilde (2006). \"Soluble HLA-G in rheumatoid arthritis.\" Hum Immunol 67(8): 561-567. Vossenaar, E. R., N. Despres, E. Lapointe, A. van der Heijden, M. Lora, T. Senshu, W. J. van Venrooij and H. A. Menard (2004). \"Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin.\" Arthritis Res Ther 6(2): R142-150. Wacleche, V. S., A. Landay, J. P. Routy and P. Ancuta (2017). \"The Th17 Lineage: From Barrier Surfaces Homeostasis to Autoimmunity, Cancer, and HIV-1 Pathogenesis.\" Viruses 9(10). Wagner, U. G., K. Koetz, C. M. Weyand and J. J. Goronzy (1998). \"Perturbation of the T cell repertoire in rheumatoid arthritis.\" Proc Natl Acad Sci U S A 95(24): 14447-14452. Wagner, U. G., P. J. Kurtin, A. Wahner, M. Brackertz, D. J. Berry, J. J. Goronzy and C. M. Weyand (1998). \"The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis.\" J Immunol 161(11): 6390-6397. Wang, C., M. Singer and A. C. Anderson (2017). \"Molecular Dissection of CD8+ T-Cell Dysfunction.\" Trends Immunol 38(8): 567-576. Wang, J. G., M. Collinge, V. Ramgolam, O. Ayalon, X. C. Fan, R. Pardi and J. R. Bender (2006). \"LFA-1-dependent HuR nuclear export and cytokine mRNA stabilization in T cell activation.\" J Immunol 176(4): 2105-2113. Wang, L., K. F. Wildt, E. Castro, Y. Xiong, L. Feigenbaum, L. Tessarollo and R. Bosselut (2008). \"The zinc finger transcription factor Zbtb7b represses CD8-lineage gene expression in peripheral CD4+ T cells.\" Immunity 29(6): 876-887. Weyand, C. M., M. Zeisbrich and J. J. Goronzy (2017). \"Metabolic signatures of T-cells and macrophages in rheumatoid arthritis.\" Curr Opin Immunol 46: 112-120. Wherry, E. J. and M. Kurachi (2015). \"Molecular and cellular insights into T cell exhaustion.\" Nat Rev Immunol 15(8): 486-499. Whitacre, J. M., J. Lin and A. Harding (2012). \"T Cell Adaptive Immunity Proceeds through Environment-Induced Adaptation from the Exposure of Cryptic Genetic Variation.\" Front Genet 3: 5. \t\n\t60\t\t\t\t\t\tWidjaja, C. E., J. G. Olvera, P. J. Metz, A. T. Phan, J. N. Savas, G. de Bruin, Y. Leestemaker, C. R. Berkers, A. de Jong, B. I. Florea, K. Fisch, J. Lopez, S. H. Kim, D. A. Garcia, S. Searles, J. D. Bui, A. N. Chang, J. R. Yates, 3rd, A. W. Goldrath, H. S. Overkleeft, H. Ovaa and J. T. Chang (2017). \"Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification.\" J Clin Invest. Wieczorek, M., E. T. Abualrous, J. Sticht, M. Alvaro-Benito, S. Stolzenberg, F. Noe and C. Freund (2017). \"Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation.\" Front Immunol 8: 292. Xu, L., G. Zhang, Y. Zhou, Y. Chen, W. Xu, S. Wu and X. Zhang (2011). \"Stimulation of B7-H3 (CD276) directs the differentiation of human marrow stromal cells to osteoblasts.\" Immunobiology 216(12): 1311-1317. Xu, Z., S. Ho, C. C. Chang, Q. Y. Zhang, E. R. Vasilescu, G. Vlad and N. Suciu-Foca (2016). \"Molecular and Cellular Characterization of Human CD8 T Suppressor Cells.\" Front Immunol 7: 549. Yamada, Y., S. Kamihira, T. Amagasaki, K. Kinoshita, M. Kusano, S. Ikeda, K. Toriya, J. Suzuyama and M. Ichimaru (1984). \"Changes of adult T cell leukemia cell surface antigens at relapse or at exacerbation phase after chemotherapy defined by use of monoclonal antibodies.\" Blood 64(2): 440-444. Yanes, R. E., C. E. Gustafson, C. M. Weyand and J. J. Goronzy (2017). \"Lymphocyte generation and population homeostasis throughout life.\" Semin Hematol 54(1): 33-38. Yin, Z., S. Siegert, L. Neure, M. Grolms, L. Liu, U. Eggens, A. Radbruch, J. Braun and J. Sieper (1999). \"The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta.\" Rheumatology (Oxford) 38(11): 1058-1067. Yoshitomi, H., N. Sakaguchi, K. Kobayashi, G. D. Brown, T. Tagami, T. Sakihama, K. Hirota, S. Tanaka, T. Nomura, I. Miki, S. Gordon, S. Akira, T. Nakamura and S. Sakaguchi (2005). \"A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice.\" J Exp Med 201(6): 949-960. \t\n\t61\t\t\t\t\t\tThesen  1. T-Zellen sind hochspezialisierte Zellen des adaptiven Immunsystems. Sie kooperieren mit dem angeborenen Immunsystem und bilden einen fundamentalen Teil des Abwehrsystems h\u00f6herer Organismen. T-Zellen verschiedener Subtypen greifen in die Pathogenese sowohl von Autoimmunkrankheiten als auch malignen Neoplasien ein. Krankheits\u00fcbergreifende Mechanismen der T-Zell-Aktivierung, -Effektorfunktion und -Inhibition konnten in der vorliegenden Arbeit identifiziert werden.  2. Virusinfektionen k\u00f6nnen Ausl\u00f6ser oder Verst\u00e4rker diverser Autoimmunkrankheiten als auch Krebserkrankungen sein und sind daher Gegenstand intensiver Forschung und bieten Ansatzpunkte f\u00fcr neue Therapien.  3. Immuntherapien sind eine vielversprechende neue Therapiestrategie gegen Krebserkrankungen. Insbesondere Molek\u00fcle die T-Zell-Antworten steuern, werden adressiert. Dabei spielt sowohl der patienten-/patientinnenspezifische Zustand des Immunsystems als auch die molekulare Signatur des individuellen Tumors eine bedeutende Rolle.  4. Eine persistierende CMV Infektion f\u00fchrt zu einem schwereren Krankheitsverlauf bei Patienten/Patientinnen mit rheumatoider Arthritis (RA). Sowohl CD4+ als auch CD8+ T-Zellen weisen CMV-spezifische ph\u00e4notypische und funktionelle Ver\u00e4nderungen auf, die mit klinischen Daten korreliert werden konnten. LIR-1 wird verst\u00e4rkt auf CD8+ T-Zellen in CMV positiven RA-Patienten/-Patientinnen exprimiert. Die Kontrolle der erh\u00f6hten zytolytischen Aktivit\u00e4t der CD8+ T-Zellen durch den biologischen Liganden HLA-G in vitro, belegt die  Funktionalit\u00e4t von LIR-1 in RA-Patienten/-Patientinnen. Das mit CMV und RA konfrontierte T-zellul\u00e4re Immunsystem kann sich in vivo nicht mehr ausreichend \u00fcber LIR-1 kontrollieren. \u00dcberschie\u00dfende Zytokine und h\u00f6here zytolytische T-Zell-Reaktivit\u00e4ten tragen bei CMV positiven RA-Patienten/-Patientinnen zum schwereren Krankheitsverlauf bei.  5. Periphere doppelt positive (CD4+CD8+) T-Zellen (DP T-Zellen) konnten erstmals als signifikant ver\u00e4nderte T-Zell-Subpopulation bei RA-Patienten/-Patientinnen identifiziert werden. Die Zellen wiesen einen von den singul\u00e4r CD4 bzw. CD8 \t\n\t62\t\t\t\t\t\tKorezeptor-tragenden T-Zellen distinkten Ph\u00e4notyp auf. DP T-Zellen bei RA-Patienten/-Patientinnen sind polyfunktionell und mit einem signifikant h\u00f6heren Effektorpotential als DP T-Zellen gesunder Probanden ausgestattet. Diese T-Zell-Subpopulation ist eng mit dem Auftreten von f\u00fcr die RA typischen Autoantik\u00f6rpern assoziiert. In CMV positiven RA-Patienten/-Patientinnen tragen sie zu der erh\u00f6hten Pathogenit\u00e4t CMV-spezifischer T-Zellen bei.  6. Das LIR-1 orthologe PIR-B wurde erstmals in murinen T-Zellen detektiert. Die Expression wird ma\u00dfgeblich durch ein inflammatorisches Milieu gef\u00f6rdert, in dem es zur Aktivierung der T-Zellen kommt. Ex vivo Analysen von T-Zellen aus Tieren mit einer Spontanarthritis (SKG Modell) wiesen hohe PIR-B Expressionslevel auf. PIR-B positive T-Zellen produzieren haupts\u00e4chlich regulatorisch wirkendes IFN\u03b3, nicht IL-17. Die funktionelle Ausgestaltung PIR-B positiver T-Zellen geht sehr gut mit dem klinischen Befund einher - h\u00f6here PIR-B Expressionslevel korrelieren mit einem milderen Arthritisverlauf.  7. Die Kombination anti-inflammatorischer und inflammatorischer Zytokine f\u00fchrte selektiv zur synergistischen Induktion von B7-H1 (PD-L1) auf Nierenkarzinomzelllinien. Andere B7 Familienmitglieder blieben in ihrer Expression von einer kombinatorischen Zytokingabe unbeeinflusst. Beteiligte Signalkaskaden schlie\u00dfen STAT6 und NF\u03baB ein. Die zytokin-induzierte Regulation von B7-H1 ist mit immunmodulatorischen Konsequenzen f\u00fcr CD8+ T-Zellen verbunden. Dieser Befund ist wichtig f\u00fcr moderne immuntherapeutische Krebsbehandlung, bei der Signalwege \u00fcber B7-H1 unterbunden werden, wodurch das T-zellul\u00e4re Immunsystem Aktionsspielraum zur\u00fcckgewinnt.  8. Der Kostimulator B7-H3 wurde erstmals auf humanen gesunden Keratinozyten in situ und in vitro an Prim\u00e4rzellen und Zelllinien auf Transkript- und Proteinebene nachgewiesen. Funktionell konnte dem Molek\u00fcl eine unterst\u00fctzende Rolle f\u00fcr die Proliferation und Zytokinsekretion CD8+ positiver T-Zellen zugeordnet werden. Die konstitutiv hohe Expression von B7-H3 in der gesunden Haut l\u00e4sst den Schluss einer die T-Zell-Hom\u00f6ostase f\u00f6rdernden Wirkung des Kostimulators zu.  \t\n\t63\t\t\t\t\t\t9. B7-H4 konnte als neue Zielstruktur im malignen Melanom identifiziert werden. Prim\u00e4rtumore und Metastasen zeigen signifikant erh\u00f6hte Expression von B7-H4 gegen\u00fcber gesunder Haut. Hohe Expression von B7-H4 auf Tumorzellen in situ konnte mit einem k\u00fcrzeren \u00dcberleben der Patienten/Patientinnen assoziiert werden. B7-H4 auf Melanomzelllinien inhibiert die anti-tumorale Immunantwort durch eine Blockade der Zytokinproduktion Antigen-spezifischer CD8 Effektor-T-Zellen.  10. Die Resultate der vorliegenden Arbeit unterstreichen die bedeutende Rolle verschiedener T-Zell-Populationen f\u00fcr das Auftreten und die Pathogenese von Autoimmunkrankheiten und Krebserkrankungen. Es wurden neue T-zellspezifische Kontrollmechanismen im Kontext beider Erkrankungsbilder identifiziert, die therapeutische Ansatzpunkte er\u00f6ffnen.     ARTHRITIS & RHEUMATISM\nVol. 64, No. 6, June 2012, pp 1740\u20131749DOI 10.1002/art.34346\n\u00a9 2012, American College of Rheumatology\nAssociation of Anticytomegalovirus Seropositivity With\nMore Severe Joint Destruction and More Frequent\nJoint Surgery in Rheumatoid Arthritis\nMatthias Pierer, Kathrin Rothe, Dagmar Quandt, Anett Schulz,\nManuela Rossol, Roger Scholz, Christoph Baerwald, and Ulf Wagner\nObjective. Expansion of autoreactive CD4 /H11545\nCD28nullT cells is associated with extraarticular disease\nmanifestations, including rheumatoid vasculitis, and it\nhas recently been demonstrated that expansion of theseT cells is associated with anticytomegalovirus (anti-CMV) seropositivity. This study was undertaken toinvestigate a possible link between latent CMV infectionand rheumatoid arthritis (RA).\nMethods. In a retrospective analysis, anti-CMV\nantibodies and clinical, serologic, and radiologic para-meters of joint destruction were examined in 202 RApatients and 272 healthy controls. In addition, fre-quencies of CD4 /H11545CD28\nnullT cells; concentrations of\nthe cytokines monocyte chemotactic protein 1 (MCP-1),\ninterferon- /H9251(IFN/H9251), and IFN-inducible protein 10; and\nanti-CMV\u2013specific T cell responses were analyzed in RApatients.\nResults. Overall, no significant difference in the\nfrequency of anti-CMV seropositivity between RA pa-tients and healthy controls was observed. Among indi-viduals older than age 55 years, however, anti-CMV IgGantibodies were significantly more frequent in RA pa-tients than controls (65.3% and 54.7%, respectively; P/H11549\n0.05). Anti-CMV seropositivity in RA patients was asso-ciated with an increased frequency of CD4 /H11545CD28\nnull\nT cells and increased serum concentrations of MCP-1.\nThe frequency of anti-CMV\u2013specific CD4 /H11545T cells pro-ducing IFN /H9253was increased in RA patients compared to\ncontrols. Most importantly, anti-CMV\u2013seropositive RApatients showed radiographic evidence of more ad-vanced joint destruction and had increased frequenciesof joint-related surgical procedures, indicating moresevere joint disease.\nConclusion. Our findings indicate that latent\nCMV infection aggravates the clinical course of RAand is associated with increased frequencies of CD4 /H11545\nCD28\nnullT cells and of CMV-specific IFN /H9253-secreting\nCD4/H11545T cells.\nIn rheumatoid arthritis (RA), disturbances in the\nT cell pool and associations with polymorphisms in T cellgenes strongly implicate CD4 /H11001T cells in disease patho-\ngenesis. Phenotypically, the peripheral T cell pool in RApatients is characterized by large and stable clonalexpansions, and by an increased frequency of CD4 /H11001\nT cells that have lost expression of the ubiquitouslyexpressed costimulatory molecule CD28 but have gainedexpression of killer cell immunoglobulin-like receptor(KIR) (1). Simultaneously, the global CD4 /H11001T cell pool\nin RA patients has an increased replicative historycompared to that in age-matched controls, which leadsto premature erosion of telomere fragments in bothnaive and memory CD4 /H11001T cells (2). It can be estimated\nthat the immune system of RA patients has grown /H1102210\nyears older than that of age-matched controls in severalaging parameters, due to premature and acceleratedimmunosenescence. Of clinical relevance is the associa-tion of clonal expansions and increased frequencies ofCD4/H11001CD28\nnullT cells with extraarticular manifesta -\ntions of the disease (3) and, in particular, with rheuma-toid vasculitis (4).\nCytomegalovirus (CMV) infection causes clini-\ncally severe infections in immunocompromised patientsSupported by the DFG (grant WA 2765/3-1).\nMatthias Pierer, MD, Kathrin Rothe, MSc, Dagmar Quandt,\nPhD, Anett Schulz, PhD, Manuela Rossol, PhD, Roger Scholz, MD,Christoph Baerwald, MD, Ulf Wagner, MD: University of Leipzig,Leipzig, Germany.\nAddress correspondence to Ulf Wagner, MD, Department\nof Internal Medicine, Division of Rheumatology, University ofLeipzig, Liebigstrasse 20, 04103 Leipzig, Germany. E-mail: ulf.wagner@medizin.uni-leipzig.de.\nSubmitted for publication January 9, 2011; accepted in re-\nvised form December 13, 2011.\n1740and exerts a profound influence on the peripheral,\ncirculating T cell pool in healthy individuals withoutapparent clinical disease. The involvement of a largefraction of the peripheral T cell pool in the CMV-induced immune response becomes evident in a massiveproliferative expansion, which has been called memoryinflation and which can be observed in both CD4 /H11001and\nCD8/H11001T cells (5,6). As a result, anti-CMV seropositivity\nis associated with accelerated immunosenescence ofCD4/H11001and CD8 /H11001T cells in otherwise healthy individ-\nuals (7) and shows several parallels with the prematureaging of the immune system that is a hallmark of RA.In particular, the emergence of CD4 /H11001CD28\nnullT cell\nclones following CMV infection (8), which is also ac-\ncompanied by a gain in the expression of KIR (9), hasindicated a possible link between RA and CMV infection.\nIn patients with RA, a clear association of anti-\nCMV seropositivity with the expansion of CD4 /H11001CD28\nnull\nT cells has previously been established (10,11), but no\nsystematic analysis of its impact on disease severity andextraarticular manifestations has been published. Giventhe strong influence of CMV infection on the emergenceof pathologic CD4 /H11001CD28\nnullKIR-expressing T cells,\nwhich are frequently associated with vasculitis, we inves-\ntigated a possible link between CMV infection, diseasesusceptibility, and the clinical course of RA.\nPATIENTS AND METHODS\nPatient population. Patients with RA (n /H11005202) were\nrecruited from the rheumatology unit of the University ofLeipzig and enrolled in this study analyzing serologic CMVstatus. The study was approved by the local ethics committee,and informed consent was obtained from all patients. As a\ncontrol group, 272 donors, who were selected for an age range\nequivalent to that in the patient cohort, were recruited fromthe local blood bank. Flow cytometric data on CD28 ex-pression on CD4 /H11001T cells were available for 139 RA patients.\nFor the analysis of CMV-induced T cell proliferation, 17patients and 11 controls were included, and for the analysis ofinterferon-\n/H9253(IFN/H9253) production, 7 patients and 7 controls were\nincluded.\nCollection of clinical data. All study patients were\nreceiving clinical care at the rheumatology unit, and a thor-ough chart review was performed at the time of study enroll-\nment. Based on the report of the last available hand and feet\nradiographs, the documented disease stage according to theSteinbrocker criteria was determined in all patients (12,13). Inaddition, results of testing for anti\u2013cyclic citrullinated peptide(anti-CCP) antibodies, rheumatoid factor (RF), and antinu-clear antibody; results of serologic testing for anti-CMV sero-positivity; and current C-reactive protein levels were availablefor all patients and were documented for the study. Allpreviously prescribed disease-modifying antirheumatic drugs(DMARDs), the duration of treatment and the cause ofdiscontinuation, as well as the history of joint-related surgical\nprocedures were recorded. Surgical procedures performed in\nthe patients included synovectomy, tenosynovectomy, osteot-\nomy for the correction of bone malalignment, arthrodesis, andjoint replacement surgery; the numbers of times these proce-dures were performed were documented.\nFlow cytometric analysis and measurement of serum\ncytokine levels by enzyme-linked immunosorbent assay(ELISA). For the quantification of CD4 /H11001CD28\nnullT cells, flow\ncytometry was performed as previously described (3). For the\ndetermination of human monocyte chemotactic protein 1(MCP-1) concentrations, a commercially available kit consist-\ning of a capture antibody and a detection antibody (DuoSet\nELISA Development kit, catalog no. DY279; R&D Systems)(detection limit 7.8 pg/ml) was used to establish the ELISAaccording to the manufacturer\u2019s instructions. Similarly, a Duo-Set ELISA Development kit (catalog no. DY266; R&D Sys-tems) (detection limit 15.6 pg/ml) was used to establish anELISA for human IFN-inducible protein 10 (IP-10). Serumconcentrations of IFN\n/H9251were determined by an ELISA on the\nbasis of a matched antibody pair (catalog no. BMS216MST;Bender MedSystems) (detection limit 15.6 pg/ml).\nAnalysis of CMV-specific proliferation and of IFN\n/H9253\nproduction by T cells. Peripheral blood mononuclear cells\n(PBMCs) from anti-CMV-seropositive RA patients and healthycontrols were separated by density-gradient centrifugation.Samples from RA patients who were anti-CCP positive andage-matched healthy controls were included in the analysis.For quantification of cell division, a fluorescence-based prolif-\neration assay was performed as previously described (14), by\nlabeling with 5,6-carboxyfluorescein succinimidyl ester (CFSE;Molecular Probes). For the proliferation analysis, PBMCs(1/H1100310\n6) were cultured for 7 days in the presence or absence\nof 1/H9262g/ml CMVpp65 peptide mixture or control peptide (15\nmers, 11 amino acid overlap; Jerini Peptide Technologies) or3\n/H9262g/ml CMV lysate or control lysate (Microbrix Biosystems)\nin 24-well plates in X-Vivo 15 (Lonza) containing 2 m M\nL-glutamine, 100 units/ml penicillin, and 100 /H9262g/ml streptomy-\ncin. For the analysis of IFN /H9253secretion, PBMCs (2 /H11003106) were\ncultured for 4 hours under the same conditions as described for\nthe proliferation analysis. The IFN /H9253secretion assay was per-\nformed according to the recommendations of the manufac-turer (Miltenyi Biotec). In all experiments using this assay,stimulation of T cells using CytoStim (Miltenyi Biotec) wasincluded as a positive control and showed similar frequencies\nof IFN\n/H9253producers among RA and healthy donor samples.\nThe following antibodies were used for counterstaining\nT cells in fluorescent conjugates of phycoerythrin or allophy-cocyanin: anti-CD4 (clone M-T466), anti-CD8 (clone BW135/80), anti-CD3 (clone BW264/56), and anti-CD71 (clone AC102)\n(all from Miltenyi Biotec). Dead cells were removed from the\nanalyses by the exclusion of propidium iodide\u2013positive cells.\nStatistical analysis. Differences in medians or means\nbetween groups were analyzed by Student\u2019s t-test or the\nMann-Whitney rank sum test as appropriate. Correlationswere evaluated using Pearson\u2019s product-moment correlationor Spearman\u2019s rank correlation coefficient. Logistic regressionanalysis was performed by stepwise removal of independentvariables using the likelihood ratio test as the criterion. Oddsratios (ORs) in multiple logistic regression analysis for inde-ANTI-CMV AND JOINT DESTRUCTION IN RA 1741pendent variables were estimated by OR /H11005e/H9252, where /H9252is the\nregression coefficient, as previously described (15).\nRESULTS\nAnalysis of anti-CMV positivity in RA patients\nand healthy controls. Sera from 202 patients with RA\nand from 272 healthy controls were analyzed for thepresence of anti-CMV IgG antibodies. The clinicalcharacteristics of the patients are shown in Table 1. Thefrequency of anti-CMV seropositivity was 56.93% in RApatients and 54.04% in healthy controls, with no signif-icant difference between the 2 populations ( P/H110050.595).\nSimilarly, no difference in the anti-CMV IgG concen-tration between RA patients and controls was detect-able.\nIn initial bivariate comparisons, anti-CMV\u2013\npositive patients were found to be significantly olderthan anti-CMV\u2013negative patients (median age 64.2 yearsand 58.5 years, respectively; P/H110210.001). Consistent with\ntheir older age, anti-CMV\u2013positive patients also had alonger disease duration between the onset of symptomsand the time of analysis, with a median of 13.5 years(interquartile range [IQR] 6\u201323 years) in anti-CMV\u2013positive patients versus a median of 8 years (IQR 3\u201317years) in anti-CMV\u2013negative patients ( P/H110050.001). Atrend toward an earlier disease onset in anti-CMV\u2013\npositive patients did not reach statistical significance(mean age at disease onset 44.5 years in anti-CMV\u2013seropositive patients versus 46.8 years in anti-CMV\u2013seronegative patients; P/H110050.25).\nThe observed influence of age on the frequency\nof latent CMV infection prompted us to perform sub-group analyses in order to investigate the rate of CMVseropositivity in different age groups. The percentage ofRA patients older than age 55 years who were anti-CMVpositive was found to be significantly higher than that ofhealthy controls of the same age (65.3% and 54.7%,respectively; P/H110050.05).\nSerologic reactivity with CMV has previously\nbeen shown to be associated with the expansion of aCD4/H11001CD28\nnullT cell compartment both in healthy\nindividuals and in RA patients (11,16). For our study\ncohort, flow cytometric data were available for 87 anti-CMV\u2013negative and 115 anti-CMV\u2013positive RA pa-tients. As previously shown, anti-CMV reactivity wasassociated with increased frequencies of CD4 /H11001CD28\nnull\nT cells (median 8.15% [IQR 1.582\u201320.392%] in anti-\nCMV\u2013seropositive patients versus 0.37% [IQR 0.16\u20130.89%] in anti-CMV\u2013seronegative patients; P/H110210.0001).\nIn fact, anti-CMV seropositivity appeared to be almost a\nTable 1. Characteristics of the RA patients*\nAll RA patients\n(n/H11005202)Anti-CMV\u2013negative\nRA patients\n(n/H1100587)Anti-CMV\u2013positive\nRA patients\n(n/H11005115)\nSex, no. male/no. female 46/156 20/67 29/86\nAge, years 62.3 (51\u201368) 58 (45\u201365) 64 (57\u201370)Disease duration before study entry, years 12 (5\u201321) 8 (3\u201317) 13 (6\u201323)IgM-RF positive, no. (%) 180 (89.1) 78 (89.6) 102 (88.7)IgM-RF titer 203 (68\u2013565) 218 (68\u2013520) 193 (68\u2013593)IgA-RF positive, no. (%)\u2020 137 (81.5) 59 (80.8) 78 (82.1)IgA-RF titer\u2020 76 (27\u2013188) 62 (24\u2013191) 93 (27\u2013188)Anti-CCP positive, no. (%)\u2020 157 (81.7) 65 (81.9) 108 (84.2)Anti-CCP titer\u2020 429 (80\u20131,600) 306 (46\u20131,600) 474 (100\u20131,600)Steinbrocker radiographic stage 3 (2\u20134) 3 (2\u20134) 3 (2\u20134)No. of synovectomies 1 (0\u20133.5) 0 (0\u20132) 1.5 (0\u20135)Total no. of joint-related surgical procedures\u2021 2 (0\u20136) 1 (0\u20135) 3.5 (1\u20138)No. of conventional DMARDs\u00a7 2 (1\u20134) 2 (1\u20134) 3 (1\u20134)TNF\n/H9251inhibitor treatment, no. (%) 39 (19.3) 18 (20.7) 21 (18.3)\nShared epitope positive, no. (%)\u00b6 90 (71.4) 34 (73.9) 56 (71.8)DR4 shared epitope positive, no. (%)\u00b6 63 (50) 22 (46.8) 41 (51.9)C-reactive protein, mg/liter\u00b6 17 (8\u201336) 15 (6\u201338) 19 (9\u201336)No. of swollen joints\u00b6 6 (2\u201312) 6 (2\u201313) 5 (2\u201312)\n* Except where indicated otherwise, values are the median (interquartile range). RA /H11005rheumatoid arthritis; IgM-RF /H11005IgM\nrheumatoid factor; anti-CCP /H11005anti\u2013cyclic citrullinated peptide; TNF\n/H9251/H11005tumor necrosis factor /H9251.\n\u2020 Data were not available for all patients.\u2021 Data on surgical procedures were available for 78 anticytomegalovirus (anti-CMV)\u2013negative and 102 anti-CMV\u2013positive patients.\u00a7 Number of successive treatment attempts with different disease-modifying antirheumatic drugs (DMARDs).\u00b6 Data were available for 126 patients.1742 PIERER ET ALprerequisite for the expansion, since only 3 patients in\nthe anti-CMV\u2013negative group had /H110225% CD4 /H11001CD28null\nT cells in their peripheral blood (Figure 1A).\nAssociation of CMV seropositivity in RA patients\nwith increased frequencies of CMV-specific IFN /H9253-\nsecreting CD4 /H11545T cells and increased serum levels of\nMCP-1. Previous studies have shown that the peripheral\nCD4/H11001T cell pool in healthy individuals contains a large\nfraction of CMV antigen\u2013specific T cells, which areconstantly proliferating toward replicative exhaustion,and which are preferentially CD4 /H11001CD28\nnull(17). In\norder to test the proliferative response of CD4 /H11001T cells\nfrom RA patients and controls toward pp65, in vitroproliferation assays of T lymphocytes were performed incultures of PBMCs from anti-CMV\u2013seropositive RApatients and healthy controls in the presence of eithera peptide mixture from the CMV antigen pp65 or acontrol peptide (Figure 1B). Antigen-specific prolifera-\ntion occurred in both the CD4 /H11001(Figure 1C) and CD8 /H11001\n(Figure 1D) T cell compartments, while proliferation inthe control cultures was significantly lower. The fre-quency of proliferating CD8 /H11001T cells was higher than\nthat of CD4 /H11001T cells. No significant difference between\nRA patients and healthy controls in the frequency ofproliferated cells was detectable. Similar results wereobtained when total CMV lysate was used as antigen inthe cultures (Figure 1E), except that CD8 T cell re-sponses were lower than CD4 T cell responses.\nParallel to the analysis of proliferation, expres-\nsion of CD71 as a cell surface activation marker onCD4/H11001T cells was determined. Again, a significantly\nhigher percentage of CD71 /H11001CD4/H11001T cells was found\nin the cultures with pp65 peptide than in those withcontrol peptide, but no significant difference between\nFigure 1. Association of cytomegalovirus (CMV) seropositivity with increased frequencies of CD4 /H11001CD28nullT cells in patients with rheumatoid\narthritis (RA), but not with increased CMV-specific proliferation of CD4 /H11001T cells. A,Frequency of CD4 /H11001CD28nullT cells as a percent of total\nCD4/H11001T cells in anti-CMV\u2013negative (n /H1100554) and anti-CMV\u2013positive (n /H1100585) RA patients. Circles represent individual patients; horizontal lines\nindicate the median. B\u2013F, Peripheral blood mononuclear cells (PBMCs) from RA patients and from healthy donors (HD) were 5,6-\ncarboxyfluorescein succinimidyl ester (CFSE)\u2013labeled, incubated with either pp65 peptide mixture, CMV lysate, control peptide, or control lysat e\nfor 7 days, and analyzed for CFSE dilution by flow cytometry. B,Representative CFSE dilutions gated on CD3 /H11001CD4/H11001live (by propidium iodide\nexclusion) T cells in RA patients and healthy donors for control peptide or pp65 peptide mixture. Cand D,Percentage of proliferated CD4 /H11001(C)\nand CD8 /H11001(D) T cells from RA patients (n /H1100517) and healthy donors (n /H1100511) in response to pp65 peptide mixture or control peptide. E,Percentage\nof proliferated CD4 /H11001and CD8 /H11001T cells from RA patients (n /H110057) and healthy donors (n /H110056) incubated with total CMV lysate. In control cultures,\na CMV-free control lysate did not induce significant proliferation (data not shown). F,Percentage of CD71 /H11001CD4/H11001T cells in cultures of PBMCs\nfrom RA patients (n /H1100513) and healthy donors (n /H110057) incubated with either a pp65 peptide mixture or a control peptide. In C\u2013F, data are shown\nas box plots. Each box represents the interquartile range. Lines inside the boxes represent the median. Lines outside the boxes represent the 10thand the 90th percentiles. /H11569/H11005 P/H110210.05 versus control peptide.ANTI-CMV AND JOINT DESTRUCTION IN RA 1743RA patients and healthy controls was detectable (Fig-\nure 1F). As expected, no significant T cell prolifera-tion in response to pp65 was detectable in anti-CMV\u2013seronegative RA patients or healthy controls (data notshown).\nIt has been shown that murine CMV infection\nleads to increased interleukin-6 production in mice,which in turn stimulates MCP-1 expression in andrelease from endothelial cells (18,19). Latent CMVinfection in humans has not been reproducibly associ-ated with a specific cytokine signature or an increasedacute-phase response. In anti-CMV\u2013seropositive pa-tients with RA, however, cytokine production could beexaggerated by the superimposed chronic autoimmuneresponse, with a consequent increase in the concentra-tions of proinflammatory mediators in anti-CMV\u2013positive patients.\nAnalysis of the concentrations of IFN\n/H9251and IP-\n10, 2 CMV-induced cytokines, revealed no differencein serum concentrations between anti-CMV\u2013negativeand anti-CMV\u2013positive patients (data not shown).However, concentrations of MCP-1 were significantlyelevated in anti-CMV\u2013positive RA patients (median89.4 pg/ml [IQR 53.6\u2013150.5 pg/ml]) versus anti-CMV\u2013negative RA patients (median 72.5 pg/ml [IQR 32.6\u2013\n141.3 pg/ml]) ( P/H110050.017), suggesting that a prolonged\nstate of endothelial cell activation might be associatedwith an aberrant immune response in anti-CMV\u2013seropositive RA patients, or, alternatively, might be in-duced by the viral infection.As a functional test of CMV-specific CD4 /H11001T\ncells, their secretion of IFN\n/H9253in response to antigen-\nspecific challenge with either pp65 peptide mixture oran irrelevant control peptide was determined in short-term cultures using an IFN\n/H9253secretion assay (Figure\n2A). Only anti-CCP\u2013positive patients were included.After in vitro stimulation with pp65 antigen, the fre-quencies of IFN\n/H9253-secreting CD4 /H11001T cells in PBMCs\nfrom RA patients were higher than those in healthycontrols (Figure 2B). Similar results were obtainedwhen total CMV lysate was added to the cultures.\nAssociation of anti-CMV IgG antibodies with\nmore severe joint disease. Several previous studies have\nshown an association of an expanded CD4 /H11001CD28\nnull\nT cell compartment with a more severe clinical course\nof RA, in particular with extraarticular disease (3,4),accelerated atherosclerosis (20), and increased jointdamage in early RA (21). The association of the fre-quency of CD4 /H11001CD28\nnullT cells with anti-CMV sero-\npositivity observed in this study prompted us, therefore,to investigate the possible influence of anti-CMV sero-positivity on the clinical severity of disease. Indeed,despite the almost identical frequency of anti-CMVIgG antibodies in patients and controls, anti-CMV sero-positivity was found to have a profound impact on theclinical course of RA.\nAnalysis of the Steinbrocker stages assigned to\nthe last available radiographs showed that joint destruc-tion due to bone erosion was more severe in anti-CMV\u2013positive patients, since the range was significantly higher\nFigure 2. Anti-CMV\u2013seropositive RA patients have increased frequencies of CMV-specific interferon- /H9253(IFN/H9253)\u2013producing CD4 /H11001T cells, and\nundergo joint surgery more frequently. PBMCs were incubated with either pp65 peptide mixture, CMV lysate, control peptide (control), or controllysate for 4 hours, and cytokine production was determined by IFN\n/H9253secretion assay followed by flow cytometric detection. A,Representative dot\nplots of CD4 /H11001IFN/H9253/H11001T cells in PBMCs from anti\u2013cyclic citrullinated peptide (anti-CCP)\u2013positive RA patients and healthy donors, incubated with\npp65 or control peptide. Plots are gated on CD3 /H11001live cells (by propidium iodide exclusion). B,Frequency of CD4 /H11001IFN/H9253production in response\nto pp65 peptide in cultured PBMCs from anti-CCP\u2013positive RA patients (n /H110057) and healthy donors (n /H110057) and in response to CMV lysate in\ncultured PBMCs from anti-CCP\u2013positive RA patients (n /H110054) and healthy donors (n /H110054). Data are shown as box plots. Each box represents the\ninterquartile range. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and the 90th percentiles. C,Numbers\nof joint-related surgical procedures performed in anti-CMV\u2013negative (n /H1100578) and anti-CMV\u2013positive (n /H11005102) RA patients. Circles represent\nindividual patients; horizontal lines indicate the median. See Figure 1 for other definitions.1744 PIERER ET ALin the anti-CMV\u2013positive group than in the anti-CMV\u2013\nnegative group, as determined by nonparametric Mann-Whitney U test, although the overlap was extensive.(For both groups, the median stage was stage III, withan IQR of stage II to stage IV [ P/H110050.044]). In addition,\nthe more severe joint destruction in anti-CMV\u2013positivepatients was illustrated by the more frequent occur-rence of Steinbrocker stages III and IV in the anti-CMV\u2013positive group compared to the anti-CMV\u2013negative group (67.8% and 51.7%, respectively) (\n/H92732/H11005\n4.738; P/H110050.03). The characteristics of the patients with\nmild joint destruction (radiographic stage 0\u2013II diseaseaccording to the Steinbrocker criteria) versus those withsevere joint destruction (stage III or IV disease accord-ing to the Steinbrocker criteria) are shown in Table 2.\nComplete documentation of the history of joint-\nrelated surgical procedures was available for 78 anti-CMV\u2013seronegative patients and 102 anti-CMV\u2013seropositivepatients. The aggravated joint disease in anti-CMV\u2013positive patients was illustrated by the increased numberof synovectomies required in this group, which was\nalmost double that in the anti-CMV\u2013negative group(median 1.5 [IQR 0\u20135] and 0 [IQR 0\u20132], respectively;P/H110050.019) (Figure 2C). When joint replacement proce-\ndures and osteotomies were included in the retrospec-tive analysis, the total number of joint-related surgicalprocedures was also higher in the anti-CMV\u2013positivegroup than in the anti-CMV\u2013negative group (median 3.5[IQR 1\u20138] and 1 [IQR 0\u20135], respectively; P/H110050.008)\n(Figure 2C).\nIn view of the older age of the anti-CMV\u2013positive\npatients, the data were analyzed for a possible linkbetween age, disease duration, and the degree of jointdestruction, since increased cumulative damage to boneand joint structures could be the underlying cause ofthe observed differences. As expected, patient agewas found to correlate with the disease duration prior tostudy inclusion (R /H110050.211, P/H110050.00313). Disease\nduration, in turn, was found to correlate closely with theobserved radiologic damage and the total number ofTable 2. Comparison of patients with mild joint destruction and patients with severe joint destruction*\nSteinbrocker stage 0\u2013II\n(n/H1100579)Steinbrocker stage III or IV\n(n/H11005123)\nAnti-CMV positive, no. (%) 37 (46.8) 78 (63.4)\u2020\nIgM-RF positive, no. (%) 68 (86.1) 112 (91.1)IgM-RF titer 142 (46\u2013520) 230 (84\u2013623)Anti-CCP positive, no. (%)\u2021 58 (77.3) 98 (84.5)Anti-CCP titer 413 (51\u20131,367) 442 (92\u20131,600)Shared epitope positive, no. (%)\u2021 29 (78.4) 61 (70.1)DR4 shared epitope positive, no. (%)\u2021 20 (54.0) 43 (48.3)C-reactive protein, mg/liter 11 (5\u201336) 19 (11\u201340)No. of swollen joints 6 (2\u201314) 6 (2\u201310)\n* Except where indicated otherwise, values are the median (interquartile range). Patients with stage 0\u2013II\ndisease according to the Steinbrocker criteria had mild joint destruction, and patients with stage III or IVdisease according to the Steinbrocker criteria had severe joint destruction. See Table 1 for definitions.\u2020P/H110050.028 versus patients with Steinbrocker stage 0\u2013II disease.\n\u2021 Data were not available for all patients.\nTable 3. Multiple logistic regression model for the prediction of severe radiologic joint destruction\n(Steinbrocker stage III or IV)*\nIndependent variable Coefficient SE P OR (95% CI)\u2020\nConstant 1.362 0.698 0.051 3.902 (0.993\u201315.334)\nAnti-CMV positivity 0.882 0.330 0.007 2.416 (1.266\u20134.610)Age at disease onset /H110020.0493 0.0118 /H110210.001 0.952 (0.930\u20130.974)\nAnti-CCP positivity 0.567 0.716 0.429 1.763 (0.433\u20137.176)RF positivity 0.452 0.579 0.435 1.572 (0.506\u20134.887)\n* The presence or absence of severe radiologic joint destruction (either Steinbrocker stage III or IV or\nSteinbrocker stage 0\u2013II, respectively) was used as the dichotomized, dependent variable in the logisticregression analysis (Hosmer-Lemeshow Pvalue for goodness of fit 0.724, likelihood ratio 27.696 [ P/H11021\n0.001]). 95% CI /H1100595% confidence interval (see Table 1 for other definitions).\n\u2020 Odds ratio (OR) that a patient positive for the variable has disease more severe than Steinbrockerstage II.ANTI-CMV AND JOINT DESTRUCTION IN RA 1745joint-related surgical procedures (R /H110050.544, P/H110210.001\nand R/H110050.637, P/H110210.001, respectively).\nIn order to exclude the older age of the CMV-\npositive patients as a dominant confounding factor un-derlying the accelerated progression of joint destructionand the increased numbers of joint-related surgicalprocedures in these patients, the analysis was repeatedafter careful age-matching of anti-CMV\u2013positive pa-tients to anti-CMV\u2013negative patients. To ensure strin-gent matching of anti-CMV\u2013negative patients to anti-CMV\u2013positive patients, age matching was performed byselecting patients from the total pool of analyzed anti-CMV\u2013negative patients with an age difference of /H113496\nmonths compared to the anti-CMV\u2013positive patients.The difference in the number of RA-related surgicalprocedures on bone and/or joint structures betweenanti-CMV\u2013positive and anti-CMV\u2013negative patientsremained significant when 62 anti-CMV\u2013positive pa-tients were compared to 62 age-matched anti-CMV\u2013negative patients (median 4 [IQR 1\u20136] and 2 [IQR0\u20135.75], respectively; P/H110050.024). When synovectomies\nand tenosynovectomies alone were analyzed, their num-ber also remained significantly higher in anti-CMV\u2013positive patients than in anti-CMV\u2013negative patients(median 2 [IQR 0\u20135] and median 0 [IQR 0\u20132], respec-tively; P/H110050.025). In fact, 36.6% of the anti-CMV\u2013\nnegative patients had not had any joint-related surgicalprocedure, compared to only 16.4% of the anti-CMV\u2013positive patients ( P/H110050.03).\nMultiple logistic regression analysis reveals a\nsignificant influence of anti-CMV seropositivity and ageat disease onset on joint destruction in RA. In order to\nanalyze the contribution of the various clinical andserologic parameters examined to the severity of jointdisease, multiple logistic regression analysis was per-formed. For this analysis, a dichotomized outcome para-meter has to be entered as a dependent variable, whichwas achieved by introducing cutoffs for radiologic joint\ndestruction (Steinbrocker stage /H11022II) and for frequent\njoint surgery ( /H110222 RA-related surgical procedures on\nbone and/or joint structures). When all relevant andavailable clinical parameters were entered into the re-\ngression analysis, the strongest predictive factor forsevere joint destruction was disease duration, mirroringthe progressive course of joint destruction in RA (datanot shown).\nIf disease duration was not entered into the\nanalysis, however, anti-CMV positivity and age at onsetof disease exerted significant effects. When the variablesanti-CCP positivity, IgM-RF positivity, age at diseaseonset, and anti-CMV seropositivity were analyzed asindependent variables, anti-CMV seropositivity was theonly parameter with an aggravating effect on both thepresence of severe radiologic joint destruction (Table 3)and on the frequency of joint surgery (Table 4). Thepatient\u2019s age at the onset of disease also exerted asignificant influence, but the effect size was minute andwas associated with a negative correlation coefficient.\nFurther multiple logistic regression analysis of\nclinical parameters revealed no influence of anti-CMVpositivity on the number of DMARD treatments initi-ated or treatment failures, steroid treatment, or diseaseactivity at the time of analysis. RF and anti-CCP anti-body levels were not increased in frequency or concen-tration in anti-CMV\u2013positive patients.\nDISCUSSION\nThis study was performed to investigate a possi-\nble link between latent CMV infection and the auto-immune disease RA, based on the hypothesis that theemergence of clonally expanded, CD4 /H11001CD28\nnullT cells\nin both conditions indicates a possible pathogenetic linkbetween them. No systematic analysis of the frequencyTable 4. Multiple logistic regression model for the prediction of a history of /H110222 RA-related surgical\nprocedures on bone and/or joint structures*\nIndependent variable Coefficient SE P OR (95% CI)\u2020\nConstant 0.845 0.760 0.266 2.328 (0.525\u201310.326)\nAnti-CMV positivity 0.955 0.356 0.007 2.599 (1.293\u20135.228)Age at disease onset /H110020.0591 0.0133 /H110210.001 0.943 (0.918\u20130.968)\nAnti-CCP positivity 0.504 0.626 0.421 1.655 (0.486\u20135.639)RF positivity 0.532 0.802 0.507 1.702 (0.354\u20138.198)\n* A history of either /H110222o r/H113492 RA-related surgical procedures on bone and/or joint structures was used\nas the dichotomized, dependent variable in the logistic regression analysis (Hosmer-Lemeshow Pvalue\nfor goodness of fit 0.834, likelihood ratio 30.344 [ P/H110210.001]). 95% CI /H1100595% confidence interval (see\nTable 1 for other definitions).\u2020 Odds ratio (OR) that a patient positive for the variable has a history of /H110222 RA-related surgical\nprocedures.1746 PIERER ET ALof anti-CMV seropositivity in RA has been published\nto date.\nWe showed that anti-CMV seropositivity by itself\nis not disproportionally common in RA. However, theobserved higher frequency of anti-CMV seropositivity inolder RA patients compared to healthy controls of thesame age indicates that latent CMV infection mightincrease susceptibility to RA, at least in individualsolder than 55 years of age. Anti-CMV seropositivity waspreviously shown to be associated with an expandedCD4/H11001CD28\nnullT cell compartment in patients with RA\n(11,16), and this association was confirmed in the pres-ent study in a much larger patient cohort.\nA direct comparison of the frequencies of CD4 /H11001\nCD28\nnullT cells in RA patients to those in anti-CMV\u2013\nseropositive or anti-CMV\u2013seronegative healthy individ-uals was not possible in the present study, since onlyserum samples were available from the healthy blooddonors. Of note, however, we and others have shownthat even in anti-CMV\u2013positive individuals, the medianfrequency of CD4 /H11001CD28\nnullT cells in healthy individ-\nuals younger than /H1101180 years of age does not exceed a\nfraction of 2.5% of circulating T cells (8,20,22,23), whilethose frequencies reach 10% and higher in RA patients(3,20,22\u201324). Accordingly, the median percentage ofCD4/H11001CD28\nnullT cells observed in the anti-CMV\u2013\npositive RA patients in this study appears to exceed theirfrequency in anti-CMV\u2013positive healthy controls by afactor of /H110113. Therefore, although CD4 /H11001CD28\nnullT cells\nare expanded primarily in anti-CMV\u2013positive individu-als, they are further increased in RA patients, in partic-ular in the presence of an extraarticular autoimmunephenomenon.\nLoss of CD28 expression on CD4 /H11001T cells has\nbeen shown to occur in 3 different scenarios. First, CMVinfection of otherwise healthy individuals induces anincrease in CD4 /H11001CD28\nnullT cells, for which no conclu-\nsive explanation has been put forward to date. Second,the increased CD4 /H11001CD28\nnullcell frequency in various\nautoimmune conditions (25\u201327) might at least partiallybe the result of chronic tumor necrosis factor exposure,which can contribute to the loss of CD28 by down-regulating CD28 expression via inhibition of the activityof the CD28 minimal promoter (28). Finally, loss ofCD28 expression seems to occur in CD4 lymphopenia,when extensive homeostatic proliferation is required toreplenish the peripheral CD4 /H11001T cell pool. This has\nbeen reported for recipients of allogeneic hematopoieticcell grafts (29) and in untreated patients with B cellchronic lymphocytic leukemia (CLL) (30), for which anexpanded population of CD4 /H11001CD28\nnull, perforin-expressing T cells enriched for human CMV specificity\n(31) has been described.\nSimilar to those lymphopenic hematologic condi-\ntions, significant restrictions in the repertoire diversityand proliferative capacity of CD4 /H11001T cells are also\npresent in RA (2,14,32), with consequences such asrepertoire disturbances, clonal expansions, and replica-tive exhaustion of the CD4 /H11001T cell compartment. In\nview of the observed profound influence of anti-CMVseropositivity on the CD4 /H11001T cell pool in RA patients,\nwe propose that latent CMV infection adds severeadditional strain on the already compromised T cellhomeostasis in RA patients, thereby exaggerating thepathologic findings.\nA proliferative response of CD4 /H11001T cells toward\nCMV antigens as well as CMV-specific IFN\n/H9253production\nhas previously been shown to be present in RA (33),but, unlike in the present study, it was not compared tothat in healthy controls. In healthy individuals, somestudies have described higher frequencies of IFN\n/H9253-\nsecreting CD4 /H11001T cells (24,34), but the findings of other\nstudies were more compatible with our results (35,36).The use of a 4-hour short-term antigen-specific restimu-lation without additional costimulation and, in particu-lar, the use of a highly specific cytokine secretion assay,along with the analysis of live cells, might have contrib-uted to the low frequencies observed in both healthycontrols and RA patients in our study. Of note, however,an RA-associated increase was detectable only in thefrequency of IFN\n/H9253-secreting but not proliferating CD4 /H11001\nT cells, which might reflect the restricted proliferativecapacity of IFN\n/H9253-secreting, pathogenetically relevant\nCD4/H11001T cells described in RA (37).\nIt can be assumed that CMV-specific CD4 /H11001T\ncells are preferentially CD4 /H11001CD28null, as previously\nshown (24), and that they are likely to express inhibitoryor activating KIR (9). In addition, CD4 /H11001CD28\nnullcells\nare known to produce excessive amounts of IFN /H9253, and\nour finding of an increased CMV-specific IFN /H9253re-\nsponse indicates that part of this CD4 /H11001CD28nullre-\nsponse might be driven by latent CMV infection.\nThe most important clinical finding of the pres-\nent study is the influence of anti-CMV seropositivity onthe radiographic progression of joint destruction, and inparticular its highly significant association with the num-ber of surgical procedures that were required. Theaggravated joint disease in anti-CMV\u2013positive patientsis an indirect confirmation of the relevance of pathologicT cells to joint destruction in RA. Consistent with thesefindings, a prospective analysis has indeed shown thatearly in the course of RA, joint destruction alreadyANTI-CMV AND JOINT DESTRUCTION IN RA 1747progresses significantly faster in patients with expanded\nCD4/H11001CD28nullT cells (21).\nVery recently, clinical observations correspond-\ning to our results have been reported for patientswith B cell CLL (38). In that study and in the presentstudy, the overall frequency of anti-CMV\u2013seropositivepatients did not differ from the frequency of anti-CMV\u2013seropositive subjects in a healthy control group.However, consistent with our observations, anti-CMV\u2013positive patients with B cell CLL not only had a mark-edly increased CMV-specific CD4 /H11001T cell response\ncomprising many CD4 /H11001CD28\nnullT cells but, more im-\nportantly, also exhibited an unfavorable clinical coursewith more infectious episodes and a reduction in overallsurvival by nearly 4 years. The authors speculate that inCLL patients, immunosuppression could trigger sub-clinical viremia that in turn activates and expands CMV-specific T cell populations (38). Similarly, DMARDtherapy in RA could lead to an expansion of CMV-specific T cell clones, although CMV reactivation, i.e.,viral DNA, was not detectable in the peripheral blood ofthe patients in this study (data not shown) or in the CLLpatients, and no association between the number ofconsecutively prescribed DMARDs and anti-CMV sero-positivity was detected in the present study.\nAn alternative explanation for the data on pa-\ntients with B cell CLL was put forward in an accompa-nying editorial (39). It was suggested that the shortenedlife expectancy might result from indirect effects, eitherdue to the dramatically expanded CMV-specific T cellsthemselves or due to the resulting constriction of theremaining T cell repertoire by those cells that competefor essential growth factors and for tissue niches re-quired for T cell homeostasis (39). In addition, severalpotentially detrimental effects, including aberrant cyto-toxicity and cytokine production, have been shown tooccur in the RA T cell repertoire, which is characterizedby restricted diversity (2,40).\nWe propose, therefore, that the exhaustive im-\nmune response due to latent CMV infection is morepronounced in RA patients than in healthy controls,leading to exaggerated immunosenescence, as indicatedby the observed frequencies of clonal expansion andCD4/H11001CD28\nnullcells. Premature immunosenescence, in\nturn, is associated with more severe joint destruction andextraarticular disease manifestations. Finally, the ob-served expansion of CD4 /H11001CD28\nnullT cells in patients\nwith rheumatoid vasculitis suggests that latent CMVinfection might even contribute to this serious condition(9). Further investigations in sufficiently powered, pref-erably prospective studies will be required for conclusiveclarification of a potential link between latent CMV\ninfection and susceptibility to RA.\nAUTHOR CONTRIBUTIONS\nAll authors were involved in drafting the article or revising it\ncritically for important intellectual content, and all authors approved\nthe final version to be published. Dr. Wagner had full access to all of\nthe data in the study and takes responsibility for the integrity of thedata and the accuracy of the data analysis.\nStudy conception and design. Pierer, Baerwald.\nAcquisition of data. Rothe.\nAnalysis and interpretation of data. Quandt, Schulz, Rossol, Scholz,\nWagner.\nREFERENCES\n1. Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ,\nWeyand CM, et al. Killer cell activating receptors function as\ncostimulatory molecules on CD4/H11001CD28nullT cells clonally ex-\npanded in rheumatoid arthritis. J Immunol 2000;165:1138\u201345.\n2. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of\nthe T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci\nU S A 1998;95:14447\u201352.\n3. Wagner U, Pierer M, Kaltenhauser S, Wilke B, Seidel W, Arnold\nS, et al. Clonally expanded CD4/H11001CD28nullT cells in rheumatoid\narthritis use distinct combinations of T cell receptor BV and BJ\nelements. Eur J Immunol 2003;33:79\u201384.\n4. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of\nunusual CD4 /H11001T cells in severe rheumatoid arthritis. Arthritis\nRheum 1997;40:1106\u201314.\n5. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C,\nRuchti F, et al. Broadly targeted human cytomegalovirus-specificCD4\n/H11001and CD8/H11001T cells dominate the memory compartments of\nexposed subjects. J Exp Med 2005;202:673\u201385.\n6. Snyder CM, Cho KS, Bonnett EL, van Dommelen S, Shellam GR,\nHill AB. Memory inflation during chronic viral infection is main-tained by continuous production of short-lived, functional T cells.Immunity 2008;29:650\u20139.\n7. Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S,\net al. Cytomegalovirus infection: a driving force in human T cellimmunosenescence. An n N Y Acad Sci 2007;1114:23\u201335.\n8. Van Leeuwen EM, Remmerswaal EB, Vossen MT, Rowshani AT,\nWertheim-van Dillen PM, van Lier RA, et al. Emergence of aCD4\n/H11001CD28/H11002granzyme B/H11001, cytomegalovirus-specific T cell subset\nafter recovery of primary cytomegalovirus infection. J Immunol2004;173:1834\u201341.\n9. Van Bergen J, Koning F. The tortoise and the hare: slowly evolving\nT-cell responses take hastily evolving KIR. Immunology 2010;131:301\u20139.\n10. Thewissen M, Somers V, Venken K, Linsen L, van Paassen P,\nGeusens P, et al. Analyses of immunosenescent markers in pa-tients with autoimmune disease. Clin Immunol 2007;123:209\u201318.\n11. Hooper M, Kallas EG, Coffin D, Campbell D, Evans TG, Looney\nRJ. Cytomegalovirus seropositivity is associated with the expan-sion of CD4\n/H11001CD28/H11002and CD8/H11001CD28/H11002T cells in rheumatoid\narthritis. J Rheumatol 1999;26:1452\u20137.\n12. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria\nin rheumatoid arthritis. JAMA 1949;140:659\u201362.\n13. Bottcher J, Pfeil A, Mentzel H, Kramer A, Schafer ML, Lehmann\nG, et al. Peripheral bone status in rheumatoid arthritis evaluatedby digital X-ray radiogrammetry and compared with multisitequantitative ultrasound. Calcif Tissue Int 2006;78:25\u201334.\n14. Wagner U, Pierer M, Wahle M, Moritz F, Kaltenhauser S,\nHantzschel H. Ex vivo homeostatic proliferation of CD4\n/H11001T cells1748 PIERER ET ALin rheumatoid arthritis is dysregulated and driven by membrane-\nanchored TNF /H9251. J Immunol 2004;173:2825\u201333.\n15. Wagner U, Kaltenhauser S, Pierer M, Seidel W, Troltzsch M,\nHantzschel H, et al. Prospective analysis of the impact of HLA-DRand -DQ on joint destruction in recent-onset rheumatoid arthritis.Rheumatology (Oxford) 2003;42:553\u201362.\n16. Thewissen M, Somers V, Hellings N, Fraussen J, Damoiseaux J,\nStinissen P. CD4\n/H11001CD28nullT cells in autoimmune disease: patho-\ngenic features and decreased susceptibility to immunoregulation.J Immunol 2007;179:6514\u201323.\n17. Fletcher JM, Vukmanovic-Stejic M, Dunne PJ, Birch KE, Cook\nJE, Jackson SE, et al. Cytomegalovirus-specific CD4\n/H11001T cells in\nhealthy carriers are continuously driven to replicative exhaustion.J Immunol 2005;175:8218\u201325.\n18. Cheng J, Ke Q, Jin Z, Wang H, Kocher O, Morgan JP, et al.\nCytomegalovirus infection causes an increase of arterial bloodpressure. PLoS Pathog 2009;5:e1000427.\n19. Anfossi N, Doisne JM, Peyrat MA, Ugolini S, Bonnaud O, Bossy\nD, et al. Coordinated expression of Ig-like inhibitory MHC class Ireceptors and acquisition of cytotoxic function in human CD8\n/H11001\nT cells. J Immunol 2004;173:7223\u20139.\n20. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G,\net al. CD4 /H11001CD28/H11002T lymphocytes contribute to early atheroscle-\nrotic damage in rheumatoid arthritis patients. Circulation 2004;109:2744\u20138.\n21. Goronzy JJ, Matteson EL, Fulbright JW, Warrington KJ, Chang-\nMiller A, Hunder GG, et al. Prognostic markers of radiographicprogression in early rheumatoid arthritis. Arthritis Rheum 2004;50:43\u201354.\n22. Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Macha-\nlinski B, et al. The expansion of CD4 /H11001CD28/H11002T cells in patients\nwith rheumatoid arthritis. Arthritis Res Ther 2003;5:R210\u20133.\n23. Schmidt D, Goronzy JJ, Weyand CM. CD4 /H11001CD7/H11002CD28/H11002T cells\nare expanded in rheumatoid arthritis and are characterized byautoreactivity. J Clin Invest 1996;97:2027\u201337.\n24. Van Bergen J, Kooy-Winkelaar EM, van Dongen H, van Gaalen\nFA, Thompson A, Huizinga TW, et al. Functional killer Ig-likereceptors on human memory CD4\n/H11001T cells specific for cytomeg-\nalovirus. J Immunol 2009;182:4175\u201382.\n25. Lamprecht P, Moosig F, Csernok E, Seitzer U, Schnabel A,\nMueller A, et al. CD28 negative T cells are enriched in granulo-matous lesions of the respiratory tract in Wegener\u2019s granuloma-tosis. Thorax 2001;56:751\u20137.\n26. Liuzzo G, Biasucci LM, Trotta G, Brugaletta S, Pinnelli M,\nDigianuario G, et al. Unusual CD4\n/H11001CD28nullT lymphocytes and\nrecurrence of acute coronary events. J Am Coll Cardiol 2007;50:1450\u20138.\n27. Dutra WO, Martins-Filho OA, Cancado JR, Pinto-Dias JC,\nBrener Z, Gazzinelli G, et al. Chagasic patients lack CD28expression on many of their circulating T lymphocytes. ScandJ Immunol 1996;43:88\u201393.28. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ. Down-regulation of\nCD28 expression by TNF-\n/H9251. J Immunol 2001;167:3231\u20138.\n29. Hirokawa M, Horiuchi T, Kawabata Y, Kitabayashi A, Saitoh H,\nIchikawa Y, et al. Oligoclonal expansion of CD4/H11001CD28/H11002T lym-\nphocytes in recipients of allogeneic hematopoietic cell grafts andidentification of the same T cell clones within both CD4\n/H11001CD28/H11001\nand CD4/H11001CD28/H11002T cell subsets. Bone Marrow Transplant 2001;\n27:1095\u2013100.\n30. Porakishvili N, Roschupkina T, Kalber T, Jewell AP, Patterson K,\nYong K, et al. Expansion of CD4 /H11001T cells with a cytotoxic\nphenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol 2001;126:29\u201336.\n31. Walton JA, Lydyard PM, Nathwani A, Emery V, Akbar A,\nGlennie MJ, et al. Patients with B cell chronic lymphocyticleukaemia have an expanded population of CD4 perforin express-ing T cells enriched for human cytomegalovirus specificity and aneffector-memory phenotype. Br J Haematol 2010;148:274\u201384.\n32. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev\n2005;204:55\u201373.\n33. Davignon JL, Boyer JF, Jamard B, Nigon D, Constantin A,\nCantagrel A. Maintenance of cytomegalovirus-specific CD4\npos\nT-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments. Arthritis Res Ther 2010;12:R142.\n34. Pourgheysari B, Khan N, Best D, Bruton R, Nayak L, Moss PA.\nThe cytomegalovirus-specific CD4\n/H11001T-cell response expands with\nage and markedly alters the CD4/H11001T-cell repertoire. J Virol\n2007;81:7759\u201365.\n35. Rentenaar RJ, Gamadia LE, van der Hoek N, van Diepen FN,\nBoom R, Weel JF, et al. Development of virus-specific CD4/H11001\nT cells during primary cytomegalovirus infection. J Clin Invest2000;105:541\u20138.\n36. Sinclair E, Black D, Epling CL, Carvidi A, Josefowicz SZ,\nBredt BM, et al. CMV antigen-specific CD4\n/H11001and CD8/H11001T cell\nIFN/H9253expression and proliferation responses in healthy CMV-\nseropositive individuals. Viral Immunol 2004;17:445\u201354.\n37. Koetz K, Bryl E, Spickschen K, O\u2019Fallon WM, Goronzy JJ,\nWeyand CM. T cell homeostasis in patients with rheumatoid\narthritis. Proc Natl Acad Sc iUSA 2000;97:9203\u20138.\n38. Pourgheysari B, Bruton R, Parry H, Billingham L, Fegan C,\nMurray J, et al. The number of cytomegalovirus-specific CD4/H11001\nT cells is markedly expanded in patients with B-cell chronic\nlymphocytic leukemia and determines the total CD4/H11001T-cell\nrepertoire. Blood 2010;116:2968\u201374.\n39. Akbar AN. The silent war against CMV in CLL. Blood 2010;116:\n2869\u201370.\n40. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional\nsubsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum\n1998;41:2108\u201316.ANTI-CMV AND JOINT DESTRUCTION IN RA 1749ARTHRITIS & RHEUMATOLOGY\nVol. 68, No. 2, February 2016, pp 337\u2013346DOI 10.1002/art.39331\nVC2016 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc.\non behalf of the American College of Rheumatology. This is an open access article underthe terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, whichpermits use and distribution in any medium, provided the original work is properly cited, the\nuse is non-commercial and no modifications or adaptations are made.\nLatent Cytomegalovirus Infection in Rheumatoid Arthritis and\nIncreased Frequencies of Cytolytic LIR-1 1CD81T Cells\nKathrin Rothe,1Dagmar Quandt,1Kristin Schubert,1Manuela Rossol,1Maria Klingner,1\nSimon Jasinski-Bergner,2Roger Scholz,1Barbara Seliger,2Matthias Pierer,1\nChristoph Baerwald,1and Ulf Wagner1\nObjective. Leukocyte immunoglobulin-like recep-\nt o r1( L I R - 1 )i su p - r e g u l a t e db yc y t o m e g a l o v i r u s( C M V ) ,which in turn, has been associated with premature agingand more severe joint disease in patients with rheumatoidarthritis (RA). The aim of this study was to investigate theexpression and functional significance of LIR-1 in CMV-positive RA patients.\nMethods. We determined the phenotype, cytolytic\npotential, CMV-specific proliferation, and HLA\u2013G\u2013trig-gered, LIR-1\u2013mediated inhibition of interferon-\ngsecretion\nof LIR-1 1T cells in RA patients and healthy controls.\nResults. We found increased frequencies of CD8 1\nT cells with CMV pp65\u2013specific T cell receptors in CMV-positive RA patients as compared to CMV-positive healthycontrols. CMV-specific CD8 1T cells in these patients\nwere preferentially LIR-1 1and exhibited a terminally dif-\nferentiated polyfunctional phenotype. The numbers of\nLIR-11CD81T cells increased with age and disease\nactivity, and showed high levels of reactivity to CMV anti-gens. Ligation of LIR-1 with soluble HLA\u2013G molecules invitro confirmed an inhibitory role of the molecule whenexpressed on CD8 1T cells in RA patients.\nConclusion. We propose that latent CMV infection\nin the context of a chronic autoimmune response inducesthe recently described \u201cchronic infection phenotype\u201d inCD81T cells, which retains anti-infectious effectorfeatures while exhibiting autoreactive cytolytic potential.\nThis response is likely dampened by LIR-1 to avoid over-whelming immunopathologic changes in the setting of theautoimmune disease RA. The known deficiency of solubleHLA\u2013G in RA and the observed association of LIR-1\nexpression with disease activity suggest, however, that\nLIR-11T cells are insufficiently controlled in RA and are\ns t i l ll i k e l yt ob ei n v o l v e di nt h ep a t h o g e n e s i so ft h ed i s e a s e .\nThe human memory T cell compartment is shaped\nnot only by antimicrobial immune responses, but also byautoimmunity and by latent infections with viruses such ascytomegalovirus (CMV) (1). The latter drive the genera-tion of terminally differentiated T cells, which are charac-terized by the loss of costimulatory molecules such asCD27 and CD28, shortened telomeres, and by the expres-sion of inhibitory natural killer (NK) cell receptors (2).CMV infection in immunocompetent hosts usually runs anasymptomatic course but has been reported to cause mas-sive clonal expansions involving up to 40% of the global Tcell pool (3). This increase over time in CMV-reactive T\ncells specific for antigens derived from latent CMV has\nbeen called memory inflation and involves both the CD4 1\nand the CD8 1T cell compartment (4,5). As a conse-\nquence, a stable CMV-reactive T cell compartment withan extremely dynamic cell turnover is established.\nClinically, CMV infection c an cause organ-specific\nor systemic infections in immunocompromised patients. Weand other investigators (6\u20138) have shown that the presenceof a latent CMV infection influ ences the clinical course and\noutcome of rheumatoid arthritis (RA), the prototypical\nT cell\u2013mediated autoimmune di sease with severe perturba-\ntions of immune homeostasis, particularly in various T lym-phocyte compartments. Similar observations have beenreported in other autoimmune diseases, such as psoriasis(9), granulomatosis with polyangiitis (10,11), Alzheimer\u2019sdisease (12), and systemic lupus erythematosus (13).\nSupported by the DFG (grant WA 2765/3-1).\n1Kathrin Rothe, PhD, Dagmar Quandt, PhD, Kristin Schubert,\nPhD, Manuela Rossol, PhD, Maria Klingner, MD, Roger Scholz, MD,\nMatthias Pierer, MD, PhD, Christoph Baerwald, MD, PhD, Ulf Wagner,MD: University of Leipzig, Leipzig, Germany;2Simon Jasinski-Bergner,\nPhD, Barbara Seliger, PhD: Martin Luther University Halle-\nWittenberg, Halle, Germany.\nAddress correspondence to Ulf Wagner, MD, Department of\nInternal Medicine, Division of Rheumatology, University of Leipzig,\nLiebigstrasse 20, 04103 Leipzig, Germ any. E-mail: ulf.wagner@medizin.\nuni-leipzig.de.\nSubmitted for publication January 8, 2015; accepted in\nrevised form August 11, 2015.\n337Latent CMV infection has been associated with\nincreased expression of the inhi bitory NK cell receptor leu-\nkocyte immunoglobulin-like receptor 1 (LIR-1; also knownas immunoglobulin-like transcript 2 and CD85j, with thegene name LILRB1) on CMV-reactive CD8 1T cells (14).\nLIR-1 belongs to a group of immunoregulatory receptorscontaining 2\u20134 immunoreceptor tyrosine-based inhibitory\nmotifs within the cytoplasmic region. Upon tyrosine phos-\nphorylation, LIR-1 recruit s the SH2 domain\u2013containing\nphosphatase 1 (SHP-1) tyro sine phosphatase or SH2\ndomain\u2013containing inositol-5\n0-phosphatase (SHIP), both\nof which are involved in negative signaling and inhibitionof cell activation (15). Furthermore, LIR-1 is expressed onalmost all immune cells, including antigen-presenting cells\nand subsets of CD4 1and CD8 1T cells (16).\nDuring the process of establ ishing latency following\nan acute CMV infection, the expression of LIR-1 on T cellsis up-regulated (17,18), which results in reduced T cell pro-liferation in the autologous mixed lymphocyte reaction(19). The increase in LIR-1 expression after CMV infection\nis sustained throughout life and is regarded as a marker of\npremature immune senescence. It has been proposed thatin otherwise healthy individuals, up-regulation of LIR-1limits collateral tissue damage due to the sustained, long-term anti-CMV immune response (20), or it regulates Tcell homeostasis (21). In conjunction with autoimmuneconditions, however, LIR-1 expression appears to have\nadditional and varying implications.\nDiminished LIR-1 expression on B cells and\naltered functionality on T cells has been reported in sys-temic lupus erythematosus patients (22). Increased LIR-1 expression was found on the lymphocytes of patients\nwith autoimmune thyroid disease (23) and multiple scle-\nrosis (24). Genetic polymorphisms of LIR-1 were foundto be associated with RA in patients not expressing RA-associated HLA\u2013DRB1 alleles (25).\nSince the effects of latent CMV infection and\nchronic immune response converge in patients with RA,\nwe hypothesized that LIR-1 might be involved in the\npathogenesis of the disease. The aim of this study, there-fore, was to investigate the expression and functional sig-nificance of LIR-1 in CMV-positive RA patients. Basedon the reported relevance of latent CMV infection to RAdisease severity, we focused our study on the phenotypeand function of polyfunctional and terminally differenti-\nated CMV-specific lymphocytes positive for LIR-1, which\nis expressed not only on CD4 1Tc e l l s ,b u ta l s o ,a n d\nmore prominently, on CD8 1Tc e l l s .\nPATIENTS AND METHODS\nPatients and tissue samples. Patients with RA\n(n563) according to the American College of Rheumatology/European League Against Rheumatism 2010 criteria (26) were\nrecruited from the rheumatology unit of the University ofLeipzig. The control group consisted of age-matched healthy\nsubjects (n 570). The CMV status of the RA patients and\nhealthy controls was determined by serologic analysis usingenzyme-linked immunosorbent assay (ELISA; Medac). Thisstudy was approved by the local e thnics committee. Samples of\nsynovium were obtained from pat ients undergoing synovectomy\nat the Department of Orthopedics at the University of Leipzig.Synovial tissue T cells were isolat ed as described previously (27).\nImmunofluorescence stai ning and flow cytometry. Tc e l l\nphenotyping was performed on freshly isolated peripheral bloodmononuclear cells (PBMCs). The following antibodies were usedin different fluorescent conjugates: anti-CD3 (BW264/56), anti-CD8 (BW135/80), anti-CD4 (M-T466), anti-CD28 (15E8), anti-\nCD27 (M-T271), anti-CD31 (AC128), anti-CD45RA (T6D11),\nanti-CD45RO (UCHL-1), anti-C CR7 (FR11-11E8), anti-CD57\n(TB03), anti\u2013programmed death 1 (anti\u2013PD-1; PD1.3.1.3) (allfrom Miltenyi Biotec), anti\u2013LIR-1 (292305 [R&D Systems] and\nGHI/75 [Miltenyi Biotec]), anti-IgG1 (11711 [R&D Systems] and\nIS6-11E5.11 [Miltenyi Biotec]), anti-CD3 (SP34-2; BD Bioscien-ces), and anti\u2013HLA\u2013A2 ( BB7.2; AbD Serotec).\nAnalysis of cells for the expression of surface markers\nwas performed using FACSCalibur and LSR II flow cytome-\nters (BD Biosciences). Data were analyzed with FlowJo soft-ware (Tree Star) and CellQuest (BD Biosciences) software.Doublets and dead cells were removed by exclusion of propi-\ndium iodide\u2013positive cells.\nDextramer staining. PBMCs from RA patients were\nisolated by Ficoll-Paque density -gradient centrifugation. For\ndetermination of CMV-specific CD8 1T cells, PBMCs from\nCMV-positive RA patients and healthy controls were stained forHLA\u2013A2 molecules. PBMCs (5 310\n5) from HLA\u2013A2\u2013positive,\nCMV-positive RA patients (n 58) and healthy donors (n 512)\nwere incubated with fluorescence- labeled monoclonal antibodies\nand an appropriate concentrat ion of dextramer complexes for\nCMV proteins pp65 (CMV pp65/HLA\u2013A*0201 NLVPMVATV )a n d\nIE-1 (CMV IE1/HLA\u2013A*0201 VLEETSVML ) (both from Immu-\ndex) in a small volume for 30 minutes at 4 8C with protection from\nthe light.\nCytotoxicity assay. Cytolytic CD8 1T cells were ana-\nlyzed by cell surface mobilization of CD107a (lysosome-associat-\ned membrane protein 1). CD8 1T cells were isolated by positive\nselection using magnetic-activated cell sorting (Miltenyi Biotec).CD8-depleted PBMCs (5 3106)w e r el o a d e dw i t h5 mgo fC M V\npp65 peptide mixture or control peptide (15-mers, 11\u2013aminoacid overlap; Jerini Peptide Technologies) for 2 hours at 37 8C.\nAfter washing, target cells and effector CD8 1T cells were seed-\ned at an effector cell\u2013to\u2013target cell ratio of 4:1. Cytotoxicityassays were performed at 37 8C for 4 hours in the presence of\n0.0125\nmg of CD107a antibody (Alexa Fluor 488\u2013conjugated;\nBioLegend). Staphylococcal enterotoxin B (SEB; 1 mg/ml) (Sig-\nma) was used as a positive control. Medium alone was used asan unstimulated control. After 1 hour of coculture, monensin (2\nmM; eBioscience) or GolgiStop (2 mM; BD Biosciences) was\nadded for the last 3 hours of cell culture. Subsequently, cells\nwere stained and measured by fluorescence-activated cell sort-ing (FACS). Dead cells were removed by exclusion of propi-dium iodide\u2013positive cells. Only experiments with .0.2%\nCD107a 1CD81T cells were included in the statistical analysis.\nProliferation assay. The fluorescence-based prolifera-\ntion analysis was performed by labeling PBMCs with 3\nmg/ml of338 ROTHE ET AL5,6-carboxyfluorescein succinimidyl ester (Molecular Probes) or\n10mMCell Proliferation dye eFluor 670 (eBioscience). Cells\n(23106) were cultured for 7 days in the presence of 1 mg/ml of\nCMV lysate or control lysate (Microbix Biosystems) or 1 mg/ml\nof SEB (Sigma) as a positive control, in X-Vivo 15 medium(Lonza) containing 2 m M\nL-glutamine, 100 units/ml of penicillin,\nand 100 mg/ml of streptomycin.\nSoluble HLA\u2013G inhibition assay. The HLA\u2013G posi-\ntive choriocarcinoma cell line JEG-3 (HTB-36; ATCC) wasstably transfected with the expression vectors of the HLA\u2013Gtargeting microRNA-152 and with the respective mock vector(as a control), as previously described (28). Soluble HLA\u2013G\u2013containing and HLA\u2013G\u2013free cell culture supernatants werecollected and stored at 2808C until time for use. A protein\nconcentration step was applied, and the soluble HLA\u2013G con-\ntent was determined by ELISA (Exbio). For inhibition assays,\nCD81T cells were stimulated with 2\nmg/ml of anti-CD3 for 6\nhours in the presence of 5 ml of supernatant containing soluble\nHLA\u2013G. Supernatant without soluble HLA\u2013G was used as acontrol. Cells were subsequently stained and measured byFACS analysis. Dead cells were removed by exclusion of propi-\ndium iodide\u2013positive cells. Intracellular staining of interferon-\ng\n(IFNg) was performed using an Inside Staining kit (Miltenyi\nBiotec).\nStatistical analysis. GraphPad Prism 5.0 software\nwas used for statistical analysis. Prior to all comparisons, anormality test was performed. Between-group differences in\nmedians or means were analyzed by Student\u2019s t-test or the\nMann-Whitney rank sum test as appropriate. Correlationswere evaluated using Pearson\u2019s product-moment correlation\nor Spearman\u2019s rank correlation coefficient.\nRESULTS\nAnalysis of CMV-specific CD8 1T cells in RA\npatients and controls. We reported previously that\nCMV-reactive CD4 1T cells, which secrete IFN gin\nresponse to CMV antigen, are more frequent in RApatients than in healthy controls (7). To investigate the\nFigure 1. Increased frequencies of cytomegalovirus (CMV)\u2013specific dextramer\u2013positive CD8 1T cells and LIR-1 1CD81T cells in rheumatoid\narthritis (RA). A,Frequency of CMV pp65/HLA\u2013A*0201 NLVPMVATV dextramer\u2013positive CD8 1T cells in healthy donors (HD; n 512) and RA\npatients (n 58). Each symbol represents an individual sample; horizontal lines and error bars show the mean 6SEM. B,Frequency of CD28\u2013\nCD81T cells in CMV-negative and CMV-positive healthy donors (n 58 and n 557) and CMV-negative and CMV-positive RA patients (n 520\nand n550). CandD,Frequency of LIR-1 1T cells in CD4 1and CD8 1T cells from healthy donors (n 563) and RA patients (n 570) ( C)\nand in CD8 1T cells from CMV-positive and CMV-negative healthy donors (n 549 and n 511) and RA patients (n 551 and n 519) ( D). Data\ninB\u2013D are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Whiskers repre-\nsent the 10th and 90th percentiles. Solid circles indicate outliers. Except where indicated otherwise, frequencies are given as the percentage of\ntotal CD8 1T cells.CMV INFECTION AND INCREASED CYTOLYTIC T CELL NUMBERS IN RA 339consequences of latent CMV infection for the CD8 1T\ncell compartment in RA, the frequency of CMV-specific\nCD81T cells was determined using CMV pp65\u2013specific\ndextramers and was found to be increased in RApatients positive for CMV and anti\u2013cyclic citrullinated\npeptide as compared to CMV-positive healthy controls\n(Figure 1A). Latent CMV infection is known to causememory inflation, with a concomitant increase in poly-\nfunctional, terminally differentiated CD4 1and CD8 1\nT cells with pathologic phenotypes (5,29). As an exam-ple of such a phenotype, we analyzed the frequencies of\nCD28\u2013 T cells and found an increase in both the CD4and the CD8 T cell compartments in CMV-positive as\ncompared to CMV-negative RA patients (Figure 1B).\nAnalysis of LIR-1 1CD81T cells in RA patients\nand controls. CMV infection is known to induce overex-\npression of LIR-1. In RA patien ts and healthy control sub-\njects, CD8 1T cells express LIR-1 more frequently than\ndo CD4 1Tc e l l s ,a sp r e v i o u s l yr e p o r t e d( 2 0 )a n da sc o n -\nfirmed by the findings of our present study (Figure 1C).\nSurprisingly, LIR-1 expression on CD8 1Tc e l l si nR A\npatients was even higher than that in healthy controls. Thisincrease was most pronounced in CMV-positive RA\npatients as compared to CMV-po sitive controls (Figure 1D).\nFigure 2. Increased frequencies of leukocyte immunoglobulin-like receptor 1 (LIR-1)\u2013positive cells among cytomegalovirus (CMV)\u2013specific dex-\ntramer\u2013positive CD8 1T cells in rheumatoid arthritis (RA). A,Representative dot plot of dextramer CMV pp65 binding to CD8 1Tc e l l s( l e f t )\nand representative histogram of LIR-1 expression on dextramer-positive CD8 1T cells (right). B,Frequencies of LIR-1 1cells among dextramer-\npositive CD8 1T cells from healthy donors (HD; n 510) and from anti\u2013cyclic citrullinated peptide\u2013positive RA patients (n 55).C,Fluorescence\nintensity of LIR-1 expression on dextramer-positive and dextramer-negative CD8 1T cells. D,Frequency of CMV pp65\u2013specific dextramer\u2013positive\ncells among LIR-1 1and LIR-1\u2013 CD8 1T cells from healthy donors (n 510) and RA patients (n 54). Values are the mean 6SEM. Data in B\nandDare shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Whiskers represent\nthe 10th and 90th percentiles. Solid circles indicate outliers.340 ROTHE ET ALIn CMV-negative RA patients, a trend toward increased\nfrequencies of LIR-1 1CD81T cells was discernible,\nbut the difference did not reach statistical significance(P50.085).\nLIR-11CD81T cells were also quantified in the\naffected joints of RA patients and were found in signifi-cant numbers, both in rheumatoid synovium and in syno-\nvial fluid, although the frequencies in the synovial\nmembrane were lower than those in the peripheral blood(Pnot significant) (data not shown).\nAnalysis of LIR-1 expression on CMV pp65\u2013specific\nCD81T cells revealed increased LIR-1 1cells among\ndextramer-positive CD8 1T cells from RA patients as\ncompared to controls (Figures 2A and B). Importantly,\nLIR-1 expression levels were also significantly higher on\ndextramer-negative CD8 1T cells from RA patients as\ncompared to controls (Figure 2C). In RA patients, moreCD81T cells were CMV pp65 specific, both among\nLIR-11and LIR-1\u2013 cells (Figure 2D). Determination of\nCD81T cells specific for CMV IE-1 revealed very low fre-\nquencies, both in RA patients and in healthy individuals\n(data not shown).\nThe frequencies of LIR-1 1CD81T cells were\nfound to increase with age (Figure 3A), as reported previ-ously (18). Of note, however, the frequencies of LIR-\n11CD81T cells were also higher when only subjects\nyounger than age 50 years were compared (Figure 3B).Clinically, increased frequencies of LIR-1 1CD81T\ncells were found to be associated with higher levels of dis-\nease activity, as indicated by a significant positive correla-tion with the Disease Activity Score in 28 joints (Figure\n3C).\nPhenotyping of LIR-1 1CD81Tc e l l s . Repeated\nchronic immune responses often result in polyfunctional, ter-\nminally differentiated, and possibly exhausted T cell pheno-types, such as the CD4 1CD7\u2013CD28\u2013 T cell subset originally\ndescribed in RA (30) or the CD8 1CD272CD282Tc e l l\nsubset (1). Phenotype characterization of LIR-1 1CD81\nT cells from RA patients by flow cytometry revealed them tobe preferentially CD27\u2013CD28\u2013 and CD28\u2013CD57 1and to\ncontain increased frequencies of CD45RA 1CCR7\u2013 effector\nT cells. Furthermore, LIR-1 1CD81T cells more frequently\nexpress the NK cell marker CD56 than do LIR-1\u2013 T cells.\nAnalysis of the \u201cexhaustion\u201d marker PD-1 revealed no dif-\nference in its expression on LIR-1 1\nCD81T cells as com-\npared to LIR-1\u2013 T cells (Figure 4A). Expression of the\nfractalkine receptor CX 3CR1, which enables T cells to\nmigrate into the rheumatoid synovium (31), was alsoincreased on LIR-1 1CD81T cells from RA patients as\ncompared to LIR-1\u2013CD8 1T cells from RA patients and\nfrom healthy controls (Figure 4B). The chemokine recep-tor CCR5, which is also associated with latent virus infec-\ntion and an effector phenotype of T cells (32), was not\ndifferentially expressed on LIR-1 1T cells from RA\npatients as compared to healthy controls (Figure 4C).\nFunctional characterization of LIR-1 1CD81T\ncells in RA. Inhibitory immune receptors, such as LIR-1,\nare expressed on T cells, where they control the magnitudeof the immune response after activation. We therefore\nanalyzed the regulation of LIR -1 expression in vitro, the\nFigure 3. Influence of age and disease activity on frequencies of LIR-1 1CD81T cells in rheumatoid arthritis (RA). A,Correlation of the fre-\nquencies of LIR-1 1CD81T cells in the peripheral blood of 35 RA patients by age group. B,Frequency of LIR-1 1CD81T cells in the periph-\neral blood of RA patients and healthy donors (HD) in 3 age groups: #50 years (n 513 and n 58, respectively), 51\u201370 years (n 524 and n 537,\nrespectively), and .70 years (n 516 and n 57, respectively). Data are shown as box plots. Each box represents the 25th to 75th percentiles.\nLines inside the boxes represent the median. Whiskers represent the 10th and 90th percentiles. Solid circles indicate outliers. C,Correlation of\nthe frequencies of LIR-1 1CD81T cells in the peripheral blood of 14 RA patients by Disease Activity Score in 28 joints (DAS28). All frequen-\ncies are given as the percentage of total CD8 1T cells.CMV INFECTION AND INCREASED CYTOLYTIC T CELL NUMBERS IN RA 341effector status of LIR-1 1CD81T cells, and the inhibitory\neffect of the LIR-1 molecule on CD8 1Tc e l l sf r o mR A\npatients.\nTo gain insight into the regulation of LIR-1,\nPBMCs from RA patients were stimulated in vitro for 6days using various stimuli. The expression of LIR-1 on\nCD81T cells was down-regulated after 2 days without\nexogenous stimuli. Expression could be maintained for4 days with anti-CD3, and it remained detectable even\nafter 6 days of culture in the presence of CMV lysate or\nphytohemagglutinin (data not shown).\nFunctionally, the cytolytic potential of LIR-\n11CD81T cells was determined by CD107a mobiliza-tion assay using flow cytometry. Significantly higher\nexpression of CD107a in response to CMV pp65\u2013loadedPBMCs was detected on CD8 1T cells from RA patients\nas compared to healthy contr ols, indicating increased\nCMV-specific cytolytic potential (Figures 5A and B). Con-trol peptide\u2013loaded antigen-presenting cells could not\ninduce CD107a expression in CD8 1Tc e l l s( d a t a n o t\nshown). In healthy controls and RA patients, increased cyto-lytic potential was mainly found in LIR-1 1CD81Tc e l l s .\nThe proliferative potential of LIR-1 1CD81T\ncells after stimulation with CMV lysate was also quanti-fied in vitro (Figures 5C and D). LIR-1 1CD81T cells\nwere not found to be proliferatively exhausted, since\nFigure 4. Phenotypic characterization of LIR-1 1CD81T cells in rheumatoid arthritis (RA). A,Frequencies of CD27\u2013CD28\u2013 T cells, CD28\u2013\nCD571T cells, CD45RA 1CCR7\u2013 T cells, programmed death 1 (PD-1)\u2013positive T cells, and CD56 1T cells in LIR-1 1CD81and LIR-1\u2013CD8 1\nT cell subsets in RA patients. Each symbol represents an individual sample; horizontal lines and error bars show the mean 6SEM. BandC,Fre-\nquencies of chemokine receptors CX 3CR11(B) and CCR5 1(C) among LIR-1 1CD81T cells and LIR-1\u2013CD8 1T cells from RA patients\n(n59) and healthy donors (HD; n 58). Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes\nrepresent the median. Whiskers represent the 10th and 90th percentiles. Solid circle indicates an outlier. LIR-1 5leukocyte immunoglobulin-like\nreceptor 1.342 ROTHE ET ALthey mounted a robust proliferative response to CMV\nlysate, which exceeded the proliferation rates of LIR-1\u2013CD81T cells both in RA patients and in healthy con-\ntrols (Figure 5D). Despite their enhanced cytolytic\npotential, however, CD8 1T cells from RA patients did\nnot show an increased proliferation rate as compared to\nhealthy controls (Figure 5C).\nS o l u b l eH L A \u2013 Gi sal i g a n do fL I R - 1a n di sk n o w n\nto evoke an inhibitory signal in most cell types. In patientswith RA, decreased serum levels of soluble HLA\u2013G have\nbeen reported (33), which may contribute to autoimmuni-\nty. Hence, we investigated the responsiveness of RACD81T cells by triggering LIR-1. Addition of exogenous\nsoluble HLA\u2013G in vitro led to decreased frequencies of\nCD107a 1CD81T cells (Figures 6A and B), indicating\nthat the inhibitory signal tr iggered by ligation of LIR-1\nwould be effective if sufficient soluble HLA\u2013G molecules\nwere available in RA. Furthermore, intracellular IFN\ng\nexpression in CD8 1T cells was also down-regulated in\ncultures with soluble HLA\u2013G (Figure 6C).DISCUSSION\nLatent CMV infection and RA share several\nphenotypical features in the T cell compartment. Inaddition, the clinical impact of CMV infection on the\nRA disease course has previously been reported (6\u20138).\nWe describe herein a population of CD8 1T cells in\nCMV-positive RA patients that exhibits proinflamma-\ntory, cytolytic, and antiviral features and is functionally\ninhibited due to up-regulated expression of LIR-1.\nIn healthy individuals, expression of LIR-1 on\nCD81T cells is up-regulated by CMV infection, possibly\nwith the goal of limiting collateral tissue damage due to thelongstanding immune response against the latent virus or,\nalternatively, as a homeost atic mechanism (6\u20138). We found\nthat the frequency of LIR-1 1CD81T cells was significant-\nly higher in CMV-positive RA patients than in CMV-\npositive healthy controls and that it increased not only with\nage, but also with higher levels of disease activity. In addi-tion, LIR-1 was up-regulated on CD8 1Tc e l l st h a tw e r e\nnot specific for CMV antigens.\nFigure 5. Functional analysis of LIR-1 1CD81T cells in rheumatoid arthritis (RA). AandB,CD107a-degranulation assay. T he representative histogram\ninAshows CD107a expression on CD8 1T cells after restimulation with cytomegalovirus (CM V) pp65 peptide\u2013loaded, staphylococcal enterotoxin B\n(SEB; positive control)\u2013loaded, or control peptide\u2013loaded antigen-presenting cells (left). The percentage of CD107a 1CD81T cells is also shown (right).\nInB, the percentage of IFN g1CD107a 1CD81T cells from RA patients (n 55) and healthy donors (HD; n 55) is shown. CandD,Proliferation of\nLIR-11CD81T cells from CMV-positive healthy donors and RA patients. The represen tative histogram in Cshows proliferation of LIR-1 1CD81Tc e l l s\nafter restimulation with CMV lysate (1 mg/ml) or control lysate (left). The proliferation rate of CD8 1T cells incubated with CMV lysate or control lysate\nfrom healthy donors (n 512) and patients with RA (n 58) is also shown (right). In D, the percentage of prol iferated LIR-1\u2013CD8 1and LIR-1 1CD81\nc e l l sf r o mh e a l t h yd o n o r s( n 512) and RA patients (n 58) in response to CMV lysate is shown. Data in A(right), C(right), and Dare shown as box plots.\nEach box represents the 25th to 75th per centiles. Lines inside the boxes represent the median. W hiskers represent the 10th and 90th percentiles. Soli d\ncircles indicate outliers. In B, each symbol represents an individual sample; horizontal lines and error bars show the mean 6SEM.CMV INFECTION AND INCREASED CYTOLYTIC T CELL NUMBERS IN RA 343In healthy individuals, lymphocytes involved in\nmemory inflation tend to acquire a specific phenotype,which was previously described as \u201cexhaustive.\u201d Morerecently, it has been suggested that this \u201cchronic infection\nphenotype\u201d represents a population of T cells that can\nstill efficiently control latent infection, while certain levelsof effector function are diminished to prevent overwhelm-ing immunopathologic changes due to collateral autor-eactivity (34). Increased LIR-1 expression on CD8 1T\ncells is likely to represent such a CMV-induced chronic\ninfection phenotype, since it is linked to latent CMVinfection in healthy individuals (18). Our results showthat in comparison to healthy controls, LIR-1 was furtherup-regulated on CD8 1T cells in RA patients. In this\nautoimmune disease, increased LIR-1 expression could\nresult from an insufficiently controlled latent CMV infec-tion, leading to higher numbers of T cells, which arerequired and recruited, or it could represent a regulatorymechanism aimed at controlling autoimmunity in RA in\nthe context of latent CMV infection.\nThe functional analysis confirmed that LIR-1 1T\ncells in RA are polyfunctional and have cytolytic potential.Their higher expression of CD56 and CD57, which is asso-ciated with increased cytoto xicity in CMV-seropositive\nhealthy individuals (1,35), might further increase their\ncytolytic potential in RA. Phenotype analysis using the Tcell differentiation markers CCR7 and CD45RA con-firmed that LIR-1 1CD81T cells are effector T cells. In\naddition, their expression of CX\n3CR1, which is known to\nbe up-regulated on CMV-specific CD4 1and CD8 1T\ncells from healthy individuals (36), might enable them tomigrate toward fractalkine gradients, which has been\nreported to occur in the rheu matoid synovium (31). Dif-\nferences in PD-1 expression between LIR-1 1and LIR-1\u2013\nCD81T cells were not significant.\nIn phases of CMV reactivation or of relevant sup-\npression of the controlling immune response, the CMV-\nspecific LIR-1 1CD81T cells appear to be able to mount\na cytolytic immune response. Numerically, only 25% ofthe CMV pp65\u2013specific CD8 1Tc e l l sa r eL I R - 1 1,a n d\n,10% of LIR-1 1cells are specific for the immunodomi-\nnant CMV antigen pp65. Even assuming that another10% of LIR-1 1cells recognize other CMV antigens, it\nstill leaves the majority of LIR-1 1CD81Tc e l l su n r e a c -\ntive to CMV. The observation that LIR-1 overexpression\nis also found on T cells that are not reactive to CMV anti-\ngens and possibly even on T cells from CMV-negative RApatients indicates that CMV-independent factors relatedto the chronic autoimmune disease are also involved.\nOur finding of increased proliferative activity is evi-\ndence against the interpretation that expression of LIR-1\non CD8 1T cells is the equivalent of T cell exhaustion,\nsince T cell exhaustion is generally regarded to be accom-panied by low proliferative capacity (37,38). Our observa-tion is consistent with a similar study showing increasedproliferative capacity of LIR-1 1CD81Tc e l l sf r o m\nhealthy controls (14). In RA, exaggerated proliferative rep-lication of LIR-1 1CD81Tc e l l sc o u l de v e nc o n t r i b u t et o\nthe observed increase in the frequency of CMV-specific\ndextramer\u2013positive CD8 1T cells, possibly due to a failure\nto \u201cswitch off\u201d ongoing immune responses. Alternatively,\nthe increased frequency of CMV-specific T cells could be a\nFigure 6. Inhibition of cytotoxic CD8 1T cells in patients with rheumatoid arthritis (RA) by soluble HLA\u2013G (sHLA\u2013G). A,Inhibition of CD107a\nexpression after the addition of medium alone, soluble HLA\u2013G (5 ml), or anti-CD3 control to in vitro cultures of CD8 1T cells. Values are the mean\n6SEM of 3 samples per group. BandC,Representative histograms showing the frequencies of CD107a 1CD81T cells ( B) and the expression of\nintracellular interferon- g(IFNg) on CD8 1T cells ( C) from RA patients after in vitro activation in medium or soluble HLA\u2013G\u2013containing or control\nsupernatants.344 ROTHE ET ALconsequence of globally increased T cell proliferation lead-\ning to replicative senescence in this disease (39), but thislatter explanation is partially contradicted by the increased\nproliferation among LIR-1 1CD81Tc e l l s .\nLIR-1 remains functional as an inhibitory receptor\nin RA, since we found LIR-1 ligation by soluble HLA\u2013G\nto block cytotoxicity in our experiments. Antigen recogni-tion by CD8 1T cells requires antigen-presenting major\nhistocompatibility complex (MHC) class I molecules to\ninteract with T cell receptors and CD8 coreceptors within\nthe tightly organized and spatially focused immunologic\nsynapse. Those MHC class I molecules are ligands for\nLIR-1, and when LIR-1 is recruited to the immunologic\nsynapse, it exerts a strong inhibitory effect, even more soif it encounters the viral high-affinity ligand UL18, which\nis expressed on the juxtaposed cells in latent CMV infec-\ntion (40). Accordingly, up-regulation of the inhibitory\nreceptor LIR-1 in RA could be an attempt to limit autor-\neactivity in order to alleviate the autoimmune disease.\nSoluble HLA\u2013G has been reported to be reduced\nin RA (33) and has been implicated in the pathogenesis\nof RA by the associations of its genetic polymorphisms\nwith disease susceptibility (41). Latent CMV infection\ndown-regulates HLA\u2013G expression (42), and decreasedlevels of soluble HLA\u2013G, in turn, could cause LIR-\n11CD81T cells in RA to become hyperactive.\nTaken together, our data suggest that the intricate\nnetwork and finely tuned crosstalk of UL18, HLA\u2013G, and\nclassic MHC class I molecules with LIR-1 is disturbedduring the course of a CMV infection in RA. As a conse-\nquence, deficiency of soluble HLA\u2013G might diminish the\ninhibitory effects of LIR-1 on CD8 1Tc e l l si nC M V -\npositive RA patients. LIR-1 1CD81T cells, in turn,\ncould also be involved in the pathogenesis of RA by con-\ntributing directly to chronic inflammation. The observed\nsignificant correlation of the frequency of LIR-1 1CD81\nT cells with disease activity strongly supports this hypothe-\nsis. At the same time, those cells might still be involved in\nthe immunologic control of the latent CMV infection,\nwhich illustrates possible unwanted side effects of immu-\nnosuppression in this disease.\nAUTHOR CONTRIBUTIONS\nAll authors were involved in drafting the article or revising it\ncritically for important intellectual content, and all authors approved\nthe final version to be published. Dr. Wagner had full access to all of\nthe data in the study and takes responsibility for the integrity of thedata and the accuracy of the data analysis.\nStudy conception and design. Rothe, Quandt, Pierer, Wagner.\nAcquisition of data. Rothe, Schubert, Rossol, Klingner, Jasinski-\nBergner, Scholz, Seliger, Pierer, Baerwald, Wagner.\nAnalysis and interpretation of data. Rothe, Quandt, Schubert, Seliger,\nWagner.REFERENCES\n1. Strioga M, Pasukoniene V, Characiejus D. CD8 1CD282and\nCD81CD571T cells and their role in health and disease.\nImmunology 2011;134:17\u201332.\n2. Akbar AN, Fletcher JM. Memory T cell homeostasis and senes-\ncence during aging. Curr Opin Immunol 2005;17:480\u20135.\n3. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C,\nRuchti F, et al. Broadly targeted human cytomegalovirus-specificCD41and CD8 1T cells dominate the memory compartments\nof exposed subjects. J Exp Med 2005;202:673\u201385.\n4. Chidrawar S, Khan N, Wei W, McLarnon A, Smith N, Nayak L,\net al. Cytomegalovirus-seropositivity has a profound influence onthe magnitude of major lymphoid subsets within healthy individ-uals. Clin Exp Immunol 2009;155:423\u201332.\n5. Snyder CM, Cho KS, Bonnett EL, van Dommelen S, Shellam\nGR, Hill AB. Memory inflation during chronic viral infection ismaintained by continuous production of short-lived, functional Tcells. Immunity 2008;29:650\u20139.\n6. Davis JM III, Knutson KL, Skinner JA, Strausbauch MA,\nCrowson CS, Therneau TM, et al. A profile of immune responseto herpesvirus is associated with radiographic joint damage inrheumatoid arthritis. Arthritis Res Ther 2012;14:R24.\n7. Pierer M, Rothe K, Quandt D, Schulz A, Rossol M, Scholz R,\net al. Association of anticytomegalovirus seropositivity with moresevere joint destruction and more frequent joint surgery in rheu-matoid arthritis. Arthritis Rheum 2012;64:1740\u20139.\n8. Davis JM, Knutson KL, Strausbauch MA, Green AB, Crowson\nCS, Therneau TM, et al. Immune response profiling in early rheu-matoid arthritis: discovery of a novel interaction of treatmentresponse with viral immunity. Arthritis Res Ther 2013;15:R199.\n9. Weitz M, Kiessling C, Friedrich M, Prosch S, Hoflich C, Kern F,\net al. Persistent CMV infection correlates with disease activityand dominates the phenotype of peripheral CD8 1T cells in\npsoriasis. Exp Dermatol 2011;20:561\u20137.\n10. Eriksson P, Sandell C, Backteman K, Ernerudh J. Expansions of\nCD41CD282and CD8 1CD282T cells in granulomatosis with\npolyangiitis and microscopic polyangiitis are associated with cyto-megalovirus infection but not with disease activity. J Rheumatol2012;39:1840\u20133.\n11. Lamprecht P, Vargas Cuero AL, Muller A, Csernok E, Voswinkel\nJ, Maass M, et al. Alterations in the phenotype of CMV-specificand total CD8 1T cell populations in Wegener\u2019s granulomatosis.\nCell Immunol 2003;224:1\u20137.\n12. Westman G, Berglund D, Widen J, Ingelsson M, Korsgren O, Lann-\nfelt L, et al. Increased inflammatory response in cytomegalovirusseropositive patients with Alzh eimer\u2019s disease. PLoS One 2014;9:\ne96779.\n13. Soderberg-Naucler C. Autoimmunity induced by human cyto-\nmegalovirus in patients with systemic lupus erythematosus. Arth-ritis Res Ther 2012;14:101.\n14. Anfossi N, Doisne J, Peyrat M, Ugolini S, Bonnaud O, Bossy D,\net al. Coordinated expression of Ig-like inhibitory MHC class Ireceptors and acquisition of cytotoxic function in human CD8 1\nT cells. J Immunol 2004;173:7223\u20139.\n15. Sayos J, Martinez-Barriocanal A, Kitzig F, Bellon T, Lopez-Botet\nM. Recruitment of C-terminal Src kinase by the leukocyte inhibitoryreceptor CD85j. Biochem Biophys Res Commun 2004;324:640\u20137.\n16. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J,\net al. A common inhibitory receptor for major histocompatibility\ncomplex class I molecules on human lymphoid and myelomono-cytic cells. J Exp Med 1997;186:1809\u201318.\n17. Monsivais-Urenda A, Noyola-Cherpitel D, Hernandez-Salinas A,\nGarcia-Sepulveda C, Romo N, Baranda L, et al. Influence ofhuman cytomegalovirus infection on the NK cell receptor reper-toire in children. Eur J Immunol 2010;40:1418\u201327.\n18. Northfield J, Lucas M, Jones H, Young NT, Klenerman P. Does\nmemory improve with age? CD85j (ILT-2/LIR-1) expression onCMV INFECTION AND INCREASED CYTOLYTIC T CELL NUMBERS IN RA 345CD8 T cells correlates with \u2018memory inflation\u2019 in human cyto-\nmegalovirus infection. Immunol Cell Biol 2005;83:182\u20138.\n19. Wagner CS, Walther-Jallow L, Buentke E, Ljunggren H, Achour A,\nChambers BJ. Human cytomegalovirus-derived protein UL18 altersthe phenotype and function of monocyte-derived dendritic cells.J Leuk Biol 2008;83:56\u201363.\n20. Saverino D, Fabbi M, Ghiotto F, Merlo A, Bruno S, Zarcone D,\net al. The CD85/LIR-1/ILT2 inhibitory receptor is expressed byall human T lymphocytes and down-regulates their functions.J Immunol 2000;165:3742\u201355.\n21. Young NT, Uhrberg M. KIR expression shapes cytotoxic reper-\ntoires: a developmental program of survival. Trends Immunol2002;23:71\u20135.\n22. Monsivais-Urenda A, Nino-Moreno P, Abud-Mendoza C, Bar-\nanda L, Layseca-Espinosa E, Lopez-Botet M, et al. Analysis of\nexpression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells frompatients with systemic lupus erythematosus (SLE). J Autoimmun\n2007;29:97\u2013105.\n23. Doniz-Padilla L, Paniagua AE, Sandoval-Correa P, Monsivais-\nUrenda A, Leskela S, Marazuela M, et al. Analysis of expressionand function of the inhibitory receptor ILT2 in lymphocytes\nfrom patients with autoimmune thyroid disease. Eur J Endocri-\nnol 2011;165:129\u201336.\n24. Martinez-Rodriguez JE, Saez-Borderias A, Munteis E, Romo N,\nRoquer J, Lopez-Botet M. Natural killer receptors distribution\nin multiple sclerosis: relation to clinical course and interferon-\nb\ntherapy. Clin Immunol 2010;137:41\u201350.\n25. Kuroki K, Tsuchiya N, Shiroishi M, Rasubala L, Yamashita Y,\nMatsuta K, et al. Extensive polymorphisms of LILRB1 (ILT2,\nLIR1) and their association with HLA\u2013DRB1 shared epitope\nnegative rheumatoid arthritis. Hum Mol Genet 2005;14:2469\u201380.\n26. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bing-\nham CO III, et al. 2010 rheumatoid arthritis classification crite-\nria: an American College of Rheumatology/European League\nAgainst Rheumatism collaborative initiative. Arthritis Rheum2010;62:2569\u201381.\n27. Rossol M, Schubert K, Meusch U, Schulz A, Biedermann B,\nGrosche J, et al. Tumor necrosis factor receptor type I expres-\nsion of CD4 1T cells in rheumatoid arthritis enables them to\nfollow tumor necrosis factor gradients into the rheumatoid syno-vium. Arthritis Rheum 2013;65:1468\u201376.\n28. Jasinski-Bergner S, Stehle F, Gonschorek E, Kalich J, Schulz K,\nHuettelmaier S, et al. Identification of 14-3-3\nbgene as a novel\nmiR-152 target using a proteome-based approach. J Biol Chem2014;289:31121\u201335.29. Karrer U, Sierro S, Wagner M, Oxenius A, Hengel H, Koszinowski\nUH, et al. Memory inflation: continuous accumulation of antiviral\nCD81T cells over time. J Immunol 2003;170:2022\u20139.\n30. Schmidt D, Goronzy JJ, Weyand CM. CD4 1CD72CD282T\ncells are expanded in rheumatoid arthritis and are characterizedby autoreactivity. J Clin Invest 1996;97:2027\u201337.\n31. Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Tanigu-\nchi K, et al. Migration of CX3CR1-positive T cells producing type1 cytokines and cytotoxic molecules into the synovium of patientswith rheumatoid arthritis. Arthritis Rheum 2002;46:2878\u201383.\n32. Fukada K, Sobao Y, Tomiyama H, Oka S, Takiguchi M. Func-\ntional expression of the chemokine receptor CCR5 on virusepitope-specific memory and effector CD8 1T cells. J Immunol\n2002;168:2225\u201332.\n33. Verbruggen LA, Rebmann V, Demanet C, de Cock S, Grosse-\nWilde H. Soluble HLA\u2013G in rheumatoid arthritis. Hum Immu-nol 2006;67:561\u20137.\n34. Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P,\nZehn D. T cell differentiation in ch ronic infection and cancer: func-\ntional adaptation or exhaustion ? Nat Rev Immunol 2014;14:768\u201374.\n35. Almehmadi M, Flanagan BF, Khan N, Alomar S, Christmas SE.\nIncreased numbers and functional activity of CD56 1T cells in healthy\ncytomegalovirus positive subje cts. Immunology 2014;142:258\u201368.\n36. Hertoghs KM, Moerland PD, van Stijn A, Remmerswaal EB, Yong\nSL, van de Berg PJ, et al. Molecular profiling of cytomegalovirus-induced human CD8 1T cell differentiation. J Clin Invest 2010;120:\n4077\u201390.\n37. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill\nBJ, Crotty LE, et al. Expression of CD57 defines replicativesenescence and antigen-induced apoptotic death of CD8 1T\ncells. Blood 2003;101:2711\u201320.\n38. Joshi NS, Kaech SM. Effector CD8 T cell development: a bal-\nancing act between memory cell potential and terminal differen-tiation. J Immunol 2008;180:1309\u201315.\n39. Weyand CM, Yang Z, Goronzy JJ. T cell aging in rheumatoid\narthritis. Curr Opin Rheumatol 2014;26:93\u2013100.\n40. Yang Z, Bjorkman PJ. Structure of UL18, a peptide-binding\nviral MHC mimic, bound to a host inhibitory receptor. Proc Natl\nAcad Sci U S A 2008;105:10095\u2013100.\n41. Veit TD, Vianna P, Scheibel I, Brenol CV, Brenol JC, Xavier RM,\net al. Association of the HLA\u2013G 14-b p insertion/deletion polymor-\nphism with juvenile idiopathic arthritis and rheumatoid arthritis.\nTissue Antigens 2008;71:440\u20136.\n42. Pizzato N, Garmy-Susini B, Le Bouteiller P, Lenfant F. Down-reg-\nulation of HLA\u2013G1 cell surface expression in human cytomegalo-virus infected cells. Am J Reprod Immunol 2003;50:328\u201333.346 ROTHE ET ALPeripheral CD4CD8 Double Positive T Cells with a\nDistinct Helper Cytokine Profile Are Increased in\nRheumatoid Arthritis\nDagmar Quandt, Kathrin Rothe, Roger Scholz, Christoph W. Baerwald, Ulf Wagner *\nClinics for Gastroenterology and Rheumatology, Division of Rheumatology, University of Leipzig, Leipzig, Saxony, Germany\nAbstract\nPeripheral CD4CD8 double positive (DP) T cells have been reported to play a role in several autoimmune diseases, virus\ninfections and cancer. In rheumatoid arthritis (RA), both CD4 and CD8 single positive (SP) T cells are known to be involved inthe pathogenesis, but the role of peripheral CD4CD8 DP T cells has not been investigated in detail. Anti cyclic citrullinated\nantibodies (ACPA) positive and ACPA negative RA patients, patients with systemic lupus erythematodes (SLE) and age\nmatched healthy donors (HD) were enrolled in the analysis. The frequencies and phenotype of DP T cells in PBMC wereinvestigated. In addition, DP T cells were quantified in biopsies from rheumatoid synovium. After in vitro restimulation, thecytokine production of DP T cells was investigated in cultures of PBMC. CMV specific cytokine secretion as well as\nproliferation was analyzed following antigen specific restimulation after an appropriate culture duration. DP T cells were\nfound more frequently in RA patients than in healthy controls or patients with SLE. These DP T cells express abTCRs, are of a\nmemory phenotype and share features of both CD4 as well as CD8 SP T cells. Importantly, DP T cells were found to also bepresent in the rheumatoid synovium. Further characterization of DP T cells from RA patients revealed increased production\nof IL-21 and IL-4, implying a possible role as T helper cells. In addition, DP T cells in RA seem to contribute to the\ninflammatory process, because they produce significantly more IFN cthan counterparts from HD and are increased in CMV +\nRA patients. Given their capacity to produce a variety of cytokines (IL4, IL21 and IFN c), their association with ACPA positive\nRA and their presence in the synovium, we suggest an important role of double positive T cells in the pathogenesis of\nrheumatoid arthritis.\nCitation: Quandt D, Rothe K, Scholz R, Baerwald CW, Wagner U (2014) Peripheral CD4CD8 Double Positive T Cells with a Distinct Helper Cytokine Profile Are\nIncreased in Rheumatoid Arthritis. PLoS ONE 9(3): e93293. doi:10.1371/journal.pone.0093293\nEditor: Oliver Frey, University Hospital Jena, Germany\nReceived November 9, 2013; Accepted March 3, 2014; Published March 25, 2014\nCopyright: /C2232014 Quandt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits\nunrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.\nFunding: This study was supported by the German Research Foundation (WA 2765/3-1). The author(s) acknowledge support from the German Research\nFoundation (DFG) and Leipzig University within the program of Open Access Publishing. The funders had no role in study design, data collection and ana lysis,\ndecision to publish, or preparation of the manuscript.\nCompeting Interests: The authors declare that they have no competing interest.\n* E-mail: ulf.wagner@medizin.uni-leipzig.de\nMaterials and Methods\nPatients and Healthy Individuals\nA total of 59 RA patients according to the 2010 EULAR/ACR\ncriteria (female: 46, male: 13, mean age 59.4 years, range 34\u201379years) were recruited, among them 39 ACPA\n+and 20 ACPA2\npatients. 39% of the RA patients were treated with biologicals incombination with conventional standard therapy. Sex and agedistribution in ACPA\n+versus ACPA2patients was similar. In\naddition, 8 SLE patients (all female, mean age 44.3 years, range21\u201354 years) were included. Blood of 36 HD (female: 21, male: 15,mean age of 57.1 years, range 25\u201371 years) who never hadevidence of a chronic inflammatory disorder were recruited ascontrols. The 4 RA patients undergoing knee surgery (2 male, 2female) were all ACPA\n+.\nEthics Statement\nWritten consents were obtained from all patients and healthy\ndonors. The local ethics committee of the University of Leipzigapproved the study.Antibodies and Reagents\nRPMI 1640 was from Lifetechnologies. X-Vivo15 media was\nsupplied by Lonza. aCD3, aCD4, aCD8 (recognizing the achain),\naCD28, aCD45RO, aCD56, aCCR7, a-IL17, aTCR a24-Ja18\n(clone: 6B11), cytokine secretion assays for IFN cand IL-4, a-\nfibroblast microbeads and Cytostim were purchased fromMiltenyi. Collagenase, Hyaluronidase and DNAse were all fromSigma-Aldrich. aCD45 and aCD38 were from Immunotools.CFDA-SE was purchased from Molecular Probes/Invitrogen.Intra staining Kit, aCD16, aCD8 band aCD3 were from Beckton\nDickinson. aCXCR5 was supplied by R&D Systems and aIL21was from ebioscience. The Beta Mark TCRV bRepertoire Kit was\nsupplied by Beckman Coulter. The antibodies were used indifferent conjugates of FITC, PE, PerCp, APC, APC-Vio770 andPE-Cy7.\nPBMC Generation and FACS Analysis ex vivo\nPBMCs were isolated from EDTA whole blood or buffy coats.\nPlasma was always discarded from whole blood samples prior toFicoll-gradient for PBMCs isolation. Subsequently a erythrocytelysis step with lysis-buffer was applied. Cells were stained with\nPLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e93293\ndifferent antibodies and kept on ice throughout the assay. Live Cell\nanalysis (use of PI) with doublet exclusion (LSR II) were performed\non a FACS CaliburTMor a LSR II (both Beckton Dickinson)\nusing Cellquest, FACS DIVA and FlowJo software.\nCMV Specific Cytokine Production and Proliferation\nThese assays were performed as described recently. [1] In brief,\n16106PBMC were CFDA-SE labeled and cultured for 7 days\n(proliferation) or left unlabeled and cultured for 4 hrs (2 6106,\nIFNcsecretion) in the presence of CMV lysate/control lysate\n(Microbrix Biosystems Inc) of 3 mg/ml in 24-well plates in X-\nVIVO 15 medium.\nShort Term Culture and Staining for Cytokine Analysis\nPBMCs were cultured in X-Vivo 15 supplemented with 1% of\neach glutamin and penicillin/streptomycin in a density of 5 6106\nfor cytostim (1:50) or 3 6106for PMA (20 ng/ml and Ionomycin\n(0.5mg/ml). Culture time was 4 hrs for both and Monensin\n(2mM) was added to the last 3 hrs of PMA/Ionomycin cultures.\nCytokines were either detected with cytokine secretion assays\n(IFN- cand IL-4) following the manufactures protocol by Miltenyi\nor by intracellular staining (IL-21 and IL-17) using an intra\nstaining Kit.\nTissue Digestions and Leucocyte Extraction\nSynovial biopsies from RA patients undergoing surgery were\nobtained and leucocyte isolation was performed as follows. Tissue\nwas cut into pieces and incubated with an enzyme solution\n(collagenase, hyaluronidase, DNAse in RPMI) for 90 min and 37 u\nunder constant rotation. Single cell suspension was obtained using\ngauze and smooth mechanical disruption of digested tissue.\nSubsequently cells were sorted for non-fibroblasts using anti-\nfibroblast microbeads from Miltenyi. Non-fibroblast were used for\nFACS analysis and CD45 staining was used additionally to other\nantibodies in order to discriminate non-leucocytes.\nStatistics\nStatistical evaluation was performed using Prism version 3.0cx\nsoftware. Mann-Whitney test, unpaired student\u2019s t-test and\ncorrelation analysis with spearmen were applied.\nIntroduction\nPeripheral CD4CD8 double positive (DP) T cells have first been\nidentified more than 20 years ago. Like their progenitors in the\nthymus, they express the coreceptors CD4 and CD8 simulta-\nneously, but in contrast to immature double positive thymocytes,\nthey show varying degrees of coreceptor expression, and display a\nmemory phenotype but no markers of recent thymic emigrants [2\u2013\n4]. DP T cells can be found in the blood of healthy individuals\nwhere they account for about 1% of all T cells within PBMCs, but\nare also present in the skin of melanoma patients and in systemic\nsclerosis [5,6]. During the cause of severe virus infections such as\nHIV and Hepatitis, increased frequency of DP T cells have been\ndescribed, which are Ag-specific and of high effector potential.\n[2,7]. DP T cells can provide B cell help both by production of\nappropriate cytokines and by cell contact due to their T helper like\nphenotype [5,6], but they can also acquire killer like capacity [7,8].\nIn rheumatoid arthritis, CD4 +Th cells play a pivotal role in the\npathogenesis, as indicated by numerous genetic associations of the\ndisease with polymorphisms in T cell related genes as well as bythe clinical efficacy of CD28 co-stimulation [10] and CD4 co-\nreceptor blockade [9] [11]. The peripheral CD4 +T cell pool in\nRA is characterized by several alterations including a paucity ofna\u0131\u00a8ve T cells and recent thymic emigrants, an increased memory\npool and a global loss of T cell receptor diversity accompanied by\nlarge clonal expansions [12,13].\nB cell autoreactivity is also essential in RA pathogenesis, as\nindicated by autoantibody production and by the clinical efficacy\nof B cell depletion [14]. The T cell help required for this has been\nsuggested to involve CD40-CD40L interactions [15], but addi-\ntionally other receptors such as BAFF-R [16] have been identifiedmore recently. The result is the production of disease relevant\nautoantibodies like anti-citrullinated peptide antibodies (ACPA),\nanti-RA33, RF and others. ACPA positive RA in particular hasbeen associated with more severe joint destruction [1], frequent\nextraarticular manifestations and enhanced subclinical artherio-\nsclerosis [17].\nA possible role of CD4CD8 DP T cells in the pathogenesis of\nRA has not been investigated.\nHere we report, that CD4CD8 double positive T cells are\nexpanded in the peripheral blood in ACPA\n+RA and can also be\nfound in the rheumatoid synovium. DP T cells in RA showfeatures of T helper cells by the production of IL-4 and IL-21.\nInterestingly, CMV\n+RA patients show increased frequencies of\nthese cells and their number correlates positively with CMVspecific IFN cproducers. In line with this, a high number of these\ncells have lost the CD28 costimulator and DP T cells of RA\npatients show higher amounts of IFN cproducers than HD\ncounterparts. Our data are the first demonstrating a role for\nCD4CD8 double positive T cells in RA.\nResults\nACPA+RA Patients have Increased Frequencies of\nPeripheral DP T cells\nTotal CD4CD8 DP T cells were quantified as percentage of\ntotal CD3+T cells in PBMC, and three subpopulations\n(CD4hiCD8lo, CD4hiCD8hiand CD4luCD8hi) according to the\nlevel of coreceptor expression could be distinguished as shown in\nfigure 1A. CD4hiCD8loDP T cells are the most prominent of the\nDP cell populations and were found to be significantly more\nfrequent in PBMC from ACPA positive RA patients when\ncompared to healthy controls, SLE patients or ACPA negativeRA patients (mean%: RA ACPA\n+1.93, RA ACPA21.07, HD\n1.24 and SLE 0.58, figure 1B). Total frequencies of CD4CD8 DP\nT cells were also higher in ACPA positive than in ACPA negativepatients (figure 1C). The total CD4CD8 DP population will be\nused in all subsequent displays throughout the manuscript, unless\notherwise stated. In the RA patient population no influence of ageon the frequency of DP T cells was discernible (figure 1 D). Such a\ncorrelation was demonstrated for healthy individuals by others\n[18] and was also found in our own data for HD. (data not shown)A trend towards a further decrease of DP T cells in SLE patients\ncompared to age matched controls did not reach statistical\nsignificance.\nDP T cells in RA Belong to the Memory Pool of TCR abT\ncells and Display No Marker of iNKT cells\nThe previously described expansion of the memory pool in RA\npatients [12] was apparent in the analysis of CD4 SP T cells, 70%\nof which had a central memory phenotype characterized by\nexpression of CD45RO and CCR7 (figure 2A). In agreement withprevious reports [2,7], the majority of CD4CD8 DP T cells was\nalso found to belong to the memory pool (87.9%). Analysis of\nCD45RO and CCR7 expression identified 58.4% as central\nmemory cells (see figure 2A) and 29.5% as effector memory cells.Double Positive T Cells in RA\nPLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e93293The described spectrum of memory markers on DP T cells from\nRA patients did not differ from healthy controls (data not shown).\nWith regards to activation markers, DP T cells did not differ\nfrom CD4 and CD8 SP cells in their expression of CD38.Expression of the T cell activation marker HLA-DR [19],however, was found on DP T cells more frequently than onCD4 SP cells, but less frequently than on CD8\n+SP lymphocytes\n(figure 2B). In healthy donors, in contrast, HLA-DR expression onDP T cells did not differ from that of CD4 SP T cells (data notshown. CD56, which can also serve as activation marker for Tcells [34], was also found significantly more frequently on DP Tcells than on CD4 SP T cells (figure 2D). Other markers associatedwith activation/regulation like CD69 and CTLA-4 were not\nexpressed on DP T cells (data not shown).\nIn peripheral blood from RA patients, CD4CD8 DP T cells\nexpressed almost exclusively (99,3%) abT cell receptors, which\nwas comparable to CD4 SP T cells (99,3%, figure 2 C). DP T cellswere not chT cells (data not shown). Distribution of abandch\nTCR expression in the T cell subpopulations was similar in HD(data not shown). In accordance with previous reports [35],CD4\nhiCD8loDP T cells in RA do not express abCD8\nheterodimers but aahomodimers, whereas CD8 SP cells are\nalmost exclusively CD8 abpositive (figure 2C).\nDP T cells in HD have been described to partially belong to a\npopulation of T cells with NK phenotype, called NKT cells. [4]\nFigure 1. Increased frequencies of peripheral CD4CD8 DP T cells in ACPA+rheumatoid arthritis patients. PBMC were isolated from RA\npatients (ACPA+, n = 37, ACPA2, n = 20), healthy donors (n = 36), and patients with SLE (n = 8), and FACS analyses from live cells (PI staining used for\nexclusion of dead cells) were performed. Analyses for CD4CD8 double positive T cells are always pregated on CD3 positive T cells. A)Representative\nFACS plot from one RA patient, showing CD4CD8 double positive T cells, R1 = CD4hiCD8lo, R2 = CD4hiCD8hiand R3 = CD4luCD8hiB)Comparison of\nfrequencies of CD4hiCD8loT cells in PBMCs of ACPA+/2RA, HD and SLE patients. C)Total CD4CD8 DP T cells in ACPA+(n = 19) and ACPA2(n = 20) RA\npatients. D)Correlation analysis for frequencies of CD4hiCD8loT cells with age in ACPA+RA patients. Box plots depict median, interquartile range and\n10\u201390 percentile. Significance as given, *p ,0.05, **p ,0.01.\ndoi:10.1371/journal.pone.0093293.g001Double Positive T Cells in RA\nPLOS ONE | www.plosone.org 3 March 2014 | Volume 9 | Issue 3 | e93293To determine a possible NKT cell phenotype of DP T cells in RA,\nwe used an antibody recognizing the TCRV a24-Ja18:Vb11,\ndescribed for invariant iNKT cells, and a combination of anti-CD16 together with anti-CD56 to check for non-invariant NKTcells. The frequency of iNKT cells was not significantly increasedin the DP fraction (0.59% 60.13) when compared to CD4 SP or\nCD8 SP cells (0.31% vs. 0.32%) (figure 2D). Frequencies of CD16\n+\ncells were low but were significantly increased in DP T cells\n(4.8%61.1) when compared to CD4 SP cells (figure 2D). Co-\nstaining of CD56 and CD16 on DP T cells revealed the presenceof some infrequent (2.4% 60.47) CD16\n+CD56+cells which\npossibly fall into the category of non-invariant NKT cells (datanot shown).\nTo investigate the TCR repertoire used by DP T cells of RA\npatients, we performed FACS analysis using 24 differentantibodies recognizing a broad range of TCR BV chains. TheBV usage within DP T cells of 10 RA patients is divers and doesnot differ significantly from CD4 SP or CD8 SP. (figure 3A) 5patients showed a substantial overrepresentation of individual BVelements (BV2, BV17 and/or BV21.3) (representative examplesgiven in figure 3B), possibly indicating antigen-driven clonal\nexpansion.\nDP T cells are Present in the Synovial Tissue and Display\nFeatures of T helper Cells\nThe target organ in rheumatoid arthritis is the synovium.\nTherefore we were interested in identifying DP T cells in thesynovium of inflamed joints. As demonstrated in figure 4A we dofind CD4CD8 double positive T cells (pregated on CD3\n+T cells)\nin the synovium (mean: 2.5%). Of note, the same RA patients alsoshowed CD19\n+B cells in the synovium (figure 3A).\nTo explore the potential of CD4CD8 DP T cells to provide B\ncell help, the CXCR5 expression was analyzed, since thischemokine receptor has been described to be present on severalsubpopulation of T follicular helper (Tfh) cells, although withvarying support for antibody secretion [20]. The results showedthat DP T cells from RA patients can express CXCR5, althoughthe fraction of CXCR5 positive cells is higher in CD4 SP than inCD4CD8DP cells (mean: 9.5% vs. 4.1.%, p = 0.03, figure 4B).\nFigure 2. Phenotypic characterization of CD4CD8 DP T cells in RA patients. PBMC from RA patients were isolated and FACS analyses from\nlive cells were performed (PI staining used for exclusion of dead cells). CD3 pregated cells were further gated on CD4 single, CD8 single and on\nCD4CD8 double positive T cells. A)Distribution of CD45RO2CCR7+(naive) CD45RO+CCR72(effector memory) and CD45RO+CCR7+(central memory)\ncells in the cell populations indicated. n = 5 5 B)Percentage of T cells positive for CD38 (n = 10) and HLA-DR (n = 11). C)Percentage of cells bearing a\nTCR alpha-beta (n = 10) and cells positive for CD8 b(n = 9) in the T cell populations indicated. ( D)Percentage of cells positive for CD16 (n = 10), CD56\n(n = 15) and for TCRV a24-Ja18 (n = 11, marker for iNKT) in the T cell populations indicated. In all graphs, lines represent means and SEM. Significance\nas given, *p ,0.05, **p ,0.01, ***p ,0.001.\ndoi:10.1371/journal.pone.0093293.g002Double Positive T Cells in RA\nPLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e93293Similar frequencies were found in DP T cells from healthy\nindividuals (mean 5.1%, data not shown).\nAs functional and possibly more specific markers of Tfh cells,\nthe ability to secrete IL-4 and IL-21 following restimulationin vitro was determined, since both cytokines are required for Bcell help [20,21]. Determination of IL-4 secretion of DP T cellsupon in vitro short term restimulation with Cytostim showed asubstantial fraction of them to produce IL-4 (figure 4C). Impor-tantly, this percentage of IL-4 producers was significantly higher inRA patients than in healthy controls (mean: 1.99% vs. 0.71%,p = 0.0006).\nMost importantly, however, a large fraction of DP cells (15\u2013\n19%) was found to produce IL-21, compared to only 2% of CD4SP T cells (figure 4D). No difference between the IL-21 productionof DP T cells from healthy donors compared to those from RApatients was detectable (figure 4D).\nDP T cells in RA Preferentially Produce IFN cbut not IL-17\nSeveral abnormal T cell subpopulations are pathogenetically\nrelevant in RA, among them Th17 cells and IFN cproducers [22\u2013\n24]. Using cytokine secretion assays as well as intracellular FACSanalysis, IFN cand IL17 expression was determined in vitro after\nshort term restimulation with the MHC-TCR crosslinker Cytostim(IFNc) or with PMA/Ionomycin (IL-17). Frequencies of cytokine\nproducers were calculated as percentage of total CD4CD8 DP Tcells, since cytokine expression was not restricted to a particularsubpopulation (CD4\nhiCD8loor CD4luCD8hi) of DP T cells.\nIn RA patients, significantly more DP T cells produced IFN c\nthan CD4 SP or CD8 SP T cells (mean 21.1% vs. 3.9% or 12.7%,p = 0.0001 and p = 0.012, respectively) (figure 5A). In HD, incontrast, there was no significant difference in the percentage ofIFNcproducers between the 3 different T cell populations (CD4\nor CD8 SP and DP T cells, data not shown). Most importantly, thefrequency of IFN cproducing DP T cells in RA patients\nsignificantly exceeds the frequency found in HD (11.4%)(figure 5A).\nResults for IL-17 were less conclusive. IL-17 was mainly\nproduced by CD4 SP T cells, and not by CD8 SP or DP positive Tcells (figure 5B). Nevertheless, a trend towards higher IL-17production was seen in CD4 SP T cells from RA patientscompared to CD4 SP from HD T cells (figure 5B).\nFigure 3. TCR BV distribution in CD4CD8 double positive T cells of RA patients. PBMC from RA patients were isolated and FACS analyses\nfrom live cells were performed (PI staining used for exclusion of dead cells). CD3 pre-gated cells were further gated on CD4 single, CD8 single and on\nCD4CD8 double positive T cells. Bar charts depict the percentage of cells positive for each BV element in the indicated T cell subpopulations\ninvestigated. A)Mean distribution of 24 TCR BV elements in peripheral blood T cells from 10 RA patients. B)Examples of the individual distribution of\n24 TCR BV elements in 4 RA patients.doi:10.1371/journal.pone.0093293.g003Double Positive T Cells in RA\nPLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e93293DP T cells are more Frequent in Latent CMV Infection and\nCorrelate with the Occurrence of CMV Specific Cytokine\nProducers\nLatent CMV infection in rheumatoid arthritis is associated with\na more severe cause of joint destruction, as published recently byour group and others [1,17]. This association was limited to ACPApositive RA. Based on the observed increase of DP T cells inACPA positive RA, which are readily able to produce IFN cin\nresponse to polyclonal stimuli, we decided to stratify the patients\naccording to the presence or absence of anti-CMV IgG antibodiesin the serum. The results showed significantly higher frequenciesof CD4\nhiCD8loDP positive T cells, in anti-CMV IgG positive RA\npatients compared to CMV2patients (mean 1.81% vs 0.71%,\np = 0.007, figure 6A). This difference remained significant, if theanalysis was restricted to ACPA positive patients only (mean2.27% vs. 1.55%, p = 0.039). Interestingly, the highest frequenciesof CD4CD8 DP T cells (mean%: 2.27) were found in patientssimultaneously positive for anti-CMV IgG and ACPA (data notshown).CD4\n+CD28nullT cells are increased in RA patients and\nassociated with a more severe course of the disease [13,25]. Inaddition, they are known to occur in the course of a latent CMVinfection both in RA patients and in healthy controls. Therefore,the frequency of CD4\n+CD28nullT cells was determined in the RA\npatients and found to correlated with the percentages of totalCD4CD8 DP T cells (figure 6B). This correlation was restricted toACPA\n+RA patients and was not present in ACPA negative\npatients. Furthermore, DP T cells were found to preferentiallyhave lost CD28 expression (mean%: 19,4, n = 13) in ACPApositive RA patients when compared to CD4 SP (mean%: 1.97) Tcells, while the frequency of CD28 negative cells was even higherin CD8 SP (mean%: 33) T cells (figure 6B).\nFinally, in order to investigate the CMV response, we\nrestimulated (4 hrs) PBMC from anti-CMV IgG seropositive RApatients with CMV lysate or control lysate and determined theCMV specific IFN cproduction of CD4 SP T cells and CD4CD8\nDP T cells by cytokine secretion assay. The frequency of CMVspecific IFN cproducers was found to correlate with the\nfrequencies of total CD4CD8 DP T cells in CMV\n+RA patients\nFigure 4. CD4CD8 double positive T cells are present in the synovium of RA patients and produce T helper 2 like cytokines. A) Single\ncell suspensions were prepared from synovial biopsies from RA patients (n = 4) and analyzed by flow cytometry using anti-CD19, anti-CD3, anti-CD4and anti-CD8 monoclonal antibodies (PI staining used for exclusion of dead cells). Representative FACS plots are depicted. Each data point represen ts\none experiment. B)PBMCs from RA patients (n = 6) were isolated and FACS analysis from live cells were performed (PI staining used for exclusion of\ndead cells). Cells were pre-gated on CD3+T cells, and CXCR5 expression was analyzed in the subpopulation indicated. C)PBMC were stimulated\nin vitro for 4 hrs with Cytostim. Subsequently, an IL-4 specific secretion assay was performed, and expression of CD4 and CD8 was determined in vital\ncells (PI staining used for exclusion of dead cells) pre-gated on CD3. Percentage of IL-4 producing CD4CD8 double positive T cells in HD (n = 7) and RApatients (n = 8) is given. D)PBMCs from HD (n = 4) and RA (n = 4) were stimulated with PMA/Iono for 4 hrs, and intracellular staining for IL-21 was\nperformed. Cells are counterstained with anti-CD3, anti-CD4 and anti-CD8. Depicted is the percentage of cytokine producers in total CD4CD8 DP Tcells and in CD4 SP cells. Box plots in C) and D) show median, interquartile range, and 10\u201390 percentiles. Significance as given, *p ,0.05.\ndoi:10.1371/journal.pone.0093293.g004Double Positive T Cells in RA\nPLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e93293(figure 6C). Interestingly, the CMV specific IFN cresponse of\nCD4CD8 DP T cells from RA patients was significantly higher(2.09) than in HD (0.67) (figure 6D). The antigen-induced, CMVspecific proliferation of CD4 SP T cells, in contrast, did notcorrelate with the frequency of DP T cells (figure 6E).Discussion\nThe study was conducted to investigate a possible role for\nperipheral CD4CD8 double positive T cells in the pathogenesis ofrheumatoid arthritis.\nThe results show, that in RA patients, a significant number of\nmature T cells are indeed double positive for both co-receptors,\nFigure 5. CD4CD8 double positive T cells from RA patients produce inflammatory IFN c.PBMC from RA and HD were stimulated in vitro\nfor 4 hrs with Cytostim (A) or PMA/Iono (B). Subsequently, cytokine specific secretion assays (A) or intracellular stainings (B) were performed and c ells\nwere counterstained with anti-CD3, anti-CD4 and anti-CD8. Flow cytometric cytokine analysis were performed on live cells for IFN csecretion (PI\nstaining used for exclusion of dead cells) or on fixed cells for intra-cellular staining for IL-17, in each case after pre-gating on CD3+T cells. A)\nPercentage of IFN cproducing T cells in samples from rheumatoid arthritis patients (n = 12, left panel and grey box in the right panel) and healthy\ndonors (n = 13, clear box in the right panel) among CD4 SP, CD8 SP and CD4CD8 DP T cells. B)Percentage of IL-17 producing CD4 SP and CD4CD8\ndouble positive T cells from RA patients (n = 4) and HD (n = 4). Presented box plots show median, interquartile range, and 10\u201390 percentiles.Significance as given, *p ,0.05, **p ,0.01, ***p ,0.001.\ndoi:10.1371/journal.pone.0093293.g005Double Positive T Cells in RA\nPLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e93293CD4 and CD8. Those cells, which can also be found in healthy\nindividuals \u2013 although in significantly lower numbers \u2013 preferen-tially display a memory phenotype, and have been reported tobear no markers of na\u0131 \u00a8ve T cells or recent thymic emigrants [3]\nwhich makes it unlikely that they escaped from the thymus asdouble positive cells.\nInstead, their co-receptor expression pattern with higher CD4\nthan CD8 expression, and the fact that CD4\nhiCD8loare the most\nprominent DP T cell subpopulation, as well as the generallypresumed pivotal role of CD4 +MHC class II restricted T\nlymphocytes in RA, suggests that those cells were originally CD4SP T cells, which gained expression of the second co-receptorCD8. De novo CD8 expression in CD4\n+T cells under the\ninfluence of cytokines like IL-4 has already been described decadesago [26], but the paucity of IL-4 typically found in RA, makessuch cytokine driven CD8 expression as an explanation for theemergence of DP T cells in RA less likely. Nevertheless, theincreased IL-4 production of DP T cells in RA may sustain theirCD8 expression in an autocrine manner.Two new studies published very recently offer an alternative\nexplanation, since they have identified defined transcriptionprograms which can initiate CD8 gene expression in CD4 SP Tcells, for example the silencing of the transcription factor Thpok[27,28] The precise mechanism underlying the emergence of DPT cells in RA remains to be determined, however.\nIncreased numbers of double positive T cells were detectable\nonly in ACPA positive and not in ACPA negative RA patients.This suggests their involvement in the autoreactive T cell helpprovided for auto-reactive, antibody producing B cells in thisdisease. In line with this, a fraction of the double positive T cellswas found to express the typical marker of T follicular helper cells,CXCR5. The percentage of CXCR5 positive cells amongstdouble-positive T cells was lower, however, than their percentageamongst CD4 SP T cells, which argues against a preferential roleof DP T cells as TfH cells. Nevertheless, a proportion of DP T cellsmight provide B cell help, especially by their production ofcytokines with a role in T-B cell collaboration, in particular of IL-21. The site for this B cell help could be non classical follicular\nFigure 6. Frequencies of CD4CD8 double positive T cells are increased in CMV positive RA patients and correlate with CMV specific\nINFcproducers. A) PBMC were isolated from CMV+RA patients (n = 28) and CMV2RA patients (n = 12) and analyzed by flow cytometry using anti-\nCD19, anti-CD3, anti-CD4 and anti-CD8 monoclonal antibodies (PI staining used for exclusion of dead cells). B)Correlation of the frequency of total\ndouble positive T cells with CD4+CD28nullT cells in ACPA+RA patients (left graph) and comparison of frequencies of CD28nullcells among CD4 SP,\nCD8 SP and total DP T cells (right graph). C\u2013D) PBMCs were restimulated with CMV-lysate for 4 hrs in vitro. Subsequently, an INF cspecific secretion\nassay was performed and cells were counterstained with aCD3, aCD4 and aCD8. Flow cytometric cytokine analyses were performed on live cells (PIstaining used for exclusion of dead cells) pre-gated on CD3+T cells. C)Depicted is the correlation of CMV specific INF cproducing CD4 T cells with the\nfrequencies of CD4CD8 DP cells from the same donor (n = 16). D)CMV specific INF cproducing CD4CD8 DP T cells from RA (n = 5) and HD (n = 5) are\nshown. E)PBMCs were labeled with CFDA-SE and restimulated with CMV-lysat (n = 13) for 7 d in vitro. Depicted is the correlation of CMV specific CD4\nT cell proliferation with the frequencies of CD4CD8 DP cells from the same donor. Presented box plots show median, interquartile range, and 10\u201390percentiles. Significance as given, *p ,0.05, **p ,0.01, ***p ,0.001.\ndoi:10.1371/journal.pone.0093293.g006Double Positive T Cells in RA\nPLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e93293centers, which are found in the synovium of a sizable fraction of\nRA patients. [29,30].\nRA patients with ACPA positive disease have a more severe\ncourse of the disease with extra-articular manifestations and\nincreased subclinical arteriosclerosis compared to ACPA- patients\n[17]. The increased frequency of CD4CD8 DP T cells in our study\nin ACPA positive RA might reflect the more pronounced immune\ndeviations in those patients and indicates that those cells might be\ninvolved in the destructive immune response in this disease.\nPhenotypic characterization of DP T cells in RA reveals them to\nbeabT cells of a memory phenotype. Similar characteristics have\nbeen published for DP T cells in healthy donors [3].\nNK T cells have received increasing attention in autoimmunity\nresearch recently. DP T cells in RA are not invariant NKT cells,\nbut a small fraction was positive for markers for non-invariant\nNKT cells. This is in contrast to published data [4] for HD and\nmight indicate a pathogenetically relevant, disease specific role of\nDP T cell subpopulations in RA. Furthermore, TCR BV analysis\nreveals an overrepresentation of individual BV elements (BV2,\nBV17 and/or BV21.3) in DP T cells of some RA patients, possibly\nindicating antigen-driven clonal expansion.\nDP T cells are present in the rheumatoid synovium. In addition,\nour results show that a high percentage of DP T cells have lost\nexpression of the ubiquitous costimulatory molecule CD28, and\nthat their frequency is increased in CMV+RA patients.\nCD4+CD28nullSP T cells are found in 25\u201370% of RA patients\nand are associated with a more severe course of the disease\n[13,25,31]. Recently, we reported CMV+RA to be associated with\na more severe course of joint destruction [1], and latent CMV\ninfection is known to lead to an expansion of CD4+CD28nullT\ncells both in RA patients and in healthy individuals.\nThe present study showed enhanced frequencies of DP T cells\nin CMV+RA. Recently, we reported an increased CMV specific\nIFNcproduction in RA compared to CMV+healthy controls. [1]\nFurthermore, the frequency of DP T cells in the present study was\nfound to correlate with the frequency of CD4+CMV specific IFN c\nproducers. Interestingly, a low but significant fraction of CD4 SP\nT cells, and even higher frequencies of the DP T cells in RA do\nproduce CMV specific IFN c, more frequently though than T cells\nfrom HD. This is in line with virus specific DP T cells described inHIV patients [7]. Taken together, those results suggests that DP T\ncells are at least in part the results of the same RA specific, CMV\ntriggered perturbation in the peripheral T cell pool, which also\nleads to the occurrence of CD4+CD28nullT cells. A CMV specific\nenhanced effector response for DP T cells has already been found\nin HD [8] and DP T cells are therefore likely also to be involved in\nthe enhanced CMV response in RA.\nIndependently of CMV specificity, we found DP T cells to\nproduce high amounts of IFN c, but no IL-17, upon polyclonal\nstimulation. IFN cis a key cytokine driving the autoimmune\nresponse in RA [23,32]. DP T cells in healthy, aging individuals\nare known to be capable of producing IFN cupon polyclonal\nrestimulation [33]. CD28 negative Th cells in RA have also been\nshown to secrete IFN cupon autoreactive stimulation, and in line\nwith this, the DP T cells in RA are also preferentially CD28\nnegative. Therefore, CD4CD8 DP T cells in RA seem to be part\nof the pathological T cell pool characterized by replicative\nexhaustion, aberrant IFN cproduction and phenotypic alterations\nincluding the loss of the ubiquitous co-stimulatory molecule CD28.\nDP T cells might be the result of a differentiation program set inplace in terminally differentiated memory Th cells, that is switched\non under conditions associated with immunosenescence, including\nthe memory inflation observed in latent CMV infection or the\nchronic autoimmune response in rheumatoid arthritis.\nConclusion\nIn summary, we are the first to demonstrate increased\nfrequencies of peripheral CD4CD8 double positive T cells in\nACPA positive RA.\nDP T cells are present in the inflamed synovium. These cells\ndisplay features of T helper cells by the production of IL-4 and IL-\n21. Furthermore, the production of IFN c, loss of CD28 and the\nassociation with CMV positive RA imply a functional contribution\nto the pathogenesis of the disease.\nAuthor Contributions\nConceived and designed the experiments: DQ UW. Performed the\nexperiments: DQ KR. Analyzed the data: DQ KR. Contributed reagents/\nmaterials/analysis tools: RS CB. Wrote the paper: DQ UW.\nReferences\n1. Pierer M, Rothe K, Quandt D, Schulz A, Rossol M et al. (2012) Association of\nanticytomegalovirus seropositivity with more severe joint destruction and more\nfrequent joint surgery in rheumatoid arthritis. Arthritis Rheum 64(6): 1740\u2013\n1749.\n2. Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B et al. (2004)\nPeripheral CD4( +)CD8( +) T cells are differentiated effector memory cells with\nantiviral functions. Blood 104(2): 478\u2013486.\n3. Parel Y, Chizzolini C (2004) CD4 +CD8+double positive (DP) T cells in health\nand disease. Autoimmun Rev 3(3): 215\u2013220.\n4. Zloza A, Al-Harthi L (2006) Multiple populations of T lymphocytes are\ndistinguished by the level of CD4 and CD8 coexpression and require individual\nconsideration. J Leukoc Biol 79(1): 4\u20136.\n5. Desfrancois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A et al. (2010)\nDouble positive CD4CD8 alphabeta T cells: a new tumor-reactive population inhuman melanomas. PLoS One 5(1): e8437.\n6. Parel Y, Aurrand-Lions M, Scheja A, Dayer JM, Roosnek E, et al. (2007)\nPresence of CD4 +CD8+double-positive T cells with very high interleukin-4\nproduction potential in lesional skin of patients with systemic sclerosis. Arthritis\nRheum 56(10): 3459\u20133467.\n7. Frahm MA, Picking RA, Kuruc JD, McGee KS, Gay CL et al. (2012) CD4 +\nCD8+T cells represent a significant portion of the anti-HIV T cell response to\nacute HIV infection. J Immunol 188(9): 4289\u20134296.\n8. Suni MA, Ghanekar SA, Houck DW, Maecker HT, Wormsley SB et al. (2001)\nCD4( +)CD8(dim) T lymphocytes exhibit enhanced cytokine expression,\nproliferation and cytotoxic activity in response to HCMV and HIV-1 antigens.\nEur J Immunol 31(8): 2512\u20132520.\n9. Scheerens H, Su Z, Irving B, Townsend MJ, Zheng Y et al. (2011)\nMTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatmentof patients with rheumatoid arthritis: a phase I randomized, double-blind,\nplacebo-controlled study incorporating pharmacodynamic biomarker assess-\nments. Arthritis Res Ther 13(5): R177.\n10. Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: a Cochrane\nsystematic review. J Rheumatol 37(2): 234\u2013245.\n11. Horneff G, Burmester GR, Emmrich F, Kalden JR (1991) Treatment of\nrheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum\n34(2): 129\u2013140.\n12. Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet\n373(9664): 659\u2013672.\n13. Wagner U, Pierer M, Kaltenhauser S, Wilke B, Seidel W et al. (2003) Clonally\nexpanded CD4 +CD28null T cells in rheumatoid arthritis use distinct\ncombinations of T cell receptor BV and BJ elements. Eur J Immunol 33(1):79\u201384.\n14. Dorner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for\nautoimmune disease. Nat Rev Rheumatol 5(8): 433\u2013441.\n15. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ (1994) The role of CD40\nin the regulation of humoral and cell-mediated immunity. Immunol Today15(9): 406\u2013411.\n16. Daridon C, Burmester GR, Dorner T (2009) Anticytokine therapy impacting on\nB cells in autoimmune diseases. Curr Opin Rheumatol 21(3): 205\u2013210.\n17. Gerli R, Bartoloni Bocci E, Sherer Y, Vaudo G, Moscatelli S et al. (2008)\nAssociation of anti-cyclic citrullinated peptide antibodies with subclinicalatherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 67(5):724\u2013725.\n18. Ghia P, Prato G, Stella S, Scielzo C, Geuna M et al. (2007) Age-dependent\naccumulation of monoclonal CD4 +CD8+double positive T lymphocytes in the\nperipheral blood of the elderly. Br J Haematol 139(5): 780\u2013790.Double Positive T Cells in RA\nPLOS ONE | www.plosone.org 9 March 2014 | Volume 9 | Issue 3 | e9329319. Holling TM, van der Stoep N, Quinten E, van den Elsen PJ (2002) Activated\nhuman T cells accomplish MHC class II expression through T cell-specific\noccupation of class II transactivator promoter III. J Immunol 168(2): 763\u2013770.\n20. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L et al (2011)\nHuman blood CXCR5( +)CD4( +) T cells are counterparts of T follicular cells\nand contain specific subsets that differentially support antibody secretion.\nImmunity 34(1): 108\u2013121.\n21. O\u2019Shea JJ, Paul WE (2010) Mechanisms underlying lineage commitment and\nplasticity of helper CD4 +T cells. Science 327(5969): 1098\u20131102.\n22. Cho BA, Sim JH, Park JA, Kim HW, Yoo WH et al. (2012) Characterization of\nEffector Memory CD8( +) T Cells in the Synovial Fluid of Rheumatoid Arthritis.\nJ Clin Immunol 32 (4): 709\u2013720.\n23. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid\narthritis. Nat Rev Immunol 7(6): 429\u2013442.\n24. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY et al. (2005) Early rheumatoid\narthritis is characterized by a distinct and transient synovial fluid cytokine profileof T cell and stromal cell origin. Arthritis Res Ther 7(4): R784\u2013795.\n25. Schmidt D, Martens PB, Weyand CM, Goronzy JJ (1996) The repertoire of\nCD4+CD28- T cells in rheumatoid arthritis. Mol Med 2(5): 608\u2013618.\n26. Paliard X, Malefijt RW, de Vries JE, Spits H (1988) Interleukin-4 mediates CD8\ninduction on human CD4 +T-cell clones. Nature 335(6191): 642\u2013644.\n27. Mucida D, Husain MM, Muroi S, van Wijk F, Shinnakasu R et al. (2013)\nTranscriptional reprogramming of mature CD4( +) helper T cells generates\ndistinct MHC class II-restricted cytotoxic T lymphocytes. Nat Immunol 14(3):\n281\u2013289.28. Reis BS, Rogoz A, Costa-Pinto FA, Taniuchi I, Mucida D (2013) Mutual\nexpression of the transcription factors Runx3 and ThPOK regulates intestinalCD4( +) T cell immunity. Nat Immunol 14(3): 271\u2013280.\n29. Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC et al. (2009) Ectopic\nlymphoid structures support ongoing production of class-switched autoantibod-ies in rheumatoid synovium. PLoS Med 6(1): e1.\n30. MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM et al. (2003)\nExtrafollicular antibody responses. Immunol Rev 194: 8\u201318.\n31. Gerli R, Vaudo G, Bocci EB, Schillaci G, Bistoni O, et al. (2009) Different roles\nfor anti-cyclic citrullinated peptide antibodies and CD4 +CD28null cells in the\nacceleration of atherosclerosis in rheumatoid arthritis: comment on the article byFarragher et al. Arthritis Rheum 60(2): 631\u2013632.\n32. Miossec P, Kolls JK (2012) Targeting IL-17 and TH17 cells in chronic\ninflammation. Nat Rev Drug Discov 11(10): 763\u2013776.\n33. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M et al. (2000)\nInflamm-aging. An evolutionary perspective on immunosenescence.Ann N Y Acad Sci 908: 244\u2013254.\n34. Kelly-Rogers J, Madrigal-Estebas L, O\u2019Connor T, Doherty DG (2006)\nActivation-induced expression of CD56 by T cells is associated with areprogramming of cytolytic activity and cytokine secretion profile in vitro.Hum Immunol 67: 863\u2013873.\n35. Lambert C, Ibrahim M, Iobagiu C, Genin C (2005) Significance of\nunconventional peripheral CD4 +CD8dim T cell subsets. J Clin Immunol\n25(5): 418\u2013427.Double Positive T Cells in RA\nPLOS ONE | www.plosone.org 10 March 2014 | Volume 9 | Issue 3 | e93293Eur. J. Immunol. 2017. 47: 1457\u20131467 Kathrin Rothe et al. DOI: 10.1002/eji.201646747 1457\nBasic\nAdaptive immunity\nResearch Article\nAutoimmune arthritis induces paired\nimmunoglobulin-like receptor B expression on CD4+\nT cells from SKG mice\nKathrin Rothe1, Nora Raulien1,G a b r i e l eK \u00a8ohler2, Matthias Pierer1,\nDagmar Quandt\u22171and Ulf Wagner\u22171\n1University of Leipzig, Department of Internal Medicine, Division of Rheumatology, Leipzig,\nGermany\n2Klinikum of Fulda, Institute of Pathology, Fulda, Germany\nThe chronic, destructive autoimmune arthritis in SKG mice, which closely resembles\nhuman rheumatoid arthritis, is the result of self-reactive T cells escaping thymic deletion.\nSince the inhibitory receptor LIR-1 is up-regulated on auto-reactive T cells in human\nrheumatoid arthritis, the role of its murine ortholog PIR-B was investigated. Peripheral\nCD4+T cells from SKG mice were found to frequently express PIR-B, and this population\nproduces more frequently IL-17 upon in vitro stimulation compared to PIR-B\u2212cells. A\nmuch larger fraction of PIR-B+T cells, however, was found to secret no IL-17, but IFN- \u03b3.\nWith regards to the clinical course of the disease, high frequencies of PIR-B+CD4+T\ncells were found to be associated with a milder course of arthritis, suggesting that the\nnet effect of PIR-B expression is suppression of autoreactive T cells. Our results indicate\nthat overexpression of PIR-B on IL-17-producing SKG CD4+T cells might represent an\neffective counter-regulatory mechanism against the destructive potential of those cells.\nMore importantly, a major population of PIR-B+T cells in SKG mice appears to play an\ninhibitory role by way of their IFN- \u03b3production, since high frequencies of those cells\nameliorate the disease.\nKeywords: ArthritisrCD4+T cellsrInhibitory receptorsrPIR-BrSKG\n/pcAdditional supporting information may be found in the online version of this article at the\npublisher\u2019s web-site\nIntroduction\nRheumatoid arthritis (RA) is a chronic debilitating autoimmune\ndisease primarily affecting small joints of hands and feet, which\ncan be associated with systemic autoimmunity leading to major\norgan vasculitis. T lymphocytes are generally regarded as impor-\ntant players in the autoimmune process, primarily due to the HLA\nclass II associations of the disease.\nCorrespondence: Prof. Ulf Wagner\ne-mail: ulf.wagner@medizin.uni-leipzig.deSubsequent studies reported the emergence of oligoclonal\nT-cell expansions and multiple phenotypic aberrations in T cells\nfrom RA patients. We and others described increased frequen-\ncies of circulating CD4+CD28nulland of extra-thymic CD4+CD8+\ndouble-positive T cells in RA patients [1\u20136]. Altered T-cell signal-\ning capacity\u2014possibly due to chronic tumor necrosis factor (TNF)\nexposure\u2014has also been described in RA [7, 8]. In addition, Th17-\ncell differentiation and function seems to be a major factor in RA\npathogenesis [9\u201311].\n\u2217These authors contributed equally to this work.\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu1458 Kathrin Rothe et al. Eur. J. Immunol. 2017. 47: 1457\u20131467\nWe previously reported in a clinical cohort of RA patients an\nincreased frequency of CD8+T cells expressing LIR-1, an inhibitory\nreceptor that has been associated with autoimmune thyroid dis-\nease [12] and multiple sclerosis [13]. To elucidate the role of LIR-1\npositive lymphocytes in autoimmune arthritis, we chose the spon-\ntaneous murine SKG arthritis model due to its close resemblance\nto the human diseases RA. BALB/c ZAP-70W163C-mutant (SKG)\nmice are characterized by a mutation in the gene encoding the Src\nhomology 2 (SH2) domain of a component of the T-cell receptor\nsignaling complex, zeta-chain-associated protein kinase 70, which\ncauses chronic autoimmune arthritis in BALB/c mice [14, 15].\nAltered T-cell signal transduction results in positive selection of\notherwise negatively selected, i.e. deleted, auto-reactive T-cell\nclones. Subsequently, auto-reactive T cells enter the periphery\nand become pathogenic after activation. SKG mice spontaneously\ndevelop arthritis in a microbially conventional environment but\nnot under speci\ufb01c pathogen-free (SPF) conditions [16]. Injection\nof zymosan, a yeast cell wall extract, induces activation of the\ninnate immune system via toll-like receptor signaling and drives\ndifferentiation of pathogenic T cells, thereby triggering arthritis\neven under SPF conditions [16, 17].\nBased on the structural and genomic homology analysis as well\nas on similarities in their inhibitory intracellular signal transduc-\ntion pathways, the murine paired immunoglobulin-like receptor B\n(PIR-B) is considered to be the mouse ortholog of LIR-1.\nPIR-B is expressed on B cells, mast cells, antigen presenting\ncells [18\u201320] or prethymic progenitors [21], but not on mature\nT cells or natural killer (NK) cells [19, 22]. It has been shown to\nbind both classical and nonclassical MHCI molecules on opposing\ncells (trans), but cis interactions of PIR-B - MHCI have also been\ndescribed on mast cells or dendritic cells [23\u201325]. Both cis and\ntrans interactions appear to induce constitutive tyrosine phospho-\nrylation in PIR-B+cells [26, 27] and the resulting suppression by\nPIR-B may contribute to maintain their resting state. Furthermore,\nectopic expression of PIR-B on peripheral T cells was shown to reg-\nulate T-cell activation [22]. These observations indicate an impor-\ntant role of PIR-B in cell inhibition and consequently immune\ntolerance [23].\nBased on these \ufb01ndings, we sought to investigate the contribu-\ntion of PIR-B expression in autoimmune arthritis model. We report\nhere that in analogy to LIR-1 expression in the human disease RA,\nPIR-B is up-regulated on peripheral T lymphocytes in murine SKG\narthritis. PIR-B-expressing CD4+T cells display an effector pheno-\ntype and contain not only pro-in\ufb02ammatory Th17 cells, but also\nIFN-\u03b3producers likely to exert an inhibitory effect in the chronic\nautoimmune process.\nResults\nPIR-B+CD4+T cells occur frequently in SKG mice and\nincrease further with arthritis development\nBased on our previous \ufb01nding of increased LIR-1-expressing on\nT lymphocytes in human RA, and in particular in more severedisease, we investigated the expression of the LIR-1 ortholog PIR-\nB on T cells in the SKG arthritis model, which is regarded as the\nmurine arthritis model with the closest resemblance to human RA.\nIn contrast to the tissue and cell type distribution patterns of\nPIR-B reported in the literature [18, 19], we found strong expres-\nsion of PIR-B on a large fraction of CD4+T cells from arthritic\nSKG mice and on a low percentage of CD4+T cells from control\nmice of the BALB/c background strain (Fig. 1A). Expression of\nPIR-B mRNA in CD4+T cells was con\ufb01rmed by RT-PCR (Support-\ning Information Fig. 1). The difference between the two mouse\nstrains was present in CD4+T cells isolated from either spleen or\nlymph nodes. In the BALB/c background strain, no PIR-B+Tc e l l s\nwere detectable in lymph nodes or peripheral blood, and only low\nfrequencies in the spleen (Fig. 1A).\nIn SKG mice, the microbial environment is known to determine\nincidence and severity of arthritis, while increasing age is also an\naggravating factor. This led us to investigate the in\ufb02uence of those\nfactors on the frequency of PIR-B+in SKG CD4+T cells. Mice bred\nunder non-SPF conditions, which develop a severe and progressive\narthritis, were found to have signi\ufb01cantly higher frequencies of\nPIR-B-expressing CD4+T cells than mice kept under microbially\nclean, germ free SPF housing (Fig. 1B). Nevertheless, SKG mice\nbred under SPF housing still had higher frequencies of those cells\ncompared to control BALB/c mice (Fig. 1B). A marginal increase\nof frequencies of PIR-B+CD4+T cells in aged BALB/c mice kept\nunder non-SPF conditions did not reach statistical signi\ufb01cance (5.2\nto 7.8%, p=0.42, Fig. 1B).\nAnalysis of PIR-B expression in B cells, macrophages and den-\ndritic cells revealed no signi\ufb01cant differences between BALB/c\nand SKG mice (Fig. 1C), and no deviations from the frequencies\nreported previously [18] for other mouse strains. As expected, PIR-\nB was expressed on almost 100% of macrophages and dendritic\ncells with no differences between BALB/c and SKG mice (Fig. 1C).\nPIR-B expression can be induced by T-cell receptor\nstimulation and indicates an activated phenotype\nFor phenotypic analysis and functional characterization of PIR-B+\nCD4+T-lymphocytes, splenic CD4+T cells from 6 month old SKG\nmice were used (Fig. 1D). Analysis of the phenotype of PIR-B+\nCD4+T cells from SKG mice showed that nearly 30% of them\nexpressed CD25, with no signi\ufb01cant differences between PIR-B+\nand PIR-B\u2212T cells (Fig. 1D). CD27 was found on the majority of\nCD4+T cells, but the frequencies of CD27+CD4+T cells were\nsigni\ufb01cantly decreased among PIR-B+compared to PIR-B\u2212CD4+\nT cells. PD-1 as a marker for ongoing inhibitory signaling and\nT-cell exhaustion was expressed on few cells, but the frequencies\nof PD-1+cells were nevertheless signi\ufb01cantly increased on PIR-B+\ncells (Fig. 1D). CD69 was analyzed as a second activation marker\nand was found to be expressed more frequently on PIR-B+than\non PIR-B\u2212CD4+T cells (Fig. 1D).\nPIR-B expression on SKG CD4+T cells was inducible in vitro\nby incubation with CD3 antibody (Fig. 2A). Following in vitro\nstimulation of splenocytes with anti-CD3/ CD28, the resulting\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euEur. J. Immunol. 2017. 47: 1457\u20131467 Adaptive immunity 1459\nFigure 1. SKG mice show increased frequencies of PIR-B-expressing CD4+T cells with an activated phenotype. (A) Representative \ufb02ow cytometry\nplots show surface expression of PIR-B on splenic CD4+T cells from aged BALB/c and SKG mice (40 weeks old, left). Depicted are frequencies\nof PIR-B+CD4+T cells in peripheral blood ( n=2 versus5), spleen ( n=5 versus8) and lymph nodes ( n=5 versus 5) from 40-week-old SKG mice\nwith clinical signs of arthritis (right). (B) Frequencies of PIR-B+CD4+T cells from young and aged SKG ( n=5\u201311) and BALB/c ( n=3\u20136) mice, born\nand kept under SPF or non-SPF conditions. (C) PIR-B surface expression of B cells, macrophages and dendritic cells (DCs) isolated from spleens of\nBALB/c and SKG ( n=4) mice. (D) Frequencies of CD25+,C D 6 9+,C D 2 7+and PD-1+among PIR-B\u2212and PIR-B+splenic CD4+T cells from 6 month old\nSKG mice ( n=7).\nCircles represent individual mice; data in each graph are from single, independent experiments except graph B, where results from two independent\nexperiments were pooled; horizontal lines indicate mean \u00b1SEM. Box plot represents median (horizontal line), interquartile range (box) and\nminimum and maximum values. All frequencies are given as percent of total CD4+T-cell frequency unless indicated otherwise. Levels of\nsigni\ufb01cance as indicated. For statistical analysis Mann\u2013Whitney test or Wilcoxon signed rank test was used.\nfrequencies of PIR-B+CD4+T cells were signi\ufb01cantly higher in\nSKG than in the genetic background strain BALB/c (Fig. 2A and\nSupporting Information Fig. 2).\nTo test the functional response of T cells, their cytokine pro-\nduction was analyzed. Splenocytes from SKG and BALB/c mice\nwere stimulated in vitro with anti-CD3/CD28 antibody, and IFN- \u03b3\nsecretion was determined. Following in vitro stimulation, BALB/c\nCD4+T cells were found to contain approximately 2% IFN- \u03b3-\nsecreting cells whereas frequencies of IFN- \u03b3secretors were signif-\nicantly lower among CD4+T cells from SKG mice (Fig. 2B). Nev-\nertheless, in both SKG and BALB/c CD4+T cells, the frequencies\nof IFN- \u03b3producers were signi\ufb01cantly higher in PIR-B+compared\nto PIR-B\u2212CD4+T cells (Fig. 2C).\nIn vitro activation with PMA/ionomycin leads to\nincreased IFN- \u03b3and IL-17 production in SKG T cells\nSince T-cell receptor signaling is known to be attenuated in CD4+\nT cells from SKG mice, we used an alternative activation pro-\ntocol with phorbol 12-myristate 13-acetate (PMA) and the Ca2 +\nionophore ionomycin to bypass proximal TCR signaling. Divergent\nresults from stimulation with anti-CD3 versus PMA/ionomycin\nhave been interpreted as a possibility to distinguish impaired prox-\nimal TCR signaling due to the ZAP-70W163C-mutation from signaltransduction further downstream, which does not differ between\nSKG and BALB/c mice [28].\nIFN-\u03b3production of BALB/c CD4+T cells was stimulated by\nPMA/ionomycin in approximately 5% of the cells (Fig. 3A and B).\nThe effect of PMA/ionomycin on CD4+T cells from SKG mice,\nhowever, was signi\ufb01cantly different from the results seen with\nTCR ligation. The PKC mediated stimulation with PMA/ionomycin\ninduced high frequencies of IFN- \u03b3producers among CD4+\nT cells from SKG mice, which signi\ufb01cantly exceeded the frequen-\ncies observed in BALB/c (Fig. 3A and B).\nSince Th17-cells have been reported to be a pathogenetically\nrelevant cell population in SKG arthritis [28] we also investigated\nthe frequency of IL-17-producing CD4+T cells. Stimulation of\nsplenic CD4+T cells with PMA/ionomycin was found to induce\nIL-17- production\u2014determined by intracellular cytokine\nstaining\u2014in a subpopulation of CD4+T cells from SKG\nmice, but not from BALB/c mice (Fig. 3C).\nSeparate analysis of the PMA/ionomycin induced cytokine pro-\nduction of PIR-B+and PIR-B\u2212CD4+T cells con\ufb01rmed that approx-\nimately 5% of both PIR-B+and PIR-B\u2212CD4+T cells from BALB/c\nmice produce IFN- \u03b3with no signi\ufb01cant difference between the two\npopulations (Fig. 4A and B). As expected, neither population con-\ntained signi\ufb01cant frequencies of IL-17-producers (Fig. 4A and C).\nIn SKG mice, in contrast, we found signi\ufb01cant differences\nbetween PIR-B+and PIR-B\u2212CD4+T cells. While the frequencies\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu1460 Kathrin Rothe et al. Eur. J. Immunol. 2017. 47: 1457\u20131467\nFigure 2. TCR-mediated activation induces PIR-B expression, but not IFN- \u03b3secretion of splenic SKG CD4+T cells. (A) Representative dot plots and\nbar chart show PIR-B expression on CD4+T cells from BALB/c ( n=6) and SKG mice ( n=6) following in vitro stimulation with anti-CD3 (5 \u03bcg/mL)\nand anti-CD28 (2 \u03bcg/mL) versus controls. Data shown as mean \u00b1SEM of PIR-B+CD4+T cells in the medium control (control) and after stimulation\n(anti-CD3/anti-CD28). (B) Representative dot plots and bar chart of IFN- \u03b3secretion of CD4+T cells from BALB/c ( n=6 and SKG ( n=6) mice after\nin vitro stimulation with CD3/CD28 antibody for 4 h compared to the medium control. Bar chart depicts the frequency of IFN- \u03b3-producing CD4+\nT cells (mean \u00b1SEM) from BALB/c and SKG mice in the medium control and upon stimulation with anti-CD3/CD28 (right). Data from (B) and (C)\nfrequency of IFN \u03b3-producing CD4+T cells among PIR-B+and PIR-B\u2212CD4+T cells ( n=6). Bar charts show results (mean \u00b1SEM) from the indicated\nnumber of mice, which were pooled from three independent experiments. All frequencies are given as percent of total CD4+T-cell frequency\nunless indicated otherwise. For statistical analysis Mann\u2013Whitney test or Wilcoxon signed rank test was used.\nof IFN- \u03b3producers were generally higher in SKG mice, we found\nthe highest percentages of IFN- \u03b3producers among PIR-B+SKG\nCD4+T-cell (Fig. 4D and E). The strong production of IL-17 in\nSKG CD4+T cells reported above was detectable in both PIR-B+\nand PIR-B\u2212CD4+T cells. However, PIR-B+SKG CD4+Tc e l l s\ncontained a signi\ufb01cantly greater fraction of IL-17-producers thanPIR-B\u2212ones, and the frequencies of IL-17-producers among PIR-\nB+CD4+T cells were the highest observed in this study (Fig. 4D\nand F).\nHowever, direct ex vivo analysis of PIR-B+and PIR-B\u2212SKG\nCD4+T cells without in vitro stimulation revealed no detectable\nIL-17-secretion (data not shown).\nFigure 3. CD4+T cells from SKG produce high amounts of IFN- \u03b3and IL-17. (A\u2013C) Intracellular IFN- \u03b3and IL-17 production of splenic CD4+T\ncells from 6 month old BALB/c ( n=6) or SKG mice ( n=7) was determined after 4 h stimulation with PMA (20 ng/mL) and ionomycin (1 \u03bcg/mL).\nRepresentative dot plots (A) and frequency of IFN- \u03b3producers (B) and IL-17 producers (C) among stimulated CD4+T cells, compared to unstimulated\nmedium controls (medium). All frequencies are given as percent of total CD4+T-cell frequency. Bar charts show results (mean \u00b1SEM) from the\nindicated number of mice, which were pooled from three independent experiments. Levels of signi\ufb01cance as indicated. For statistical analysis\nMann\u2013Whitney test or Wilcoxon signed rank test was used.\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euEur. J. Immunol. 2017. 47: 1457\u20131467 Adaptive immunity 1461\nFigure 4. PIR-B+CD4+T cells from SKG mice are potent IL-17 producers. (A\u2013C) Intracellular IFN- \u03b3and IL-17 production of splenic PIR-B+and\nPIR-B\u2212CD4+T cells from 6 month old BALB/c ( n=6) or SKG mice ( n=7) was determined after 4 h stimulation via PMA (20 ng/mL) and ionomycin\n(1\u03bcg/mL). (B, D) Representative dot plots and frequency of (B) IFN- \u03b3producers and (C) IL-17 producers among stimulated PIR-B+and PIR-B\u2212BALB/c\nCD4+T cells, compared to unstimulated controls are shown. (D\u2013F) Intracellular IFN- \u03b3and IL-17 production of splenic CD4+T cells from SKG mice\nstimulated with PMA and ionomycin for 4 h. (D) Representative dot plots and (E, F) bar charts depicting the frequency of IFN- \u03b3producers (E) and\nIL-17 producers (F) among stimulated PIR-B+and PIR-B\u2212SKG CD4+T cells compared to controls. All frequencies are given as percent of total\nCD4+T-cell frequency. Bar charts show results (mean \u00b1SEM) from the indicated number of mice, which were pooled from three independent\nexperiments. Levels of signi\ufb01cance as indicated. For statistical analysis Mann\u2013Whitney test or Wilcoxon signed rank test was used.\nIL-17-producing T cells are preformed while induced\nPIR-B+T cells are limited to IFN- \u03b3production\nIn order to test the stability of the PIR-B phenotype in vitro, PIR-B+\nand PIR-B\u2212CD4+\nT cells from SKG mice were preselected by cell sorter and\nincubated with and without PMA/ionomycin stimulation (Fig. 5A\nand B). The results show that PIR-B is up-regulated upon acti-\nvation in approximately 10\u201315% of the previously PIR-B\u2212CD4+\nT cells (Fig. 5C), while all PIR-B+T cells remained positive under\nthe conditions described (data not shown).\nWhen cytokine production was investigated, PMA/ionomycin\nstimulation was found to induce IFN- \u03b3+cells among both PIR-B+\nand PIR-B\u2212CD4+T cells (Fig. 5B). Again, the frequencies of IFN- \u03b3\nproducers were signi\ufb01cantly higher in PIR-B+CD4+T cells, both\nin in vivo preformed and in vitro induced PIR-B+T cells (Fig. 5D).\nIL-17 production, in contrast, was only found in the sorted\nPIR-B+CD4+T cells, which had already expressed PIR-B in\nvivo (Fig. 5B). In the ex vivo PIR-B\u2212cell population, which in\nvitro had\u2014upon stimulation with PMA/ionomycin\u2014converted to\nPIR-B-positivity (Fig. 5C), only minimal IL-17-production was\ndetectable, which was lower than in in vivo preformed PIR-B+\ncells (Fig. 5D).\nTo investigate mechanistically the in\ufb02uence of PIR-B signal-\ning on IL-17-production, Th17-differentiation experiments were\nperformed in vitro. For this, CD62L+na\u00a8\u0131ve CD4+T cells were sep-\narated from BALB/c mice, since the ZAP70 mutation in the SKG\nstrain prevents ef\ufb01cacious in vitro Th17-differentiation.\nThe results shown in Fig. 6A indicate that ligation of PIR-B\nwith a speci\ufb01c monoclonal antibody did in\ufb02uence neither the fre-\nquency of emerging Th17-cells in those cultures (Fig. 6A) nor the\nexpression level of IL-17 (data not shown).Expansion of the PIR-B-expressing CD4+\nT-cell compartment is associated with lower\narthritis scores\nThe observed preferential production of IL-17 in a small per-\ncentage of PIR-B+cells indicates a pro-in\ufb02ammatory and tis-\nsue destructive effect of those cells. However, production of this\npathogenetically relevant cytokine could be elicited by in vitro\nstimulation, but was not detectable in PIR-B+SKG CD4+Tc e l l s\ndirectly ex vivo (data not shown).\nThe strong bias towards IFN- \u03b3production in a much larger\nfraction of PIR-B+cells, in contrast, indicates a potentially\nbene\ufb01cial effect of those cells in SKG arthritis, since IFN-\n\u03b3is known to inhibit Th17-differentiation in this disease\n[28]. This dichotomy prompted us to investigate the clini-\ncal consequences of increased PIR-B frequencies in the SKG\nmice.\nThe frequency of PIR-B+CD4+T cells in arthritic SKG mice\ndetermined ex vivo at 40 weeks of age was found to exert some\nin\ufb02uence on disease severity. When mice with PIR-B frequencies\namong CD4+T cells above 35% (cut off represents the median of\ndetermined frequencies of PIR-B+CD4+T cells) were compared\nto those with fewer PIR-B+cells, their arthritis score was lower\nwith a signi\ufb01cant difference at 32 weeks of age (Fig. 6B). In a\nseparate experiment, the individual arthritis scores reached after\n40 weeks showed a clear inverse correlation with the frequency of\nPIR-B+CD4+T cells determined (Fig. 6C). Histological analysis of\nthe affected joints con\ufb01rmed the association with disease severity\nwith regards to immune cell in\ufb01ltration and bone destruction. The\nhistological scores reached at 40 weeks of age showed a signi\ufb01cant\ninverse correlation with the frequency of PIR-B+CD4+Tc e l l s\n(Fig. 6D and E).\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu1462 Kathrin Rothe et al. Eur. J. Immunol. 2017. 47: 1457\u20131467\nFigure 5. The PIR-B-expressing phenotype of SKG CD4+T cells is stable in vitro and is associated with IL-17 secretion. (A) Splenic CD4+T cells\nwere separated and sorted for PIR-B+and PIR-B\u2212T cells. Representative dot plots show sort strategy and re-analysis of sorted PIR-B+and PIR-B\u2212\nCD4+T cells. (B) Representative dot plots show intracellular IFN- \u03b3and IL-17 production in sorted PIR-B+(top) and PIR-B\u2212SKG CD4+T cells (bottom)\nafter stimulation with PMA (20 ng/mL) and ionomycin (1 \u03bcg/mL) for 3 h. The frequency of IFN- \u03b3(left) and IL-17 producers (right) in PIR-B+and\nPIR-B\u2212SKG CD4+T cells ( n=8) is shown. (C) Representative dot plots show PMA/ionomycin induced surface PIR-B expression and intracellular\nIFN-\u03b3and IL-17 production after stimulation with PMA/ionomycin. (D) Separate analysis of previously PIR-B\u2212CD4+T cells, which became positive\n(top) or remained negative (bottom). Representative dot plots show IFN- \u03b3and IL-17 production of previously PIR-B\u2212CD4+T cells after stimulation\nwith PMA/ionomycin. Frequencies of IL-17+and IFN- \u03b3+among PIR-B+and PIR-B\u2212CD4+T cells from SKG mice ( n=7) are shown.\nBar charts show results (mean \u00b1SEM) from the indicated number of mice, which were pooled from three independent experiments. Levels of\nsigni\ufb01cance as indicated. For statistical analysis Mann\u2013Whitney test or Wilcoxon signed rank test was used.\nDiscussion\nPreviously, we and others have described an association of\nlatent CMV\u2013triggered immunosenescence with RA, in particu-\nlar in patients with more severe disease [29\u201333]. LIR-1, an\ninhibitory receptor associated with T-cell compartment deviations\ncharacteristically induced in CMV infection, was found to be up-\nregulated on CD8+T cells from RA patients [30].This prompted\nus to investigate the expression of its murine ortholog PIR-B\nin an animal model of RA. We report here for the \ufb01rst time\nthat PIR-B is up-regulated on peripheral CD4+T cells of SKG\nmice.\nThe chosen SKG arthritis is caused by a mutation in the gene\nfor ZAP-70, which leads to attenuated TCR signaling [14]. The\nfunctional consequence of this mutation is thymic selection of\nauto-reactive T cells, which have attenuated TCR signaling, but\nreact against self-antigens, [16]. We show here that a large frac-\ntion of the self-reactive CD4+T-cell pool in SKG mice is expressing\nPIR-B. PIR-B expression reached more than 25 % of CD4+T cells,in particular in aged mice, but was found only at low levels in\nthe background strain BALB/c strain. This up-regulation occurs\nin arthritic mice and inducible to some extent in vitro, indicating\nthat PIR-B+T cells are not selected in the SKG thymus due to the\nZAP-70 mutation, but acquire this phenotype postthymically in the\nperiphery as a consequence of chronic arthritis. Accordingly, PIR-\nB+CD4+T cells from arthritic SKG mice are activated and show\ndecreased CD27 and increased PD-1-expression, indicating a pref-\nerential effector-memory differentiation status [34] with features\nof T-cell exhaustion. SKG mice have been suggested to be lym-\nphopenic and, in analogy to human RA, be characterized by an\nincreased homeostatic proliferation [35]. Accordingly, expansion\nof senescent and/or exhausted T-cell populations could contribute\nto increased PIR-B expression in SKG mice.\nIn SKG arthritis, CD4+T cells are commonly regarded as\nthe most relevant cell population, and increased frequencies of\nPIR-B+CD4+T cells in arthritic mice are likely pathogeneti-\ncally relevant [14]. Importantly, PIR-B+CD4+T cells are also\nmore frequent in SKG mice housed under SPF conditions which\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euEur. J. Immunol. 2017. 47: 1457\u20131467 Adaptive immunity 1463\nFigure 6. PIR-B ligation does not in\ufb02uence Th17-differentiation, and PIR-B expression ameliorates arthritis. (A) Splenic CD4+CD62L+T cells from\nBALB/c mice were sorted and cultured without stimulation (unstimulated control) or under Th17-differentiating conditions in the presence of\nanti-PIR-B or control antibody (IgG). Incubation under Th17-differentiating conditions in medium alone was used as a negative control. After 3 d,\ncells were stimulated with PMA (20 ng/mL) and ionomycin (1 \u03bcg/mL) and stained for intracellular IL-17 production. Representative dot plots show\nintracellular IL-17 production of CD4+T cells under the indicated culture conditions of eight mice from one independent experiment. Horizontal\nlines indicate the mean \u00b1SEM. Levels of signi\ufb01cance as indicated. For statistical analysis Mann\u2013Whitney test was used. (B) Clinical arthritis score\nwas determined over 20 weeks of SKG mice ( n=16) bred under non-SPF conditions. After 40 weeks, frequencies of splenic PIR-B+CD4+T cells\nfrom SKG mice were determined and correlated with (C) arthritis score ( n=13) and (D) histology score ( n=12). Cut off represents the median\nof determined frequencies of PIR-B+CD4+T cells. Circles represent individual mice. Line illustrates linear regression. Levels of signi\ufb01cance as\nindicated. For statistical analysis Spearman correlation test was used. (E) Histologic images representative for mild (score 1, left panel) or seve re\narthritis (score 3, right panel).\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu1464 Kathrin Rothe et al. Eur. J. Immunol. 2017. 47: 1457\u20131467\ndo not develop arthritis. This could be a consequence of the\ninvolvement of CD4+T cells with attenuated TCR signaling in\nthe early, antigen-speci\ufb01c events taking place due to the ZAP-\n70 mutation even before autoimmunity ensues, and might indi-\ncate an inhibitory effect of PIR-B expression already in this pre-\nclinical phase. Such an inhibitory function of PIR-B in chronic\narthritis could subsequently be even more effective at sites of\nchronic in\ufb02ammation. PIR-B has been reported to bind S100 A9\n(also known as migration inhibitory factor-related protein 14 -\nMRP14- or calgranulin B) [36, 37], which is overexpressed in\nrheumatoid synovium and is found in increased concentration\nboth in serum and synovial \ufb02uid of patients with RA [38, 39],\nwhile a decrease in S100A9 serum concentrations is associated\nwith clinical improvement of the symptoms [40]. In addition,\nthe human nonclassical MHC molecule HLA-G is also a ligand\nfor LIR-1 and PIR-B [41] and treatment with soluble HLA-G\nproduces excellent antiin\ufb02ammatory effects in collagen-induced\narthritis [42].\nPIR-B has been shown to trigger an inhibitory signal in mast\ncells [25], eosinophils [43], macrophages [44, 45] and dendritic\ncells [46], but its role on T cells is only poorly understood.\nT cells of PIR-B de\ufb01cient mice are characterized by increased IL-\n4 and decreased IFN- \u03b3production [46], indicating a regulatory\nrole in Th1/ Th2-balance. T or B-cell development is not altered\nin PIR-B de\ufb01cient mice, and no overt autoimmune phenotype is\ndetectable [22]. Ectopic expression of PIR-B on peripheral T cells,\nhowever, has been shown to trigger an inhibitory signal leading\nto suppression of proximal TCR signaling and attenuation of the\nIFN\u03b3response [22].\nIn established, destructive SKG arthritis, IL-17 has been shown\nto be the pivotal cytokine, since the disease does not occur in\nIL-17-de\ufb01cient SKG mice [28]. In our experiments, no IL-17 pro-\nduction was detectable in PIR-B+CD4+T cells, when analyzed\ndirectly ex vivo. This is in contrast to previous reports [28],\nbut this discrepancy might be the result of the longer obser-\nvation period of 40 weeks in our experiments compared to 12\nweeks in previous studies. The frequency of PIR-B expressing cells\nincreases with age, and the ef\ufb01cacy of PIR-B inhibition might\nresult in the observed in vivo suppression of IL-17 production after\n40 weeks.\nThe consequences of lymphocytic PIR-B expression for IFN- \u03b3\nproduction are more complex, however. Imada et al. used thymo-\ncytes from a PIR-B-expressing transgenic mouse model with nor-\nmal TCR signal transduction and saw a reduced IFN- \u03b3response,\nwhich they interpreted as the result of cis-binding of PIR-B to MHC\nclass I on the same cell surface. In contrast to this study, we saw an\nincrease of IFN- \u03b3secretion of ZAP-70 mutated SKG CD4+T cells\nexpressing PIR-B, and PIR-B frequencies correlated with milder\narthritis.\nIFN-\u03b3is known to ameliorate SKG arthritis due to suppressed\nexpansion of Th17-cells in SKG mice, while an IFN \u03b3knockout\ncauses severe exacerbation [28]. IFN \u03b3-de\ufb01cient SKG mice develop\narthritis even under SPF conditions, possibly indicating the sup-\npressive effect of PIR-B+IFN-\u03b3producers in SKG control mice. It\nseems feasible therefore, that the IFN- \u03b3secretion of PIR-B+T cellscontributes to the lower arthritis scores in mice with strong PIR-\nB expression. This hypothesis is further supported by our obser-\nvation that IFN- \u03b3production is increased in PIR-B+SKG CD4+\nT cells, underlining their potential role as \u201csuppressors\u201d of autoim-\nmunity.\nIn contrast to PIR-B and IFN- \u03b3expression, IL-17 production\nwas not inducible in PIR-B\u2212cells by in vitro PMA/ionomycin stim-\nulation, indicating that the IL-17 producers are preformed in vivo\nand are likely stable over longer periods of time. IL-17 differen-\ntiation also appears to be resistant to inhibitory PIR-B signaling,\nsince PIR-B ligation did in\ufb02uence IL-17 differentiation in vitro.\nIn summary, a small fraction of PIR-B+CD4+T cells, which can\nbe induced in vitro to produce IL-17, appears to be an auto-reactive\npopulation that is partially inhibited in vivo due to their PIR-B sig-\nnaling. In addition, the results presented suggest that PIR-B+,I F N -\n\u03b3\u2212producing CD4+T cells, which occur in much higher frequen-\ncies, are an ef\ufb01cacious inhibitory cell population in SKG arthritis.\nThose results support our previous \ufb01ndings of LIR-1 overexpres-\nsion in human RA. If triggering of inhibitory signals via LIR-1\nligation results in increased IFN- \u03b3production, than this might be\na new therapeutic approach to RA or other autoimmune disease\nresponsive to IL-17 inhibition.\nMaterials and methods\nMice\nFemale SKG and BALB/c mice were bred (BALB/c from the\nMedizinisch-Experiementelles Zentrum (MEZ) Leipzig or Jackson\nLaboratory) and maintained under SPF conditions or non-SPF con-\nditions at the medical faculty of the University of Leipzig/MEZ.\nAnimal studies were approved by the local regulatory agency\n(University of Leipzig).\nHistopathologic assessment\nSKG mouse right hind paws were \ufb01xed in formalin, decalci\ufb01ed, put\nin paraf\ufb01n, cut and stained with H&E. The sections were scored at\n40- and 200-fold magni\ufb01cation by two independent observers, for\ncellular in\ufb01ltrations, exudations and pannus, bone erosions and\ncartilage destructions.\nA semiquantitative graded scale from 0 to 3 was used as pre-\nviously reported [47]: 0: no changes, 1: mild changes with low\nclinical signs of in\ufb02ammation with cell in\ufb01ltration, 2 moderate\nchanges with cell in\ufb01ltrations, low pannus and cartilage destruc-\ntions and 3: severe changes with strong cell in\ufb01ltration, pannus\nand cartilage destructions.\nScoring of joint swelling\nIncidence and severity of arthritis were scored every week as\ndescribed previously [14]. Scoring was performed as follows:\n0: no joint swelling, 1: swelling of one \ufb01nger joint, 2: at least\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euEur. J. Immunol. 2017. 47: 1457\u20131467 Adaptive immunity 1465\ntwo swollen \ufb01nger joints, 3: mild swelling of wrist or ankle, 4:\nsevere swelling of wrist and ankle. Scores of all forepaws and\nhind paws were totaled for each mouse.\nPreparation of peripheral cells\nPeripheral mononuclear cells were isolated from spleen and\nlymph nodes (iliac and inguinal) by disruption via cell strainer\n(70\u03bcm; BD) and erythrocytes lysed with erythrocytes lysis buffer\n(CC Pro). After washing step with PBS, splenocytes were passed\nagain through a cell strainer to remove cell aggregation. Peripheral\nblood cells were isolated by \ufb01coll paque centrifugation.\nAntibodies\nThe following antibodies were used: anti-CD3 (clone 145-\n2C11), anti-CD4 (clone: GK1.5), anti-CD19 (clone: 6D5), anti-\nPD-1 (clone: HA2-7B1), anti-CD11b (clone M1/70.15.11.5), anti-\nCD11c (clone: N418) (all from Miltenyi Biotec), anti-CD25\n(BD Biosciences, clone: PC61), anti-CD27 (eBioscience, clone:\nLG.7F9), and anti-CD69 (eBioscience, clone: H1.2F3), anti-PIR-\nA/B (Biolegend, clone 6C1) and isotype control, PIR-B (R&D, clone\n326414) and isotype control rat IgG2a (R&D), anti-IL-17 (Biole-\ngend, clone: TC11-18H10.1) and anti- IFN- \u03b3(Biolegend, clone:\nXMG1.2) and isotype control Rat IgG1 (Biolegend).\nCell staining and FACS\n5\u00d7105freshly isolated cells from blood, lymph nodes and spleen\nwere centrifuged and incubated with conjugated antibodies for\n10 min at 4 \u00b0C, washed and analyzed by \ufb02ow cytometry. Mouse Fc-\nblocking anti-CD16/CD32 (BD Biosciences) antibodies were used\nwhen PIR-A/B or PIR-B surface staining was performed. Dead cells\nwere excluded from analysis by addition of propidium iodide or\n\ufb01xable viability dye (eBioscience).\nWhen the study was initiated, commercially available anti-\nbodies speci\ufb01c for PIR-B could not discriminate between PIR-A\nand PIR-B. Accordingly, the PIR-A/B speci\ufb01c antibody (Biolegend,\nclone 6C1) was used. During the study, an antibody speci\ufb01c for\nPIR-B became available (R&D, clone 326414) and was tested on\nfreshly isolated splenocytes. The results indicated, that the anti-\nbody speci\ufb01c for PIR-B stained slightly less cells than the PIR-A/B\nspeci\ufb01c one, most likely due to expression of PIR-A on some PIR\u2013\nB-expressing T cells. The PIR-B speci\ufb01c antibody was used for all\nexperiments then.\nThroughout the manuscript, the antibody used in the individual\nexperiments is indicated speci\ufb01cally. Gating strategy is shown once\nin supporting information (Supporting Information Fig. 3).\nFor \ufb02ow cytometry analysis, FACS Calibur and LSR II (BD Bio-\nsciences) and corresponding software applications CellQuest and\nFlowjo were used.IFN- \u03b3secretion assay\n1\u00d7106splenocytes were cultured in X-Vivo 15 medium and\nstimulated with 5 \u03bcg/mL plate-bound anti-CD3 and soluble anti-\nCD28 (2 \u03bcg/mL) antibody for 4 h. IFN- \u03b3secretion assay (Miltenyi\nBiotec) was performed immediately afterwards. Then cells were\nstained for CD4, CD3 and PIR-B surface expression. Dead cells\nwere excluded from analysis by addition of propidium iodide.\nCell sorting and Th17 differentiation\nCD4+T cells from spleen of BALB/c wildtype mice were separated\nby magnetic cells sorting using CD4+T-cell isolation kit (Miltenyi)\nand stained in PBS with 1% FCS for 10 min at 4 \u00b0Cw i t ha n t i - C D 4 ,\nanti-CD3 and anti-CD62L antibodies (all from Miltenyi). Na \u00a8\u0131ve\nCD4+CD62L+T cells were sorted using a BD FACS ARIA sorter.\nFor Th17 differentiation, sorted cells were activated by plate-\nbound anti-CD3 (eBioscience; 4 \u03bcg/mL) and anti-CD28 antibodies\n(eBioscience; 5 \u03bcg/mL) and cultured in X-Vivo 15 medium in the\npresence of the following cytokines: 2 ng/mL rhTGF- \u03b2,2 0n g / m L\nrmIL-6, 5 ng/mL rmIL-23; 10 \u03bcg/mL anti-IFN- \u03b3and 10 \u03bcg/mL\nanti-IL-4-antibodies (all from eBioscience). Next, a monoclonal\nanti-PIR-B antibody or control antibody (both from R&D) was\nadded to the cell culture. After 3 d, cells were stimulated with\nPMA (20 ng/mL) and ionomycin (1 \u03bcg/mL) for 4 h and stained\nfor intracellular IL-17 production (as described below).\nIntracellular cytokine production\nFor analysis of intracellular cytokine production, CD4+T cells from\nspleen were isolated by magnetic cell separation (MACS, Miltenyi\nBiotec) and stimulated with 20 ng/mL PMA and 1 \u03bcg/mL iono-\nmycin in the presence of Golgi-Stop (1 \u03bcg/mL, BD Biosciences) for\n4 h. Intracellular staining of IFN- \u03b3and IL-17 was performed using\nthe Inside Staining Kit (Miltenyi Biotec) or BD Cyto\ufb01x/Cytoperm\n(BD Biosciences). Dead cells were removed by staining with Fix-\nable Viability Dye (eBioscience).\nRNA isolation, reverse transcription (RT) and real-time\nPCR analysis\nFACS-sorted cells were resuspended in Sigma TRI Reagent (Sigma,\nTaufkirchen, Germany) and stored at -80 \u00b0C. After extraction with\nchloroform, RNA was precipitated with isopropanol, washed twice\nwith 70% ethanol and resuspended in DEPC water (all: Roth, Karl-\nsruhe, Germany). In order to eliminate genomic DNA, RNA was\ntreated with RNase-free DNase I (2,5 units per sample; Thermo\nFisher Scienti\ufb01c GmbH, Germany) in the presence of RiboLock\nRNase inhibitor (20 units per sample; Thermo Fisher Scienti\ufb01c\nGmbH, Germany). Subsequently, RNA transcription to comple-\nmentary DNA (cDNA) with High capacity cDNA Reverse Transcrip-\ntion Kit (Applied Biosystems, Germany) using a blend of random/\noligo (dT) 18 primer was performed according to manufacturer\u2018s\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu1466 Kathrin Rothe et al. Eur. J. Immunol. 2017. 47: 1457\u20131467\ninstruction. RT-qPCR was processed in duplicates with the iTaq TM\nUniversal SYBRR/circlecopyrtGreen Supermix (BIO-RAD, Germany) in iCycler\niQTM5 (BIO-RAD, Germany). Following primers were used for\nRT-qPCR: mm hprt for: 5/prime-GTTGGATACAGGCCAGACTTTGTTG-\n3/primeand mm hprt rev: 5/prime-GATTCAACTTGCGCTCATCTTAGGC-3/prime;\nmm PirB for: 5/prime-AGGATGGAGTGGAGCTGAAC-3/primeand mm PirB\nrev: 5/prime-TGATTGTTTGCTCCTTGGCC\u20133/prime. The relative quanti\ufb01ca-\ntion of the transcripts was done by the 2(-/Delta1/Delta1Ct) method.\nStatistical analysis\nFor statistical analysis, GraphPad Prism 5.0 software (GraphPad\nSoftware, La Jolla, CA, USA) was used. Prior to all comparisons,\na normality test was performed. Differences in medians or means\nbetween groups of the same mice were analyzed by Wilcoxon\nsigned rank test or the Mann\u2013Whitney rank sum test for differ-\nent animals. Correlations were evaluated using Pearson\u2019s product-\nmoment correlation or Spearman\u2019s rank correlation coef\ufb01cient.\nAcknowledgments: This work was supported by a grant from\nthe Deutsche Forschungsgemeinschaft (WA 2765/3-1). We thank\nS. Sakaguchi for providing SKG mice and M. Protschka for RT-PCR\nperformance and analysis.\nCon\ufb02ict of interest: The authors declare no commercial or \ufb01nan-\ncial con\ufb02ict of interest.\nReferences\n1Pawlik, A. ,Ostanek, L. ,Brzosko, I. ,Brzosko, M. ,Masiuk, M. ,Machalinski,\nB. and Gawronska-Szklarz, B. , The expansion of CD4( +)CD28(-)T cells in\npatients with rheumatoid arthritis. Arthritis Res. Ther. 2003. 5(4): R210\u2013\nR213.\n2Warrington, K. J. ,Takemura, S. ,Goronzy, J. J. and Weyand, C. M. ,\nCD4+,CD28- T cells in rheumatoid arthritis patients combine features\nof the innate and adaptive immune systems. Arthritis Rheum. 2001. 44(1):\n13\u201320.\n3Schmidt, D. ,Goronzy, J. J. and Weyand, C. M. ,C D 4 +CD7- CD28- T cells\nare expanded in rheumatoid arthritis and are characterized by autoreac-\ntivity. J. Clin. Invest . 1996. 97(9): 2027\u20132037.\n4Wagner, U. ,Pierer, M. ,Kaltenhauser, S. ,Wilke, B. ,Seidel, W. ,Arnold, S.\nand Hantzschel, H. , Clonally expanded CD4 +CD28null T cells in rheuma-\ntoid arthritis use distinct combinations of T cell receptor BV and BJ ele-\nments. Eur. J. Immunol . 2003. 33(1): 79\u201384.\n5Gizinski, A. M. and Fox, D. A. , T cell subsets and their role in the patho-\ngenesis of rheumatic disease. Curr. Opin. Rheumatol . 2014. 26(2): 204\u2013210.\n6Quandt, D. ,Rothe, K. ,Scholz, R. ,Baerwald, C. W. and Wagner, U. , Periph-\neral CD4CD8 double positive T cells with a distinct helper cytokine\npro\ufb01le are increased in rheumatoid arthritis. PloS One 2014. 9(3):\ne93293.7C o p e ,A .P . ,Schulze-Koops, H. and Aringer, M. , The central role of T cells\nin rheumatoid arthritis. Clin. Exp. Rheumatol . 2007. 25(5 Suppl 46): S4\u2013\n11.\n8Thomas, R. ,Turner, M. and Cope, A. P. , High avidity autoreactive T\ncells with a low signalling capacity through the T-cell receptor: central\nto rheumatoid arthritis pathogenesis? Arthritis Res. Ther . 2008. 10: 210.\nhttps://doi.org/10.1186/ar2446\n9Gaffen, S. L. , Role of IL-17 in the pathogenesis of rheumatoid arthritis.\nCurr. Rheumatol. Rep . 2009. 11(5): 365\u2013370.\n10Shahrara, S. ,P i c k e n s ,S .R . ,Dor\ufb02eutner, A. and Pope, R. M. , IL-17 induces\nmonocyte migration in rheumatoid arthritis. J. Immunol . 2009. 182(6):\n3884\u20133891.\n11Cai, L. ,Yin, J. P. ,Starovasnik, M. A. ,Hogue, D. A. ,Hillan, K. J. ,Mort,\nJ. S. and Filvaroff, E. H. , Pathways by which interleukin 17 induces artic-\nular cartilage breakdown in vitro and in vivo. Cytokine 2001. 16(1): 10\u2013\n21.\n12Doniz-Padilla, L. ,Paniagua, A. E. ,Sandoval-Correa, P. ,Monsivais-\nUrenda, A. ,Leskela, S. ,Marazuela, M. and Gonzalez-Amaro, R. , Analysis\nof expression and function of the inhibitory receptor ILT2 in lymphocytes\nfrom patients with autoimmune thyroid disease. Eur. J. Endocrinol . 2011.\n165(1): 129\u2013136.\n13Monsivais-Urenda, A. ,Nino-Moreno, P. ,Abud-Mendoza, C. ,Baranda,\nL.,Layseca-Espinosa, E. ,Lopez-Botet, M. ,Gonzalez-Amaro, R. et al. ,\nAnalysis of expression and function of the inhibitory receptor ILT2\n(CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients\nwith systemic lupus erythematosus (SLE). J. Autoimmun . 2007. 29(2\u20133): 97\u2013\n105.\n14Sakaguchi, N. ,Takahashi, T. ,Hata, H. ,Nomura, T. ,Tagami, T. ,\nYamazaki, S. ,Sakihama, T. et al. , Altered thymic T-cell selection due\nto a mutation of the ZAP-70 gene causes autoimmune arthritis in mice.\nNature 2003. 426(6965): 454\u2013460.\n15Sakaguchi, S. ,Sakaguchi, N. ,Yoshitomi, H. ,Hata, H. ,Takahashi, T. and\nNomura, T. , Spontaneous development of autoimmune arthritis due to\ngenetic anomaly of T cell signal transduction: Part 1. Semin. Immunol .\n2006. 18(4): 199\u2013206.\n16Yoshitomi, H. ,Sakaguchi, N. ,Kobayashi, K. ,Brown, G. D. ,Tagami,\nT.,Sakihama, T. ,Hirota, K. et al. , A role for fungal [2]-glucans\nand their receptor Dectin-1 in the induction of autoimmune arthri-\ntis in genetically susceptible mice. J. Exp. Med . 2005. 201(6): 949\u2013\n960.\n17LeibundGut-Landmann, S. ,Gross, O. ,Robinson, M. J. ,Osorio, F. ,Slack,\nE. C. ,Tsoni, S. V. ,Schweighoffer, E. et al. , Syk- and CARD9-dependent\ncoupling of innate immunity to the induction of T helper cells that pro-\nduce interleukin 17. Nat. Immunol . 2007. 8(6): 630\u2013638.\n18Kubagawa, H. ,B u r r o w s ,P .D .a n dC o o p e r ,M .D . , A novel pair of\nimmunoglobulin-like receptors expressed by B cells and myeloid cells.\nProc. Natl. Acad. Sci . 1997. 94(10): 5261\u20135266.\n19Kubagawa, H. ,Chen, C. C. ,Ho, L. H. ,Shimada, T. S. ,Gartland, L. ,Mash-\nburn, C. ,Uehara, T. et al. , Biochemical nature and cellular distribution of\nthe paired immunoglobulin-like receptors, PIR-A and PIR-B. J. Exp. Med .\n1999. 189(2): 309\u2013318.\n20Lebbink, R. J. ,Ruiter, T. ,de and Verbrugge, A. ,Bril, W. S. and Meyaard,\nL., The mouse homologue of the leukocyte-associated Ig-like receptor-1\nis an inhibitory receptor that recruits Src homology region 2-containing\nprotein tyrosine phosphatase (SHP)-2, but not SHP-1. J. Immunol . 2004.\n172(9): 5535\u20135543.\n21Masuda, K. ,Kubagawa, H. ,Ikawa, T. ,Chen, C.-C. ,Kakugawa, K. ,Hattori,\nM.,Kageyama, R. et al. , Prethymic T-cell development de\ufb01ned by the\nexpression of paired immunoglobulin-like receptors. EMBO J. 2005. 24(23):\n4052\u20134060.\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euEur. J. Immunol. 2017. 47: 1457\u20131467 Adaptive immunity 1467\n22Imada, M. ,Masuda, K. ,Satoh, R. ,Ito, Y. ,Goto, Y. ,Matsuoka, T. ,Endo,\nS. et al. , Ectopically expressed PIR-B on T cells constitutively binds to\nMHC class I and attenuates T helper type 1 responses. Int. Immunol . 2009.\n21(10): 1151\u20131161.\n23Takai, T. , Paired immunoglobulin-like receptors and their MHC class I\nrecognition. Immunology 2005. 115(4): 433\u2013440.\n24Endo, S. ,Sakamoto, Y. ,Kobayashi, E. ,Nakamura, A. and Takai, T. , Reg-\nulation of cytotoxic T lymphocyte triggering by PIR-B on dendritic cells.\nProc. Natl. Acad. Sci. USA 2008. 105(38): 14515\u201314520.\n25Masuda, A. ,Nakamura, A. ,Maeda, T. ,Sakamoto, Y. and Takai, T. ,C i s\nbinding between inhibitory receptors and MHC class I can regulate mast\ncell activation. J. Exp. Med . 2007. 204(4): 907\u2013920.\n26Maeda, A. ,Kurosaki, M. ,Ono, M. ,Takai, T. and Kurosaki, T. , Require-\nment of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2\nfor paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory\nsignal. J. Exp. Med . 1998. 187(8): 1355\u20131360.\n27Ho, L. H. ,Uehara, T. ,Chen, C.-C. ,Kubagawa, H. and Cooper, M. D. ,C o n -\nstitutive tyrosine phosphorylation of the inhibitory paired Ig-like recep-\ntor PIR-B. Proc. Natl. Acad. Sci . 1999. 96(26): 15086\u201315090.\n28Hirota, K. ,Hashimoto, M. ,Yoshitomi, H. ,Tanaka, S. ,Nomura, T. ,Yam-\naguchi, T. ,Iwakura, Y. et al. , T cell self-reactivity forms a cytokine milieu\nfor spontaneous development of IL-17 +Th cells that cause autoimmune\narthritis. J. Exp. Med . 2007. 204(1): 41\u201347.\n29Pierer, M. ,Rothe, K. ,Quandt, D. ,Schulz, A. ,Rossol, M. ,Scholz, R. ,\nBaerwald, C. ,et al. , Association of anticytomegalovirus seropositivity\nwith more severe joint destruction and more frequent joint surgery in\nrheumatoid arthritis. Arthritis Rheum . 2012. 64(6): 1740\u20131749.\n30Rothe, K. ,Quandt, D. ,Schubert, K. ,Rossol, M. ,Klingner, M. ,Jasinski-\nBergner, S. ,Scholz, R. et al. , Latent cytomegalovirus infection in rheuma-\ntoid arthritis and increased frequencies of cytolytic LIR-1 +CD8+T Cells.\nArthritis Rheumatol . 2016. 68(2): 337\u2013346.\n31Davis, J. M. IIIrd., Knutson, K. L. ,Skinner, J. A. ,Strausbauch, M. A. ,\nCrowson, C. S. ,T h e r n e a u ,T .M . ,Wettstein, P. J. et al. , A pro\ufb01le of\nimmune response to herpesvirus is associated with radiographic joint\ndamage in rheumatoid arthritis. Arthritis Res. Ther . 2012. 14(1): R24.\nhttps://doi.org/10.1186/ar3706\n32Davis, J. M. ,Knutson, K. L. ,Strausbauch, M. A. ,Green, A. B. ,Crowson,\nC. S. ,Therneau, T. M. ,Matteson, E. L. et al. , Immune response pro-\n\ufb01ling in early rheumatoid arthritis: discovery of a novel interaction of\ntreatment response with viral immunity. Arthritis Res. Ther . 2013. 15(6):\nR199.\n33Almanzar, G. ,Schmalzing, M. ,Trippen, R. ,Hofner, K. ,Weissbrich, B. ,\nGeissinger, E. ,Meyer, T. et al. , Signi\ufb01cant IFNgamma responses of CD8 +\nT cells in CMV-seropositive individuals with autoimmune arthritis. J. Clin.\nVirol . 2016. 77: 77\u201384.\n34Baars, P. A. ,Sierro, S. ,Arens, R. ,Tesselaar, K. ,Hooibrink, B. ,Klenerman,\nP. and van Lier Rene, A. W. , Properties of murine (CD8 +)CD27- T cells.\nEur. J. Immunol . 2005. 35(11): 3131\u20133141.\n35Goronzy, J. J. ,Li, G. ,Yang, Z. and Weyand, C. M. , The janus head of\nT cell aging - autoimmunity and immunode\ufb01ciency. Front. Immunol . 2013.\n4: 131. https://doi.org/10.3389/\ufb01mmu.2013.00131\n36Arnold, V. ,Cummings, J.-S. ,Moreno-Nieves, U. Y. ,Didier, C. ,Gilbert, A. ,\nBarr \u00b4 e-Sinoussi, F. ,Scott-Algara, D. et al. , S100A9 protein is a novel ligand\nfor the CD85j receptor and its interaction is implicated in the control of\nHIV-1 replication by NK cells. Retrovirology 2013. 10(1): 1\u201311.\n37Moreno-Nieves, U. Y. ,Didier, C. ,Levy, Y. ,Barre-Sinoussi, F. and Scott-\nAlgara, D. , S100A9 Tetramers, Which are Ligands of CD85j, Increase\nthe Ability of MVAHIV-Primed NK Cells to Control HIV Infection. Front.\nImmunol . 2015. 6: 478. https://doi.org/10.3389/\ufb01mmu.2015.0047838K a n g ,K .Y . ,Woo, J.-W. and Park, S.-H. , S100A8/A9 as a biomarker for\nsynovial in\ufb02ammation and joint damage in patients with rheumatoid\narthritis. Korean J. Intern. Med . 2014. 29(1): 12\u201319.\n39Obry, A. ,Lequerr \u00b4 e, T. ,Hardouin, J. ,Boyer, O. ,Fardellone, P. ,Philippe,\nP.,Le Lo \u00a8 et, X. et al. , Identi\ufb01cation of S100A9 as biomarker of respon-\nsiveness to the methotrexate/etanercept combination in rheuma-\ntoid arthritis using a proteomic approach. PLoS ONE 2015. 9(12):\ne115800.\n40Andres Cerezo, L. ,Mann, H. ,Pecha, O. ,Plestilova, L. ,Pavelka, K. ,Vencov-\nsky, J. and Senolt, L. , Decreases in serum levels of S100A8/9 (calprotectin)\ncorrelate with improvements in total swollen joint count in patients\nwith recent-onset rheumatoid arthritis. Arthritis Res. Ther . 2011. 13(4):\nR122.\n41Liang, S. ,Baibakov, B. and Horuzsko, A. , HLA-G inhibits the functions of\nmurine dendritic cells via the PIR-B immune inhibitory receptor. Eur. J.\nImmunol. 2002. 32(9): 2418\u20132426.\n42Kuroki, K. ,Hirose, K. ,Okabe, Y. ,Fukunaga, Y. ,Takahashi, A. ,Shiroishi,\nM.,Kajikawa, M. et al. , The long-term immunosuppressive effects of\ndisul\ufb01de-linked HLA-G dimer in mice with collagen-induced arthritis.\nHuman Immunol . 2013. 74(4): 433\u2013438.\n43Ben Baruch-Morgenstern, N. ,Shik, D. ,Moshkovits, I. ,Itan, M. ,Karo-\nAtar, D. ,Bouf\ufb01, C. ,Fulkerson, P. C. et al. , Paired immunoglobulin-like\nreceptor A is an intrinsic, self-limiting suppressor of IL-5-induced\neosinophil development. Nat. Immunol . 2014. 15(1): 36\u201344.\n44Karo-Atar, D. ,Moshkovits, I. ,Eickelberg, O. ,Konigshoff, M. and Munitz,\nA., Paired immunoglobulin-like receptor-B inhibits pulmonary \ufb01brosis\nby suppressing pro\ufb01brogenic properties of alveolar macrophages. Am. J.\nR e s p i r .C e l lM o l .B i o l . 2013. 48(4): 456\u2013464.\n45Munitz, A. ,Cole, E. T. ,Beichler, A. ,Groschwitz, K. ,Ahrens, R. ,Stein-\nbrecher, K. ,Willson, T. et al. , Paired immunoglobulin-like receptor B\n(PIR-B) negatively regulates macrophage activation in experimental col-\nitis.Gastroenterology 2010. 139(2): 530\u2013541.\n46Ujike, A. ,Takeda, K. ,Nakamura, A. ,Ebihara, S. ,Akiyama, K. and Takai,\nT., Impaired dendritic cell maturation and increased T(H)2 responses in\nPIR-B(-/-) mice. Nat. Immunol . 2002. 3(6): 542\u2013548.\n47Pierer, M. ,Schulz, A. ,Rossol, M. ,Kendzia, E. ,Kyburz, D. ,Haentzschel,\nH.,Baerwald, C. et al. , Herpesvirus entry mediator-Ig treat-\nment during immunization aggravates rheumatoid arthritis in the\ncollagen-induced arthritis model. J. Immunol . 2009. 182(5): 3139\u2013\n3145.\nAbbreviations: IFN-\u03b3: Interferon gamma \u00b7IL-17 : interleukin 17 \u00b7PIR-B :\nPaired immunoglobulin-like receptor B \u00b7PMA : phorbol 12-myristate 13-\nacetate \u00b7RA: rheumatoid arthritis \u00b7SKG : SKG mouse strain (Sakaguchi)\n\u00b7Th17 : T helper cell 17 \u00b7TNF : tumor necrosis factor\nFull correspondence: Prof. Ulf Wagner, Department of Internal Medicine,\nDivision of Rheumatology, University Leipzig, Liebigstr. 20, 04103\nLeipzig, Germany\nFax:+49-(0)341-9724709\ne-mail: ulf.wagner@medizin.uni-leipzig.de\nReceived: 27/9/2016\nRevised: 5/5/2017\nAccepted: 23/6/2017\nAccepted article online: 30/6/2017\nC/circlecopyrt2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euLetter  to  the  Editor\nHigh  constitutive  B7-H3  expression  on  human\nkeratinocytes  supports  T  cell  immunity\nOptimal  T  cell  responses  require  T  cell  receptor  (TCR)  activation\nand  signaling  mediated  by  co-receptors,  which  are  often  members\nof  the  B7  family  (B7-1,  B7-2,  BB-1,  B7-H1  =  PD-L1,  B7-DC,  B7-H2,\nB7-H3  /C0  B7-H7).  They  exert  co-stimulatory  and/or  co-inhibitory\neffects  and  their  balance  determines  the  fate  of  Tcell  responses  [1].\nIn  melanoma  a  relatively  high  B7-H4  expression  was  detected,which  was  associated  with  a  more  aggressive  tumor  behavior,\npoorer  survival  and  altered  immune  cell  in\ufb01ltration  [2].  In\naddition,  a  strong  expression  of  B7-H3  was  found  in  melanoma\ncells,  but  also  in  keratinocytes  of  the  basal  layer  of  peri-tumoral\nepidermis,  even  in  cases  of  benign  melanocytic  nevi  [2].  Since  the\nnumber  of  T  cells  in  healthy  skin  exceed  twice  that  of  peripheral\nblood  [3]  and  several  studies  demonstrated  the  collaborative\npartnership  of  CD8+T  cells  and  keratinocyte  in  co-cultures  [4],  we\nfocused  on  the  role  of  B7-H3  on  keratinocytes  and  its  potential  role\nin  T  cell  immunity  by  co-culture  assays.  We  addressed  the  question,\nFig.  1.  Constitutively  high  expression  levels  of  B7-H3  mRNA  as  well  as  protein  in  human  skin  and  keratinocytic  and  melanocytic  cells.\nA)  IHC  was  performed  as  described  in  Materials  and  Methods.  Healthy  human  skin  was  stained  with  an  anti-B7-H3  mAb  (a),  while  a  competition  assay  using  recombinant\nmouse  B7-H3  protein  served  as  control  (b).\nB)  Real  time  PCR  data  for  the  expression  of  B7-H3  mRNA  on  HaCaT  and  a  representative  melanoma  cell  line  (BUF1286)  are  given.  Using  a  B7-H3  plasmid  as  standard,  B7-H3\ntranscript  levels  per  10.000  transcripts  \u00df-actin  are  shown.  Representative  data  from  3  independent  experiments  are  depicted.\nC)  Surface  B7-H3  (bold  line)  expression  on  HaCaT  (left  side)  and  a  representative  melanoma  cell  line  (BUF1286,  right  side)  as  determined  by  \ufb02ow  cytometry  are  depicted.  Thin\nline  represents  a  respective  isotype  control.  Blockade  of  the  B7-H3  staining  on  HaCaT  cells  was  included  as  speci \ufb01city  control.  Representative  histograms  from  at  least  3\nindependent  staining \u2019s  are  shown.\nD)  B7-H3  surface  expression  was  determined  by  \ufb02ow  cytometry  and  depicted  as  mean  \ufb02uorescence  intensity  (MFI)  for  primary  human  melanocytes,  keratinocytes  and\nkeratinocyte  cell  line  HaCaT.  Combined  data  from  2  independent  experiments  are  shown.\nE)  Surface  expression  of  different  immune  relevant  markers  including  B7-H  molecules  as  determined  by  \ufb02ow  cytometry,  depicted  as  median  \ufb02uorescence  intensity  (median)\nfor  HaCaT  cells  +//C0  IFNg  treatment  are  given.  Combined  data  from  3  independent  experiments  are  shown.  Signi\ufb01cance  as  given**p  <  0.01,***p  <  0.001.\nhttp://dx.doi.org/10.1016/j.jdermsci.2017.02.287\n0923-1811/  \u00a9  2017  Japanese  Society  for  Investigative  Dermatology.  Published  by  Elsevier  Ireland  Ltd.  All  rights  reserved.Journal  of  Dermatological  Science  xxx  (2017)  xxx \u2013xxx\nG  Model\nDESC  3163  No.  of  Pages  3\nPlease  cite  this  article  in  press  as:  D.  Quandt,  et  al.,  High  constitutive  B7-H3  expression  on  human  keratinocytes  supports  T  cell  immunity,  J\nDermatol  Sci  (2017),  http://dx.doi.org/10.1016/j.jdermsci.2017.02.287Contents  lists  available  at  ScienceDirect\nJournal  of  Dermatological  Science\njourna  l  home  page  :  www.jdsjournal.com\nwhether  the  increased  B7-H3  expression  in  basal  keratinocytes  is\neither  a  universal  sign  of  human  epidermis  irrespective  of  the\ntopographical  region,  or  solely  in\ufb02uenced  by  a  primary  skin  tumor\nof  benign  or  malignant  nature.\nWhile  Youngnak-Piboonratanakit  and  co-authors  [5]  detected\nan  expression  of  the  inhibitory  B7  family  member  B7-H1  on\nkeratinocytes  and  could  demonstrate  an  inhibitory  role  on  T  cell\nimmunity  in  the  in\ufb02amed  skin,  there  exists  so  far  no  information\nabout  B7-H3  expression  in  keratinocytes.  Therefore,  the  expression\nof  B7-H3  was  determined  in  human  keratinocytes  in  situ  by\nimmunohistochemistry  (IHC)  of  67  different  skin  samples  from  31\nmelanoma  patients  using  an  anti-B7-H3  monoclonal  antibody\n(mAb).  Staining  with  anti-B7-H3  mAb  exhibited  a  high  frequency\nof  positivity  (97.0%  (65/67))  among  all  the  samples  analyzed.  As\nrepresentatively  shown  in  Fig.  1a  adjacent  skin  from  benign  lesions\nwith  96.8%  (30/31)  positivity  and  adjacent  skin  from  malignant\nlesions  with  97.2%  positivity  (35/36)  displayed  both  an  intracellular\nand  surface  expression  (score  2\u20133)  of  B7-H3  on  keratinocytes  in\nsitu.  The  B7-H3  staining  varied  between  different  biopsies  from\nlack  of  expression  (score  0),  weak  (score  1),  moderate  (score  2)  to\nstrong  (score  3)  expression.  The  speci \ufb01city  of  the  B7-H3  staining\nwas  controlled  as  described  in  Materials  and  Methods  and  is\ndepicted  in  (Fig.  1a,  (b)).\nWith  the  exception  of  two  skin  samples  obtained  from  the  same\npatient  that  showed  no  B7-H3  staining,  epidermal  keratinocytes  of\nall  other  samples  expressed  B7-H3  without  any  signi\ufb01cant\ndifference  in  the  quality  of  B7-H3  expression  in  keratinocytes\nadjacent  to  either  benign  or  malignant  tumors  (Supplementary\nTable  1).  High  mRNA  expression  levels  of  B7-H3  was  found  in\nhealthy  tissues  of  various  organs,  whereas  protein  expression  was\nmore  restricted  [6].  Although  considerable  numbers  of  tumors  of\ndistinct  origin  have  been  analyzed  for  the  expression  of  B7-H\nfamily  members  [7],  there  is  only  little  information  available  onB7-H3  expression  and  function  in  healthy  human  tissues  and\nin\ufb02ammatory  skin  diseases.  In  addition,  high  levels  of  B7-H3\nmRNA  (Fig.  1b)  and  surface  protein  expression  (Fig.  1c-e)  were\ndetected  in  vitro  on  HaCaT  cells,  primary  keratinocytes  and\nmelanocytes  con\ufb01rming  the  in  situ  data.  In  contrast  to  earlier\npublished  literature  [8]  HaCaT  cells  were  HLA-A2  negative  (Fig.  1e),\nbut  HLA-A31  positive  as  determined  by  genetic  typing  (data  not\nshown).\nTo  study  the  regulation  of  B7-H3,  HaCaT  cells  were  treated  with\nIFNg.  When  compared  to  untreated  HaCaT  cells,  no  change  in  B7-\nH3  expression  was  found  upon  treatment  with  this  cytokine,\nwhereas  known  immune  markers  like  B7-H1,  ICAM-1,  HLA-I  and\nHLA-II  are  highly  upregulated  by  IFNg  exposure  (Fig.  1e).  A\nconstitutive  B7-H3  expression  that  was  unaltered  by  in\ufb02ammatory\ncytokines  like  TNFa,  IFNg,  IL-1\u00df  or  IL-17,  was  previously  shown  for\n\ufb01broblast-like  synoviocytes  and  skin  \ufb01broblasts  [9].  The  precise\nfunction  of  the  trans -membranous  B7-H3  molecule  is  currently\ncontroversially  discussed:  While  some  studies  described  enhanced\nT  cell  effector  functions  in  the  presence  of  B7-H3  [6],  the  majority\nof  reports  assume  rather  an  inhibitory  effect  of  this  molecule  [10].\nIt  is  now  well  accepted  that  there  exists  both  co-stimulatory  as  well\nco-inhibitory  B7-H3  receptors  on  T  cells,  but  the  exact  nature  of  the\nreceptors  is  still  under  debate.\nThe  function  of  B7-H3  on  keratinocytes  with  respect  to  T  cell\nimmunity  was  tested  by  downregulating  B7-H3  expression  in\nHaCaT  cells  with  B7-H3  shRNA  (Fig.  2a).  This  caused  a  12-fold\nreduction  of  B7-H3  surface  expression,  while  the  expression  of\nother  T  cell  immune  markers  like  B7-H1  and  HLA  class  I  antigen\nexpression  remained  unaltered  (Fig.  2a).  Co-cultivation  of  shB7-H3\ntransfectants  with  sorted  CD8+T  cells  from  HLA-A31  mismatched\ndonors  resulted  in  a  reduced  T  cell  proliferation,  CD69  expression\nas  well  as  TNF-a  production  when  compared  to  co-cultivation  with\nB7-H3high-expressing  HaCaT  cells  (Fig.  2b  and  c)  suggesting  a  T  cell\nFig.  2.  B7-H3  on  keratinocytes  supports  T  cell  immunity.\nA)  Inhibition  of  B7-H3  is  shown  by  \ufb02ow  cytometry.  HaCat  cells  were  stable  transfected  with  shRNA  speci \ufb01c  for  B7-H3  (sh_B7H3)  or  control  shRNA  (con_sh)  followed  by\nsubsequent  FACS  sorting  for  high  or  low  B7-H3  expression.  Cells  were  kept  under  G418  selection  until  use  for  co-culture  experiments.  B7-H1  and  HLA  class  I  expression  were\nnot  affected  by  B7-H3  speci \ufb01c  shRNA.  Marker  expression  was  independently  analyzed  3  times.  Signi\ufb01cance  as  given  p  <  0.05\nB  +  C)  CD8+T  cells  were  MACS  sorted  from  PBMC  (n  =  6)  and  co-cultured  for  5  days  with  90  gy  irradiated  B7-H3high(control  shRNA)  or  B7-H3low(B7-H3  shRNA)  expressing\nHaCaT  cells.  Proliferation  (CD45+CFSElow)  and  CD69  expression  (CD45+CD69+CFSElow)  (B)  as  obtained  by  \ufb02ow  cytometry  and  TNFa  secretion  (C)  as  obtained  by  ELISA  are\nshown.  Signi\ufb01cance  as  given  p  <  0.05.2  Letter  to  the  Editor  /  Journal  of  Dermatological  Science  xxx  (2017)  xxx\u2013xxx\nG  Model\nDESC  3163  No.  of  Pages  3\nPlease  cite  this  article  in  press  as:  D.  Quandt,  et  al.,  High  constitutive  B7-H3  expression  on  human  keratinocytes  supports  T  cell  immunity,  J\nDermatol  Sci  (2017),  http://dx.doi.org/10.1016/j.jdermsci.2017.02.287supporting  role  of  B7-H3  on  keratinocytes.  We  found  a  rather  low\nallo-speci \ufb01c  T  cell  response  upon  keratinocyte  co-culture  with\nCD8+T  cells  from  different  donors.  In  other  studies,  low  dose  PHA\nwas  added  to  keratinocytes-T  cell  co-culture  assays  [5]  or  co-\nculture  assays  were  performed  with  polyclonal  activated  T  cells  to\nboost  otherwise  low  CD4+and  CD8+T  cell  responses  obtained  with\nperipheral  T  cells  ex  vivo  [4].  Addition  of  anti-CD3  to  keratinocytes-\nT  cell  co-culture  assays  also  boosted  T  cell  responses  (data  not\nshown),  whereas  cultures  with  B7-H3lowkeratinocytes  showed\nlower  T  cell  effector  functions  in  the  presence  of  anti-CD3.\nTaken  together,  our  data  suggest  that  a  basal  expression  of  B7-\nH3  on  keratinocytes  may  contribute  to  a  constitutive  immunologi-\ncal  function  of  human  epidermis.  Further  experiments  in  autolo-\ngous  settings  are  needed  to  clarify  whether  B7-H3  indeed\nmaintains  T  cell  homeostasis  and  prevents  overreaction  to  various\nand  even  minor  exogenous  or  endogenous  signals  biologically\nnegligible  or  even  unwanted.  Hence  it  seems  most  interesting  to\nclarify  whether  basal  keratinocytes,  which  are  the  \ufb01rst  to  meet\nepidermotropic  lymphocytes,  are  pathogenetically  involved  in\nlymphocyte-mediated  in\ufb02ammatory  epidermal  disorders,  like\nlichen  planus,  cutaneous  variants  of  lupus  erythematosus  and\ngraft-versus-host  disease  and  even  psoriasis  vulgaris  and  allergic\nor  irritant  contact  dermatitis.\nFunding\nThis  work  was  sponsored  by  a  grant  from  the  Wilhelm  Roux\nProgram  of  the  Martin  Luther  University  Halle-Wittenberg  (D.  Q.)\nand  a  grant  from  the  Mildred  Scheel  Foundation  (107967),  Bonn  (B.\nS.,  D.  Q.).\nCon\ufb02ict  of  interest  statement\nNone  to  declare.\nAcknowledgments\nThe  authors  would  like  to  thank,  Anja  Lippert,  Diana  Boettcher,\nNicole  Sperling,  Christel  Lindhof  and  Jana  Beer  for  discussions  and\ntechnical  assistance.\nAppendix  A.  Supplementary  data\nSupplementary  data  associated  with  this  article  can  be  found,  in\nthe  online  version,  at  http://dx.doi.org/10.1016/j.jdermsci.2017.\n02.287 .\nReferences\n[1]  S.  Ceeraz,  E.C.  Nowak,  R.J.  Noelle,  B7  family  checkpoint  regulators  in  immune\nregulation  and  disease,  Trends  Immunol.  34  (11)  (2013)  556 \u2013563.[2]  D.  Quandt,  E.  Fiedler,  D.  Boettcher,  W.  Marsch,  B.  Seliger,  B7-h4  expression  in\nhuman  melanoma:  its  association  with  patients'  survival  and  antitumor\nimmune  response,  Clin.  Cancer  Res.  17  (10)  (2011)  3100 \u20133111.\n[3]  R.A.  Clark,  Skin-resident  T  cells:  the  ups  and  downs  of  on  site  immunity,  J.\nInvest.  Dermatol.  130  (2)  (2010)  362 \u2013370.\n[4]  J.H.  Peters,  G.S.  Tjabringa,  E.  Fasse,  V.L.  de  Oliveira,  J.  Schalkwijk,  H.J.  Koenen,  I.\nJoosten,  Co-culture  of  healthy  human  keratinocytes  and  T-cells  promotes\nkeratinocyte  chemokine  production  and  RORgammat-positive  IL-17\nproducing  T-cell  populations,  J.  Dermatol.  Sci.  69  (1)  (2013)  44\u201353.\n[5]  P.  Youngnak-Piboonratanakit,  F.  Tsushima,  N.  Otsuki,  H.  Igarashi,  U.  Machida,  H.\nIwai,  Y.  Takahashi,  K.  Omura,  H.  Yokozeki,  M.  Azuma,  The  expression  of  B7-H1\non  keratinocytes  in  chronic  in\ufb02ammatory  mucocutaneous  disease  and  its\nregulatory  role,  Immunol.  Lett.  94  (3)  (2004)  215 \u2013222.\n[6]  A.I.  Chapoval,  J.  Ni,  J.S.  Lau,  R.A.  Wilcox,  D.B.  Flies,  D.  Liu,  H.  Dong,  G.L.  Sica,  G.\nZhu,  K.  Tamada,  L.  Chen,  B7-H3:  a  costimulatory  molecule  for  T  cell  activation\nand  IFN-gamma  production,  Nat.  Immunol.  2  (3)  (2001)  269 \u2013274.\n[7]  B.  Seliger,  D.  Quandt,  The  expression,  function,  and  clinical  relevance  of  B7\nfamily  members  in  cancer,  Cancer  Immunol.  Immunother.:  CII  61  (8)  (2012)\n1327 \u20131341 .\n[8]  T.  Akeda,  K.  Yamanaka,  K.  Tsuda,  Y.  Omoto,  E.C.  Gabazza,  H.  Mizutani,  CD8+  T\ncell  granzyme  B  activates  keratinocyte  endogenous  IL-18,  Arch.  Dermatol.  Res.\n306  (2)  (2014)  125 \u2013130.\n[9]  C.N.  Tran,  S.G.  Thacker,  D.M.  Louie,  J.  Oliver,  P.T.  White,  J.L.  Endres,  A.G.\nUrquhart,  K.C.  Chung,  D.A.  Fox,  Interactions  of  T  cells  with  \ufb01broblast-like\nsynoviocytes:  role  of  the  B7  family  costimulatory  ligand  B7-H3,  J.  Immunol.\n180  (5)  (2008)  2989 \u20132998 .\n[10]  J.  Leitner,  C.  Klauser,  W.F.  Pickl,  J.  Stockl,  O.  Majdic,  A.F.  Bardet,  D.P.  Kreil,  C.\nDong,  T.  Yamazaki,  G.  Zlabinger,  K.  P\ufb01stershammer,  P.  Steinberger,  B7-H3  is  a\npotent  inhibitor  of  human  T-cell  activation:  no  evidence  for  B7-H3  and\nTREML2  interaction,  Eur.  J.  Immunol.  39  (7)  (2009)  1754 \u20131764 .\nDagmar  Quandt1\nInstitute  of  Medical  Immunology,  Martin  Luther  University  Halle-\nWittenberg,  Halle  (Saale),  Germany\nEckhard  Fiedler1\nDepartment  of  Dermatology  and  Venereology,  Martin  Luther\nUniversity  Halle-Wittenberg,  Halle  (Saale),  Germany\nAnja  M\u00fcller\nInstitute  of  Medical  Immunology,  Martin  Luther  University  Halle-\nWittenberg,  Halle  (Saale),  Germany\nWolfgang  Ch.  Marsch\nDepartment  of  Dermatology  and  Venereology,  Martin  Luther\nUniversity  Halle-Wittenberg,  Halle  (Saale),  Germany\nBarbara  Seliger *\nInstitute  of  Medical  Immunology,  Martin  Luther  University  Halle-\nWittenberg,  Halle  (Saale),  Germany\n1These  authors  contributed  equally  to  this  work.\n*  Corresponding  author.\nE-mail  address:  immunologie@uk.halle.de  (B.  Seliger).\nReceived  22  November  2016\nReceived  in  revised  form  30  January  2017\nAccepted  13  February  2017Letter  to  the  Editor  /  Journal  of  Dermatological  Science  xxx  (2017)  xxx\u2013xxx  3\nG  Model\nDESC  3163  No.  of  Pages  3\nPlease  cite  this  article  in  press  as:  D.  Quandt,  et  al.,  High  constitutive  B7-H3  expression  on  human  keratinocytes  supports  T  cell  immunity,  J\nDermatol  Sci  (2017),  http://dx.doi.org/10.1016/j.jdermsci.2017.02.287RESEARCH Open Access\nSynergistic effects of IL-4 and TNF \u03b1on the\ninduction of B7-H1 in renal cell carcinoma cells\ninhibiting allogeneic T cell proliferation\nDagmar Quandt, Simon Jasinski-Bergner, Ulrike M\u00fcller, Bianca Schulze and Barbara Seliger*\nAbstract\nBackground: The importance of B7-H molecules for the T cell/tumor communication and its impact on renal cell\ncarcinoma (RCC) progression and prognosis has been recently described. Cytokine treatment of RCC has earlierbeen shown to be beneficial in preclinical settings, but its clinical implementation has not proven to be as effective.\nThis might be partially explained by the yet incomplete picture of cellular alterations in tumor cells upon cytokine\ntreatment investigated in detail in this study.\nMethods: RCC tumor cell lines were treated with different cytokines alone or in combination. The constitutive and/or\ncytokine-induced expression of cytokine receptors signaling components and B7-H molecules in RCC cells were analysedby qPCR and flow cytometry. A mcherry reporter gene construc t containing B7-H1 promoter was cloned and its activity\nwas determined upon transfection in cyt okine-stimulated cells. Cytokine pretr eated tumor cells were co-cultured with\nallogeneic CD8\n+T cells from healthy donors and T cell proliferation as well as cytokine secretion was determined.\nResults: A heterogeneous, but constitutive B7-H1,-H2,-H3 and H4 expression was found on human RCC cell lines. IL-4\nand TNF \u03b1treatment led to strong synergistic induction of B7-H1 in RCC cells, whereas B7-H2 was only increased by\nTNF\u03b1. In contrast, B7-H3 and B7-H4 expression were not altered by these cytokines. Treatment of RCC cells with TNF \u03b1\nand IL-4 was accompanied by an activation of signaling molecules like NF- \u03baB, I\u03baB and STAT6. The cytokine-mediated\nup-regulation of B7-H1 was due to transcriptional control as determined by an increased B7-H1 promoter activity in\nthe presence of IL-4 and TNF \u03b1. Despite HLA class I and LFA-1 were also increased, the cytokine-mediated up-regulation\nof B7-H1 was more pronounced and caused an inhibition of allospecifc CD8+T cell proliferation.\nConclusion: Thus, IL-4 and TNF \u03b1, which could be released by immune cell s of the tumor microenvironment, are\nable to control the B7-H1 expression in RCC thereby altering T cell responses. These data are of importance forunderstanding the complex interplay of tumor cells with immune cells orchestrated by a number of different soluble\nand membrane bound mediators and for the implementation of check point antibodies directed against B7-H1.\nKeywords: Renal cell carcinoma, Costimulation, T cells, Anti-tumor response, B7-H molecules\nBackground\nRenal cell carcinoma (RCC) is the most common kidney\ncancer type with an incidence of 5.8 in 100.000 people\nin the Western world [1] causing death of 5327 patients/\nyear in Germany [2]. These results document the needfor ongoing research to identify novel therapeutic strat-\negies and to investigate mechanisms of tumor immune\nescape. RCC is considered an immunogenic tumor asdemonstrated by a high frequency of tumor-infiltrating im-\nmune cells, a relatively high incidence of spontaneous re-currences as well as by the efficacy of immunotherapies,\nlike DC-based vaccines, engin eered autologous tumor cells,\ntargeting T cell-tumor interaction, stem cell transplantationand treatment with cytokines [3].\nB7 molecules are a growing protein family with diverse\nfunctions on both immune and tumor cells. They play inparticular a key role in the crosstalk of the immune sys-\ntem and cancer tissues in different tumor entities [4]. B7\nfamily members are mainly described to modulate T cell\n* Correspondence: barbara.seliger@uk-halle.de\nInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg,Magdeburger Str. 2, Halle 06112, Germany\n\u00a9 2014 Quandt et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative\nCommons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, andreproduction in any medium, provided the original work is properly credited. The Creative Commons Public DomainDedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,unless otherwise stated.Quandt et al. Journal of Translational Medicine 2014, 12:151\nhttp://www.translational-medicine.com/content/12/1/151responses as second signal in cooperation with the first\nsignal, the antigen recognition mediated by binding of the\nT cell receptor (TCR) with the major histocompatibilitycomplex (MHC). These signals can be of co-inhibitory or\nco-stimulatory nature. Interestingly, also a reverse signal-\ning in B7 family member expressing cells has been discov-ered [5]. The B7 family comprises B7-1 (CD80), B7-2\n(CD86), B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L),\nB7-H3, B7-H4 and B7-H6 [6,7]. Many tumors of distinctorigin express B7-H molecules, in particular B7-H1. There-\nfore, monoclonal antibodies (mAb) targeting PDL1/B7-H1\non tumor cells or the PD1 receptor expressed by immunecells have been developed for the treatment of tumors.\nThese antibodies are currently implemented in clinical tri-\nals demonstrating promising objective response rates invarious tumors [8].\nIn the context of RCC B7-H1 expression of tumor le-\nsions is associated with a worse prognosis of RCC pa-tients [9]. The prognostic relevance of B7-H1 in RCC\nwas further strengthened by the fact that B7-H1 mRNA\nis increased in early metastasis when compared to pri-mary lesions suggesting that B7-H1 might serve as\nmarker of a metastatic signature in RCC [10].\nCytokines are a family of modulatory proteins or gly-\ncoproteins that bind to their respective receptors on a\nvariety of different immune and cancer cells thereby in-\nducing different downstream signaling processes. Studiesof cytokines are complicated due to their pleiotropy and\napparent redundancies of action [11].\nOver two decades one conventional treatment regime for\npatients with RCC included cytokines like IFN- \u03b1and IL-2.\nDespite the results were promising in preclinical settings\n[12-14], the clinical efficacy was rather poor with anti-tumoral responses ranging between 10 \u201320% [15-18]. This\nmight be due to the lack of knowledge of the tumor micro-\nenvironment, the molecular alterations and heterogeneityof tumors including those concerning the B7 family mem-\nbers in tumor and immune cells upon cytokine treatment.\nWith the exception of interferon (IFN)- \u03b3[19,20] the\neffect of different cytokines on the regulation of B7-H\nmolecules on RCC cells is widely unknown. Therefore,\nthis study analyzed the regulation of B7-H molecules\nupon cytokine treatment in RCC in detail. B7-H1 surface\nexpression was most dramatically altered upon IL-4 andTNF\u03b1. This enhancement occurred at the transcriptional\nlevel by direct upregulation of the B7-H1 promoter ac-\ntivity, which was associated with an inhibition of T cellproliferation.\nMaterials and methods\nCell lines and PBMC from healthy donors\nThe following RCC cell lines were used in the study and\noriginally established from RCC patients in Mainz (MZ)\nor in Halle (Hal): MZ2514RC, MZ1257RC, MZ1790RC,MZ1774RC, MZ2733RC, MZ2877RC, Hal31RC, Hal162RC,\nHal87RC and Hal149RC. The two melanoma cell lines\nBUF1088Mel and UKRV-Mel-14a have been recentlydescribed [21] and were either a kind gift from S. Ferrone\n(Pittsburgh, USA) or obtained from the European tumor\ncell line data base (ESTAB project; see www.ebi.ac.uk/ipd/estdab). Buffy coats were obtained from healthy donor\n(HD) of the blood bank of the University Hospital Halle.\nThe Institutional Review Board (Ethics Committee) at theUniversity Hospital in Halle (Germany) approved this\nstudy.\nReagents\nMonoclonal antibodies (mAb) f or flow cytometric analysis\nwere: \u03b1CD8, \u03b1HLA-I (clone B9.12.1), \u03b1CD40 and \u03b1ICAM-\n1 from Beckman Coulter (Krefeld, Germany); \u03b1PD1,\n\u03b1CD80, \u03b1NF-\u03baB (pS529), \u03b1I\u03baBa n d \u03b1pSTAT6 from Becton\nDickinson (Heidelberg, Germany); \u03b1B7-H4 from AbD ser-\notec; \u03b1ICOS, \u03b1B7-H4, \u03b1B7-H1, \u03b1B7-H2 and \u03b1CD107a\nfrom ebioscience (Frankfurt, Germany); \u03b1B7-H3, \u03b1TNFRI\nand fluorokine biotinylated human IL-4 staining kitwere used from R&D systems (Wiesbaden, Germany).\nRespective isotypes were purchased from BD Bioscience\nor Beckman Coulter, respectively. The antibodies wereused unconjugated and/or as direct conjugates with\nFITC, Alexa-488, PE, APC or PE-Cy7. Recombinant\nTNF \u03b1and IL-4 for the treatment of RCC cell lines were\npurchased from ImmunoTools (Friesoythe, Germany).\nIL-2 (Proleukine, Pharmacy, University of Halle, Germany),\nphorbol myristate acetate (PMA), propidiumiodid andionomycin from Sigma-Aldrich (Steinheim, Germany)\nwere used. \u03b1CD8 microbeads were obtained from Miltenyi\nBiotech (Gladbach, Germany). RPMI1640 and DMEMwere purchased from Invitrogen (Karlsruhe, Germany), X-\nVIVO15 from Lonza (Basel, Switzerland). The fix and perm\nkit for intracellular stainings was from BD Bioscience.\nThe following antibodies for cell culture were employed:\n\u03b1CD3 (clone OKT3) and \u03b1B7-H1 (clone MIHI) from\nebioscience, purified mIgG1 and mIgG2a from Millipore(Eschborn, Germany) and \u03b1HLA-I (clone w6/32) obtained\nfrom culture supernatants of hybridomas.\nFlow cytometry\nFlow cytometric analyses were essentially performed as re-\ncently described [21]. In brief, 1 \u00d7 105cells were stained\nwith fluorescent-labeled antibodies, while dead cells were\nexcluded using PI staining. For determination of the IL-4\nreceptor expression an indirect staining method usingIL-4-biotin followed by Avidin-FITC according to man-\nufacturers \u2019protocols was employed. For intracellular\nflow cytometric analyses of signal transduction compo-nents paraformaldehyde-fixed tumor cells were used, sub-\nsequently treated with permeabilizing buffer (methanol)\nprior to antibody staining. Flow cytometry was performedQuandt et al. Journal of Translational Medicine 2014, 12:151 Page 2 of 12\nhttp://www.translational-medicine.com/content/12/1/151using either a FACSscan \u2122,F A C S C a l i b u r \u2122or a FACSCanto \u2122\n(all Becton Dickinson) or FC500 (Beckman Coulter) flow\ncytometer and CellQuest \u2122or CXP \u2122and FlowJo \u2122(Tree\nStar) software, respectively.\nCytokine treatment of tumor cells\n3\u00d7105tumor cells/well were seeded into 6 well plates in\nDMEM/10% FCS. Cytokines (IL-4 at 1000U/ml and TNF \u03b1\nat 800 U/ml) were added the following day for 30 min or4\u201372 hrs as indicated for the subsequent analysis.\nPCR analysis\nTotal cellular RNA from frozen cell pellets was extracted\nusing RNAeasy MiniKit (Qiagen Hilden, Germany) and\nreversely transcribed into cDNA (Fermentas, St. Leon-RotGermany) as recently described [22]. Semi-quantitative\nRT-PCR from cellular RNA was performed using the\nfollowing oligonucleotide primers: For IL-4 fw: 3 \u2032cagttc\ntacagccaccatgaga 5 \u2032rev: 3 \u2032catgatcgtctttagcctttc 5 \u2032for, IL-\n4R\u03b1fw: 3 \u2032tctacttgcgagtggaagatga 5 \u2032rev: 3 \u2032ctccaaatgttgac\ntgcatagg 5 \u2032,TNF\u03b1fw: 3 \u2032gtgcttgttcctcagcctct 5 \u2032rev: 3 \u2032gctt\ngtcactcggggttc 5 \u2032,TNFRI fw: 3 \u2032gccaggagaaacagaacacc 5 \u2032\nrev: 3 \u2032gggataaaaggcaaagacca 5 \u2032and for \u03b2-actin fw: 3 \u2032tcct\ngtggcatccacgaaact 5 \u2032rev: 3 \u2032gaagcatttgcggtggacgat 5 \u2032.Real-\ntime PCR (Cybr Green, Invitrogen) analysis for B7-H1\nand B7-H4 from cellular RNA was performed using the\nfollowing oligonucleotide primers: H1: fw: 3 \u2032gaactacctc\ntggcacatcct 5\u2032rev: 3 \u2032gcccattccttcctcttgtc 5\u2032,H 4 :f w :3 \u2032agg\ncttctctgtgtgtctcttc 5 \u2032rev: 3 \u2032cttgctcttgtttgctcactcc 5 \u2032.\nCloning of the reporter gene vector\nGenomic DNA was isolated from the B7-H1 expressing\nmelanoma cell line UKRV-Mel-14a using the QIAampDNA Mini Kit (Qiagen) according the manufacturers \u2019\nprotocol. The B7-H1 promoter was amplified by PCR\nwith Taq DNA polymerase Kit (Invitrogen) employingthe forward primer 5 \u2032-AAAGGTACCTAGAAGTTCAG\nCGCGGGATA-3 \u2032and the reverse primer 5 \u2032-AAAGGAT\nCCCAGCGAGCTAGCCAGAGATA-3 \u2032. The specific PCR\nproduct was purified and cloned into the pMiR REPORT\nvector (Ambion, Austin, Texas, USA) using the restriction\nenzymes KpnI and BamHI (Fermentas) replacing the CMVpromoter as recently described [23]. For replacing the\nluciferase (luc) reporter gene by the red fluorescent m-\ncherry protein, the m-cherry sequence was amplifiedfrom the pmR-m-cherry vector (Clontech, Mountain View,\nCA, USA) applying the forward primer 5 \u2032-AAAGGATC\nCATGGTGAGCAAGGGCGAGGA-3 \u2032and the reverse\nprimer 5 \u2032-AATGTGGTATGGCTGATTAT-3 \u2032. The PCR\nproduct was digested with BamHI (Fermentas) and SpeI\n(NEB, Ipswich, MA, USA) and cloned behind the B7-H1promoter sequence in the pMiR REPORT backbone re-\nplacing the luciferase gene. The plasmid map is shown in\nAdditional file 1: Figure S1.Cell transfection\nThe reporter gene plasmid was stably transfected into themelanoma cell line BUF1088Mel using the EffecteneTransfection Reagent (Qiagen, Hilden, Germany). Stable\ntransfectants were selected with puromycin (pur) and a\npur-resistant batch culture was generated. Transfectedcells were cytokine treated as described above and flow cy-\ntometric analyses were performed 72 hrs post stimulation.\nTumor-T cell co-culture assays\nTumor cells were pretreated with cytokines as described\nabove, detached, washed with PBS (3 x times), counted\nand seeded with 1 \u20132\u00d71 05into 96 or 24 well plates.\nPeripheral blood mononuclear cells (PBMC) were ob-tained by Ficoll gradient from buffy coats of healthy vol-\nunteers. T cells were sorted for CD8\n+cells (purity > 98%)\nand co-cultivated tumor cells as described [21]. For pro-liferation assays, T cells were labeled with CDFA-SE\n(Lifetechnologies, Darmstadt, Germany) according to\nmanufacturers \u2019instructions) and tumor cells were pre-\ntreated with \u03b1HLA-I or anti-B7-H1 for 30 min prior to\n5 day co-culture assays. Proliferation data are presented\nas division index (DI) that is the average number of celldivisions that a cell in the original population has under-\ngone. For the determination of IFN \u03b3secretion tumor\ncells were co-cultured with T cells for 4 hrs. Cell culturemedium for the coculture assays was X-VIVO15.\nDetection of cytokine release\nTo determine IFN- \u03b3secretion of T cells the IFN- \u03b3secre-\ntion assay (Miltenyi) was performed following the manu-\nfacturer \u2019s instructions. T cells stimulated with PMA/\nionomycin (10 ng/ml and 1 \u03bcg/ml) served as a positive\ncontrol. TNF \u03b1production of tumor cells was analyzed\nfrom culture supernatants using a TNF \u03b1-specific ELISA\naccording to manufacturer \u2019s instructions (ebioscience).\nStatistical analysis\nStatistical analyses were performed using Prism 3.0 and\ndepending on controlled data normality distribution\nMann Whitney U Test or student \u2019s t test was used.\nResults\nCytokine receptor expression as a prerequisite for\ncytokine activity in RCC cells\nThe constitutive expression of the IL-4 and TNF \u03b1recep-\ntors and and their ligands were determined in RCC celllines. Using conventional qPCR TNF \u03b1, but not IL-4\nmRNA expression levels were detected in the different\nRCC cell lines (Figure 1A). Despite prominent TNF \u03b1\ntranscription rather low secretion levels of this cytokine\nwere detected in one/five RCC cell lines tested (Figure 1B).\nIn contrast, both the IL-4R \u03b1and TNFRI were expressedQuandt et al. Journal of Translational Medicine 2014, 12:151 Page 3 of 12\nhttp://www.translational-medicine.com/content/12/1/151at the mRNA (Figure 1C) and protein level (Figure 1D) as\ndetermined by qPCR and flow cytometry, respectively.\nIL-4 and TNF \u03b1synergistically enhance B7-H1 expression\nin RCC cells\nA heterogeneous, but constitutive cell surface protein\nexpression of B7-H family members was detected in the\ntested RCC cell lines (Table 1). While B7-H1 to B7-H4were expressed on all RCC cell lines, the degree of ex-\npression was quite diverse with the highest levels for B7-\nH3 followed by B7-H2 and B7-H1, whereas only weak,but detectable B7-H4 expression levels were found\n(Table 1). In addition, qPCR analysis revealed low B7-H4\nmRNA levels (Additional file 2: Figure S2). 2/3 RCC lineswere also weakly positive for B7-DC (data not shown).\nUpon treatment with either IL-4 and TNF \u03b1alone or in\ncombination, the B7-H molecule expression was differen-tially affected: B7-H4 transcription (data not shown) and\nprotein expression (Figure 2) was unaltered by this cyto-\nkine treatment. Despite high constitutive expression levels,a slight cytokine-mediated induction of B7-H3 was shown,\nwhich was most prominent in RCC31 upon IL-4 and\nTNF\u03b1treatment. B7-H2 was induced by TNF \u03b1, but not byIL-4 in the RCC cell line analyses, while combined TNF \u03b1\nwith IL-4 treatment had no additional effects (Figure 2).The most prominent induction was found for B7-H1 in\nall RCC cell lines by treatment with either cytokine,\nwhile combination treatment caused synergistic effects\nC)A)\nHal31RC MZ1257RC\nPBMC MZ2514RC\nMZ1790RC Hal162RCIL-4\nTNF-\u03b1\u03b1\n\u00df-actin\nPBMCIL-4R- \u03b1\u03b1\nTNFRI- \u03b1\u03b1\n\u00df-actinB)\nD)\ncountsHal31RC Hal162RC\nIL-4R\nTNFRIHal31RC MZ1257RC\nMZ2514RC MZ1790RC\nHal162RC\nFigure 1 Expression analysis of IL-4, TNF \u03b1and their receptors in RCC cell lines. A) Constitutive TNF \u03b1mRNA expression, but lack of IL-4\nmRNA expression was determined by conventional qPCR in different RCC cell lines (Hal31RC, MZ1257RC, MZ2514RC, MZ1790RC, Hal161RC) and in\nPBMC, which served as positive control. Representative data of at least 3 different experiments are shown. B)TNF\u03b1secretion of different RCC cell\nlines TNF \u03b1secretion was determined in Hal31RC, MZ1257RC, MZ2514RC, MZ1790RC, Hal161RC using ELISA. Representative data out of at least 3\ndifferent experiments are shown. C)The IL-4R \u03b1and TNFRI- \u03b1expression was determined by qPCR in the diff erent RCC cell lines and in PBMC, which served\nas positive control. Represen tative data of at least 3 diff erent experiments are shown. D)Flow cytometric analyses of IL-4R and TNF \u03b1RI demonstrated\nthe constitutive expression of IL-4R and TNFRI on Hal31RC and Hal161RC. Th e results are expressed as histograms. Bold line: staining, thin line:\ncontrol. TNFRI is stained with an anti-TNFRI-PE labeled antibody, bold line: staining, thin line: isotype control. Representative data of at least 3different experiments are shown.\nTable 1 Constitutive B7-H1-B7-H4 expression in renal cell\ncarcinoma cell lines as determined by FACS, isotype controlstainings were implemented\ncell lines B7-H1 B7-H2 B7-H3 B7-H4\nHal31RC + + ++ +/ \u2212\nHal78RC + + ++ +/ \u2212\nHal149RC + + ++ +/ \u2212\nHal162RC ++ ++ ++ +/ \u2212\nMZ1774RC + + +++ +/ \u2212\nMZ1790RC +/\u2212 ++ ++ +/ \u2212\nMZ1257RC + + ++ +/ \u2212\nMZ2514RC + + ++ +/ \u2212\nMZ2733RC + + ++ +/ \u2212\nMZ2877RC + + ++ +/ \u2212\n+/\u2212: 5-20% positive; +: 20-50% positive; ++ : > 50-100% positive; +++: 100%\npositive, and staining intensity > 10 fold to isoytpe control.Quandt et al. Journal of Translational Medicine 2014, 12:151 Page 4 of 12\nhttp://www.translational-medicine.com/content/12/1/151on B7-H1 protein expression (Figure 2 and Figure 3A),\nw i t ha<6f o l di n c r e a s ei nR C C 3 1c e l l s( F i g u r e3 A ) .F u r -\nthermore, IFN \u03b3treatment of RCC cells increased B7-\nH1 mRNA and protein expression (data not shown)\nconfirming recent reports [19].\nIn addition, other cytokines like IFN \u03b1, IFN \u03b2, TGF \u03b2,\nIL-6 and IL-10 were tested for their ability to modulate\nB7-H expression on RCC cells, but none of them altered\nthe expression levels of these molecules. The lack of the\ncytokine-mediated effects on B7-H family members was\nspecific, since these cytokines modulate e.g. HLA class Imolecule expression (data not shown).\nTranscriptional control of cytokine-mediated induction of\nB7-H1\nTo identify the kinetics of IL-4- and TNF \u03b1-mediated\nregulation of B7-H1 expression RCC cells were treated\nfor different time points with IL-4 and TNF \u03b1alone or in\ncombination before qPCR and flow cytometry was per-\nformed. Already 4 hrs post combined cytokine treatment\na significant induction of B7-H1 mRNA was detected(Figure 3B). Treatment with IL-4 alone only marginally\nincreased the B7-H1 transcript levels throughout the\ntime points tested, whereas TNF \u03b1alone induced a sig-\nnificant increase in B7-H1 mRNA levels at 24 hrs post\ntreatment. Combined cytokine treatment had always the\nstrongest impact on B7-H1 mRNA (Figure 3B). An en-hanced protein expression was only detected at later\ntime points, with a maximal induction at 72 hrs post cyto-\nkine treatment. These results pointed towards a regulation\nat the transcriptional rather than posttranscriptional level,\ne.g., by protein stabilization.\nIn order to test B7-H1 regulation at the transcriptional\nlevel in more detail, promoter binding prediction pro-\ngram (TESS) was used to determine direct binding sitesfor STAT6 (downstream of IL-4 signaling) and NF \u03baB\n(p65, downstream of TNF \u03b1) on the B7-H1 promoter\n(\u2212952 to \u22121 bp before transcript start). A weak binding\nsite for STAT6 (TTACAAGAA) and two overlapping\nhigh affinity binding sites for NF \u03baB (GGAAAGTCCA;\nAGGAAAGTCCAAC) were found in the B7-H1 pro-moter. One NF \u03baB binding site in the B7-H1 promoter\nFigure 2 Significant increase of B7-H1 surface expression by IL-4 and TNF \u03b1treatment of RCC cell lines. Different RCC cell lines (Hal31RC,\nHal161RC, MZ1790RC) were treated with either IL-4 or TNF \u03b1alone before B7-H expression was determined by flow cytometry as described in\nMaterials and Methods at 72 hrs. A)Shown are FACS histogram overlay plots for B7-H1, B7-H2, B7-H3 and B7-H4. Each plot shows overlay graphs,\ndepicting constitutive protein expression and expression upon single or combined cytokine treatment. Representative data of at least 3 differentexperiments are shown. B)Cytokine-mediated induction of B7-H1 and B7-H2 in % using constitutive expression levels as reference value. Combined\ndata of 3 different experiments are given.Quandt et al. Journal of Translational Medicine 2014, 12:151 Page 5 of 12\nhttp://www.translational-medicine.com/content/12/1/151has been shown to control B7-H1 expression in renal\ntubular cells [24].\nBased on this finding B7-H1 promoter studies were per-\nformed [25]. The wild type B7-H1 promoter constructhooked to the mCherry fluorescent protein was stably trans-\nfected into BUF088Mel cells (Additional file 1: Figure S1).\nTransfectants were subsequen tly left untreated or treated\nwith either cytokine (IL-4 or TNF \u03b1) alone or in combination\nbefore promoter activity was determined 72 hrs later. As\nshown in Figure 3C, an enhanced B7-H1 promoter activityas determined by flow cytometry of the mCherryfluorescence was found upon single and more pronounced\nupon combined treatment with IL-4 and TNF \u03b1.T h i ss u g -\ngests a transcriptional upregulation of B7-H1, which\nmight be mediated by activation of STAT6 and NF \u03baB.\nAlterations in pSTAT6, NF \u03baB, LFA-1, CD40 and HLA class I\nantigen expression levels upon treatment of RCC cells\nwith IL-4 and TNF \u03b1\nIn addition to the regulation of B7-H molecules by cyto-\nkine treatment downstream signal cascade components\nand other processes known to be of relevance for the T\nA)\nB7-H14h 8h 24h 72h\nuntreatedIL-4TNF\u03b1\u03b1\nIL-4 +TNF\u03b1\nuntreatedIL-4TNF\u03b1\nIL-4 + TNF\u03b1\nuntreated IL-4TNF\u03b1\nIL-4 +TNF\u03b1\nuntreatedIL-4TNF\u03b1\nIL-4 + TNF\u03b1\nB) C)\nFigure 3 Time kinetic of B7-H1 expression and B7-H1 promoter targeting upon combined cytokine treatment with IL-4 and TNF \u03b1.A )\nHal31RC was treated with either IL-4 or TNF \u03b1alone and with the combination of the two cytokines. B7-H1 protein expression was analyzed at\nthe time points indicated by flow cytometry. Shown are fold increase in B7-H1 expression compared to untreated cells. Representative data of at\nleast 3 different experiments are shown. B)B7-H1 mRNA expression in Hal31RC upon treatment with either IL-4 or TNF \u03b1alone and with the\ncombination of the two cytokines for the time points indicated are shown. Using a B7-H1 plasmid as standard, B7-H1 transcript levels per 10.000\ntranscripts \u03b2-actin are shown. Data are obtained by real time PCR. Representative data of 3 different experiments are shown. C)BUF1088Mel was\ntransfected with the mCherry B7-H1 promoter construct and stimulated with IL-4 and TNF \u03b1. The mCherry fluorescence was measured after 72 hrs\nby FACS and a representative histogram plot is depicted. The bar graph shows the combined result of a total of 3 independent assays.Quandt et al. Journal of Translational Medicine 2014, 12:151 Page 6 of 12\nhttp://www.translational-medicine.com/content/12/1/151cell/tumor interaction and the growth behavior of RCC\ncells were investigated.\nA growth inhibition of RCC cells was detected upon\nIL-4 addition, which was not further pronounced in the\npresence of TNF \u03b1(Additional file 3: Figure S3). In con-\ntrast, TNF \u03b1alone had no influence on the cell prolifera-\ntion, which is in discrepancy to earlier published data\nshowing an increased proliferation upon TNF \u03b1treat-\nment, but a strong influence of the culture media condi-tions were found [26].\nFollowing IL-4 treatment alone or in combination with\nTNF\u03b1phosphorylation of STAT6, a key signal molecule\ndownstream the IL-4 receptor, was detected by flow cy-\ntometry (Figure 4A). A known key downstream effector\nof TNF \u03b1signaling is represented by NF \u03baB. An enhanced\nexpression and activation of NF \u03baB was found in TNF \u03b1\nas well as TNF \u03b1- and IL-4-treated RCC cells (Figure 4A).\nNext to the upregulation of NF \u03baB the inhibitory subunit\nof NF \u03baB, named IkB, was downregulated upon TNF \u03b1\ntreatment in RCC cells (data not shown). Downregula-\ntion/degradation of I \u03baB as a part of the classical NF \u03baB\npathway activation has been described earlier [27].Additional important molecules for T cell/tumor com-\nmunication are CD40, a costimulator of the TNF-R family,\nthe adhesion molecule CD54 (LFA-1) and HLA class I an-tigens. As shown in Figure 4B all these surface molecules\nwere upregulated by the treatment of RCC cells with IL-4\nand TNF \u03b1, either alone or in combination. The combined\ntreatment of IL-4 and TNF \u03b1had an additive (CD40, HLA\nclass I) or a synergistic effect (LFA-1) on the protein ex-\npression, respectively (Figure 4B).\nB7-H1 blocks allospecific T cell proliferation\nB7-H1 has been shown to modulate T cell responses.[19,28] To test the functional consequences of increased\nB7-H1 on RCC cells upon IL-4 and TNF \u03b1treatment co-\nculture assays of tumor cells with allospecific T cellswere performed. A decreased CD8\n+T cell proliferation\nwas detected upon co-cultivation of T cells with IL-4\npretreated as well as with IL-4 and TNF \u03b1pretreated\ntumor cells (Figure 5A and B). The direct influence of\nboth cytokines on T cells was eliminated by 3 times\nwashing of cytokine-treated tumor cells, prior to co-culture assays. The decreased proliferation of CD8\n+T\nA) B)\nTNF\u03b1\u03b1IL-4pSTAT6 NFkB(pS529)\nIL-4+\nTNF\u03b1\u03b1\nFigure 4 Involvement of signaling components and change of HLA-I, CD40 and CD54 expression upon combined cytokine treatment\nwith IL-4 and TNF \u03b1in RCC cell lines. Hal31RC was treated with either IL-4 or TNF \u03b1alone and with the combination of the two cytokines. A)\nIntracellular pSTAT6 as well as NF \u03baB (pS529) at 30 min post stimulation were analyzed by flow cytometry. Gray filled graph represents constitutive\nexpression and black bold line represents cytokine-induced expression of either signaling component. Numbers on gates are percentage of positive\ncells compared to medium control. Representative data of at least 5 different experiments are shown. B)HLA class I, CD40, CD54 expression\n72 hrs post cytokine treatment were analyzed by flow cytometry. Data are presented as fold increase when compared to constitutive expression of\nthese molecules on untreated Hal31RC. Data are mean \u00b1 SEM of 9 different experiments.Quandt et al. Journal of Translational Medicine 2014, 12:151 Page 7 of 12\nhttp://www.translational-medicine.com/content/12/1/151cells upon co-culture with IL-4- and TNF \u03b1-pretreated\ntumor cells could be partially converted by the use of an\nanti-B7-H1 blocking antibody as proof for the inhibitory\nrole of B7-H1 on tumor cells (Figure 5C).\nTo identify the possible binding partner of B7-H1 on\nT cells, an anti-PD1 antibody was used for staining todetect the most likely candidate PD1. Indeed, PD1 was\nexpressed in 10.05 \u00b1 1.17% of CD8\n+T cells analyzed\n(Figure 5D). Since CD80 expression on T cells has beenpostulated [29] and CD80 can additionally bind B7-H1\n[30] its CD80 expression was determined on T cells. In\naddition, since B7-H2 expression is known to be in-creased upon treatment with TNF \u03b1, ICOS, the ligand of\nB7-H2 was analyzed on CD8\n+T cells prior to co-culture\nassays. As shown in Figure 5D, CD80 and ICOS wereonly very weakly expressed on CD8\n+T cells.Important CD8+T cell effector functions are cytokine\nproduction and the ability to kill target cells. As determined\nflow cytometry IFN \u03b3secretion by CD8+T cells was un-\naltered upon co-culture with cytokine-treated RCC cells\n(Figure 5E). Furthermore, the killing ability of CD8+T cells\nwas determined by measurement of CD107a degranula-tion, CD8\n+T cells upregulated CD107a expression upon\nco-culture with RCC cells, but no specific changes with re-\nspect to co-culture with cytokine pretreated tumor cellswere found (data not shown).\nDiscussion\nThe present study was undertaken to discover the distri-bution and regulation of B7-H family members in RCC\nby cytokines released from immune cells of the tumor\nmicroenvironment. Interesting, a synergistic increase of\nFigure 5 Block of allogeneic CD8+T cell proliferation upon coculture with RCC cells pretreated with IL-4 and TNF \u03b1. A-C) Hal31RC cells\nwere treated with either IL-4 or TNF \u03b1alone and with the combination of both cytokines. CD8+T cells from allogeneic PBMCs were sorted, CFDA-SE\nlabeled and cocultured with cytokine pretreated RCC31Hal. A)Representative FACS histogramm plots of proliferated CD8+Tcells cocultured with\nuntreated (u RCC) as compared to IL-4 or TNF \u03b1pretreated Hal31RC (4 + T RCC) are shown. The division index (DI) is given. B)Summary of CD8+T\ncell proliferation on cytokine pretreated Hal31RC. The division index (DI) is given. Pan anti-HLA class I antibody (w6/32) served as specificity con trol.\nData are means of 4 different donors \u00b1 SEM. C)Partial reversal of T cell proliferation inhibition upon coculture of CD8+T cells with anti-B7-H1 antibody\nor respective isotype control preincubated Hal31RC. Hal31RC were pretreated with IL-4 and TNF \u03b1for 3 days. Data represent the mean of 3 different\ndonors \u00b1 SEM. D)Analyses of constitutive B7H ligand expression, ICOS, CD80 and PD-1 on allogeneic CD8+T cells prior to coculture with RCC31. Data\nrepresent means of 7 different donors \u00b1 SEM. E)IFN\u03b3production of isolated CD8+T cells upon coculture of cytokine pretreated Hal31RC cells. Data are\nmeans of 3 different donors \u00b1 SEM.Quandt et al. Journal of Translational Medicine 2014, 12:151 Page 8 of 12\nhttp://www.translational-medicine.com/content/12/1/151B7-H1 surface expression in RCC cells upon treatment\nwith IL-4 and TNF \u03b1was found. As early as 4 hrs after\ntreatment, B7-H1 mRNA was significantly enhancedresulting in 6- fold increase in protein surface expression\nby 72 hrs and was mediated by an upregulation of the\nB7-H1 promoter activity by combined IL-4 and TNF \u03b1\ntreatment. In addition, the increase in B7-H1 protein\nsurface expression on RCC cells was associated with a\ndecreased allospecific T cell proliferation upon co-culture experiments.\nDetailed analysis showed a constitutive, but variable\nsurface expression of B7-H1 to B7-H4 molecules onRCC cells. Expression of B7-H1, B7-H3 and B7-H4 in\nsituhas been correlated with a worse clinical outcome\nof RCC patients [9,31,32]. In all tested RCC cell lines,B7-H4 was rather weakly expressed. In contrast B7-H3\nwas strongly expressed on RCC cell lines. To the best of\nour knowledge, we are the first to show B7-H2 expressionon RCC cells. There exist random reports showing expres-\nsion of this molecule in human tumors such as glioblast-\noma [33] and melanoma [34]. B7-H2 on glioma cells leadsto an increase in T cell-mediated anti-tumor immunity [35].\nIn addition, B7-H1 expression on RCC cells was con-\nfirmed with a weak or intermediate expression level byall RCC cell lines tested. Testing of the constitutive cyto-\nkine expression revealed a weak TNF \u03b1production by\none RCC cell line, while all others were negative. Thesedata are in line with earlier reports describing that some\nRCC cells are able to produce TNF \u03b1[36]. Furthermore,\nRCC cells in our study lack IL-4 expression thereby con-firming previous published data [37]. A prerequisite to\nrespond to a particular cytokines is the expression of the\nrespective cytokine receptors. Both the IL-4R as well asTNFRI expression was found on all RCC cells tested.\nTNF\u03b1acts via TNFRI and II both expressed on RCC\ncells [38]. IL-4R expression on RCC cells in vitro and in\nsitu has been demonstrated before [39]. Interestingly,\nstructural differences for IL-4R on RCC cells when com-\npared to immune cells exist, which might partially ex-plain the differential outcome of IL-4 action in these\ncells [37]. Most of the RCC cell lines tested in the\npresent study showed a very good and reliable response\nto IL-4 and TNF \u03b1treatment as demonstrated by phos-\nphorylation of STAT6, enhancement of pNF \u03baB and\ndownregulation of IkB.\nGiven the importance of B7-H molecules for the out-\ncome of RCC patients and the presence of cytokines inthe tumor microenvironment, the regulation of these\nfamily members upon treatment with various cytokines\nwas determined. As already described, upregulation ofB7-H1 expression by IFN \u03b3was confirmed [19]. In\naddition the most prominent effect on the regulation of\nB7-H1 was found using combined IL-4 and TNF \u03b1treat-\nment. B7-H1 was transcriptionally controlled by thesecytokines. B7-H2 was only upregulated by TNF \u03b1treat-\nment, but not by IL-4.\nIL-4 and TNF \u03b1can both be produced by different im-\nmune cells and thus represent components of the tumor\nmicroenvironment. In RCC TNF \u03b1is produced by tumor-\nassociated macrophages (TAM) [40]. TAMs can be subdi-vided into classical M1 phenotype macrophages that pro-\nduce and dependent on proinflammatory cytokines, such\nas TNF \u03b1and into alternative M2 phenotype macrophages\n[41]. M2 macrophages are characterized by the production\nof IL-10, TGF- \u03b2and are induced by IL-4. The ratio of M1/\nM2 TAMs together with the number and phenotype ofdendritic cells, myeloid derived suppressor cells (MDSC)\nand the Th1/Th2 balance determine the cytokine milieu\nand thereby the anti-tumor response in the tumor micro-environment. Already 15 years ago CD4\n+Th cells of the\nTh1 (predominantly IFN \u03b3) and Th2 (predominantly IL-4)\ncells as well as CD8+T cells have been shown to play a\nkey role for an effective anti-tumor response. Further-\nmore, IL-4 has a tremendous impact on the anti-tumor\nimmunity by shifting the Th1/Th2 balance [42]. The im-portance for IL-4 in RCC is demonstrated by the existence\nof a functional polymorphism in the IL-4 gene ( \u2212590 T)\nleading to an enhanced expression of this cytokine, whichis correlated with an increased risk of developing RCC\n[43] and a decreased survival [44] when compared to RCC\npatients carrying the other haplotype ( \u2212590C). In contrast\nto earlier reports, IL-4 can reduce tumor growth suggest-\ning that the time point and local distribution of high IL-4\nlevels have an impact on RCC progression. Of importance,microarray data reveal a positive correlation of B7-H1\nwith TNF \u03b1, NFkB and STAT6 (http://r2.amc.nl) in kidney\ntumor tissue in vivo, nicely supporting our data of a linkedB7-H1 expression with these cytokines.\nIn addition to IFN- \u03b3, the regulation of B7-H expres-\nsion by cytokines has been studied earlier, but mostly onimmune cells and not on RCC cells. Kryzek and co-\nauthors showed an increase of B7-H4 in TAMs upon\ntreatment with IL-6 or IL-10 [45]. Similar to our find-ings TNF \u03b1upregulates B7-H2 on embryonic fibroblasts\n[46] and endothelial cells [47], while IL-4 did not modu-\nlate B7-H2 and the combined treatment had no add-\nitional effect [47]. Interestingly, on human endothelial\ncells TNF \u03b1together with IFN \u03b3synergistically affect in-\nduction, whereas TNF \u03b1alone did not induce any B7-H1\nexpression [48].\nAs already proposed by and confirmed in this study\ncombined IL-4 and TNF \u03b1treatment exerts a synergistic\neffect on the increase of HLA class I antigen expression\nin RCC cells, which might enhance T cell-based anti-tumor responses [13]. This was further supported by an\nincreased expression of components of the APM leading\nto increased HLA class I surface antigen expression inRCC cells upon IFN- \u03b3treatment [30]. Since anotherQuandt et al. Journal of Translational Medicine 2014, 12:151 Page 9 of 12\nhttp://www.translational-medicine.com/content/12/1/151hallmark of effective T cell response is cell adhesion,\nICAM1 expression was analyzed. ICAM1 expression was\nhighly upregulated upon combined IL-4 and TNF \u03b1treat-\nment, which can support T cell/tumor interaction. This is\nin line with published data demonstrating that TNF \u03b1in-\nduces ICAM1 expression [49].\nAs functional consequences of cytokine-mediated en-\nhanced B7-H1 on RCC tumor cells, a decreased allospe-\ncific CD8+T cell proliferation was found, which could\nbe partially converted by addition of an anti-B7-H1 anti-\nbody. Since PD1 was the only substantially expressed re-\nceptor on the CD8+T cells used in the co-culture assays,\nit is therefore most likely responsible for this effect. This\nassay nicely resembles the in vivo situation, since en-\nhanced PD1 expression on tumor-infiltrating immunecells has been found in RCC and could be associated\nwith poor patients \u2019prognosis [50]. However, IFN- \u03b3and\nCD107a mobilization was not altered in CD8\n+T cells\nupon co-culture with cytokine pre-treated tumor cells.\nAn inhibitory effect of B7-H1 on CD8+T cells has already\nbeen described in different studies. A block in T cell pro-liferation owing to B7-H1 has been shown before with\noverexpression or blocking of B7-H1, but not with\ncytokine-pretreated cells [51, 52,20]. Additionally, a dir-\nect decrease of CD8\n+T cell killing and cytokine pro-\nduction upon co-culture assays with anti-B7-H1\nblocking antibody for human TCR tg CD8+T cells in\nRCC has been found [19]. On the other hand, Dong\nand coworkers (2002) showed that TCR tg human CTL\nare equally able to kill B7-H1 over-expressing melan-oma cells, but a B7-H1 dependent induction of T cell\napoptosis was detected [28]. Together with the findings\nof this study the data demonstrate the powerful influ-ence of B7-H1 on the modulation of different T cell ef-\nfector responses, which highly appear to depend on the\nco-culture systems chosen.\nThe observed block of T cell proliferation on CD8\n+T cells\nco-cultured with single IL-4-treated RCC cells could be\ndue to an additionally interaction of PD1 on T cellswith its second ligand B7-DC. A weak constitutive ex-\npression of B7-DC was found that could be also a subject\nto regulation by IL-4 similar as shown for macrophages\n[53] possibly not to TNF \u03b1as analyzed for monocytes [52].\nB7-DC has been shown to inhibit human T cell prolifera-tion by PD1 binding [51].\nHigh dose TNF \u03b1has been used to treat solid tumors,\nbut due to many side effects upon systemic administra-tion the success rate has been rather low, and strategies\nto administer this cytokine more locally had been devel-\noped for e.g. melanoma patients [54], but have not beenused to treat RCC.\nPhase II clinical trials using IL-4 for the treatment of\nRCC were not beneficial for these patients [16,18].This might be at least partially explained by thedecreased T cell proliferation capacity upon co-culture\nassays with IL-4-treated RCC cells. TNF \u03b1alone had no\neffect on T cell effector responses in the setting usedin our study, although TNF \u03b1treatment exerted benefi-\ncial anti-tumor effects in a xenograft mouse model\nwith RCC tumors [12].\nConclusion\nC o n c l u d i n gt h ed a t a ,t h i ss t u d ys h o w e df o rt h ef i r s tt i m eadetailed analysis of B7-H molecule regulation upon cyto-\nkine treatment in RCC. B7-H1 exhibited the strongest sen-\nsitivity to IL-4 and TNF \u03b1by a synergistic upregulation in\nRCC cells and is controlled at the transcriptional level by\ndirect promoter targeting. The importance of this B7-H1\ninduction is demonstrated by an inhibition of T cell prolif-eration thereby contributing to the proposed significance\nof B7-H1 in cancer immunity. The study furthermore sup-\nports the rational of using B7-H1/PD1 checkpoint anti-bodies for the treatment of tumor patients.\nAdditional files\nAdditional file 1: Figure S1. Reporter gene plasmid map for B7-H1.\nAdditional file 2: Figure S2. B7-H4 mRNA as determined by real time\nPCR is given. Transcript numbers are calculated using a \u03b2-actin and B7-H4\nplasmid as template. Representative data from 2 experiments are shown.\nAdditional file 3: Figure S3. Growth inhibition of cells treated with IL-4\nand the combination of IL-4+TNF \u03b1for 3 different RCC cell lines is shown.\nSame numbers of cells were seeded into wells and cells were equally\ndetached and counted using trypan blue exclusion at the end of culture\ntime (72hrs). Combined data of three different experiments are shown.\nAbbreviations\nAPM: Antigen processing machinery; CTL: Cytotoxic T lymphocyte; NF \u03baB: Nuclear\nfactor kappa B; IFN: Interferon; IL: Interleukin; luc: Luciferase; mAb: Monoclonalantibodies; MHC: Major histocompatible complex; RCC: Renal cell carcinoma;\nSTAT: Signal transducer and activator of transcription; TAA: Tumor-associated\na n t i g e n s ;T A M :T u m o r - a s s o c i a t e dm a c r o p h a g e s ;T C R :Tc e l lr e c e p t o r ;T N F :T u m o rnecrosis factor.\nCompeting interests\nThe authors declare that they have no competing interests.\nAuthors \u2019contributions\nDQ carried out main part of experiments, interpretation of results and wrotethe manuscript, SJ-B carried out the promoter studies, UM performed part ofthe FACS analysis and the real time PCR experiments, BSc performed part of\nthe T cell assays and BSe conceived of the study, participated in its design\nand coordination and was involved in writing the manuscript. All authorsread and approved the final manuscript.\nAcknowledgments\nThe authors would like to thank J\u00fcrgen Bukur, Chiara Massa and DagmarRiemann for discussions, experimental assistance and generation of RCC celllines. In addition, we would like to thank Sylvi Magdeburg for excellent\nsecretarial work.\nGrant support\nThis work was sponsored by a grant from the Wilhelm Roux Program\nof the Martin Luther University Halle-Wittenberg (D. Q.), Deutsche\nForschungsgemeinschaft, GRK 1591 (B.S.) and a grant from the MildredScheel Foundation, Bonn (B. S., D. Q.).Quandt et al. Journal of Translational Medicine 2014, 12:151 Page 10 of 12\nhttp://www.translational-medicine.com/content/12/1/151Received: 25 November 2013 Accepted: 28 April 2014\nPublished: 30 May 2014\nReferences\n1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer\nstatistics. CA Cancer J Clin 2011, 61:69\u201390.\n2. Organization WH: mortality database: http://globocan.iarc.fr/Pages/\nfact_sheets_cancer.aspx 07/05/2013.\n3. Escudier B: Emerging immunotherapies for renal cell carcinoma. Ann\nOncol 2012, 23(8):35 \u201340.\n4. Seliger B, Quandt D: The expression, function, and clinical relevance of B7\nfamily members in cancer. Cancer Immunol Immunother 2012, 61:1327\u20131341.\n5. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L: B7-H1 is a ubiquitous\nantiapoptotic receptor on cancer cells. Blood 2008, 111:3635\u20133643.\n6. Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M: B7-H6/NKp30\ninteraction: a mechanism of alerting NK cells against tumors. Cell Mol Life\nSci2011, 68:3531\u20133539.\n7. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev\nImmunol 2005, 23:515\u2013548.\n8. Tang PA, Heng DY: Programmed death 1 pathway inhibition in\nmetastatic renal cell cancer and prostate cancer. Curr Oncol Rep 2013,\n15:98\u2013104.\n9. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS,\nSengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon\nED:Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma\npatients with long-term follow-up. Cancer Res 2006, 66:3381\u20133385.\n10. Sanjmyatav J, Steiner T, Wunderlich H, Diegmann J, Gajda M, Junker K: A\nspecific gene expression signature characterizes metastatic potential in\nclear cell renal cell carcinoma. J Urol 2011, 186:289\u2013294.\n11. Smith AJ, Humphries SE: Cytokine and cytokine receptor gene\npolymorphisms and their functionality. Cytokine Growth Factor Rev 2009,\n20:43\u201359.\n12. Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wuest T,\nStenner F, Perani A, Cohen L, Knuth A, Divgi C, Jager D, Scott AM, Ritter G,Old LJ, Renner C: Targeted therapy of renal cell carcinoma: synergistic\nactivity of cG250-TNF and IFNg. Int J Cancer\n2009, 125:115\u2013123.\n13. Hoon DS, Okun E, Banez M, Irie RF, Morton DL: Interleukin 4 alone and\nwith gamma-interferon or alpha-tumor necrosis factor inhibits cellgrowth and modulates cell surface antigens on human renal cellcarcinomas. Cancer Res 1991, 51:5687\u20135693.\n14. Ikemoto S, Narita K, Yoshida N, Wada S, Kishimoto T, Sugimura K, Nakatani T:\nEffects of tumor necrosis factor alpha in renal cell carcinoma. Oncol Rep\n2003, 10:1947\u20131955.\n15. Bockorny B, Dasanu CA: Intrinsic immune alterations in renal cell\ncarcinoma and emerging immunotherapeutic approaches. Expert Opin\nBiol Ther 2013, 13:911\u2013925.\n16. Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland\nM, Doroshow JH, Ernest ML, Mier JW: Phase II studies of recombinant\nhuman interleukin-4 in advanced renal cancer and malignant melanoma.\nJ Immunother Emphasis Tumor Immunol 1994, 15:147\u2013153.\n17. Motzer RJ, Russo P, Nanus DM, Berg WJ: Renal cell carcinoma. Curr Probl\nCancer 1997, 21:185\u2013232.\n18. Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR,\nCrawford ED: Phase II trial of recombinant human interleukin-4 in\npatients with advanced renal cell carcinoma: a Southwest oncologygroup study. J Immunother 2002, 25:352\u2013358.\n19. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski\nTF, Theobald M, Andreesen R, Mackensen A: Blockade of PD-L1 (B7-H1)\naugments human tumor-specific T cell responses in vitro. Int J Cancer\n2006, 119:317\u2013327.\n20. Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, Shinya E,\nTakahashi H, Tamada K, Chen L, Dan K, Ogata K: Interferon-gamma and\ntumor necrosis factor-alpha induce an immunoinhibitory molecule,B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic\nsyndromes. Blood 2010, 116:1124\u20131131.\n21. Quandt D, Fiedler E, Boettcher D, Marsch W, Seliger B: B7-h4 expression in\nhuman melanoma: its association with patients \u2019survival and antitumor\nimmune response. Clin Cancer Res 2011, 17:3100\u20133111.\n22. Wulfanger J, Biehl K, Tetzner A, Wild P, Ikenberg K, Meyer S, Seliger B:\nHeterogeneous expression and functional relevance of the ubiquitincarboxyl-terminal hydrolase L1 in melanoma. Int J Cancer 2013, 133:2522\u2013\n2532.23. Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B: Identification of\nE2F1 as an important transcription factor for the regulation of tapasin\nexpression. J Biol Chem 2010, 285:30419 \u201330426.\n24. Chen Y, Zhang J, Guo G, Ruan Z, Jiang M, Wu S, Guo S, Fei L, Tang Y, Yang\nC, Jia Z, Wu Y: Induced B7-H1 expression on human renal tubular\nepithelial cells by the sublytic terminal complement complex C5b-9. Mol\nImmunol 2009, 46:375\u2013383.\n25. Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Muller\nA, Hiebl B, Holzhausen HJ, Seliger B: HER-2/neu mediates oncogenic\ntransformation via altered CREB expression and function. Mol Cancer Res\n2013, 11:1462\u20131477.\n26. Falkensammer C, Johrer K, Gander H, Ramoner R, Putz T, Rahm A, Greil R,\nBartsch G, Thurnher M: IL-4 inhibits the TNF-alpha induced proliferation\nof renal cell carcinoma (RCC) and cooperates with TNF-alpha to induceapoptotic and cytokine responses by RCC: implications for antitumorimmune responses. Cancer Immunol Immunother 2006, 55:1228\u20131237.\n27. Waddick KG, Uckun FM: Innovative treatment programs against cancer. I.\nRas oncoprotein as a molecular target. Biochem Pharmacol 1998,\n56:1411\u20131426.\n28. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu\nJ, Zhu G, Tamada K, Lennon VA, Celis E, Chen L: Tumor-associated B7-H1\npromotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med 2002, 8:793\u2013800.\n29. Kochli C, Wendland T, Frutig K, Grunow R, Merlin S, Pichler WJ: CD80 and\nCD86 costimulatory molecules on circulating T cells of HIV infected\nindividuals. Immunol Lett 1999, 65:197\u2013201.\n30. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ: Programmed\ndeath-1 ligand 1 interacts specifically with the B7-1 costimulatorymolecule to inhibit T cell responses. Immunity 2007, 27:111\u2013122.\n31. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson\nRH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED: Tumor cell and\ntumor vasculature expression of B7-H3 predict survival in clear cell renalcell carcinoma. Clin Cancer Res 2008, 14:5150\u20135157.\n32. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM,\nLeibovich BC, Blute ML, Cheville JC, Kwon ED: B7-H4 expression in renal\ncell carcinoma and tumor vasculature: associations with cancer\nprogression and survival. Proc Natl Acad Sci U S A 2006, 103:10391 \u201310396.\n33. Schreiner B, Wischhusen J, Mitsdoerffer M, Schneider D, Bornemann A,\nMelms A, Tolosa E, Weller M, Wiendl H: Expression of the B7-related\nmolecule ICOSL by human glioma cells in vitro and in vivo. Glia2003,\n44:296\u2013301.\n34. Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL:\nExpression of ICOS on human melanoma-infiltrating CD4 + CD25high-\nFoxp3+ T regulatory cells: implications and impact on tumor-mediatedimmune suppression. J Immunol 2008, 180:2967\u20132980.\n35. Wallin JJ, Liang L, Bakardjiev A, Sha WC: Enhancement of CD8+ T cell\nresponses by ICOS/B7h costimulation. J Immunol 2001, 167:132\u2013139.\n36. Mizutani Y, Bonavida B, Nio Y, Yoshida O: Overcoming TNF-alpha and drug\nresistance of human renal cell carcinoma cells by treatment with\npentoxifylline in combination with TNF-alpha or drugs: the role ofTNF-alpha mRNA downregulation in tumor cell sensitization. J Urol 1994,\n151:1697\u20131702.\n37. Obiri NI, Puri RK: Characterization of interleukin-4 receptors expressed on\nhuman renal cell carcinoma cells. Oncol Res 1994, 6:419\u2013427.\n38. Al-Lamki RS, Sadler TJ, Wang J, Reid MJ, Warren AY, Movassagh M, Lu W,\nMills IG, Neal DE, Burge J, Vandenebeele P, Pober JS, Bradley JR: Tumor\nnecrosis factor receptor expression and signaling in renal cell carcinoma.Am J Pathol 2010, 177:943\u2013954.\n39. Varricchio F, Obiri NI, Haas GP, Puri RK: Immunostaining of interleukin-4\nreceptor on human renal cell carcinoma. Lymphokine Cytokine Res 1993,\n12:465\u2013469.\n40. Ikemoto S, Yoshida N, Narita K, Wada S, Kishimoto T, Sugimura K, Nakatani T:\nRole of tumor-associated macrophages in renal cell carcinoma. Oncol Rep\n2003, 10:1843\u20131849.\n41. Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R,\nSantoni G, Montironi R, Tortora G, Cascinu S: Emerging role of tumor-\nassociated macrophages as therapeutic targets in patients with\nmetastatic renal cell carcinoma. Cancer Immunol Immunother 2013,\n62:1757\u20131768.\n42. Pardoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor\nimmunity. Curr Opin Immunol 1998, 10:588\u2013594.Quandt et al. Journal of Translational Medicine 2014, 12:151 Page 11 of 12\nhttp://www.translational-medicine.com/content/12/1/15143. Zhu J, Ju X, Yan F, Qin C, Wang M, Ding Q, Zhang Z, Yin C: Association of\nIL-4 -590 T>C polymorphism and risk of renal cell carcinoma in a Chinese\npopulation. Int J Immunogenet 2010, 37:459\u2013465.\n44. Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R: Interleukin-4\npromoter polymorphisms: a genetic prognostic factor for survival in\nmetastatic renal cell carcinoma. J Clin Oncol 2007, 25:845\u2013851.\n45. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P,\nCuriel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W: B7-H4\nexpression identifies a novel suppressive macrophage population in\nhuman ovarian carcinoma. J Exp Med 2006, 203:871\u2013881.\n46. Swallow MM, Wallin JJ, Sha WC: B7h, a novel costimulatory homolog of\nB7.1 and B7.2, is induced by TNFalpha. Immunity 1999, 11:423\u2013432.\n47. Youngnak-Piboonratanakit P, Tsushima F, Otsuki N, Igarashi H, Omura K,\nAzuma M: Expression and regulation of human CD275 on endothelial\ncells in healthy and inflamed mucosal tissues. Scand J Immunol 2006,\n63:191\u2013198.\n48. Mazanet MM, Hughes CC: B7-H1 is expressed by human endothelial cells\nand suppresses T cell cytokine synthesis. J Immunol 2002, 169:3581\u20133588.\n49. Makgoba MW, Sanders ME, Shaw S: The CD2-LFA-3 and LFA-1-ICAM\npathways: relevance to T-cell recognition. Immunol Today 1989,\n10:417\u2013422.\n50. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC,\nKwon ED: PD-1 is expressed by tumor-infiltrating immune cells and is\nassociated with poor outcome for patients with renal cell carcinoma. Clin\nCancer Res 2007, 13:1757\u20131761.\n51. Pfistershammer K, Klauser C, Pickl WF, Stockl J, Leitner J, Zlabinger G, Majdic\nO, Steinberger P: No evidence for dualism in function and receptors:\nPD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J\nImmunol 2006, 36:1104\u20131113.\n52. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai\nY, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA,Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T,Sharpe AH, Freeman GJ: PD-L2 is a second ligand for PD-1 and inhibits\nT cell activation. Nat Immunol 2001, 2:261\u2013268.\n53. Loke P, Allison JP:\nPD-L1 and PD-L2 are differentially regulated by Th1\nand Th2 cells. Proc Natl Acad Sci U S A 2003, 100:5336\u20135341.\n54. Lejeune FJ, Ruegg C, Lienard D: Clinical applications of TNF-alpha in\ncancer. Curr Opin Immunol 1998, 10:573\u2013580.\ndoi:10.1186/1479-5876-12-151\nCite this article as: Quandt et al. :Synergistic effects of IL-4 and TNF \u03b1on\nthe induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneicT cell proliferation. Journal of Translational Medicine 2014 12:151.\nSubmit your next manuscript to BioMed Central\nand take full advantage of: \n\u2022 Convenient online submission\n\u2022 Thorough peer review\n\u2022 No space constraints or color \ufb01gure charges\n\u2022 Immediate publication on acceptance\n\u2022 Inclusion in PubMed, CAS, Scopus and Google Scholar\n\u2022 Research which is freely available for redistribution\nSubmit your manuscript at \nwww.biomedcentral.com/submitQuandt et al. Journal of Translational Medicine 2014, 12:151 Page 12 of 12\nhttp://www.translational-medicine.com/content/12/1/151Human Cancer Biology\nB7-H4 Expression in Human Melanoma: Its Association with Patients\u2019\nSurvival and Antitumor Immune Response\nDagmar Quandt1, Eckhard Fiedler2, Diana Boettcher1, Wolfgang Ch Marsch2, and Barbara Seliger1\nAbstract\nPurpose: Cancers have developed a number of strategies to escape immune responses including the\ndifferential expression of costimulatory molecules of the B7 family. B7-H3 and B7-H4 have recently been\ndescribed in different tumor entities but the relevance for melanoma has not yet been studied so far.\nExperimental Design: Using immunohistochemistry, B7-H3 and B7-H4 expression was studied on 29\nmelanoma lesions. Survival curves and log-rank tests were used to test the association of protein expressionwith survival. Cell lines were evaluated for B7-H3 and B7-H4 expression by PCR and flow cytometry.Functional T-cell\u2013tumor coculture assays were carried out with in vitro generated tumor transfectants.\nResults: B7-H3 and B7-H4 expression was detected in primary tumor lesions (29 of 29 and 28 of 29) and\nin metastases (28 of 29 and 26 of 29). The numbers of CD68\n\u00femacrophages were significantly lower in\npatients with low B7-H4 expression, whereas CD8\u00feT-cell infiltrates were independent of expression levels.\nFurthermore, a survival benefit for patients with B7-H4 low expressing melanoma was found, whereas B7-H3 was not associated with any clinical parameter. All 23 melanoma cell lines analyzed expressed B7-H3and B7-H4 mRNA and protein, but B7-H4 was restricted to intracellular compartments. On silencing of B7-H3 by specific shRNA tumor-associated antigen\u2013specific T cell responses were unaltered. Overexpression ofB7-H4 on melanoma cells did not alter the cytotoxicity of different CD8\n\u00feeffector cells, but drastically\ninhibited cytokine production.\nConclusions: Our study provides for the first time evidence of B7-H4 expression on melanoma cells as\na mechanism controlling tumor immunity which is associated with patients \u2019survival. Clin Cancer Res;\n17(10); 3100\u201311. /C2112011 AACR.\nIntroduction\nMalignant metastatic melanoma represents a severe\ntumor disease with a bad prognosis. Current treatment\nregimens are often not very successful, in particular, inpatients with unresectable stage III and IV melanoma.\nTherefore, ongoing research aims in getting new insights\ninto this disease thereby concentrating on the interplay withthe immune system. For a number of reasons, melanomas\nare considered as immunogenic tumors due to (i) the\nexistence of immune-cell infiltrates that are associated withbetter patients\u2019 outcome (1\u20137), (ii) the relatively high\nincidence of spontaneous tumor regression, (iii) thedescription of numerous tumor-associated antigens (TAA)and respective T-cell responses over the years (4, 5), and\nfurthermore, (iv) the responsiveness of melanoma patients\nto immune therapies, such as cytokines like interleukin 2(IL-2; ref. 6) and IFN- a(7),aCTLA-4 treatment (8) or\ncombined strategies of adenovirus encoding MART-1 alongwith IL-2 applications (9).\nThe activation of T cells is controlled by 2 signals. The first\nis provided by the binding of the specific T-cell receptor\n(TCR) on T cells to a peptide\u2013HLA complex on antigen-\npresenting cells (APC) or HLA class I\u2013positive tumor cells.The second signal for proper T-cell activation is given by\ncostimulatory molecules (10). The outcome of costimula-\ntion can either be costimulatory or coinhibitory, whichhighly depends on the time of expression of costimulators,\nreceptor availability, and on the status of the T cells.\nWhereas the prototype of costimulatory molecules of theB7 family, B7-1 and B7-2, are predominantly influencingnaive T-cell functions (11), the more recently identified\nmembers of this family, the B7-H molecules, predomi-\nnantly control the effector phase of T-cell responses (12).The growing B7-H family comprises of many surface mole-\ncules, among them are B7-H1 (PD-L1), B7-H2 (ICOS-L),\nand B7-H3 and B7-H4 (B7x, B7S1; ref. 11). Even thoughmany studies have shown an inhibitory role for B7-H4 (13)\nin the setting of progressive renal disease, a costimulatory\nactivity of B7-H4 has also been proposed (14). So far, the\nAuthors' Affiliations:1Martin Luther University Halle-Wittenberg, Institute\nof Medical Immunology; and2Department of Dermatology and Venereol-\nogy, Martin-Luther-University Halle, Halle, Germany\nNote: Supplementary data for this article are available at Clinical Cancer\nResearch Online (http://clincancerres.aacrjournals.org/).\nD. Quandt and E. Fiedler contributed equally to this work.\nCorresponding Author: Barbara Seliger, Institute of Medical Immunology,\nMagdeburger Str. 2, 06112 Halle, Germany. Phone: 49-345 557 4054; Fax:\n49-345 557 4055; E-mail: Barbara.Seliger@medizin.uni-halle.de\ndoi: 10.1158/1078-0432.CCR-10-2268\n/C2112011 American Association for Cancer Research.Clinical\nCancer\nResearch\nClin Cancer Res; 17(10) May 15, 2011 3100\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 receptor for B7-H4 has not been identified (12). B7-H3 has\nbeen shown to promote T-cell responses possibly via an\nactivating receptor called TLT-2 (15) and on the contrary to\ninhibit T-cell responses by a not yet identified inhibitoryreceptor (16).\nIn the last decade, members of the B7-H family have\nbeen shown to be expressed in different tumor entities,mostly with an adverse clinical association (17). In mela-\nnoma, high levels of B7-H1 expression have recently been\nshown to be positively associated with reduced patient\u2019ssurvival (18) extending earlier studies on the role of B7-H1for the antitumor immune response (19), whereas for B7-\nH2 (ICOS-L) in situ expression data are available, but the\nclinical significance is unclear (20). Tumor-associated B7-\nH3 has been described in a number of different tumor\nentities, for example, in prostate and renal cell cancer\n(RCC) and neuroblastoma (12). The level of expressionof B7-H3 correlates to different clinical outcomes; whereas\nin gastric cancer patients (21), high expression levels of B7-\nH3 were associated with increased patients \u2019survival, the\nlevel of B7-H3 negatively interferes with patients \u2019outcome\nin RCC (22). The role of B7-H3 in tumor immunity is\ntherefore under debate and in particular, its function in\nhuman antitumor CD8\n\u00feT-cell responses has not been\nanalyzed in detail. Similarly, B7-H4 expression has also\nbeen shown in a number of different tumor entities, such as\nRCC, ovarian, and breast cancer (17). B7-H4 is mostlyassociated with poor patients \u2019outcome. The role for B7-H4\nin the direct interaction of tumor cells with CD8\n\u00feT cells\nhas hardly been studied so far. Because melanoma lesionsare often infiltrated by immune cells with diminished\neffector functions (23), the antimelanoma immune\nresponse could also be controlled by the immunosuppres-sive action of costimulatory molecules expressed on tumorcells.\nTo elucidate the role of B7-H3 and B7-H4 in melanoma,\npatients\u2019 material as well as cell lines were assayed for in\nvivoand in vitro expression data and clinical significance.\nB7-H3 and B7-H4 were found to be expressed in primarylesions and in metastases of stage III and IV metastatic\nmelanoma patients. No clinical relevance of B7-H3 expres-\nsion was detected, but patients with B7-H4 low expressingprimary melanoma had a survival benefit. In line with the\npatients \u2019data, in vitro studies showed that tumor-associated\nB7-H4 inhibits cytokine production of different antitumor\neffector T cells in T-cell\u2013tumor coculture assays. These datashow for the first time B7-H3 and B7-H4 expression in\nmelanoma lesions and more remarkably show a functional\nconsequence of B7-H4 for the patients \u2019outcome and an in\nvitro anti tumor response in metastatic melanoma.\nMaterials and Methods\nPatients\u2019 material\nFrom the histology databa se of the Department of\nDermatology and Venereology of the University ofHalle-Wittenberg (Halle , Germany), patients \u2019samples\nwere retrospectively selecte d, from whom a histologically\npreserved primary tumor ( cutaneous malignant mela-\nnoma), samples from cutaneous or subcutaneous (lymph\nn o d e )m e t a s t a s e sa sw e l la sm a t e r i a lo fab e n i g nc u t a -\nneous lesion were available. Twenty-nine of the cases\nfulfilled this criteria and 26 of the patients belong clini-\ncally to stage III and 3 of the patients to stage IV mela-\nnoma. Among the patients, 16 (B7-H3) or 17 (B7-H4)were men and 13 or 12 women, respectively, with a mean\nage of 60.9 (27\u201384) at the primary tumor resection. The\n29 cases could be classified into 17 superficial spreadingmelanoma (SSM), 5 nodular melanoma (NM), 2 acrallentiginous melanoma (ALM), and 5 unclassified mela-\nnoma (UCM) with a mean Breslow index of 4.23 (0.65\u2013\n9). The mean appearance of melanoma metastases was\n1.88 (0\u20137.4) years after primary tumor resection and\nmetastases used for histological sections were grouped\ninto 3 cutaneous, 4 subcutaneous, 12 lymph node, and 10nonspecified (close to cutaneous) metastases. The benign\nlesions comprise melanocyte-derived naevi, epidermal\ncyst, and acanthomes. The Ethics Committee at the Uni-versity Hospital in Halle (Germany) approved this study.\nImmunohistochemistry\nFive-microgram thick paraffin-embedded serial sections\nwere stained for melanoma markers, B7-H3 and B7-H4 and\nimmune cell infiltrates using a Ventana Benchmark-XT\nsystem. Counterstaining of sections with hematoxylin(Ventana Medical Systems Inc.) was carried out. The fol-\nlowing monoclonal antibodies (mAb) were used: aHMB-\n45 (Dako), aMelan-A A103 (Dako), aCD4 (Neomarkers),\naCD8 (Dako), aCD56 (Novocastra Laboratories Ltd.),\naCD68 (Dako), a-podoplanin (clone D2-40, Dako),\naB7-H3 (5 mg/mL) from R&D Systems and aB7-H4 (10\nmg/mL), clone H74, from eBioscience. Stainings were car-\nried out essentially as described (24), with the exceptionthat the ultraView Universal Alkaline Phosphatase Red\nDetection Kit (Ventana Medical Systems Inc.) was usedas detection system. The immune cell infiltrates were eval-\nuated in a semiquantitative fashion using a scoring fromTranslational Relevance\nSome members of the B7 family are expressed in\ntumors of distinct origins and appear to be involved\nin escape from immunosurveillance. We describe for thefirst time B7-H3 and B7-H4 expression in primary and\nmetastatic melanoma lesions. Tumor B7-H4 expression\nwas associated with a poor survival of melanomapatients. To understand the functional role of tumorB7-H4, we carried out HLA-I\u2013restricted T-cell\u2013tumor\ncoculture assays. On B7-H4 overexpression, TAA-speci-\nfic T-cell\u2013cytokine response was inhibited, showing theimportance of B7-H4 for the anti-melanoma immune\nresponse. The knowledge of differential B7-H4 expres-\nsion and the subsequent effect for the antitumorimmune response could be of great help for the treat-\nment of melanoma patients.B7-H3 and B7-H4 in Melanoma\nwww.aacrjournals.org Clin Cancer Res; 17(10) May 15, 2011 3101\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 0 to 3 (for CD4, CD8, and CD56), 0: no positive cells\ndetected; 1: less than 5% positive cells of total infiltrate; 2:\nmultifocal diverse single cells and groups; 3: like in 2 plustumor underlying lymph infiltrate. CD68-positive cells are\ngiven as percent positive cells of the immune infiltrate in the\ntumor section. Dermatopathologists evaluated the expres-sion of B7-H3 and B7-H4 in histological sections in a blindfashion. Results were scored as 0 (negative), 1 (heteroge-\nneous), and 2 (positive) when the percentage of stained\ntumor cells was less than 25, between 25 and 75, and morethan 75, respectively. In addition, the staining intensity was\nscored as 0 (negative), 1 (weak), 2 (moderate), and 3\n(strong). The results were then analyzed according to Armesand colleagues (25) combining the scores for frequency and\nquality. Combined scores of 0 to 5 were given distinguishing\nlow (scores 0\u20133) and high (scores 4 and 5) B7-H3 and B7-H4 expression, respectively. B7-H3 and B7-H4 stainingswere initially established on tonsilar tissue.\nThe specificity of the stainings in the tumor lesions was\ncontrolled by using the mIgG1 isotype control antibody(AbD Serotec) and by employing a competition assay. The\ncompetition assay was carried out by preincubation of 75\nmg/mL of recombinant mouse B7-H4 protein (R&D Sys-\ntems) with the B7-H4 antibody for 45 minutes at room\ntemperature before following the staining protocol. In\naddition, the D2-40 antibody, which stains lymph vessels,but neither tumor cells nor immune cells in the sections\nwas used.\nCells, cell lines, reagents, antibodies, and peptides\nThe 23 melanoma cell lines analyzed have been recently\ndescribed (26) and were either a kind gift from S. Ferrone or\nfrom the European tumor cell line data base (ESTABproject; see www.ebi.ac.uk/ipd/estdab). The RCC cell line\nHal31RCC and MZ2733RCC were generated in house from\ntumor lesions of clear cell RCC patients. Epstein-Barr virus(EBV)-transformed HLA-A02 restricted B cells were gener-\nated by W \u20acolfel and colleagues (27) and Bukur (in house)\nfrom healthy blood donors. SKOV3, SKBR3, and T2 cells\nwere obtained from the American Tissue Culture Collec-\ntion (ATCC). Tumor cell lines were cultured as described\nbefore (26, 28). Peripheral blood mononuclear cells(PBMC; HLA-A02\n\u00fe) from healthy donors were obtained\nfrom the blood bank of the university hospital.\nIL-2 (Proleukine, Pharmacy, University of Halle), Triton\nX-100 (Merck KGaA), phorbol myristate acetate (PMA),propidium iodide, and ionomycin from Sigma-Aldrich\nwere used. SureSilencing shRNA (short hairpin RNA) plas-\nmids for human B7-H3, were purchased from SABioscience.aCD8 microbeads was obtained from Miltenyi Biotech.\nThe following antibodies for cell culture were employed:\naCD3 (clone OKT3) from eBioscience), purified mIgG2a\nfrom (Millipore), and aHLA-I (clone w6/32) obtained\nfrom culture supernatants of hybridomas (28).\nMonoclonal antibodies (mAb) for flow cytometric analy-\nsis were: aCD8, aHLA-I (clone B9.12.1), aCD25,\naCD45RO, aICAM-1 from Beckman Coulter; aCD28 and\naCD27 from Becton Dickinson; aB7-H4 from AbDserotec; aB 7 - H 4a sw e l la sw a s aCD45RA from eBioscience;\naCCR7 as well as aB7-H3 were used from R&D systems.\nRespective isotypes were purchased from BD Bioscience orBeckman Coulter. The antibodies used were unconjugated\nand/or as direct conjugates with FITC, Alexa-488, PE, APC\nor PE-Cy7. HLA-A2\u2013restricted peptides, Tyr\n368\u2013376 pep\n(seq. YMNGTMSQV; ref. 29), and MART 27\u201335 pep\n(seq. AAGIGILTV; ref. 30) were synthesized by Peptides\nand Elephants.\nFlow cytometry\nFlow cytometric life cell analyses were essentially carried\nout as described before (26). The specificities of the B7-H3\nand B7-H4 stainings were controlled by preincubation of\ncells with a 100 /C2fold excess of the respective unconjugated\nantibody or irrelevant mouse IgG1. Forward/side scatter\ngating and propidium iodide staining in life cell analysisexcluded dead cells. Intracellularly protein expression was\ndetected as described before (31). Cytometric analyses were\ncarried out using a FACSscan (Becton Dickinson) or FC500(Beckman Coulter) flow cytometer and CellQuest or CXP\nand FlowJo (Tree Star) software.\nRT-PCR\nTotal cellular RNA from frozen cell pellets was extracted\nusing RNAeasy Mini Kit (Quiagen) and reversely tran-\nscribed into cDNA (Fermentas). Semiquantitative reverse\ntranscriptase PCR (RT-PCR) from cellular RNA was carried\nout using the following oligonucleotide primers: for B7-H4forward, 3\n0-aggcttctctgtgtgtctcttc-50and reverse, 30-cttgct-\ncttgtttgctcactcc; for B7-H3 forward, 30-ctgtctgtctcattg-\ncactgc-50and reverse: 30-caggctatttcttgtccatcat-50; and for\nb-actin forward, 30-tcctgtggcatccacgaaact-50and reverse:\n30-gaagcatttgcggtggacgat-50.\nTransfection and generation of stable transfected celllines\nB7-H4 was cloned after RT-PCR from mRNA of\nMZ2733RCC cells into pCMVIrNeo vector (32) followingtransfection of melanoma cells. In brief 3 /C210\n5BUF 1088\ncells were seeded in 6-well plates and transfected thefollowing day using Lipofectamine 2000 (Invitrogen) with3mg plasmid containing the B7-H4 transgene or the empty\nvector (later on referred to as control). Twenty-four hours\nlater the cells were selected with 400 mg/mL G418 and\nsingle cell clones were obtained by serial dilutions in 96-\nwell plates. The transfectants were kept under selective\npressure throughout their cell-culture period, except for\nthe coculture with T cells. The stability of transgene expres-sion was randomly controlled.\nTo generate CD8\n\u00feprimed T cell lines from healthy\ndonors, melanoma cells were transfected with a B7-2\u2013containing plasmid (32), similar as described above.\nStable B7-H3\u2013specific shRNA (cgtgtgctggagaaagatcaa) or\nirrelevant shRNA (referred to as sh control) expressionvectors with a neomycin resistance were transfected intomelanoma cells using Lipofectamine 2000 (Invitrogen)\nand 3 mg of the respective plasmid. Transfected cells wereQuandt et al.\nClin Cancer Res; 17(10) May 15, 2011 Clinical Cancer Research 3102\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 treated with 400 mg/mL G418 and in addition, cells were\nsorted on a FACSvantage (Becton Dickinson) for the lowest\nB7-H3 expression before using the cells for experiments.The B7-H3 repression on shRNA treatment and sorting was\nstable for at least 5 months.\nT-cell culture\nThe MART-1\u2013specific T cell clone (A42) was kindly\nprovided by Rivoltini [originally described by Kawakami\nand colleagues (33)] and was kept as well as expanded forexperiments with a modified rapid expansion protocol\ndescribed by Ho and colleagues (34). In brief, culture\nmedium was RPMI 1640 supplemented with 10% heatinactivated male AB serum (c-c pro), 1% P/S, 1% gluta-\nmine, and 1% HEPES. T cells (1 /C210\n5) were incubated with\n5/C2106irradiated (90 Gy) EBV B cells \u00fe2.5/C2107\nirradiated (30 Gy) PBMC \u00fe100 U/mL IL-2 and 30 ng/\nmLaCD3 for 12 days. EBV B cells and peripheral blood\nmononuclear cells (PBMC) were loaded with 40 mg/mL\nMART-1 peptide 2 hours before addition of T cells. On\nday 4 and day 8, the complete or half of the medium,\nrespectively, was exchanged and IL-2 (100 U/mL) was\nadded.\nCD8\u00feprimed T cells (T-cell line) were obtained by the\nfollowing protocol: PBMC were obtained by a Ficoll gra-dient of buffy coats from healthy donors. Subsequently,CD8\n\u00feT cells were isolated by a positive sort with aCD8\nMiltenyi beads following the companies \u2019instructions. CD8\nT cells (1 /C2106) were incubated with 1 /C2106irradiated\nCD8 depleted PBMC (30 Gy, same donor) and 1 /C2105\nirradiated B7-2 transfected BUF1088 (90 Gy) in 24-well\nculture dishes. After 3 days, IL-2 (100 U/mL) was added to\nthe culture. On day 7, CD8\u00feT cells were restimulated with\nthe same cells and same ratio like the primary culture and\nIL-2 (100 U/mL) was added on day 3.\nChromium release assay\nCytotoxicity assays were carried out in MART-1 T-cell\u2013\nspecific culture medium using 1 /C2106target cells labeled\nwith 100 mCi51sodium chromat (Hartmann Analytics) for\n1 hour at 37/C14C, 5% CO 2and washed 3 times. For experi-\nments with MART-1\u2013specific T cells, the transfected tumor\ncells were pulsed with MART-1 peptide (20 mg/mL) for 1\nhour. For blocking experiments, melanoma transfectants\nwere preincubated for 30 minutes at 37/C14C, 5% CO 2with\n200mg/mL aHLA class I\u2013specific mAb w6/32 or the corre-\nsponding antiimmunoglobulin isotype control. Chrome-labeled cells (2 /C210\n3) were incubated with the respective\neffectors at different E:T ratios for 4 hours at 37/C14C. Effector\nT cells were taken from day 12 (MART-1) or day 21 (primedCD8) cultures or thawed at the day of the assay. Specific\nlysis was calculated as [cpm (effector cells)\u2013cpm (sponta-neous)/cpm (Triton X-100)\u2013cpm (spontaneous)] /C2100%.\nCytokine detection by IFN-g secretion assay and\nELISA\nEffector T cells were taken from day 12 (MART-1) or\nday 21 (primed CD8) cultures or thawed at the day of theassay. For experiments with MART-1\u2013specific T cells, the\ntransfected tumor cells were pulsed with MART-1 peptide\n(20mg/mL) for 1 hour. T-cell\u2013tumor cocultures were car-\nried out in an E:T ratio of 1:1 for 16 hours at 37\n/C14C, 5% CO 2.\nPMA/ionomycin (10 ng/mL and 1 mg/mL) stimulation\nserved as assay control.\nThe IFN- gsecretion assay was carried out following the\nmanufacturer\u2019s instructions (Miltenyi). ELISAs for IL-2 and\nTNFawere carried out from culture supernatants according\nto manufacturer\u2019s instructions (eBioscience).\nStatistics\nStudents unpaired ttest was applied for differences in\ncytokine production. Mann\u2013Whitney Utest was used for\nthe comparison of the immunohistochemistry (IHC) score\nin normal skin, primary tumor lesions, and metastases. TheKaplan\u2013Meier method was used to analyze survival dataand the log-rank (Mantel\u2013Cox) test was taken to control\ndifferences in patients survival. Mann\u2013Whitney Utest or\nFisher\u2019s exact test were applied for checking the association\nof B7-H3 or B7-H4 expression with clinical parameters. All\nstatistical analyses were carried out using prism GraphPad\n5.0 and values of P<0.05 were considered significant.\nResults\nB7-H3 and B7-H4 expression in metastatic melanoma\nIHC was carried out using tissue samples from 29 mel-\nanoma patients with complete material of normal skin,primary tumor, and metastases. The obtained sections ofmelanoma tissues were first analyzed for melanoma mar-\nker expression to ensure subsequent analyses of tumor cells\nin the serial sections. Individual sections from all 29patients were positively stained ( /C2480% of the tumor cells)\nwith antibodies directed against melanoma marker HMB45(gp100) and Melan-A (MART-1; Fig. 1A and I, and data notshown; ref. 35), confirming the affiliation to tumor tissue.\nStainings with aB7-H3 and aB7-H4 mAb exhibited a high\nfrequency (B7-H3: primary, 100% 29 of 29 and metastases,\n97% 28 of 29; B7-H4: primary, 97% 28 of 29 and metas-\ntases, 90% 26 of 29) of intracellular and surface expression\non tumor cells in situ as representatively shown in Figure\n1B, C, J, and K and Supplementary Figure S1. Normal skinsurrounding the benign lesions of the same patients\nrevealed either no B7-H3 or B7-H4 staining or a very weak\nsignal with a mean IHC score of 1.44 for B7-H3 and 1.21for B7-H4 (Fig. 2A and B), for all normal skin tissues\nanalyzed. In contrast, the mean IHC score for B7-H3\nand B7-H4 of all primary melanoma or metastases ana-lyzed was above 3 and thereby significantly increased when\ncompared with normal skin (Fig. 2A and B). Furthermore,\nthe mean IHC score for both molecules did not differ in theprimary tumor versus metastases (Fig. 2A and B). Thespecificity of the B7-H3 and B7-H4 staining was controlled\nas described in Materials and Methods and are depicted in\nFigure 1D, E, and L. According to the quality and quantityof the staining (Materials and Methods), groups of B7-H3\nor B7-H4 low (scores 0\u20133) and high (scores 4 and 5)B7-H3 and B7-H4 in Melanoma\nwww.aacrjournals.org Clin Cancer Res; 17(10) May 15, 2011 3103\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 expression in tumor lesions were identified, respectively.\nWith the exception of 1 tumor lesion, all the other tumorlesions concomitantly expressed B7-H3 and B7-H4 in the\nprimary tumor.\nAnalysis of immune cell infiltrates in B7-H3 or B7-H4\nlow and high expressing groups\nTaylor and colleagues showed the association of immune\ncell infiltrates with the clinical outcome of melanoma\npatients (2). Furthermore, the B7-H3 and B7-H4 expres-\nsion identified on melanoma cells could directly modulate\nT cell or NK cell responses, making it important to analyzethe immune infiltrate into this tumor. The melanoma\nlesions analyzed in this study had only marginal T helper\ncell (CD4\n\u00fe) as well as NK cell (CD56\u00fe) infiltration (Fig. 1F\nand data not shown). The immune cell infiltrate comprised\nmainly of CD8\u00fecytotoxic T cells and CD68\u00femacrophages\n(Fig. 1G and H). There exists no correlation of B7-H3\nexpression levels and the frequency of CD8\u00feor CD68\u00fe\nimmune cell infiltration in primary tumor tissues andmetastases (Supplementary Table SI). In contrast, a signif-icant increase in CD68\n\u00feimmune cell infiltration was\ndetected in the B7-H4 high expressing melanoma (mean\nof 25.3% CD68\u00fecells) versus 12.8% CD68\u00fecells in the B7-\nH4 low expressing primary tumors (Table 1). CD8\u00feT-cell\ninfiltration was independent of the B7-H4 expression levelin primary tumor as well as metastatic lesions (Table 1).Lower B7-H4 expression in patients is associated with\nbetter survival\nWith respect to sex, age, Breslow score, and melanoma\nsubtype, no association was found between the level of B7-H3 or B7-H4 expression and the disease course (Table 1and Supplementary Table SI). B7-H3 expression in mela-\nnoma lesions was not associated with patients \u2019survival\n(Supplementary Table SI). More interesting, even though\nthe number of patients is small, the overall survival ofpatients with B7-H4 low lesions ( n\u00bc8) according to\nanalysis on the primary tumor tissue with a median survivalof 106.9 month was significantly ( P<0.05) higher than\nthat for patients with B7-H4 high lesions ( n\u00bc21) with a\nmedian survival of 42.2 month (Fig. 2C). Of note, at thetime of the primary tumor resection, all patients wereclassified as stage I or II of melanoma. All the 29 patients\nin our study eventually progressed to stage III or stage IV\nmelanoma, but display a different overall survival. Theseresults suggest a role of B7-H4 expression in the progression\nof metastatic melanoma.\nB7-H3 and B7-H4 expression on melanoma cell lines\nTo confirm the data obtained with the patients material\nand to find insights into how B7-H4 might influence\npatients \u2019survival, a total of 23 melanoma cell lines were\nanalyzed in vitro for their expression of B7-H3 and B7-H4.\nBoth molecules were expressed on the mRNA level\nHMB-45\nA B C D\nE F G H\nI J K L250 \u03bcmB7-H3 B7-H4Control\nBlock\nB7-H3 B7-H4Control\nD2-40MART -1\nMART -1Isotype CD4 CD8 CD68\nFigure 1. Representative immunohistochemical analysis of B7-H3 and B7-H4 expression in tissue sections of melanoma patients. A \u2013H, primary melanomas:\nHMB-45, inset MART-1 (A), B7-H3 (B), B7-H4 (C), block control (D), isotype (E), CD4 (F), CD8 (G), and CD68 (H). I \u2013L, melanoma metastases: HMB45\n(I), B7-H3 (J), B7-H4 (K), control (D2-40 lymphatic endothelium staining; L). IHC was carried out as described in Materials and Methods.Quandt et al.\nClin Cancer Res; 17(10) May 15, 2011 Clinical Cancer Research 3104\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 (Supplementary Table SII) although B7-H3 transcript levels\nexceed those of B7-H4 (data not shown). Concerning B7-\nH3 protein expression flow cytometry revealed a profound\nexpression of the molecule on the surface of the melanomacell lines (Fig. 3A). Tumor cell lines of distinct histology\nwith known B7-H3 expression like RCC and ovarian ade-\nnocarcinoma (12) served as controls and also stainedpositive for B7-H3 (Fig. 3A). The specificity of the B7-H3mAb was additionally confirmed by blockade with the\nunconjugated form prior to staining with the direct con-\njugate (Fig. 3C). In contrast, despite B7-H4 mRNA expres-sion (Supplementary Table SII) none of the 23 cell lines\nanalyzed as representatively shown for 2 randomly selectedcell lines, expressed B7-H4 on the cell surface (Fig. 3B).\nCells of different tumor histology, with known B7-H4\nexpression like breast carcinoma cells and RCC (17) cellsserved as controls and showed positive B7-H4 stainings\n(Fig. 3B). A low, but repeatable staining for B7-H4 on the\ncell surface was also detectable for EBV-transformed B cells(Fig. 3B; ref. 36). To proof whether melanoma cells expressB7-H4 protein at all, intracellular flow cytometry stainings\nwere carried out. The analyses using 2 commercial available\nmonoclonal aB7-H4 antibodies revealed B7-H4 positivity\nof all cell lines tested (Fig. 3B; Supplementary Table SII and\ndata not shown). The specificity of the aB7-H4 mAb clone\nMIH43 and clone H74 was controlled via blockade of the\nstaining on the B7-H4 overexpressing BUF1088 cells with\nthe unconjugated form of the same antibody (Fig. 3C and\ndata not shown). In line with data from Kryzek andcolleagues in ovarian cancer, IL-4, IL-6, and IL-10 didnot induce/increase B7-H4 surface expression on mela-\nnoma cells (ref. 37, data not shown). In addition, IFN g\nand TNF aalso did not modulate B7-H4 expression on\nmelanoma cell lines.\nRole of B7-H3 in immune response against melanoma\nTo define the role of B7-H3 in the antitumor immune\nresponse, B7-H3 expression was inhibited to more than\n90% on melanoma BUF1088 cells using stable shRNAexpression vectors (Fig. 4A). Silencing of B7-H3 did neither\ninfluence HLA class I expression nor ICAM-I as shown by\ntheir comparable expression on both sh B7-H3- and shcontrol\u2013treated BUF1088 cells (Fig. 4A). This is importantto note, as HLA class I and ICAM-I have an impact on the\noutcome of antitumor T-cell responses (38, 39). Chro-\nmium release assays showed that B7-H3 does not influenceTAA-specific CD8\n\u00feT cell mediated killing, as the percen-\ntage of killing of sh B7-H3- and sh control\u2013treatedBUF1088 is comparable (Fig. 4B). The specificity of theMART-1 T cell clone was proven using MART-1\n27\u201335 and\ntyrosinase peptide loaded T2 cells (Supplementary Fig. S2).In addition, the IFN gsecretion by MART-1\u2013specific T cells\non T-cell\u2013tumor coculture is unaffected by the level of B7-\nH3 expression (Fig. 4C).\nIt has been proposed that B7-H3 can protect glioblas-\ntoma cells from NK-cell\u2013mediated killing (40). Using pre-\nactivated NK cells from healthy donors, no difference in\nkilling of differential B7-H3\u2013expressing melanoma cells\nwas found (data not shown).\nB7-H4 on melanoma cell lines does not change\nCD8\n\u00feT-cell\u2013mediated cytotoxicity, but inhibits\nT-cell\u2013cytokine production\nAlthough the number of CD8\u00feT cell infiltrates did not\ndiffer in the B7-H4 low versus high expressing melanomacells, still a functional impairment of this cells is feasible, asthe activity of tumor infiltrating lymphocytes in the tumor\nmass is often blocked (23). It has been shown that B7-H4\ncan inhibit different T-cell functions (12). To define therole for B7-H4 in the T-cell antitumor immune response,\nB7-H4 was overexpressed in the melanoma cell line\n5\n4\n3\n2\n1\n0\nNormal skinA\nB\nC\nB7-H4 expression\n(IHC score)\n5\n4\n3\n2\n1\n0\n100\n80\n60\n40\nB7-H4highB7-H4lowP < 0.05\nn = 21n = 8\n20\n0\n0 50 100\nTime in monthPercent survival\n150 200B7-H3 expression\n(IHC score)Primary tumor******\n******Metastases\nNormal skin Primary tumor Metastases\nFigure 2. Summarized B7-H3 and B7-H4 expression levels on tissue\nsections of melanoma patients and correlation of patients \u2019overall survival\nto B7-H4. A and B, tissue sections of normal skin, primary tumor, and\nmetastases of 29 melanoma patients were analyzed for B7-H3, P\u00bc0.0001\n(A) and B7-H4, P<0.0001 (B) by immunohistochemistry. C, patients were\ngrouped into low (scores 0\u2013 3,n\u00bc8) and high (scores 4 and 5, n\u00bc21) B7-\nH4 expression according to immunohistochemistry data in primary tumor\nsections; P<0.05.B7-H3 and B7-H4 in Melanoma\nwww.aacrjournals.org Clin Cancer Res; 17(10) May 15, 2011 3105\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 BUF1088, which did not change the expression levels of\nHLA class I surface antigens nor ICAM-I (Fig. 5A). Thecostimulatory members of the B7-H family often do not\ninfluence the initial priming of T cells, but rather the\neffector phase (12). Therefore, 2 different effector CD8\n\u00fe\nT cells were used for these analyses, the MART-1\u2013specific Tcell clone and in vitro primed CD8\n\u00feT cells. The latter T cells\nwere raised on melanoma cell lines and probably display abroad specificity against melanoma associated antigens.Prior to coculture assays, the surface marker composition\nwas determined by flow cytometry. CD8\n\u00feprimed T cells\nanalyzed on day 7 after the 2nd restimulation (day 21)suggesting a central memory phenotype of cells\n(CD45RA/C0, CCR7\u00fe, CD28\u00fe, CD27\u00fe; ref. 41). In contrast,\nthe MART-1\u2013specific T cells display marker of terminal\ndifferentiated effector memory cells (CD45RA/C0, CD28/C0,\nCD27/C0), but still express the central memory marker CCR7\n(Supplementary Fig. S3A). On coculture assays with these\nCD8\u00feeffector cells, no difference in CD8\u00feT-cell\u2013mediated\nkilling of B7-H4 overexpressing melanoma cells wasdetected (Fig. 5B, Supplementary Fig. S3B). In the nextstep, it was analyzed whether tumor-associated B7-H4 had\nan influence on T cell cytokine production. A marked\ninhibition of 40% and 42% of IFN gproduction of theseTable 1. B7-H4 expression and its correlation to clinical parameters in metastatic melanoma patients\nPrimary tumor Metastasis\nLow, n\u00bc8 High, n\u00bc21 P Low, n\u00bc9 High, n\u00bc20 P\nSex: F/M 5/3 8/13 0.406 5/4 8/12 0.688\nBreslow index 3.25 /C61.77 4.32 /C62.31 0.339 3.00 /C62.01 4.47 /C62.19 0.088\nSubtype 1 4 0 5\nUCM 1 1 1 1\nALM 5 12 7 10\nSSM 1 4 1 4\nNM\nAge 57.2/C619.1 64 /C615.1 0.527 56.7 /C614.8 62.9 /C615.0 0.311\nCD8 infiltrates 2.13 /C60.83 2.05 /C61.12 0.96 1.56 /C60.73 1.75 /C60.55 0.449\nCD68 infiltrates 12.8 /C68.7 25.3 /C610.3 0.007 19.7/C69.72 24.3 /C612.2 0.407\nBUF1286A\nB\nC\ncountscountscounts\ncountsB7-H3\nB7-H4\nB7-H4 B7-H3mlgG1-PE\nblock with irrelev. mlgG1+B7-H3-PE\nblock with unconj. B7-H3+B7-H3-PEB7-H3-PEmlgG1-PE\nb\nlock with irrelev. mlgG1+B7-H4-488\nblock with unconj. B7-H4+B7-H4-488B7-H3-488Colo857 Hal31RCC SKOV3\nBUF1379\nsurface\nIntraBUF1286 Hal31RCC EBV-B cell SKBR3Figure 3. Constitutive B7-H3 and\nB7-H4 expression on melanoma\ncell lines. A, surface B7-H3 (bold\nline) expression on representativemelanoma (BUF1286 andColo857) cell lines and cells ofdifferent histology are depicted.Thin line represents a respectiveisotype control. B, surface and\nintracellular B7-H4 (bold line,\nclone MIH43) expression onrepresentative melanoma(BUF1379 and BUF1286) cell linesand on cells of different histologyare depicted. Thin line represents\na respective isotype control. C,\nspecificity control of B7-H3 andB7-H4 surface staining. Theseanalyses were carried out usingmelanoma cell lines BUF1383 (B7-H3) and BUF1088 transfected with\nB7-H4 construct (B7-H4).\nRepresentative histograms fromat least 3 independent stainingsare shown.Quandt et al.\nClin Cancer Res; 17(10) May 15, 2011 Clinical Cancer Research 3106\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 different T cells on coculture with B7-H4 overexpressing\nmelanoma cells, was detected (Fig. 5C). In addition, IL-2\nand TNF- asecretion by MART-1\u2013specific T cells was sig-\nnificantly reduced ( P<0.01) on coculture with B7-H4\noverexpressing melanoma cells (Fig. 5D).\nDiscussion\nThe expression and functional relevance of members of\nthe B7 costimulatory family in tumor lesions of distincthistology have been frequently reported (13, 17). Limited\ndata are available for melanoma and in particular, the\nexpression and significance of B7-H3 and B7-H4 moleculeshave not yet been analyzed in detail.\nIn this study, immunohistochemistry showed B7-H3 and\nB7-H4 stainings in primary tumor lesions and metastases.Moreover, there exist a correlation between the level of B7-\nH4 expression and clinical data, like macrophage infiltra-\ntion and patient\u2019s survival. In vitro data using T-cell\u2013tumor\ncoculture revealed an inhibitory effect for tumor B7-H4 oncytokine production of different CD8\n\u00feT effector cells.\nB7-H4 expression was detected with a high frequency\nranging from 97% 28 of 29 in the primary tumors to 90%26 of 29 in the metastases (Fig 1C and K and Table 1).\nTheses data were in accordance to the high frequency ofB7-H4 in breast carcinoma lesions with a positive stainingpattern of 95% in the primary and 98% of metastatic\nlesions (42), other studies analyzing RCC (43) and lungcancer (44) show B7-H4 expression in only 60% and 43%\nof the cases, respectively. In contrast to our data the groups\nof Choi and Gajewski did not detect B7-H4\u2013positive mel-anoma lesions (13, 45). This discrepancy might beexplained by the cohort of melanoma patients analyzed,\nwhich was not described in both reports as well as by the\nmethodology used. Chen and colleagues employed frozensections for IHC, whereas our study was conducted on\nparaffin-embedded tissues. In addition, a different B7-H4\u2013\nspecific mAb and a distinct protocol were used.\nComparable to B7-H4, B7-H3 expression was detected in\nmelanoma lesions with a positive B7-H3 staining patternfor 100% of the primary and 97% of the metastatic lesions(Table I and Supplementary Table SII). In other tumor\nentities, the frequency of tumor B7-H3\u2013positive cases var-\nied from 46% in RCC (22) to 96% in prostate cancer (46).As described by others (42, 47), a low expression of bothB7-H3 and B7-H4 with a score of 1 to 2 was detected in\nnormal skin surrounding the benign lesions of the same\npatients (Fig. 2A and B).\nIn accordance with findings in gastric (48) and RCC (43)\npatients, an increased survival of melanoma patients with\nsh control A\nBC\nMART-1\u2013specific T cells MART-1\u2013specific T cells\n4015\n10\n5\n0T cells + sh control\nT cells + sh B7-H3\nT cells + sh B7-H3 + w6/32\nT cells + sh B7-H3 + mlgG2a\nT cells + sh control + sh B7-H3 + sh B7-H3\n+ w6/32+ sh B7-H3\n+ mlgG2a% Killing\n% IFN-\u03b3 \u03b3+CD8+ T cells\n30\n20\n10\n0\n20:1 10:1 5:1 2.5:1 1.2.5:1 0.625:1counts\nB7-H3 HLA-I ICAM-1sh B7-H3sh control\nsh B7-H3sh controlsh B7-H3\nFigure 4. B7-H3 on melanoma cells does not influence TAA-specific CD8 T cell responses. A, transfectants with stable B7-H3 sh plasmids as compared\nwith stable control sh plasmids are shown: black bold line, sh control BUF 1088 with respective staining; black thin line, sh control BUF 1088 isotype\ncontrol; gray filled curve, sh B7-H3 BUF 1088 with respective staining; gray dotted line, sh B7-H3 BUF 1088 isotype control. Representative histogramsfrom at least 3 independent stainings are shown. B, standard\n51Chrom assays for killing of MART peptide loaded BUF 1088 sh B7-H3 transfectant ( ~)a s\ncompared with sh control transfectant BUF 1088 (&) on coculture with different ratios of MART-1 \u2013specific T cells are depicted. MART-1 \u2013specific tumor\nkill is controlled by aHLA-I antibody (w6/32; r) and with a respective isotype (mIgG2a) antibody ( /C9). Representative data from 3 to 5 independent experiments\nare shown. C, IFN- g\u2013specific cytokine secretion assay on coculture of BUF 1088 sh B7-H3 transfectant and sh control transfectant BUF1088 with\nMART-1 \u2013specific T cells was carried out. Results are depicted as percent CD8\u00feIFNg\u00feT cells. T-cell \u2013specific cytokine production is controlled by\naHLA-I antibody (w6/32) and with a respective isotype (mIgG2a) antibody. Representative data of 1 of 5 similar experiments are shown.B7-H3 and B7-H4 in Melanoma\nwww.aacrjournals.org Clin Cancer Res; 17(10) May 15, 2011 3107\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 lower B7-H4 expressing tumor was found (Fig. 2C). It is\nnoteworthy that the number of cases analyzed in mela-\nnoma is rather low, which is due to the selection criteria\n(material of normal skin, primary tissue, and metastases ofthe same patients) and needs to be extended in the future\nby focusing on primary melanoma tissues. In line with the\nIHC in melanoma lesions, B7-H4 mRNA and proteinexpression were found on melanoma cell lines (Supple-\nmentary Table SII and Fig. 3). Noteworthy, B7-H4 surface\nexpression was not detectable on the melanoma cell lines,but on ovarian cells, whereas intracellular B7-H4 wasfound in all the melanoma cell lines tested (Fig. 3 and\nSupplementary Table SII). The mechanism retaining B7-H4\nin the cytosol has not yet been investigated.\nTo understand the underlying immune mechanism, the\nfrequency and composition of the tumor immune infil-trates of the melanoma cases in our cohort were deter-mined. Predominantly CD8\n\u00feand CD68\u00fecells were\ndetected in the lesions, but only CD68\u00feand not CD8\u00fe\ninfiltrates were positively associated with higher B7-H4expression (Table 1). The number of lymphocyte infiltrates\nhas been correlated to patient\u2019s survival in some studies (2,\n49), but not in others (50, 51). Even more important thanthe frequencies of immune infiltrates is the functionality of\nthe immune cells (52). Due to the observed inhibitory\neffect of tumor B7-H4 on T cell function in vitro (Fig. 5C\nand D), we suggest that B7-H4 expression in tumor lesionsmight also modulate CD8\n\u00feT cell function in vivo .\nOverexpression of B7-H4 on melanoma cells resulted in\nan inhibition of T-cell functions (Fig. 5C and D), which wascomparable to the inhibitory role of B7-H4 in other settings\n(13). In contrast to Ou and colleagues (53), our data\ncontrol A\nB\nDCMART-1\u2013specific T cells\n50\n120\n100\n80\n60\n40\n20\n0120\n100\n80\n60\n40\n20\n025\n20\n1510\n5\n040\n30\n20\n10\n040\n30% KillingIL-2, pg/mL\nTNF\u03b1 \u03b1, pg/mL\n% IFN\u03b3 \u03b3+ CD8+ T cells\n% IFN\u03b3 \u03b3+ CD8+ T cells\n20\n10\n0\n20:1 10:1 5:1 2.5:1 1.25:1 0.625:1MART-1\u2013specific T cells\nMART-1\u2013specific T cells MART-1\u2013specific T cells\n****Primed CD8 T cells\n\u201342%T cells + control\u201340%\nT cellsT cells + B7-H4\nT cells + B7-H4 + w6/32\nT cells + B7-H4 + mlgG2aB7-H4 HLA-I ICAM-1countsB7-H4control\nB7-H4control\nB7-H4\n+ Control + B7-H4 + B7-H4\n+ w6/32\nT cells + Control + B7-H4 + B7-H4\n+ w6/32T cells + Control + B7-H4 + B7-H4\n+ w6/32T cells + Control + B7-H4 + B7-H4\n+ w6/32\nFigure 5. B7-H4 expression on melanoma cells does not influence TAA-specific CD8 T cell kill, but inhibits cytokine production. A, overexpression variant for\nB7-H4 as compared with empty vector (control) is shown: black bold line, control-transfected BUF 1088 with respective staining; black thin line,\ncontrol-transfected BUF 1088 isotype control; gray filled curve, B7-H4 \u2013transfected BUF 1088 with respective staining; gray dotted line, B7-H4 transfected\nBUF 1088 isotype control. Representative histograms from at least 3 independent stainings are shown. B, standard51Chrom release assays for killing of\nMART peptide loaded BUF 1088 B7-H4 transfectant (~) as compared with control transfectant (&) on coculture with different ratios of MART-1 \u2013specific T\ncells are depicted. MART-1 \u2013specific tumor kill is controlled by aHLA class I antibody (w6/32; r) preincubation and with a respective isotype (mIgG2a) antibody\n(/C9). Representative data from 3 to 5 independent experiments are shown. C, IFN- g\u2013specific cytokine secretion assay on coculture of BUF 1088 B7-H4\ntransfectant and control transfectant with MART-1 T cells or primed CD8 T cells was carried out. Results are depicted as percent CD8\u00feIFNg\u00feT cells.\nT-cell \u2013specific cytokine production is controlled by aHLA-I antibody (w6/32) preincubation. Representative data of 1 of 4 (MART-1 T cells) and 1 of 3 (CD8\nprimed) similar experiments are shown. D, IL-2 and TNF- aproduction by MART-1\u2013 specific T cells on coculture with BUF 1088 B7-H4 transfectants and control\ntransfectants of BUF 1088 cells were analyzed by standard ELISAs. MART-1 \u2013specific cytokine production is controlled by aHLA-I antibody (w6/32)\npreincubation. Representative data of 1 of 3 similar experiments are shown.Quandt et al.\nClin Cancer Res; 17(10) May 15, 2011 Clinical Cancer Research 3108\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 revealed that B7-H4 had no direct influence on the killing\nability of CD8\u00feT cells, but on cytokine production, in\nparticular of IFN- g, TNF- a, and IL-2 (Fig. 5B\u2013D). Interest-\ningly, also murine tumor B7-H2 had no direct influence on\nkilling of mastocytoma cells, but still enhanced tumor\nrejection (54). In addition, CD28 costimulation doesnot affect lysis of TCR-engrafted T cells, but did have animpact on cytokine responses (55). Inflammatory cyto-\nkines have a number of diverse functions in the antitumor\nimmune response (56). They not only serve as growthfactors, but IFN- gand TNF- aexhibit chemotactic potential\nvia direct (at least TNF- a) or indirect mechanisms, the latter\nmediated by IL-8 and MCP-1 enhancement (57, 58). Inhi-bition of monocytes/macrophage recruitment to the tumor\nsite appeared not to be the defect in the lesions described in\nthis study, as high B7-H4 expression on tumors was asso-ciated with increased macrophage density (Table 1). There-fore, other mechanisms might lead to the reduced survival\nin the high B7-H4 expressing melanoma cases. Possibly,\nreduced IFN- glevels at the tumor site might impact the\ntumor escape by lower tumor HLA class I and adhesion\nmolecule expression, which in turn might leads to an even\nmore decreased T-cell response (38).\nFurthermore, other studies reported a suppressive effect\nof B7-H4\n\u00fetumor\u2013associated macrophages on DC-induced\nTAA-specific CD8\u00feT cell responses in triple cultures of\novarian cancer (37). Due to the lack of surface B7-H4\nexpression in ovarian cancer lesions, the inhibitory role\nof B7-H4 in ovarian cancer might be due to B7-H4 expres-sion on TAMs (37). In contrast, other groups detected B7-H4 expression on the cell surface of ovarian cancer lesions\nas well as on cell lines in vitro (59, 60) suggesting the\npossibility of a direct interaction between CD8\n\u00feT cells and\nB7-H4 on tumor cells also in ovarian cancer patients. A B7-H4\u2013positive immune cell infiltrate was detected in mela-\nnoma lesions, which does not rule out the possibility thattumor-associated B7-H4\u2013positive macrophages might also\nconfer suppressive activity on tumor infiltrating CD8\n\u00feT\ncells in melanoma (data not shown). Because the B7-H4\u2013\npositive immune infiltrate was not further characterized,\nthe CD8\u00feT cells themselves might express B7-H4, which is\nin line with published data (61).\nDespite no association between clinical parameters and\nimmune cell infiltration with B7-H3 expression levels wasfound in melanoma patients (Supplementary Table SI), a\nrole for B7-H3 in melanoma could not be excluded, inparticular, as B7-H3 expression on tumor cells could act on\nreceptor bearing nonimmune cells like fibroblasts. The\nrecently identified receptor TLT-2 exhibits a broad expres-sion on cells (12). In addition, even though B7-H3 was also\nexpressed on tumor cells of ovarian cancer, only the B7-H3\nexpression on the tumor vasculature was associated withpatients \u2019survival (62). B7-H3 on tumor cells did enhance\nCD8\n\u00feT cell effector functions in humans (63) in vitro .\nThese findings are in accordance with patient data docu-menting a positive correlation of B7-H3 with increased\nsurvival in gastric and pancreatic tumor patients (21, 47).\nIn contrast, an inhibitory role for B7-H3 on T cell effectorfunctions has been documented, but the assays were notcarried out with tumor cells, instead with APCs or with B7-\nH3Ig (16, 64). This B7-H3\u2013induced inhibitory functions\nwould be in line with a positive association of increasedmortality in RCC patients (22). Certainly a distinct receptor\nexpression in the different experimental settings and more\nimportant in the different tumor entities might be respon-sible for these discrepancies. B7-H3 protein expression on a\nsmall number of melanoma cell lines had been previously\nshown in vitro (65). In our study, all tumor cell lines tested\nwere unambiguously B7-H3 mRNA and surface proteinpositive (Supplementary Table SII and Fig. 3). Human\nTAA\u2013specific T-cell\u2013tumor coculture assays with modu-\nlated B7-H3 revealed no differences in T-cell responses(Fig. 4).\nIn summary, an association of B7-H4 expression with\nincreased death in melanoma patients was found. The in\nvitro data suggest as underlying mechanism a decreased\ncytokine production of TAA-specific T cells on strong B7-H4 expression on tumor cells. This could subsequently leadto a reduced T-cell proliferation and lower HLA class I\nsurface expression at the tumor site that finally might result\nin tumor immune evasion. These data presented here couldhave an important impact on the consideration of newtherapeutic strategies against metastatic melanoma.\nDisclosure of Potential Conflicts of Interest\nThere is no conflict of interest with any of the authors concerning\ncommercial affiliations, consultancies, stock or equity interests, and\npatent-licensing arrangements.\nAcknowledgments\nThe authors would like to thank Hubert Ludwiczak, J \u20acurgen Bukur, Chiara\nMassa, Anja Lippert, Christel Lindhof, and Dagmar Riemann for discus-\nsions, technical assistance, and sorting of cells.\nGrant Support\nThis work was sponsored by a grant from the Wilhelm Roux Program of the\nMartin Luther University Halle-Wittenberg (D. Quandt) and a grant from theMildred Scheel Foundation, Bonn (B. Seliger and D. Quandt).\nThe costs of publication of this article were defrayed in part by the\npayment of page charges. This article must therefore be hereby markedadvertisement in accordance with 18 U.S.C. Section 1734 solely to indicate\nthis fact.\nReceived August 25, 2010; revised November 27, 2010; accepted\nDecember 14, 2010; published OnlineFirst March 4, 2011.\nReferences\n1.Clark WH. Jr., From L, Bernardino EA, Mihm MC. The histogenesis\nand biologic behavior of primary human malignant melanomas of theskin. Cancer Res 1969;29:705 \u201327.2.Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity inpatients with cutaneous melanoma. J Clin Oncol 2007;25:869\u2013 75.B7-H3 and B7-H4 in Melanoma\nwww.aacrjournals.org Clin Cancer Res; 17(10) May 15, 2011 3109\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 3.Clemente CG, Mihm MC. Jr., Bufalino R, Zurrida S, Collini P,Cascinelli N.\nPrognostic value of tumor infiltrating lymphocytes in the vertical growthphase of primary cutaneous melanoma. Cancer 1996;77:1303 \u201310.\n4.Vujanovic L, Butterfield LH. Melanoma cancer vaccines and anti-\ntumor T cell responses. J Cell Biochem 2007;102:301 \u201310.\n5.Van Der Bruggen P, Stroobant V, Van Pel A, Van Den Eynde BJ.\nT-cell defined tumor antigens:peptide database [updated 2009Jul 27]. Available from: http://www.cancerimmunity.org.peptidedata-base/Tcellepitopes.htm. Cancer Immun.\n6.Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, WeberJS, Parkinson DR, et al. Treatment of 283 consecutive patients withmetastatic melanoma or renal cell cancer using high-dose bolusinterleukin 2. JAMA 1994;271:907\u2013 13.\n7.Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS,\nErnstoff MS, et al. High-dose interferon alfa-2b significantly prolongsrelapse-free and overall survival compared with the GM2-KLH/QS-21\nvaccine in patients with resected stage IIB-III melanoma: results of\nintergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370\u2013\n80.\n8.Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the\ntreatment of melanoma. Cancer J 2009;15:169 \u201373.\n9.Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P,\nMarincola FM, et al. Immunizing patients with metastatic melanoma\nusing recombinant adenoviruses encoding MART-1 or gp100 mela-noma antigens. J Natl Cancer Inst 1998;90:1894 \u2013900.\n10.Schwartz RH. T cell anergy. Annu Rev Immunol 2003;21:305 \u201334.\n11.Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. AnnuRev Immunol 2005;23:515\u2013 48.\n12.Yi KH, Chen L. Fine tuning the immune response through B7-H3 and\nB7-H4. Immunol Rev 2009;229:145 \u201351.\n13.Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory\nreceptors in anti-tumor immunity. Immunol Rev 2009;229:126 \u201344.\n14.Chen Y, Yang C, Xie Z, Zou L, Ruan Z, Zhang X, et al. Expression of thenovel co-stimulatory molecule B7-H4 by renal tubular epithelial cells.Kidney Int 2006;70:2092 \u20139.\n15.Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H, AzumaM. Triggering receptor expressed on myeloid cell-like transcript 2(TLT-2) is a counter-receptor for B7-H3 and enhances T cellresponses. Proc Natl Acad Sci U S A 2008;105:10495 \u2013500.\n16.Leitner J, Klauser C, Pickl WF, St \u20acockl J, Majdic O, Bardet AF, et al. B7-\nH3 is a potent inhibitor of human T-cell activation: no evidence for B7-\nH3 and TREML2 interaction. Eur J Immunol 2009;39:1754 \u201364.\n17.Zou W, Chen L. Inhibitory B7-family molecules in the tumour micro-environment. Nat Rev Immunol 2008;8:467 \u201377.\n18.Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al.Tumor cell expression of programmed cell death-1 ligand 1 is aprognostic factor for malignant melanoma. Cancer 2010;116:1757 \u2013\n66.\n19.Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, et al.Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell\nresponses in vitro . Int J Cancer 2006;119:317 \u201327.\n20.Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM,\nWhiteside TL. Expression of ICOS on human melanoma-infiltratingCD4\n\u00feCD25highFoxp3\u00feT regulatory cells: implications and impact on\ntumor-mediated immune suppression. J Immunol 2008;180:2967\u2013 80.\n21.Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu KF, et al. Relationshipbetween co-stimulatory molecule B7-H3 expression and gastric car-\ncinoma histology and prognosis. World J Gastroenterol 2006;12:457 \u2013\n9.\n22.Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al.\nTumor cell and tumor vasculature expression of B7-H3 predict survi-val in clear cell renal cell carcinoma. Clin Cancer Res 2008;14:5150 \u20137.\n23.Boon T, Coulie PG, Van Den Eynde BJ, Van Der Bruggen P. Human T\ncell responses against melanoma. Annu Rev Immunol 2006;24:175 \u2013\n208.\n24.Fiedler E, Helmbold P, Marsch WC. Increased vessel density in\npsoriasis: involvement of lymphatic vessels in the papillary dermis.Br J Dermatol 2008;159:258\u2013 61.\n25.Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al.\nDistinct molecular pathogeneses of early-onset breast cancers inBRCA1 and BRCA2 mutation carriers: a population-based study.\nCancer Res 1999;59:2011 \u20137.\n26.Kamphausen E, Kellert C, Abbas T, Akkad N, Tenzer S, Pawelec G,\net al. Distinct molecular mechanisms leading to deficient expression\nof ER-resident aminopeptidases in melanoma. Cancer ImmunolImmunother 2010;59:1273 \u201384.\n27.W\u20acolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde\nKH, Knuth A. Lysis of human melanoma cells by autologous cytolytic\nT cell clones. Identification of human histocompatibility leukocyteantigen A2 as a restriction element for three different antigens. JExp Med 1989;170:797 \u2013810.\n28.Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler\nI, et al. Functional role of human leukocyte antigen-G up-regulation inrenal cell carcinoma. Cancer Res 2003;63:4107 \u201311.\n29.W\u20acolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum\nB\u20acuschenfelde KH, et al. Two tyrosinase nonapeptides recognized on\nHLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur JImmunol 1994;24:759 \u201364.\n30.Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, RobbinsPF, et al. Induction of tumor-reactive CTL from peripheral blood and\ntumor-infiltrating lymphocytes of melanoma patients by in vitro sti-\nmulation with an immunodominant peptide of the human melanoma\nantigen MART-1. J Immunol 1995;154:2257 \u201365.\n31.Quandt D, Hoff H, Rudolph M, Fillatreau S, Brunner-Weinzierl MC. Anew role of CTLA-4 on B cells in thymus-dependent immuneresponses in vivo . J Immunol 2007;179:7316 \u201324.\n32.Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B. Gene\ntransfer of the Co-stimulatory molecules B7 \u20131 and B7 \u20132 enhances the\nimmunogenicity of human renal cell carcinoma to a different extent.\nScand J Immunol 1999;50:242 \u20139.\n33.Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, YannelliJR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-\nrestricted tumor infiltrating lymphocytes. J Exp Med 1994;180:\n347\u201352.\n34.Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD. In vitro methods\nfor generating CD8\n\u00feT-cell clones for immunotherapy from the naive\nrepertoire. J Immunol Methods 2006;310:40 \u201352.\n35.Yaziji H, Gown AM. Immunohistochemical markers of melanocytic\ntumors. Int J Surg Pathol 2003;11:11 \u20135.\n36.Song H, Park G, Kim YS, Hur I, Kim H, Ryu JW, et al. B7-H4 reverse\nsignaling induces the apoptosis of EBV-transformed B cells throughFas ligand up-regulation. Cancer Lett 2008;266:227 \u201337.\n37.Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4expression identifies a novel suppressive macrophage population inhuman ovarian carcinoma. J Exp Med 2006;203:871\u2013 81.\n38.Seliger B. Different regulation of MHC class I antigen processing\ncomponents in human tumors. J Immunotoxicol 2008;5:361 \u20137.\n39.van de Stolpe A, Van Der Saag PT. Intercellular adhesion molecule-1.\nJ Mol Med 1996;74:13 \u201333.\n40.Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B,\nSementa AR, et al. Identification of 4Ig-B7-H3 as a neuroblastoma-\nassociated molecule that exerts a protective role from an NK cell-\nmediated lysis. Proc Natl Acad Sci U S A 2004;101:12640 \u20135.\n41.Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, et al.Four functionally distinct populations of human effector-memoryCD8\n\u00feT lymphocytes. J Immunol 2007;178:4112 \u20139.\n42.Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, et al.B7-h4 is highly expressed in ductal and lobular breast cancer. Clin\nCancer Res 2005;11:1842 \u20138.\n43.Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM,\net al. B7-H4 expression in renal cell carcinoma and tumor vasculature:associations with cancer progression and survival. Proc Natl Acad SciU S A 2006;103:10391 \u20136.\n44.Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, et al. B7-H3\nand B7-H4 expression in non-small-cell lung cancer. Lung Cancer\n2006;53:143\u2013 51.\n45.Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, et al.Genomic organization and expression analysis of B7-H4, an immuneinhibitory molecule of the B7 family. J Immunol 2003;171:4650 \u20134.Quandt et al.\nClin Cancer Res; 17(10) May 15, 2011 Clinical Cancer Research 3110\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 46.Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, et al.\nExpression of immunosuppresive B7-H3 ligand by hormone-treatedprostate cancer tumors and metastases. Clin Cancer Res 2009;15:\n2174 \u201380.\n47.Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M,\nEsposito I, et al. Expression of the costimulatory molecule B7-H3 isassociated with prolonged survival in human pancreatic cancer. BMCCancer 2009;9:463.\n48.Jiang JT, Wu CP, Shen YP, Zheng L, Wu J, Ji M, et al. Influence of co-\nstimulatory molecules B7-H4 expression on the prognosis of patients\nwith gastric cancer treated with cytokine-induced killer cells adoptiveimmunotherapy. Zhonghua Wei Chang Wai Ke Za Zhi 2010;13:366 \u2013\n70.\n49.Day CL Jr, Sober AJ, Kopf AW, Lew RA, Mihm MC, Hennessey P, et al.\nA prognostic model for clinical stage I melanoma of the upperextremity. The importance of anatomic subsites in predicting recurrent\ndisease. Ann Surg 1981;193:436\u2013 40.\n50.Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year\noutcome for patients with cutaneous melanoma in a population-based study. Cancer 1996;78:427 \u201332.\n51.Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Clinical andhistopathologic predictors of survival in patients with malignant mel-\nanoma: a population-based study in Sweden. J Natl Cancer Inst\n1994;86:761 \u20139.\n52.Oble DA, Loewe R, Yu P, Mihm MC, Jr. Focus on TILs: prognosticsignificance of tumor infiltrating lymphocytes in human melanoma.Cancer Immun 2009;9:3.\n53.Ou D, Wang X, Metzger DL, Ao Z, Pozzilli P, James RF, et al.\nSuppression of human T-cell responses to beta-cells by activation\nof B7-H4 pathway. Cell Transplant 2006;15:399 \u2013410.\n54.Wallin JJ, Liang L, Bakardjiev A, Sha WC. Enhancement of CD8\n\u00feT cell\nresponses by ICOS/B7h costimulation. J Immunol 2001;167:132\u2013 9.\n55.Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, et al. T-\ncell activation by recombinant receptors: CD28 costimulation isrequired for interleukin 2 secretion and receptor-mediated T-cellproliferation but does not affect receptor-mediated target cell lysis.\nCancer Res 2001;61:1976 \u201382.\n56.Yoo SY, Lee SY, Yoo NC. Cytokine expression and cancer detection.\nMed Sci Monit 2009;15:RA49 \u201356.\n57.Barker JN, Sarma V, Mitra RS, Dixit VM, Nickoloff BJ. Marked syner-\ngism between tumor necrosis factor-alpha and interferon-gamma inregulation of keratinocyte-derived adhesion molecules and chemo-tactic factors. J Clin Invest 1990;85:605\u2013 8.\n58.Rekdal O, Konopski Z, Svendsen JS, Winberg JO, Espevik T, Osterud\nB. The TNF Receptors p55 and p75 Mediate Chemotaxis of PMN\nInduced by TNFalpha and a TNFalpha 36\u2013 62 Peptide. Mediators\nInflamm 1994;3:347\u2013 52.\n59.Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, et al.The immunomodulatory protein B7-H4 is overexpressed in breast andovarian cancers and promotes epithelial cell transformation. Exp CellRes 2005;306:128\u2013 41.\n60.Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, et al.B7-H4 overexpression in ovarian tumors. Gynecol Oncol 2006;100:44\u201352.\n61.Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4,a molecule of the B7 family, negatively regulates T cell immunity.Immunity 2003;18:849\u2013 61.\n62.Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, et al.Tumor associated endothelial expression of B7-H3 predicts survival inovarian carcinomas. Mod Pathol 2010.\n63.Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: acostimulatory molecule for T cell activation and IFN-gamma produc-tion. Nat Immunol 2001;2:269\u2013 74.\n64.Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki\nW, et al. The B7 family member B7-H3 preferentially down-regulates T\nhelper type 1-mediated immune responses. Nat Immunol 2003;4:899\u2013\n906.\n65.Zhou YH, Chen YJ, Ma ZY, Xu L, Wang Q, Zhang GB, et al. 4IgB7-H3 isthe major isoform expressed on immunocytes as well as malignantcells. Tissue Antigens 2007;70:96 \u2013104.B7-H3 and B7-H4 in Melanoma\nwww.aacrjournals.org Clin Cancer Res; 17(10) May 15, 2011 3111\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 2011;17:3100-3111. Published OnlineFirst March 4, 2011. Clin Cancer Res\u00a0\u00a0 Dagmar Quandt, Eckhard Fiedler, Diana Boettcher, et al. \u00a0 Patients' Survival and Antitumor Immune ResponseB7-H4 Expression in Human Melanoma: Its Association with\n\u00a0 Updated version\n\u00a0  10.1158/1078-0432.CCR-10-2268doi:Access the most recent version of this article at:\n\u00a0 MaterialSupplementary\n\u00a0  http://clincancerres.aacrjournals.org/content/suppl/2011/05/18/1078-0432.CCR-10-2268.DC1Access the most recent supplemental material at:\n\u00a0 \u00a0 \n\u00a0 \u00a0 \n\u00a0 Cited articles\n\u00a0  http://clincancerres.aacrjournals.org/content/17/10/3100.full#ref-list-1This article cites 63 articles, 22 of which you can access for free at:\n\u00a0 Citing articles\n\u00a0  http://clincancerres.aacrjournals.org/content/17/10/3100.full#related-urlsThis article has been cited by 11 HighWire-hosted articles. Access the articles at:\n\u00a0 \u00a0 \n\u00a0 E-mail alerts  related to this article or journal. Sign up to receive free email-alerts\n\u00a0 SubscriptionsReprints and \n\u00a0 . pubs@aacr.org Department atTo order reprints of this article or to subscribe to the journal, contact the AACR Publications\n\u00a0 Permissions\n\u00a0 . permissions@aacr.org Department atTo request permission to re-use all or part of this article, contact the AACR Publications\nResearch. on June 8, 2017. \u00a9 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Published OnlineFirst March 4, 2011; DOI: 10.1158/1078-0432.CCR-10-2268 Appendix Selbstst\u00e4ndigkeitserkl\u00e4rung Hiermit erkl\u00e4re ich an Eides statt, dass ich die hier vorliegende Habilitationsschrift  selbst\u00e4ndig und nur unter Verwendung der angegebenen Literatur und Hilfsmittel angefertigt  habe.  Ein Habilitationsverfahren wurde an keiner anderen Universit\u00e4t er\u00f6ffnet oder beantragt.  Fr\u00fchere Habilitationsversuche sind nicht unternommen worden.     Halle, den 12.04.2018      Dr. Dagmar Quandt    Danksagung Herzlich m\u00f6chte ich mich bei Frau Prof. Heike Kielstein f\u00fcr die jahrelange erfolgreiche Zusammenarbeit, das damit entgegengebrachte Vertrauen und die Unterst\u00fctzung bei der Umsetzung meiner Habilitation bedanken. Ich bedanke mich bei Frau Prof. Barbara Seliger f\u00fcr die M\u00f6glichkeit, mich in ihrem Institut eigenen wissenschaftlichen Projekten zu widmen und mich weiter zu qualifizieren. F\u00fcr die Begleitung meiner wissenschaftlichen Karriere m\u00f6chte ich mich dar\u00fcber hinaus insbesondere bei Frau Prof. Monika Brunner Weinzierl, Herrn Prof. Andreas Radbruch, Herrn Prof. Ulf Wagner und Herrn Prof. Christoph B\u00e4rwald bedanken. Konstruktive Kritik, Motivation, Bereitstellung von finanziellen Mitteln und die \u00dcberlassung und Unterst\u00fctzung verschiedener eigener Forschungsprojekte haben diesen Weg ma\u00dfgeblich begleitet und zu dieser Qualifikationsstufe gef\u00fchrt. Prof. W. Ch. Marsch und PD Dr. Gerald Schlaf gilt mein Dank f\u00fcr die ermunternden Worte und Unterst\u00fctzung zur Fertigstellung dieser Schrift. Ich bedanke mich des Weiteren bei zahlreichen Kooperationspartnern/-partnerinnen, die mir durch eine Zusammenarbeit Einblicke in ihre spannenden Projekte gew\u00e4hrten und mir die M\u00f6glichkeit gaben, an diesen teilzuhaben. Au\u00dferdem m\u00f6chte ich mich bei meiner Familie, Partnern und Freunden bedanken, die diesen oft steinigen Weg mit mir gegangen sind und mich in meinem Willen, dieses Ziel zu verfolgen, unterst\u00fctzt haben. Mitarbeitern/Mitarbeiterinnen der Tierhaltung in den medizinischen Fakult\u00e4ten Leipzig und Halle und allen anderen Mitarbeitern/Mitarbeiterinnen von Serviceeinrichtungen, die zum Gelingen der Forschungsarbeiten beitrugen, gilt ebenfalls mein besonderer Dank. Patienten/Patientinnen und gesunden Probanden/Probandinnen danke ich f\u00fcr die Bereitstellung ihrer biologischen Pr\u00e4parate. Den Mitarbeitern/Mitarbeiterinnen und Doktoranden/Doktorandinnen der Sektion Rheumatologie der Universit\u00e4tsmedizin Leipzig, des Institutes f\u00fcr Medizinische Immunologie und des Institutes f\u00fcr Anatomie und Zellbiologie der Universit\u00e4tsmedizin Halle sowie den Studenten/Studentinnen der Biologie/Biochemie und der Medizin beider Universit\u00e4ten gilt mein Dank f\u00fcr ein kooperatives Arbeitsumfeld und die tatkr\u00e4ftige Unterst\u00fctzung bei den durchgef\u00fchrten Forschungsprojekten.    Curriculum vitae  Pers\u00f6nliche Angaben  Name  Dagmar Quandt; geb. G\u00e4rtner Staatsangeh\u00f6rigkeit deutsch Geburtsdatum  29.07.1975 Geburtsort  Stollberg, Deutschland Email  Dagmar.Quandt@uk-halle.de   Hochschulausbildung  2006 Promotion an der Fakult\u00e4t f\u00fcr Naturwissenschaften der Humboldt Universit\u00e4t Berlin mit dem Titel: In vivo und in vitro Immunregulation durch T- und B-Lymphozyten: Die besondere Rolle von CTLA-4 (Note: 1, mdl. Verteidigung summa cum laude) 2001 - 2006 Doktorandin am Deutschen Rheumaforschungs-Zentrum (DRFZ) Berlin, AG Molekulare Immunologie, Betreuer: Prof. M.C. Brunner-Weinzierl/Prof. A. Radbruch  1999-2000 Diplomarbeit Die Funktion des Aktinzytoskelettes bei der Aktivierung humaner Monozyten durch LPS unter Einflu\u00df von aktin- und immunmodulierenden Substanzen unter Leitung von Prof. Dr. S. Hauschildt an der Universit\u00e4t Leipzig (Note: 1,8) 1997-1998 Studentin an der Universit\u00e9 des Sciences et Technologies de Lille / Frankreich F\u00e4cher: Pflanzenphysiologie und Immunologie  1994-2000 Studium u. Diplom der Biologie an der Universit\u00e4t Leipzig/ Sachsen (Note:1,8)  Wissenschaftlicher Werdegang  ab 2017 Leiterin der assoziierten Nachwuchsgruppe der AG Kielstein\u201c am Institut f\u00fcr Anatomie und Zellbiologie der Martin-Luther-Universit\u00e4t Halle/Wittenberg ab 2016 Projektleiterin am Institut f\u00fcr Medizinische Immunologie der Martin-Luther- Universit\u00e4t Halle/Wittenberg ab 2014 Wissenschaftliche Mitarbeiterin am Institut f\u00fcr Medizinische Immunologie der Martin-Luther-Universit\u00e4t Halle/Wittenberg 2011 - 2014 Wissenschaftliche Mitarbeiterin an der Klinik f\u00fcr Gastroenterologie und Rheumatologie, Sektion Rheumatologie an der Universit\u00e4tsmedizin Leipzig 2006 - 2011 Wissenschaftliche Mitarbeiterin am Institut f\u00fcr Medizinische Immunologie der Martin-Luther-Universit\u00e4t Halle/Wittenberg 2005 - 2006 Laborleitung in der Arbeitsgruppe Molekulare Immunologie von Frau PD Dr.  M. Brunner-Weinzierl am DRFZ/Charit\u00e9 in Berlin \nStipendien/Drittmittel/Konsortien  2016 Projektleitung (FKZ 30/40), MLU Halle, 85.000/p.a. 2016 Stipendium zur Teilnahme am Keystone Kongress in Vancouver, Kanada  2.000 Euro  2016 GRK ProMMoAge (GRK2155), assoziierter Postdoc 2015 Auszeichnung (Young Investigator Award) der amerikanischen Gesellschaft f\u00fcr Immuntherapie (SITC), 3.000 Euro 2007-2011 Drittmittelf\u00f6rderung der Deutschen Krebshilfe (Mildred-Scheel Stiftung) f\u00fcr 3 Jahre, eigene Postdoc Stelle eingeschlossen (107967), 100.000/p.a. 2006-2007 Anschubfinanzierung im Wilhelm-Roux-Programm (FKZ 15/31) Martin-Luther-Universit\u00e4t Halle/Wittenberg, 30.000 Euro 2004 - 2016 diverse Reisestipendien zur Teilnahme an Kongressen im europ\u00e4ischen und au\u00dfer-europ\u00e4ischen Ausland, ca. 6.000 Euro 2003 \u2013 2004 Doktorandenstipendium zur F\u00f6rderung des wissenschaftlichen Nachwuchses (Naf\u00f6g) der Humboldt-Universit\u00e4t, 8.500 Euro  2003 2-monatiger Forschungsaufenthalt am Institut f\u00fcr Zell-, Tier- und Populationsbiologie an der Universit\u00e4t zu Edinburgh, Schottland bei Prof. D. Gray gef\u00f6rdert durch ein Kurzzeitstipendium des DAAD, 2.500 Euro  Publikationen 19 Originalarbeiten, 3 \u00dcbersichtsartikel, 3 Konferenzpaper, Summe Zitate: 588  H-Index 12 (Web of Science)  Betreute Promotions-, Master- und Bachelorarbeiten 4x, 2x, 2x  Gutachter f\u00fcr Wissenschaftsjournale Oncotarget, Arthritis Research & Therapy  Halle, den 12.04.2018      Dr. Dagmar Quandt ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}